annual report content sciencele strategic report global healthcare company business model chairmans statement ceo statement financial performance longterm priority purpose culture improve quality human life help people feel well key performance indicator live long industry trend stakeholder engagement goal pharmaceutical world innovative bestperforming trust vaccine healthcare company consumer healthcare trust strategy risk management bring differentiate highquality need healthcare product group financial review people possible global business scientific corporate governance technical knowhow talented people chairman governance statement longterm priority board priority underpin ambition build performance corporate executive team focus culture align value expectation responsible leadership division responsibility innovation composition succession invest scientific technical excellence develop launch evaluation pipeline new product meet need patient payer nomination committee report consumer audit risk internal control audit risk committee report performance science committee report deliver growthbased performance invest effectively corporate responsibility business develop people execute competitively committee report trust section statement responsible company commit use science director report technology address health need product affordable remuneration report available modern employer chairman annual statement value expectation annual report remuneration value patient focus transparency respect integrity remuneration policy summary expectation courage accountability development teamwork remuneration policy report financial statement director statement responsibility independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare uk gaap investor information cautionary statement quarterly trend inside cover document cautionary statement fiveyear record forwardlooke statement product development pipeline product competition nonifrs measure intellectual property use number adjust nonifrs measure report performance business principal risk uncertainty total report result represent group overall performance ifrs adjust result proforma growth rate nonifrs measure consider addition share capital share price substitute superior information present accordance ifrs adjust result dividend nonifrs measure define page reconciliation near financial calendar ifrs measure page annual general meeting believe adjusted result consider total result provide investor tax information shareholder analyst stakeholder helpful complementary information understand well shareholder service contact financial performance position group period period allow group law regulation performance easily compare majority peer company group company measure management planning reporting purpose glossary term directly comparable similarly describe measure companiesstrategic report governance remuneration financial statement investor information business model global business discover develop manufacture innovative medicine vaccine consumer healthcare product day help improve health million people world operation span value chain identify ability launch new product successfully research develop testing groundbreaking grow sale exist portfolio key discovery regulatory approval manufacture commercial success patient consumer commercialisation deliver transformational medicine vaccine consumer healthcare product include employee country billion pack medicine million vaccine outstanding scientific technical knowhow dose billion consumer healthcare product deep expertise regulation intellectual property commercialisation work worldleade capital allocation framework invest expert form strategic partnership complement business provide return exist capability shareholder form dividend share value growth pay dividend p share innovation critical improve health create deliver billion free cash flow financial value researchbase healthcare company rely intellectual property protection help ensure positive contribution communitie reasonable return investment operate create employment work continue research develop new innovative supplier pay tax offer broad range medicine invest billion rd employee benefit include preventative healthcare pharmaceutical vaccine focus science service able attract retain related immune system human genetic good people deliver purpose great advanced technology consumer healthcare contribution improve health people leverage scientific expertise deep consumer world medicine vaccine insight create healthcare product meet consumer healthcare product consumer demand pharmaceutical vaccine consumer healthcare pharmaceutical business world large vaccine worldleade consumer healthcare broad portfolio innovative company revenue deliver vaccine business combine science establish medicine respiratory protect people stage life consumer insight create innovative hiv immunoinflammation oncology rd focus develop everyday healthcare brand strengthen rd pipeline vaccine infectious disease consumer trust expert recommend focus immunology human combine high medical need finalise agreement genetic advanced technology strong market potential pfizer combine consumer help identify transformational healthcare business new medicine patient read read read turnover turnover turnover respiratory hiv meningitis wellness immunoinflammation shingle oral health oncology influenza nutrition establish pharmaceutical establish vaccine skin health total total total gsk annual report business model continue prepare future invest rd new product new programme use unique catalyst separation order successful increase investment rd reset capability cost base company new product deliver future growth announce help support delivery significant value creation new approach rd significant opportunity new gsk new consumer progress strengthen pipeline particularly oncology healthcare medicine vaccine pipeline new gsk clear opportunity drive common major approval regulatory approach rd science relate immune system submission positive readout pivotal study converge pharmaceutical vaccine progress new asset pivotal study enable effective allocate complete transaction tesaro budget share technical scientific expertise deliver merck kgaa strengthen position pipeline regardless modality oncology initiate alliance build platform programme seek improve technology genomics university california capability create efficiency global support cell therapy lyell immunopharma function continue simplify focus manufacture positive clinical datum generate progress network ensure supply chain ready launch strengthen pipeline underpin decision new speciality medicine rationalise portfolio increase investment rd year divestment create new company new consumer healthcare company programme early consistent strategic priority support build key technology infrastructure previous announcement start twoyear programme expertise necessary operate standalone company prepare gsk separation new lead company believe increase investment pipeline new new gsk biopharma company rd approach product effective implementation new focus science relate immune system use twoyear programme set new company genetic new technology new consumer strong foundation future performance financial healthcare company categoryleade power brand benefit cost report associate programme innovation base science consumer insight set page intention remain separate year close transaction result formation new consumer healthcare joint venture july capital allocation capital allocation framework key priority capital invest business rd pipeline include business development vaccine capacity innovation new product improve shareholder return dividend performance cash target x x cover generation return dividend growth trust strict discipline return gsk annual report strategic report governance remuneration financial statement investor information chairman statement delight introduce gsk annual report chairman passionate life sciences work industry year sector know meaningful difference patient people world gsk proud history innovation environment social governance esg exciting future ahead join gsk irresistible year require compliance opportunity create world revise uk corporate governance code lead consumer health business create increase emphasis value esg factor overall biopharma business found todays lead scientific performance please find gsk purpose platform board outstanding management team strategy priority place deliver longterm value lead emma determine achieve society shareholder need great prominence clear gsk deliver good operating performance start good place growth sale earning good cash generation emma team sucessfully focus strengthen gsk strong foundation global health innovation pipeline deliver strong commercial execution continue play important role promise datum evident contribution growth new candidate tb vaccine recognition gsk leadership product result antimicrobial resistance major global health threat good demonstration access affordability medicine innovation critical issue industry society company see good progress group priority strengthen continue focused make product affordable pharmaceutical pipeline particularly oncology available responsible pricing strategic access filing asset move pivotal trial board programme partnership particularly please positive datum come asset acquire tesaro transaction tackle climate change require action gsk commit play company deliver distinctive new approach rd focus reduce carbon footprint line paris immune system use genetic advance analytical agreement assess opportunity risk technology advance formation transition low carbon economy present partnership include university california andme lyell attraction new talent board change organisation long term new approach progress search judy lewent promise deliver productive rd organisation successor chair audit risk committee deliver high number differentiate medicine delight judy agree stay year area board science committee working facilitate transition stepping board closely management agm whilst mindful uk corporate governance code indicate nonexecutive director month conversation serve year firmly believe smooth shareholder please report strong support transition good interest company shareholder strategic direction company intention separate new company successfully deliver set detail section board governance group initiate new programme help prepare reevaluate priority board committee separation consequently establish new architecture able support oversee creation board committee work closely management outstanding new organisation provide support oversight year year sir philip hampton stand board capital allocation anticipate year annual report iain mackay board support management clear framework capital chief financial officer replace simon dingemans allocation prioritise investment pharmaceutical d like opportunity thank philip simon pipeline building vaccine supply capacity discipline service gsk support business development opportunity finally thank gsk employee partner framework course board mindful shareholder customer support warm welcome return shareholder return p share expect total shareholder return sir jonathan symonds chairman gsk annual report ceo statement pleased progress longterm priority innovation performance trust strengthen pipeline improve operational execution reshape group growth sale earning continue build capability new platform group sale grow actual exchange rate technology notably pioneer new partnership constant exchange rate billion good university california establish stateoftheart performance particularly consider laboratory crispr geneedite technology year generic version advair biotech company lyell development new cell therapy please partnership andme new product drive increase sale reflect progressing identify new target innovation focus commercial execution shingrix work immunology oncology neurology shingle vaccine remarkable year sale cardiovascular disease billion successful biopharma launch year product receive prestigious prepare future prix galien award innovation respiratory see strong deliver innovation priority recent growth trelegy nucala hiv new twodrug datum readout progress regimen dovato juluca contribute sale million strengthen pipeline underpin decision increase investment rd new product total group operating margin increase percentage longterm growth point adjust operate margin decrease percentage point cer reflect decision invest time continue focus operational new product priority pipeline programme execution include deliver successful integration total earning share p actual consumer healthcare follow completion exchange rate cer adjust earning share transaction pfizer july grow actual exchange rate cer p prepare separation group achieve strong cash generation free cash flow previously state intention separate billion expect announce dividend year closing transaction p expect initiate twoyear programme prepare new company new gsk biopharma company rd approach landmark year rd focus science relate immune system use ceo strengthen rd pipeline genetic advanced technology new consumer priority significant progress healthcare company worldleade portfolio brand leadership dr hal barron chief scientific officer scale deliver major approval regulatory filing new medicine positive readout asset pivotal new programme aims use unique catalyst study progress new asset pivotal study separation set competitive capability cost base biologic company help deliver significant value creation patient consumer shareholder progress reflect successful prioritisation development pipeline core area hiv respiratory building trust fast emerge area oncology gsk consistently continue action particularly pleased pivotal datum zejula ovarian broad contribution society addition delivery cancer belantamab mafodotin multiple myeloma financial return good progress believe asset potential transform trust commitment place respond patient treat underserved cancer type increase investor interest environmental social governance esg performance please rank medicine vaccine currently pharma company dow jones sustainability index clinical development expect sector potential product approval expect substantial proofofconcept datum include combination study immunooncology agent innovative vaccine respiratory syncytial virus rsv chronic obstructive pulmonary disease copd gsk annual report strategic report governance remuneration financial statement investor information ceo statement continue notable recent initiative relate people culture global health health security follow publication continue work develop performancefocuse excellent data candidate tb vaccine early culture strong emphasis ethic value build secure groundbreaking agreement new trust internally remain key priority regular employee gate medical research institute develop vaccine survey help review level employee engagement use lowincome country new alliance reflect pleased achieve excellent engagement score aim sustainable approach global health level organisation course year focus effort expertise science research pursue broad agenda promote inclusion partner ensure development diversity female representation organisation delivery file regulatory submission new increase particularly senior management level gsk formulation late hiv medicine expand recognise stonewall lgbt rights group access use child resource poor setting global employer please science research significant progress effort recognise gsk leadership access talent dedication gsk people work medicine foundation antimicrobial resistance want thank enormous contribution benchmark count february support global response outbreak cause coronavirus sarscov form collaboration cepi coalition epidemic preparedness innovation institution company vaccine adjuvant technology available development emma walmsley effective vaccine virus chief executive officer area trust agenda work hard reduce environmental impact underpin public target goal reduce impact quarter report set approach climate change risk include voluntary disclosure recommendation taskforce climaterelate financial disclosure tcfd gsk annual report financial performance total result growth turnover turnover cer turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost profit disposal interest associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p perform operating profit total operating profit million compare cost sale million reduce remeasurement charge total cost sale percentage turnover contingent consideration liability consumer percentage point high aer percentage point healthcare option charge increase profit disposal high cer term primarily reflect increase increase value share hindustan unilever cost major restructuring programme unwind limited receive disposal horlick fair value uplift inventory arise completion consumer healthcare brand partly offset increase consumer healthcare joint venture pfizer continue charge major restructure significant legal matter adverse pricing pressure pharmaceutical partly offset favourable product mix vaccine tax charge million represent effective tax rate sell general administration total result reflect total sga cost percentage turnover different tax effect adjust item percentage point high aer percentage point high cer included increase significant legal charge noncontrolle interest arise settlement exist matter provision allocation total earning noncontrolle interest ongoing litigation increase investment result amount million million increase acquisition tesaro great promotional product support primarily increase allocation viiv healthcare particularly new launch profit research development earning share total rd expenditure million turnover total earning share p compare p aer cer reflect significant increase increase earning share primarily reflect study clinical trial material investment oncology reduce remeasurement charge contingent increase spending progression key nononcology consideration liability option increase asset partly offset saving early phase portfolio value share hindustan unilever limited receive reprioritisation late disposal horlick consumer healthcare brand reduce effective tax rate increase share operating incomeexpense aftertax profit associate result nonrecurre net operating income primarily reflect profit income tax benefit innoviva disposal rabie tickborne encephalitis vaccine number asset disposal increase value share hindustan unilever limited receive disposal horlick consumer healthcare brand gsk annual report strategic report governance remuneration financial statement investor information financial performance continue total adjust result total report result represent group overall performance gsk undertaking number boardapprove major restructuring programme response significant change gsk use number adjust nonifrs measure group trading environment overall strategy report performance business adjust result follow material acquisition cost cash noncash nonifrs measure consider addition programme provide individual element substitute superior information present approve meet accounting recognition criterion accordance ifrs full definition result charge incur number year gsk believe adjust result consider follow initiation major restructure programme total result provide investor analyst group initiate twoyear separation preparation stakeholder helpful complementary information programme prepare gsk separation new lead understand well financial performance position company biopharma consumer healthcare group period period allow group performance easily compare majority gsk commit continuously improve financial peer company measure reporting line evolve regulatory requirement management planning reporting purpose well practice directly comparable similarly describe measure gsk report result include month result company pfizer consumer healthcare business august gsk encourage investor analyst rely proforma growth rate cer calculate single financial measure review gsk annual report include equivalent month result include financial statement note entirety pfizer consumer healthcare business comparative period fully describe divestment intangible intangible significant total asset asset major transaction legal adjusted adjust item result amortisation impairment restructure relate item result turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p intangible asset amortisation impairment transactionrelate amortisation impairment intangible asset goodwill transactionrelated accounting adjustment relate exclude computer software significant acquisition major restructuring divestment significant legal item major restructuring cost include impairment tangible proceed cost disposal associate product asset computer software specific boardapproved business significant legal charge net insurance programme structural significant scale recovery expense settlement litigation cost individual relate project exceed million government investigation operate income include integration cost follow material acquisition royalty income item gsk annual report financial performance continue adjust result growth turnover turnover cer turnover cost sale gross profit sell general administration research development royalty income operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p perform operating profit cost sale adjust operating profit million high adjust cost sale percentage turnover aer flat cer turnover increase cer percentage point high aer percentage point adjust operate margin percentage high cer proforma basis adjust cost sale point low aer percentage point low percentage turnover percentage point cer basis proforma basis adjust high cer primarily reflect continue adverse operating profit low cer turnover increase pricing pressure pharmaceutical partly offset cer adjust proforma operating margin favourable product mix vaccine largely growth percentage point low cer basis shingrix reduction proforma adjust operating profit primarily reflect continue price pressure investment rd sell general administration promotional product support partly offset benefit adjust sga cost percentage turnover sale growth particularly vaccine favourable mix percentage point high aer percentage point vaccine consumer healthcare continue benefit high cer basis proforma basis adjust sga restructuring cost percentage turnover percentage point high cer compare primarily tax reflect increase investment result acquisition tax adjust profit amount million tesaro promotional product support particularly represent effective adjust tax rate new launch vaccine respiratory hiv partly offset reflect impact settlement continue benefit restructuring pharmaceutical number open issue tax authority tight control ongoing cost noncontrolle interest research development allocation adjust earning noncontrolle interest adjust rd expenditure million amount million million increase turnover high aer high cer primarily reflect increase allocation consumer proforma basis adjust rd expenditure grow healthcare profit reflect significant increase study clinical trial earning share material investment oncology increase spending adjust eps p compare p progression key nononcology asset partly offset aer cer adjust operating profit flat saving early phase portfolio reprioritisation cer improvement primarily result reduce late effective tax rate increase share aftertax profit associate partly offset increase net finance cost high noncontrolle interest allocation consumer healthcare profit gsk annual report strategic report governance remuneration financial statement investor information longterm prioritie longterm priority design create last value patient consumer shareholder important year execution good progress deliver objective innovation performance trust invest scientific deliver growth invest responsible company technical excellence develop effectively business commit use science launch pipeline new develop people technology address health product meet need execute competitively need product patient payer consumer affordable available modern employer objective objective objective deliver continue strong sale trelegy continue drive sale growth focus supply service level execute ellipta nucala hiv twodrug regimen operational performance portfolio network simplification shingrix successful integration tesaro deliver progress trust commitment continue strengthen pipeline deliver restructure benefit progress global health research tb execution new rd approach develop plan integration pfizer hiv accelerate priority asset optimise consumer healthcare business deliver modern employer programme recent strategic business development accelerate capability building priority empower employee transaction area include digital datum analytic feel good grow gsk progress progress progress deliver strong sale key launch group sale billion aer file fda eu regulatory submission notably shingrix sale billion cer proforma paediatric dolutegravir strengthen pipeline filing free cash flow billion release positive final phase ii result positive pivotal trial result total earning share p candidate tb vaccine build priority asset accelerate phase iiiii aer cer adjust earning collaboration bill melinda gate accelerate oncology pipeline share p aer cer medical research institute regulatory submission zejula firstline successful integration tesaro build continue development asset maintenance ovarian cancer belantamab capability priority area notably specialty develop country finalise mafodotin relapsedrefractory multiple therapy include oncology announce january myeloma dostarlimab endometrial continue delivery restructuring benefit continue embed modern employer cancer support investment innovation new programme progress engagement develop advanced technology capability launch diversity inclusion employee health significant hire partnership complete consumer healthcare jv wellbee development worldleading scientist pfizer track deliver synergy rank dow jones sustainability index pharmaceutical industry invest new talent build capability priority objective priority objective priority objective deliver innovation sale excellent prioritise spending deliver growth continue deliver ontime infull supply commercial rd supply chain return investment product execution successful consumer healthcare jv build reputation focus innovation accelerate strengthen pipeline integration include drive growth deliver progress trust commitment potential approval expect deliver synergy deliver capability building specialty pharmaceutical deliver twoyear programme prepare gsk separation new company culture commit develop right culture drive maximise performance empower enable gsk live value expectation change way work accelerate delivery longterm prioritie principal risk principal risk patient safety product quality financial control report antibribery corruption commercial practice privacy research practice party oversight environment health safety sustainability information security supply continuity risk management framework design support longterm priority page gsk annual report culture building performancefocuse culture align value expectation help achieve purpose power longterm priority gsk wellestablishe purpose help people enable culture change feel well live long strong culture change longterm commitment require value patient focus respect transparency integrity focus level company extremely proud purpose value lead companywide change incentive company operate environment scheme governance way work include change rapidly stakeholder increase implement key performance indicator standardise expectation performance review recognise culture great focus continue strengthen value expectation performance growth remain firmly purposele embed recruitment process leadership valuesbase necessary shift culture key development employee training performance evaluation delivering goal world company broad theme innovative good performing trust healthcare company focus clear accountability well expectation courage accountability development decisionmake drive pace performance teamwork sit alongside value help develop open honest straighttalke culture people behaviour need desire culture trust leader feel confident share view courage high ambition set accelerated pace business set clear objective drive smart risk take appropriate making right decision culture shift need area assertively difficult speak leader manager role model opportunity improve concern desire culture start right people significant change leader accountability take ownership single point new appointment internal movement external accountability decision making prioritise work hire year invest significantly support strategy deliver promise build high perform team hpt include development prioritise people development corporate executive team take ongoing hpt encouraging ask open honest development programme feedback continually grow individual team track progress organisation track cultural change range indicator teamwork ensure people work well board receive regular update addition specific lead align objective understand contribute indicator business area measure employee feedback longterm priority encourage diversity think company global employee survey inspire hold account focus progress embed culture prioritise innovation b discipline competitive edge speed agility deliver growth orientate performance c employee trust include pride purpose progress modern employer priority value expectation embed way work measure progress key driver culture strength talent succession plan key role effectiveness global people manager population global survey use employee engagement score additional indicator progress embed culture employee inspire purpose work good way meet longterm priority bring competitive return shareholder help patient consumer gsk annual report strategic report governance remuneration financial statement investor information key performance indicator track progress longterm priority operate key performance indicator measure performance group level business operate key performance indicator kpi review track operating kpi internally regularly corporate executive team board provide performance datum report externally employee update progress commercial sensitivity publish datum quarter performance system align employee bonus operating kpis indicate nr use number adjust relevant subset indicator remuneration noninternational financial reporting standard ifrs policy reward performance executive measure report business performance describe include measure link kpi page page include adjust result free cash flow cer growth rate nonifrs measure consider addition substitute superior information present line ifrs innovation innovation sale r pharmaceutical vaccine sale product launch year bn bna bna consumer healthcare sale product new market year total sale pipeline value progress value product pipeline rd milestone achieve nr nr nr performance group turnover r aer cer bn bn bn profit r total operating profit aer cer bn bn bn adjusted operating profit aer flat cer bn bn bn total operate margin adjust operate margin free cash flow r bn bn bnb market share market share relation competitor nr nr nr talent succession plan key role talented employee key role succession plan place nr nr nr trust employee feedback employee engagement score global employee survey supply service level percentage order deliver ontime infull nr nr nr corporate reputation reputation index stakeholder inform public measure globally market nr nr nr r link executive lti awards bonus page comparative information reflect sale product meet definition b revise include proceed sale intangible asset nr report externally gsk annual report industry trend healthcare industry operate rapidly change environment strong growth potential strategy design respond context maximise opportunity mitigate risk operate dynamic environment shape fast intellectual property ip protection important continue change interdependent global trend continue incentivise innovation helps researchbase healthcare responsive change environment monitor company ensure reasonable return investment industry trend engage key stakeholder group allow continue conduct research develop page new innovative medicine ip protection expire challenge patent upheld generic competitor global healthcare industry rapidly capture large share market vaccine biologic face exposure generic global growth project rise estimate competition patent cliff require high downward revision capital investment highly technical manufacturing previous world economic outlook rise geopolitical tension process complex regulatory quality requirement increase uncertainty future global trading system international cooperation take toll business global trend opportunity challenge confidence investment decision change demographic global healthcare market continue grow demographic change increase demand preventive worldwide pharmaceutical sale total billion therapeutic healthcare product september north america remain large pharmaceutical market share global world population continue grow estimate sale europe represent china second billion people worldwide global population large individual country pharmaceutical sale represent predict grow billion virtually country global sale global vaccine sale rise experience population ageing proportion approximately billion world population project nearly double global consumer healthcare market estimate people live city affluence approximately billion grow size global middle class project approximately billion people billion healthcare sector remain intensely competitive company increasingly pursue merger acquisition partnership strengthen pipeline portfolio response see significant activity oncology speciality care factor contribute rise demand healthcare company merger notably include area focus oncology bristolmyer squibb acquire celgene abbvie respiratory pressure healthcare system acquire allergan restrain spending growth innovation priority invest develop launch pipeline new product meet change need patient payer consumer page ensure product serve broad demographic global health pricing strategy page imf world economic outlook update iqvia data internal datum httpspopulationunorgwpppublicationsfileswpp highlightspdf httpswwwwhointnewsroomfactsheetsdetailageingandhealth httpoecdobserverorgnewsfullstoryphpaidanemerging middleclasshtml gsk annual report strategic report governance remuneration financial statement investor information industry trend continue advance science technology europe majority market establish price rapid advance innovative science technology control process place national healthcare authority transform sector cell therapy technology continually look sharpen tool response cell live medicine change definition change market dynamic disparity access supply profile medicine new advance functional genomic availability eu market topic recurrent crispr change possible drug debate recent year member state repeatedly raise discovery enable researcher pinpoint novel target concern problem medicine shortage high probability success scale datum transparency price rd cost public genetic library genomic require artificial intelligence ai subsidy push roll exist flexibility eu interpret machine learning helps predict possible new legislation andor create additional hurdle market access pathway medicine growth datum improve europe emerge market international reference healthcare ecosystem helping build virtuous pricing irp continue gain traction market cycle datum technology rd regulator purchaser primary lever pricing control use technology track product effectiveness increasingly country cooperate health consumer rely digital tool manage technology assessment hta new eu hta regulation health understand genetic profile help proposal centralise clinical assessment new research effort build well understand medicine medical device genetic disease europe country implement response form hta china policy propose application advanced technology central rd boost quality efficiency value healthcare delivery approach innovation priority develop hta implementation key initiative propose core capability ai machine learn functional genomics product high clinical value particularly seek cell therapy accelerate pace identify premium price likely prioritise hta review develop novel target medicine include create especially oncology critical disease area laboratory genomics research stateoftheart lab accelerate access innovation china apply crispr gene editing technology drug discovery implement cost containment measure balance significant investment help realise healthcare budget saudi arabia establish new potential cuttingedge technology ultimately independent evidencebase hta entity help strengthen pipeline attract good maximise health gain efficient use resource scientific mind work enter finally japan pharmaceutical industry remain ambitious creative collaboration partnership concern propose use hta pricing lyell immunopharma enhance cell gene therapy control value assessment programme andme ongoing joint programme response aim improve health million people year pricing access make product available responsible price price healthcare product increase pressure sustainable business get right fundamental fund highcost innovative therapy continue attract performance trust priority set significant attention government public price medicine develop market apply call well transparency price set valuebase approach balance reward innovation great emphasis value health outcomebase pricing access affordability aim bring truly government payer budget remain subject increase differentiate innovative product bring highly effective review demand healthcare grow healthcare health outcome patient payer policy environment remain fluid payer introduce product high cost bring value patient increasingly restrictive costcontrol mechanism healthcare system invest genetic genomic government propose drug pricing big datum ai accelerate pace initiative include new international pricing index order develop transformational medicine prioritise molecule reduce healthcare cost patient government high probability success know genetically significant potential obstacle validate drug candidate twice likely implementation national drug pricing proposal multiple register medicine improve productivity state pass legislation regulation increase rd investment oversight transparency andor control pharmaceutical price organisation assess value pharmaceutical product relative price health outcomes institute clinical economic review rise prominence gsk annual report industry trend continue regulatory environment societal expectation healthcare highly regulated industry reflect public expectation business change deliver expectation product comply stringent level quality financial return company expect create value safety efficacy range stakeholder take action social environmental issue call purpose government continue introduce develop regulatory business redefine group like business approach support accelerate development roundtable lead business group say introduction new medicine encourage pharmaceutical corporation exist benefit stakeholder move away innovation regulatory authority explore progress longstanding endorsement shareholder primacy adapt regulatory science address new potentially disruptive technology digital healthcare cell order attract retain good talent company need gene therapy big datum realworld evidence work rise expectation workforce motivated crossborder harmonisation pharmaceutical regulation deliver great purpose employee work increase supranational body company strong sense purpose feel international council harmonisation geographic scope connect time likely thrive continue expand include emerge market work support introduction development time investor increasingly ask company initiative regulator different jurisdiction share articulate manage range environmental cooperate assessment regulatory submission social governance esg risk opportunity major example food drug administration fda institutional investor publicly state believe provide framework concurrent submission review esg factor impact company longterm success oncology product international partner important investment decision response company expect contribute un sustainable gsk closely monitor relevant appropriate development goal sdgs especially engage improve regulation particularly final decade delivery grow public uk europe example scientific innovation demand company play role manage climate move scope current regulation standard change mitigate climate risk address work sector engage government environmental issue plastic air pollution water explore new policy process incentive management company increase pressure support discovery delivery medicine develop address social issue human right inclusion emerge technology technique diversity fair pay direct operation supply chain pharmaceutical sector particular trust deficit remain sustained scrutiny sale marketing practice ethic compliance face additional reputational challenge relate issue like opioid crisis grow momentum antivaccine movement region response trust priority design respond multistakeholder expectation prioritise area position significant sustainable impact set public commitment support trust priority make good progress page recognise expectation move quickly need respond accordingly page mercer global talent trend study input executive hr leader employee industry country gsk annual report strategic report governance remuneration financial statement investor information stakeholder engagement engage building trust broad range stakeholder interact impact business key delivering strategy ensure success long term section statement mechanism enable management board understand consider stakeholder view oversight decision making explain section statement set incorporate reference strategic report summarise key stakeholder group engage issue matter response patient insight patient consumer enable matter consumer develop product well meet need pricing healthcare product particularly outofpocket engage expense advisory board diseasespecific patient panel differentiate product innovation base patient patient advocacy leader summit provide consumer need patient insight access reliable supply highquality safe product engagement support patient group disclose gskcom initiative empower patient valuesbased approach pricing balance involve medicine development reward innovation access affordability market research consumer sensory lab help strengthen pipeline bring innovative product uncover consumer insight patient ensure maintain high standard product quality safety investor maintain regular constructive dialogue matter investor communicate strategy performance financial performance commercial success order promote investor confidence ensure understand rd strategy successfully continue access capital develop pipeline engage management key environment social governance ongoing communication include agm quarterly esg issue mitigate risk create opportunity result call detailed company information online onetoone meeting board member senior continue report line good practice disclosure executive institutional investor include introduction progress financial target strategic goal roadshow new chairman cfo specific business rd update event eg viiv meet biannual investor analyst perception study management vaccine investor day oncology roundtable time conduct specific esg study increase engagement esg matter healthcare work healthcare professional hcp matter professional medical expert understand patient need access product scientific information ensure product administer medical responsible sale marketing practice right way expert safety efficacy differentiate innovation engage scientific dialogue increase understand increase use digital channel deliver disease management patient experience personalise effective sharing information hcp provide highquality balanced information update salesforce incentive policy attract medicine vaccine retain good talent uphold ethical standard collaboration clinical trial research hcp insight disease management patient experience inform development medicine rd partner partner scientific institution national health matter academia system business partner academia help find right partner accelerate potential medicine ensure develop differentiate healthcare product vaccine approval reach patient engage push science far advance human collaboration outstanding scientist organisation health globe dissemination advancement scientific knowledge establish joint venture strengthen innovation efficiency work world lead expert biotechs university work academic institution accelerate scientific institution improve drug discovery discovery development new medicine increase productivity rd pipeline collaborate partner open target finngen uk biobank focus identify diseaserelevant gene validate highpotential target gsk annual report stakeholder engagement continue government work government regulator advocate matter regulator policy encourage innovation promote environment value innovation drive investment efficient management healthcare spend life science patient support need scientific funding collaboration engage medicine pricing reimbursement meeting regulatory body public health threat development process ensure high quality safe new product work policymaker support operating environment engage government health agency remain competitive rd investment enable mobility demonstrate value product scientific talent accelerate uptake innovative working government build strong medicine include uk life sciences industrial strategy operating environment life science actively engage government proposal healthcare reform include successfully ensure patient access treatment regime hiv cancer maintain partner authority china ensure support global innovation include swift regulatory approval shingrix benlysta ngo work partner improve access healthcare matter multilateral service product advocate access medicine vaccine policy environment successful organisation achieve un sdgs target specific engage disease area work nongovernmental organisation ngo universal health coverage uhc future partner research develop product health system address global health challenge sustainable finance global health collaborating ngo generic manufacturer sustainably supply product develop country focus unique valueadd global health partner partnership strengthen health system develop develop product scientific expertise country drive progress global health priority partner organisation complementary capability reach create sustainable model share risk include work partner pilot implementation malaria vaccine leverage community investment programme support scientific expertise deliver impact patient supplier work thousand supplier large matter small provide good service support prompt payment small supplier deliver reliable supply highquality understanding gsk standard policy ensure safe product patient consumer compliance engage opportunity innovate grow relationship regular direct engagement business owner supplier ensure support gsk strategy update payment practice ensure small target uk supplier benefit preferential payment term engage supplier party oversight conduct business supplier share value programme conduct indepth audits high quality ethical standard ensure security supply participate crossindustry forum engage supplier develop improvement plan pharmaceutical supply chain initiative track progress identify area improvement consumer good forum improve supply expand thirdparty environment health safety chain sustainability team country priority supplier locate provide proactive support employee involve listen employee help maintain matter strong employee engagement retain talented opportunity career personal development people flexible working support balance wide responsibility engage work inclusive diverse environment regular interactive let talk event work purposeful company great line manager corporate executive team senior leader facilitate dialogue collaboration provide employee access new development internal communication platform portal resource relevant role global diversity council employee resource development need interest group cover different strand diversity large market formal flexible working carer global allemployee survey survey policy market review competitiveness employee provide feedback line manager monitor employee engagement employee survey act feedback improve engagement gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical pharmaceutical business broad portfolio innovative establish medicine respiratory hiv immunoinflammation oncology strengthen rd pipeline focus immunology human genetic advanced technology help deliver transformational medicine patient progress longterm priority innovation performance trust strengthen rd pipeline total turnover billion file eu regulatory filing asset aer flat cer submission simplify optimise advance pivotal phase iiiii strengthen capability extend use dolutegravir study specialty care medicine child live hiv accelerate oncology portfolio change sale incentive progress gepotidacin positive pivotal datum readout programme recruit retain new chemical class regulatory submission representative good antibiotic treat drug resistant zejula firstline maintenance expertise experience bacteria phase iii clinical ovarian cancer belantamab research supply chain productivity mafodotin relapsedrefractory donate million albendazole multiple myeloma dostarlimab tablet support effort end endometrial cancer lymphatic filariasis control receive approval expand intestinal worm schoolage indication key medicine child portfolio pharmaceutical regulatory invest significantly advanced inspection satisfactory technology include establish result laboratory genomics research collaborate lyell immunopharma read read read page innovation new rd approach focus science relate rd pipeline contain potential new medicine immune system use human genetic application include clinical oncology asset double advanced technology functional genomic number asset clinical oncology portfolio machine learn artificial intelligence cell therapy early approach power multipli effect science x advance asset pivotal phase iiiii technology x culture help strengthen pipeline study achieve positive regulatory decision datum accelerate pace discover develop deliver readout portfolio medicine improve patient life receive approval medicine dovato hiv prepare create new gsk drive common treatment dectova treatment influenza b new approach rd pharmaceutical vaccine selfadministration option respiratory biologic nucala enable effectively allocate capital receive expand indication medicine include share technical scientific expertise deliver pipeline zejula oral poly adpribose polymerase parp inhibitor regardless modality new biopharma company ovarian cancer benlysta world biologic evolve rd culture embrace singlepoint treatment systemic lupus erythematosus sle lupus accountable decision make smart risk taking submit filing regulatory approval reward good decision outcome expect help deliver scientific technological excellence gsk annual report pharmaceutical continue hiv oncology million people live hiv worldwide cancer remain major global cause death work longstanding commitment combat oncology aspire maximise patient survival prevent ultimately cure hiv helping transformational medicine increasingly large small people live broad portfolio asset development novel combination study pipeline focus hiv business manage viiv healthcare area immunooncology use human majority own gsk pfizer shionogi immune system treat cancer cell therapy human shareholder viiv healthcare sole global specialist tcell engineer target disease cancer epigenetic hiv pharmaceutical company forefront generegulatory system epigenome modulate innovation world hivdedicate discovery curb cancer synthetic lethality mechanism early development facility portfolio approve work synergistically destroy cancerous cell antiretroviral medicine offer range therapeutic option people live hiv include establish make good progress early therapy tivicay triumeq contain dolutegravir double number asset clinical oncology pipeline consider potent available antiretroviral achieve positive pivotal datum readout track oncology launch pivotal year viiv healthcare growing achieve accelerate clinical momentum portfolio twodrug regimen dr programme fasttracke asset acquire therapy power dolutegravir launch oncologyfocused biopharmaceutical company tesaro dovato new oncedaily singlepill dr approve successful business development collaboration treatmentnave patient eu follow include strategic alliance merck kgaa positive results gemini tango study show dovato effective dolutegravirbased strengthen oncology pipeline enhance threedrug regimen contain few antiretroviral cell gene therapy programme announce fiveyear traditional hiv treatment dovato dr juluca collaboration lyell immunopharma lyell explore way aim reduce number hiv drug people live improve function fitness tcell enhance virus lifetime follow launch response rate solid tumour cancer prevent relapse japan european market juluca achieve tcell exhaustion combine cell gene therapy reimbursement additional market programme lyell technology potential year sword study demonstrate juluca enhance activity specificity cell therapie solid longterm safety efficacy tolerability tumour cancer submit cabotegravir rilpivirine oncemonthly current oncology asset complete longacte hiv regiman regulatory review zejula oral parp inhibitor approve eu follow global atlas flair pivotal europe woman recurrent ovarian cancer phase iii study demonstrate therapy believe zejula transform treatment option effective daily oral threedrug regimen maintain patient additional ovarian cancer stage viral suppression december receive complete man woman cancer response letter fda submission follow priority review october fda work closely regulatory authority determine approve expand indication zejula lateline appropriate step regulatory review eu ongoing treatment woman advanced ovarian cancer july launch yearlong customize study associate homologous recombination deficiency identify evaluate way implement oncemonthly approval support positive result hiv regimen clinical practice programme involve phase ii quadra study approval allow address viiv healthcare employee work clinical staff healthcare unmet clinical need demonstrate zejula active provider people live hiv late line therapy woman brca mutation december file approval december file regulatory approval zejula firstline maintenance therapy woman fostemsavir firstinclass attachment inhibitor heavily platinum responsive ovarian cancer submission treatmentexperience adult hiv infection include accept fda base positive result fail current antiretroviral regimen phase iii prima study show significant exhausted treatment option submission follow reduction disease progression woman irrespective positive result week phase iii brighte study biomarker status line commitment deliver optimal hiv treatment reflect broad development plan number formulation child regulatory submission clinical study zejula combination december aim simplify optimise extend therapy progress additional ovarian cancer stage use dolutegravir paediatric hiv patient nonsmall cell lung cancer breast cancer information gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical continue belantamab mafodotin firstinclass humanise respiratory immunoconjugate bcell maturation antigen gsk world leader respiratory decade antibcma study treatment multiple pioneer development modern innovative medicine myeloma second common blood cancer asthma chronic obstructive pulmonary disease copd currently cure extensive development launch new treatment establish programme asset enable quickly broad portfolio oncedaily inhale respiratory early line treatment december file medicine industry regulatory approval follow positive result pivotal continue successful roll trelegy ellipta dreamm study explore belantamab mafodotin single inhal triple therapy copd available patient relapsedrefractory multiple myeloma market key launch include subsequently grant priority review fda japan china follow positive result phase iii secondline setting phase iii dreamm study captain study show effect trelegy treat assess belantamab mafodotin combination patient asthma file new indication standard care result inform pivotal secondline japan study start second half nucala firstinclass biologic patient severe start study dreamm fourthline eosinophilic asthma sea continue strengthen phase iii study explore use combination novel agent clinical profile approval eu new dreamm phase iii firstline study combination selfadministration option early datum realitia standard care study show nucala significantly reduce exacerbation dostarlimab pd inhibitor target endometrial cancer realworld set approval use child sixth common cancer woman evaluate sea aged provide new option difficult use monotherapy combination treat patient population immunooncology agent file regulatory approval despite advance respiratory medicine secondline endometrial cancer set late area significant unmet need continue innovate follow positive result garnet study explore nucalas potential spectrum large trial antipd monotherapy patient eosinophildriven disease report positive result advance recurrent endometrial cancer september hypereosinophilic syndrome programme enrol patient ruby firstline study support regulatory submission initiate new dostarlimab combination chemotherapy phase iii study copd data nasal polyps february announce global alliance merck programme anticipate achieve proof kgaa jointly develop bintrafusp alfa investigational concept investigational medicine bifunctional fusion protein immunotherapy currently biologic pipeline longacte antiinterleukin il development multiple difficulttotreat cancer antagonist sea antiil receptor severe asthma advanced potential registration study secondline biliary hope provide new option patient extend tract cancer group rare aggressive gastrointestinal cancer respiratory leadership future associate limited treatment option poor outcome immunoinflammation antiicos agonist antibody gsk design commit research development selectively enhance function tcell study medicine immunemediate disease lupus antibody combination therapy rheumatoid arthritis ra significant health burden considerable potential range tumour patient society research focus biology type follow positive result induce study immune system reflect aim develop immunological initiate phase iiiii study registration potential base medicine alter course inflammatory disease combination pembrolizumab firstline recurrent company biologic treatment benlysta metastatic head neck squamous cell carcinoma specifically develop approve adult paediatric lead tcell immunotherapy gsk target lupus medicine approve adult china nyeso antigen express multiple million people lupus cancer type therapy accelerate development year intravenous benlysta biologic treatment path receive european prime fda approve eu japan children breakthrough status ongoing phase ii studies synovial limited treatment option challenge disease sarcoma lung cancer multiple myeloma asset announce positive result pivotal blissln study cell therapy enhance leverage show effect benlysta active lupus nephritis technology available new collaboration inflammation kidney cause sle lyell immunopharma announce start phase iii study otilimab anti gmcsf antibody patient ra follow result phase ii baroque study million people globally affect ra chronic systemic inflammatory condition gsk annual report pharmaceutical continue pharmaceutical pipeline overview asset development focus oncology expect number pivotal readout phase compound indication pivotalregistration benlysta rituxan systemic lupus erythematosus cabotegravir la rilpivirine longacte hiv dovato hiv daprodustat hifphi anaemia fostemsavir attachment inhibitor hiv nucala copdhypereosinophilic syndromenasal polyp trelegy asthma dectova iv iv influenza nucala prefille syringe severe asthma belantamab mafodotin bcma adc multiple myeloma zejula parp inhibitor firstline maintenance ovarian cancer dostarlimab pd antagonist endometrial cancer bintrafusp alfa tgf trapantipdl biliary tract cancer otilimab rheumatoid arthritis gepotidacin uncomplicated urinary tract infection gonorrhoea icos receptor agonist head neck squamous cell carcinoma phase expansionphase ii maturation inhibitor hiv hbv aso hepatitis b ilr antagonist severe asthma nyeso tcr cancer osm antagonist systemic sclerosis sarm copd muscle weakness molibresib bet inhibitor cancer linerixibat ibat inhibitor cholestatic pruritus primary biliary cholangitis prmt inhibitor cancer gr oxytocin postpartum haemorrhage tsr tim antagonist cancer leucyl trna inhibitor tuberculosis lag ulcerative colitis tsr lag antagonist cancer phase ccl antagonist osteoarthritis pain il la antagonist asthma tlr agonist cancer broadly neutralise antibody hiv nyeso immtac cancer hpgds inhibitor duchenne muscular dystrophy prmt inhibitor cancer nemiralisib pikd inhibitor activate phosphoinositide kinase delta syndrome sting agonist cancer ox agonist cancer crk inhibitor visceral leishmaniasis combinectin entry inhibitor hiv approve progressednew inlicence alliance relationship note oncology phase study party conduct patient progression include programme pivotal phase development pivotal datum additional indication investigation phase phase ii define expansion report regulatory submission icos hnscc phase iiiii study cohort start consideration review registrational potential gsk annual report strategic report governance remuneration financial statement investor information pharmaceutical continue infectious disease fiveyear collaboration university california start phase iii study gepotidacin establish laboratory genomics research lgr new chemical class antibiotic treat drug resistant design create stateoftheart lab apply crispr bacteria urogenital gonorrhoea uncomplicate urinary gene editing technology drug discovery new laboratory tract infection mark time infection explore gene mutation cause disease aim address new oral antibiotic year develop new crisprbase technology understand result expect end gene function geneticallyvalidate target twice likely successful medicine application crispr brazil malariaendemic country drug discovery important approach improve approve kozenis radical cure p vivax malaria rd productivity singledose kozeni know krintafel new treatment p vivax malaria year lgr programme build collaboration milestone follow publication positive result andme world lead consumer research genetic detective gather phase iii study company enhance ability identify function diseaserelevant gene validate highpotential disease new technology develop novel medicine target aim begin clinical programme hepatitis b viral infection liver lead andme ongoing joint programme significant health condition include cirrhosis liver failure oncology immunology neurology cardiovascular liver cancer exercise option license ionis lgr extend relevance genetics genomic pharmaceutical antisense medicine people collaboration open target collaboration chronic hepatitis b follow positive phase ii result lead discovery new synthetic lethal target receive eu approval dectova intravenous treat cancer genomic instability wrn reqq helicase treatment influenza b cause epidemic gsk scientist collaboration sanger institute seasonal infection innovation intend hospitalise uk additional important collaboration include finngen patient complement oral version neuraminidase uk biobank dutch human functional genomics inhibitor market relenza project viiv healthcare announce fiveyear additional programme collaboration japan file regulatory approval daprodustat deliver generation medicine oral hypoxiainducible factor prolyl hydroxylase inhibitor evolving culture rd well patient anaemia associate chronic kidney equip discover deliver generation disease approve daprodustat provide new transformational medicine incentivise scientist convenient oral treatment option patient mindset singlepoint accountability smart risk leverage advanced technology take courageous decision own advanced technology central rd approach individual consensusdriven significant investment artificial intelligence significant step take rd ensure machine learn functional genomic cell therapy prioritise good asset end exit accelerate identification novel target medicine underperform programme move away therapy realise potential cuttingedge technology area base approach research help team numerous internal appointment lead focus molecule likely medicine build inhouse capability announce embrace fresh thinking new talent external partnership ambitious goal key rd role half join outside company move integrate governance model involve scientific peer review commercial input datum drive decision gsk annual report pharmaceutical continue performance pharmaceutical turnover million create specialtyready competitive supply chain aer flat cer hiv sales aer cer reliable supply core growth key therapy area million respiratory sale aer create modern agile supply chain underpin cer million sale establish pharmaceutical new technology launch specialty medicine speed million aer cer group accelerate delivery portfolio financial review detail open nextgeneration biopharmaceutical accelerate growth transition manufacture facility upper merion pennsylvania site specialty care technologicallyadvance million manufacturing hub continue align resource flexibility speed necessary make complex market therapy area brand great specialty medicine new analytical lab opportunity growth improve performance facility bring rd manufacturing team excellent execution launch hiv respiratory upper merion help develop highlyskilled major focus concentrate key market asset workforce improve technological scientific capability ongoing investment clinical evidence deliver right infrastructure research potential new genetic target compelling competitive medicine profile achieve manufacture new medicine complete strong performance new recent launch million expansion rockville maryland site include trelegy ellipta nucala juluca dovato increase manufacturing capacity benlysta line grow shift portfolio innovative singapore open new stateoftheart pharmaceutical specialty care product include oncology reinforce manufacturing facility jurong site million capability area anticipation oncology development include creation continuous launch leverage acquisition tesaro manufacture facility expansion modernisation rapid material progress develop oncology exist production unit transformation expect commercial expertise recruit outstanding people significantly improve efficiency expand capacity track record success oncology key market include manufacture asset include daprodustat rebalancing salesforce increase broad dolutegravir reduce medicine production time investment specialty care example benlysta complete exit guarulhos brazil cork additional resource new team drive strong performance ireland suzhou china site network initiate twoyear programme prepare separation exit verona italy site expect complete support longterm priority rationalise portfolio divestment plan review improve supply performance asset include prescription dermatology business ontime infull supply performance level customer engage healthcare professional improve put gsk quartile support transition specialty care benchmarke peer measure productivity focus portfolio revise incentive programme sale level rise past representative certain country allow attract year new product introduce time include retain good salesperson enhance quality successful delivery firstmarket launch dovato dialogue healthcare professional hcp help new nucala selfadministration option well serve patient change uphold ethical continue perform safety quality valuesle approach hcp engagement compliance compliance measure pharmaceutical law policy support delivery strong regulatory inspection satisfactory performance apply initially uk canada comprehensive training control monitor digital transformation ensure appropriate implementation progressing goal digital datadriven organisation continue evolve way engage hcp certain improve way harness technology develop new country improve understand new datum clinical way work drive performance increase ability experience innovative product deliver well deliver medicine patient leverage datum outcome patient include introduction unlock smarter fast interaction customer scientific workshop enable interactive debate understand impact commercial activity hcp increase use digital channel prescribing include pilot artificial intelligencedriven support scientific engagement virtual advisory board recommendation help optimise hcp engagement educational activity webinar initiative apply advanced analytic drive efficiency wellreceive positive feedback hcp business supply chain management early indication suggest change enhance manufacture commercial operation identify understand science key medicine opportunitie free resource include nucala dr hiv treatment gsk annual report strategic report governance remuneration financial statement investor information vaccine world large vaccine company revenue deliver vaccine protect people stage life rd focus develop vaccine infectious disease combine high medical need strong market potential innovation performance trust progress new candidate total turnover billion release positive final phase ii vaccine human trial aer cer result tb candidate vaccine include novel primarily drive growth announce licensing vaccine technology sam shingrix gates mri continue receive fda fast track optimise supply chain development low income designation increase shingrix production country high tb burden rsv candidate vaccine capability january increase pipeline focus receive authorisation shingrix launch rtss malaria therapeutic antimicrobial china prevention vaccine select region resistance vaccine shingle adult age malawi ghana kenya agree partnership whocoordinate pilot programme accelerate development new asset technology adjuvant technology available partner include cepi early support rapid development candidate vaccine coronavirus sarscov read read read page innovation rd approach power multipli effect category lifecycle management focus science x technology x culture focus expect development new presentation indication enable develop deliver groundbreake vaccine geographic expansion market vaccine remain forefront vaccine science leverage new classify new commercial asset vaccine disruptive technology rd culture build smart candidate potential great contribution risk take attract develop retain good commercial success future new global health people partner lead expert asset vaccine candidate high potential impact global health threat development innovative asset clinical development global health asset science include key datum readout candidate vaccine expect proprietary technology platform focus investment classify vaccine pipeline category maximum impact ensure development lifecycle management new commercial asset global sustainable back strong partnership trust health asset ensure allocate appropriate resource priority vaccine development programme deliver good value society support group strategy gsk annual report vaccine continue accelerate development candidate rsv candidate vaccine tailor meet vaccine respiratory syncytial virus rsv specific need target group maternal paediatric advanced therapeutic candidate vaccine chronic old adult give promise early result obstructive pulmonary disease copd progress strong medical need rsv candidate vaccine new strategic candidate vaccine human trial fda fast track phase iii trial rsv old adult second clostridium difficile key datum readout expect help address antimicrobial resistance maternal rsv candidate base recombinant testing sam technology rabie model fourth prefusion antigen paediatric rsv candidate harness therapeutic candidate vaccine chronic hepatitis b adenovirus vector technology old adult rsv focus work terminate hepatitis c candidate people leverage recombinant virus universal flu programme meet prefusion antigen combine adjuvant system expectation work hiv candidate vaccine key ingredient shingrix enable efficacy develop country discontinue clinical result success market show lack efficacy transfer candidate vaccine ebola marburg viruse sabin copd vaccine institute death globally cause copd vaccine currently exist prevent disease copd expertise vaccine advanced technology candidate therapeutic vaccine aim reduce allow focus technology therapeutic frequency acute exacerbation slow disease antimicrobial resistance candidate vaccine put progression copd sufferer contain bacterial strong competitive position new era therapeutic antigen adjuvant system programme vaccine pipeline increasingly expand prophylactic complement leadership medicine respiratory asset include therapeutic asset provide benefit disease date demonstrate adjuvante course life invest copd vaccine candidate safe highly immunogenic therapeutic asset include move candidate vaccine enrolment phase iib study adult chronic hepatitis b phase iii clinical development complete ahead plan study result additional benefit accelerate delivery typically involve short regulatory lead time allow accelerated clinical testing lifecycle management shingle meningitis balance focus strong pipeline active vaccine scientist foundation innovation lifecycle management market vaccine enable success continue evolve culture focus deliver new presentation reach population create environment people accountability geography establish vaccine ensure smart risk focus accelerate development timeline continue play strong role business performance simplify governance process pipeline programme evolution exist implement single point decision make early product franchise announce proposal create development organisation gsk rd twoyear shingle programme create new gsk common rd shingrix mark step change prevention shingle approach progress accelerate priority painful potentially illness vaccine address pipeline asset include accelerate delivery agerelate decline immunity achieve rsv portfolio achieve challenging efficacy age group nonlive shingle approach regulatory engagement technique vaccine combine specific antigen adjuvant adaptive clinical trial design quality design sustain immune response publish new reduce manufacture scaleup time clinical datum support use shingrix adult great risk shingle condition cancer organ develop deliver groundbreake vaccine transplant currently explore possibility rsv copd extend vaccine indication base result important factor determine development vaccine candidate pipeline burden disease shingrix receive prestigious prix galien award copd infection rsv high prevalence country available good pharmaceutical medical need key asset pipeline product germany good primary care product canada good innovative product prix galien consider rsv worlds leading award innovation excellence medical portfolio different candidate vaccine product device rsv common cause low respiratory tract infection currently vaccine protect virus lead hospitalisation adult death year gsk annual report strategic report governance remuneration financial statement investor information vaccine continue meningitis partnership market leader vaccine meningococcal partnership central innovation strategy meningitis base revenue complementary effort accelerate vaccine development collaborate portfolio bexsero target serogroup b menveo lead expert institution company access serogroups c w launch external cuttingedge technology expertise aim bexsero industryleade meningitis b vaccine scientific partner choice currently license year old phase iii external collaboration multiple field trial currently evaluate lower age indication continue build valuable partnership include month simultaneously alternative liquid presentation develop new vaccine prevent cervical cancer menveo progress phase ii trial simplify vaccine innovax xiamen university china establish preparation step healthcare provider january collaboration vbi biotech company facilitate new england journal medicine publish independent development specialise therapeutic vaccine candidate meningitis b study demonstrate real world impact patient recurrent glioblastoma establish bexsero reduce disease infant show drop partnership viome company deep expertise case uk year need direct understanding gut microflora role chronic individual protection adolescent fda disease facilitate vaccine development prevent approve indication single booster dose administration treat condition menveo individual aged year continue risk meningococcal disease year vaccine pipeline elapse previous dose remain committed develop pentavalent phase indicationvaccine meningitis abcwy vaccine target common registration shingrix immunocompromise meningococcal serogroup research effort build rotarix liquid pcv free successful vaccine bexsero menveo combine phase iii bexsero infant antigen vaccine favourable safety mmr efficacy profile follow completion phase ii study discussion regulatory phase ii therapeutic copd authority potential phase iii start key datum rsv paediatric expect publish menabcwy leverage advanced technology menveo liquid expertise capability develop apply advanced technology important differentiator malaria fractional dose lead industry adjuvant technology decade shigella continue innovate field rsv maternal adjuvant technology platform lead enhanced phase iii rsv old adult immune response play key role innovation therapeutic chronic hepatitis b adjuvant technology key component pipeline asset include rsv copd candidate vaccines clostridium difficile enable success license shingrix vaccine sam rabies model adjuvant technology available partner include cepi collaboration strengthen global response coronavirus epidemic sarscov commercial asset global health asset lifecycle management sam platform start clinical investigation inlicense alliance relationship party august potential significantly reduce porcine circo virus free formulation lead time vaccine research enable fast simple manufacturing improve vaccine potency novel technology progressing include bioconjugate generalise module membrane antigen gmma investigate shigella candidate currently phase ii trust section gsk annual report vaccine continue performance vaccine turnover million aer direct significant capital expand supply cer primarily drive growth sale shingrix chain capacity meet demand shingrix work meningitis vaccine contribute significantly growth create new purposebuilt facility expect bring group financial review detail line base strengthen manufacturing capacity achieve supply high teen million dose future growth strategy year ahead original plan meantime ambition continue grow business ahead ensure continuity supply market global vaccine market achieve objective launch shingrix phase launch prioritise key asset shingrix bexsero focus additional market china world large vaccine market improve focus efficiency divest shingrix manufacturing capacity increase site ankleshwar india tianyuan china opportunity expand vaccine geographic footprint transfer bavarian nordic time year receive regulatory approval travel vaccine rabie tickborn encephalitis shingrix china plan phase launch ensure continuity supply potential expand supply performance reach shingrix increase coverage eligible supply performance continue improve adult extend indication young demonstrate bexsero shingrix flu supply immunecompromise adult ship million dose achieve strong ontime infull otif delivery key strategic asset bexsero share global meningitis b vaccine market base twoyear programme create new gsk revenue grow bexsero main geographic focus optimise vaccine manufacturing network eu eu infant indication support commercial pipeline asset strong market advantage competitor product offer include investment lyophilisation facility fill adolescent protection short immunisation packaging technology simplification schedule allow dose take supply chain process month particularly relevant local meningitis outbreak vaccine site inspect fda passed expand shingrix bexsero belgium pertussis acellular manufacturing facility develop asset specifically market pass fda preapproval inspection new include mmr vaccine pcvfree formulation rotavirus inactivated poliovirus vaccine unit track file vaccine currently phase iii testing china plan eu approval leverage establish vaccine portfolio include cervarix digital transformation engerixb license exist vaccine progress goal digital future datadriven organisation continue improve create simple competitive supply chain way harness technology develop new way work worldclass network manufacturing site drive performance increase ability deliver vaccine country give strategic global supply people world leverage datum artificial capability allow produce deliver intelligence digital model optimise research million vaccine dose day development project supply network drive efficiency business gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare worldleade consumer healthcare business combine science consumer insight create innovative everyday healthcare brand consumer trust expert recommend oral health pain relief cold flu allergy relief digestive health vitamin mineral supplement progress longterm priority innovation performance trust market launch total turnover billion supply chain service level category include sensodyne aer cer continue improve pronamel intensive enamel repair proforma excellent ontime infull delivery tum chewy bite complete joint venture performance cool sensation pfizer combine consumer help child access new innovation rollout healthcare business track free lifechanging cleft lip include sensodyne sensitivity deliver synergies million palate surgery comprehensive gum polident cushion total annual cost saving cleft care partnership comfort smile train read read page read page innovation closed deal pfizer combine denture care consumer insight denture consumer healthcare business make number wearer experience gum discomfort regular basis globally overthecounter otc medicine therapeutic significant impact life address oral health give lead position key geography develop polident cushion comfort provide include china well cushion comfort tired tender gum provide strong denture adhesive launch proportion sale product introduce market include italy spain past year pain relief gain approval fda february deliver bestinclass innovation voltaren arthritis pain otc product combine deep consumer insight scientific temporary relief arthritis pain voltaren arthritis pain technical expertise deliver innovation prescription strength nonsteroidal antiinflammatory nsaid category example oral health launch topical gel arthritis pain available otc nearly advanced formulation enamel care pronamel intensive million americans osteoarthritis enamel repair toothpaste uk germany people globally risk enamel tum yearold brand continue innovate wear european adult age focus improve fast heartburn relief show moderate sign enamel wear formula common heartburn symptom burn sensation prove actively repair acidweakene enamel help mouth throat tum chewy bite fast people strengthen protect tooth act essential develop antacid consumer feel work address create launch sensodyne sensitivity gum tum chewy bite cool sensation go work develop approximately adult second provide cool sensation consumer population experience tooth sensitivity half cool fight heartburn fast experience gum problem new offering provide dual relief sensitivity bleed gum daily toothpaste launch market include uk turkey base nicholas hall db global otc database gsk annual report consumer healthcare continue building industryleade capability research find consumer india consumer sensory lab world enable china increasingly look product combine listen understand meet need consumer science natural traditional approach leverage year carry research involve insight develop sensodyne herbal multicare consumer consumer sensory toothpaste relief sensitive tooth capture lab consumer home gain deep understanding flavour eucalyptus fennel consumer reaction product development increase use digital technology revolutionising process help improve brand develop new one way consumer buy use healthcare product add consumer sensory lab facility joint venture pfizer opportunity build joint venture plan digital innovation capability evolve digital innovation open new lab china enhance capability hub team develop innovation focus create platform business model meet future healthcare need consumer performance consumer healthcare sale million create worldleading consumer healthcare company aer cer proforma basis sale grow complete transaction pfizer create new drive strong performance oral health category partly consumer healthcare joint venture july offset decline skin health mid year complete joint good progress integrate business venture pfizer create lead consumer healthcare day joint venture complete legal close business market include big market china accounting pfizer consumer leverage joint venture integration catalyst healthcare revenue follow close business continuity accelerate growth drive innovation sharpen issue significant employee experience issue report strategic resource allocation ensure focus investment complete appointment approximately critical right market brand generate leadership role end complete legal close strong growth high return power brand portfolio joint venture local market continue expand addition advil centrum alongside work local close remain market seven power brand include sensodyne voltaren theraflu local star brand geographically time announce joint venture announce concentrated key market tum intention separate consumer healthcare demerger emergenc chapstick caltrate fenbid year closing transaction china power brand local star drive future ready programme planning work begin prepare performance consumer healthcare reinforce global future separation focus building key leadership pain relief respiratory wellness therapeutic technology infrastructure support function necessary oral health operate standalone company work continue parallel integration joint venture delivery redefining operating model reflect global plan saving local nature brand move accountability decision make close consumer customer accelerate track deliver billion synergy speed market leverage scale expertise synergy expect achieve number area global portfolio invest key capability include network rationalisation logistics infrastructure digital datum analytic sustainability unlock growth advertising marketing sale distribution functional ensure meet expectation consumer support cost saving generate intend customer reinveste joint venture support innovation growth opportunity overall consumer healthcare joint venture target adjust operate margin percentage midtohigh work continue secure require regulatory approval propose sale horlick consumer health food drink brand unilever announce december follow strategic review nutrition portfolio progress propose merger stake glaxosmithkline consumer healthcare limited india hindustan unilever limited allow hindustan unilever limited sell distribute otc oral health brand india distribution arrangement transaction expect finalise end q subject approval gsk annual report strategic report governance remuneration financial statement investor information consumer healthcare continue lead growth win shopper customer expert create new business evolve culture expert endorsement build trust brand drive consumer customer heart decision shopper purchase decision sensodyne retain unequalled build leadership capability drive performance number leadership position dentist brand second half take step define recommend sensitivity market behaviour mindset require embed effective decision compete otc brand sell make clarity accountability courageous straight talk pharmacy continue prioritise relationship leader build strong ownership dentist pharmacist invest information acting culture ambassador business support product expert sale representative deploy streamlined decision making tool design call dentist market share relevant help identify single point accountability plan sciencebase information roll implement high shopper science labs uk singapore perform team development programme use stateoftheart technology track shopper behaviour senior leadership team emphasis straight talk real time provide rich insight consumer decision make actively listen take action shopping habit world additional satellite employee feedback perception evolution lab facility locate canada south africa mexico culture integration planning engagement headquarters major retail partner quarterly consumer healthcare pulse survey annual gsk employee survey page leverage shopper science lab strengthen customer relationship develop ecommerce digital transformation evaluation tool enable overlay digital content put digital technology heart business integrate digital prototyping tool key retailer website aim deliver meaningful interaction consumer include amazoncom tescocom simulate realistic fuel brand growth achieve efficiency saving ecommerce shopping experience shopper continue accelerate digital transformation prioritise building digital capability include hire expert new talent create simple competitive supply chain continue drive strong improvement service launch threeyear asia pacific digital accelerator customer continue excellent ontime infull service level programme drive sale digital commerce promote allow supply chain focus opportunitie digitalfirst culture region programme integrate drive value business consumer external digital expert gsk consumer healthcare team environment eliminate waste packaging cost different country asia pacific enhance digital capability build internal capacity embed agile way joint venture provide renew focus cost save working initiative lean structure nonmanufacture site team drive synergy saving increase speed decision make progress transform marketing model include optimisation manufacturing network capability strategically important area notably consolidate maximising capacity site creation cuttingedge marketing service team streamline number contract manufacturer cmo leverage technology solution datum strategic partnership use ensure right balance trust costefficient provide specialist marketing capability scale improve manufacture clear business continuity plan place quality effectiveness marketing campaign manage supply stability announce combine anonymised firstparty datum google closure agbara nigeria dehiwala sri lanka secondparty datum leverage additional technology supply chain consolidated accountability platform identify signal help target specific endtoend operation region build close audience base behaviour dynamic partnership local commercial rd team drive relevant content medium platform local innovation significantly improve supply chain agility roll new technology platform market make product frequently small batch enable track medium spend real time enable allow inventory enable respond optimise campaign performance target audience quickly effectively change consumer demand great precision create valuable party datum insight provide platform deliver improve consumer experience personalise content efficiency saving gsk annual report trust trust longterm priority essential achieve purpose drive longterm growth add value society shareholder commitment trust purpose help people feel well live long science make product modern technology address affordable available employer health need new medical innovation pricing engage people develop differentiate highquality improve health million achieve maintain competitive need medicine vaccine people year make employee engagement score consumer healthcare product product available responsible improve health price sustainable inclusion diversity business global health accelerate progress inclusion improve global health impact product reach diversity aim rd infectious disease use access strategy reach female representation senior role affect child young people million underserved people recognition global lgbt develop country focus develop country indice hiv malaria tb product health wellbeing development health security healthcare access lead company help world well prepare partner improve disease support employee health wellbee future disease outbreak prevention awareness access personal development pandemic potential tackle healthcare service million antimicrobial resistance people responsible business reliable supply ethic value datum engagement environment commit quality safety operate ethical value use datum responsibly reduce environmental reliable supply drive culture transparently improve impact quarter product patient issue respond patient scientific consumer swiftly transparently engagement society high expectation business people commitment seek address material topic rightly expect company behave responsibly relevant stakeholder business contribute tackle societal challenge operate design help respond challenge opportunity responsibly bring direct benefit society create industry society broadly page value shareholder support ability attract contribute un sustainable retain talent manage cost build trust patient development goal sdgs sciencele global consumer customer payer stakeholder healthcare company big contribution goal influence licence operate mechanism ensure healthy life promote age help identify respond different stakeholder corporate responsibility cr committee form group summarise page important board oversight trust priority commitment detailed support trust committee provide ongoing scrutiny progress priority drive progress key area commitment company address evolve significant impact ensure run view expectation broad range stakeholder business responsible way corporate executive team senior management oversee implementation trust commitment report regularly cr committee page gsk annual report strategic report governance remuneration financial statement investor information trust continue external benchmarking approach report djsi pharmaceutical industry group trust section report progress dow jones sustainability index commitment publish online detailed information atmi access medicine index leading contribution sdgs esg performance industry antimicrobial resistance benchmark summary current historical datum un global compact communication progress global reporting ftsegood member ftsegood index initiative index sustainability accounting standard board cdp receive score b cdp climate index assurance statement change cdp water name cdp supplier engagement leader gskcom responsibility report datum contribution sdgs science technology commit science technology final phase iib result candidate vaccine address health need innovation core develop partnership iavi confirm primary finding unique opportunity impact vaccine candidate show reduce risk develop global health prevention treatment infectious pulmonary tb half hivnegative adult latent tb disease urgent public health threat grow infection january announce licensing resistance antibiotic asset bill melinda gates medical research institute continue development low income country new medical innovation high tb burden line global health strategy big impact sciencele global healthcare company successfully discover develop worldleade portfolio firstinclass medicine innovative product cuttingedge science tb span different mechanism combination technology develop differentiate highquality need medicine contender transform medicine vaccine consumer healthcare product tb landscape new tb regiman effective improve health read innovation patient resistance currentlyavailable business page tb medicine global health february join partnership accelerate commitment improve global health impact new tb treatments pantb collaboration involve rd infectious disease affect child young company bill melinda gates foundation people develop country focus hiv malaria tb aim accelerate development treatment course early discovery work allow pursue promising form tb multidrug resistant form infection scientific lead develop world disease create course shorter complicated easy chaga disease leishmaniasis sleep sickness tolerate exist option need ensure sustainable collaborative model malaria translate scientific discovery benefit work fight malaria range develop medicine vulnerable patient ensure ongoing sustainability vaccine work partner strengthen health system investment global health science interest rtss vaccine vaccine help protect child product reach patient quickly seek deadly form malaria p falciparum development partnership appropriate maximise whocoordinate pilot implementation programme lead impact transfer technology party organisation local ministry health partnership path right capability focus example gsk launch select region malawi ghana transfer ebola marburg vaccine candidate kenya year child sabin vaccines institute believe transfer expect receive vaccine commit help ensure vaccine candidate technology donate million dose undertake additional develop fast efficiently bring postapproval pharmacovigilance effectiveness impact need study currently work path tuberculosis gavi potential funder ensure sustainable supply tb lead cause death infectious disease vaccine potential broad implementation worldwide represent significant public health threat pilot effective vaccine tb mark impact tafenoquine krintafelkozeni single dose radical cure disease control include drugresistant tb treatment p vivax malaria develop partnership interruption transmission help medicine malaria venture receive regulatory approval achieve world health organization target malaria endemic country brazil thailand end tb epidemic early gsk annual report trust continue hiv health security viiv healthcare commit develop vaccine medicine scientific knowhow deliver hiv treatment formulation optimise specifically help world well prepare future disease outbreak infant child age drive pandemic potential tackle antimicrobial resistance amr whole paediatric arv drug optimisation priority pandemic preparedness continue progress clinical development gsk commit play prepare programme paediatric formulation dolutegravir respond pandemic work government support partnership international maternal paediatric pandemic readiness plan support pandemic adolescent aid clinical trial network paediatric influenza preparedness agreement adopt member european network treatment aid state event declare pandemic provide realtime access pandemic december file fda eu regulatory influenza vaccine antiviral world poor submission seek approval firstever mg country commitment combination donation dispersibletablet formulation dolutegravir tiere price depend countrys gross national simplified dose regiman optimise use exist income gni gsk support s pandemic dolutegravir mg filmcoate tablet paediatric hiv patient preparedness activity include global influenza submission gateway regulatory surveillance response system worldwide network submission low middleincome country able rapidly identify respond influenza outbreak provide regulatory reference generic manufacturer include pandemic potential register paediatric formulation voluntary licensing agreement february gsk announce new collaboration established pandemic vaccine adjuvant platform publicprivate partnership clinton technology available enhance global effort develop health access initiative unitaid generic manufacturer vaccine novel coronavirus sarscov mylan macleod expedite development use adjuvant add vaccine enhance registration market entry generic formulation immune response particular importance pandemic paediatric dolutegravir resourcelimite setting aim situation reduce antigen require project reduce gap dispersible dose allow vaccine dose produce tablet formulation available generic dispersible available people collaboration announce tablet formulation available child develop coalition epidemic preparedness innovation cepi country month year university queensland second collaboration develop world disease chinabase clover biopharmaceutical pursue promise scientific lead area address antimicrobial resistance tb malaria hiv gsk amr big health challenge face world tre canto open lab spain gsk vaccines institute play lead role industry response global health gvgh italy gsk rank access medicine tre canto open lab further rd disease foundation amr benchmark performance develop world offer external researcher potential vaccine play critical role avoid need antibiotic access gsk compound library screening tool prevent bacterial viral infection vaccine scientific expertise support research tb disease diphtheria meningitis pneumonia malaria project include neglect tropical disease pertussis protect ten million individual chaga disease leishmaniasis sleep sickness bacterial infection major driver direct antibiotic gvgh aim discover effective affordable vaccine prescribe highburden infectious disease develop country addition vaccine nonbacterial infection like scientist focus translate laboratory concept influenza rotavirus malaria prevent unnecessary highquality vaccine current area work include avoidable prescribing antibiotic secondary shigella invasive nontyphoidal salmonella typhoid infection commit research develop paratyphoid fever group streptococcus new vaccine prevent mitigate amr infection february indian health regulatory authority reduce avoidable antibiotic use approve new vaccine help protect child pharmaceutical company typhoid fever develop gvgh actively research develop new antibiotic treat resistant transfer indian vaccine company infection pharmaceutical pipeline gepotidacin biological e proofofconcept demonstrate new chemical class antibiotic mechanism license vaccine create gvghs distinct currently approve antibiotic progress lab successfully develop bring market phase iii clinical research october effective partnership study treat patient uncomplicate urinary tract gskcom inside gvgh infection urogenital gonorrhoea contract strain resistant exist treatment gsk annual report strategic report governance remuneration financial statement investor information trust continue rd type bacterial infection survey antibiotic resistance soar economically sustainable current market condition programme analyse antibiotic resistance local level government recognise need financial support share finding healthcare professional hcp partner government biomedical public health body inform development local advanced research development authority antibiotic prescribing guideline defense threat reduction agency support public company share amr surveillance datum publicly private partnership aim speed discovery open datum platform run wellcome trust open development new medicine treat prevent resistant datum institute addition train hcp bacterial infection collaboration capability country appropriate use antibiotic building start implement new global limit reduce antibiotic discharge manufacturing environment antibiotic factory supplier track meet new global limit end address pharmaceutical environment environment section gskcom prepare future disease threat affordability availability make product affordable available provide prescribe medicine vaccine people world responsible pricing eligible uninsured patient strategic access programme partnership patient assistance programme pricing europe engage government payer work aim improve health million people year sustainable health system support ongoing make product available responsible price innovation example pricing trelegy ellipta reflect sustainable business economic value demonstrate costeffectiveness innovation acceptable budget offer potential recognise pricing pharmaceutical medicine costsave compare alternative vaccine important issue develop develop country understand patient payer concern develop country use innovative pricing structure affordability set price medicine access strategy extend product reach develop market apply valuebase approach page tiere pricing model vaccines balance reward innovation access affordability example base widely recognise world bank gni country classification high income upper middle income aim bring truly differentiate innovative product low middle income low income price ceiling price bring highlyeffective health outcome patient payer floor exist tier ceiling floor progressively product high cost bring value decrease tier high low income country patient healthcare system invest genetics genomic big datum ai accelerate pace develop lowincome country file develop transformational medicine prioritise patent medicine enforce historic patent molecule high probability success know allow generic company manufacture supply geneticallyvalidate drug candidate twice likely generic version gsk medicine country registered medicine improve productivity gskcom pricing access strategy rd investment price medicine accord value outcome product reach bring patient provider payer aim use access strategy reach million sensitive market societal expectation underserve people develop country product strategy include tiere pricing product pricing product launch include donation voluntary licensing agreement extend access recent launch dovato nucala autoinjector trelegy generic manufacturer set target ellipta shingrix juluca incorporate specific market product reach million people dynamic unique product profile new access strategy medicine vaccine context exist treatment option year average net price product tiere pricing principle mean reserve low fall year average list price vaccine price organisation gavi vaccine rise year average net price alliance support country gni head portfolio decrease average list example rotarix vaccine available price rise product level large single gavi country protect rotavirus increase list price take result price discount rebate allowance increase net price offer type patient total exclude reach albendazole donation assistance help ensure appropriate access medicine assess gsk annual report trust continue provide pneumococcal vaccine synflorix partnership americare direct relief gavieligible country discount price reach ihp uk map international nearly unit gsk million people commit deliver million medicine distribute humanitarian emergency dose synflorix gavi current advanced market response country commitment contract gskcom pricing access strategy distribute dose vaccine healthcare access cervarix zimbabwe support multiage cohort aim partner improve disease prevention awareness vaccination programme protect girl access healthcare service million people human papillomavirus deliver million set target reach nearly million dose oral polio vaccine unicef support global people partnership polio eradication initiative reach million child viiv healthcare invest million continue innovate help improve access vaccine positive action grant address hiv stigma lowresource setting introduce support hiv education prevention new multimonodose blowfill seal presentation vaccine positive action child programme directly reach rotavirus introduce time people commit support partnership myanmar support gavi new presentation end aids viiv healthcare mission leaving help reduce cold chain volume result low person live hiv cold chain transportation cost partner comic relief complement july viiv healthcare mark fifth anniversary effort combat malaria rd voluntary licensing agreement medicine patent project africa south east asia aim improve pool aurobindo pharma agreement currently allow malaria awareness prevention effort treatment generic manufacturer produce sell low cost single people need partnership fix dose combination product contain dolutegravir local international organisation reach adult child country high burden hiv million people include health worker private total country adult paediatric provider vulnerable population pregnant agreement respectively addition country woman child grant patent force end million people live hiv country partnership amref health africa develop world access generic dolutegravir care international save child helped train contain product possible licensing frontline health worker approximately agreement million people directly reach health worker healthcare service health facility viiv healthcare continue donate antiretroviral medicine venezuela country face partnership save child aim help reduce profound shortage basic medicine child mortality partnership reach approximately pharmaceutical company donate antiretroviral child million child people live hiv humanitarian crisis february intervention include widen immunisation donate pack antiretroviral coverage accelerate access treatment strengthen gsk donate vaccine colombia healthcare system launch new protect venezuelan migrant transit reside programme nigeria focus prevent infectious national territory rotavirus pneumococcus diphtheria disease child pertussis tetanus child receive free lifechanging surgery donate billion albendazole tablet comprehensive cleft care partnership include million support effort smile train world dental federation end lymphatic filariasis lf control intestinal worm smile train launch new twoyear project soil transmit helminth schoolage child improve oral health guidance ongoing care child benefit patient country world gsk clefts india fund smile train tollfree remain commit continue donate albendazole tablet cleft helpline provide people information lf eliminate public health problem globally cleft treatment support people reachedprotecte calculated divide total number dose supply gavi unicef number dose need complete schedule vaccination allow estimate wastage health worker datum estimate base reach partner programme level funding final datum expect available april gsk annual report strategic report governance remuneration financial statement investor information trust continue ally dengue campaign india south global contribution community health programme east asia create bring key stakeholder amount million include cash product partner prevent treat outbreak dengue fever donation volunteer time employee help potentially fatal mosquitoborne disease improve healthcare access train healthcare worker reach gskcom prevention awareness infrastructure people range programme mobilise viivhealthcarecom positive action programme community promote behaviour change modern employer modern employer believe strong employee commit improve ethnic representation experience critical attract retain motivate level gsk work new ethnicity council good people support business future remove barrier increase understanding ensure launch modern employer ambition focus equal opportunity inclusion diversity health wellbeing employee goal recognise global lgbt indices development aim ensure people empower lgbt right group stonewall recognise gsk feel good grow gsk global employer list uk stonewall engage people name employee resource group lgbt employees employee engagement important barometer gauge ally good uk gsk name people feel work gsk aim achieve good place work lgbt equality fourth consecutive maintain competitive employee engagement score year human right campaign corporate equality index survey employee feedback addition signatorie uk department longterm prioritie culture change international development charter change join good response rate survey organisation common aim ensure right freedom april september achieve dignity inclusion people disabilitie high engagement score year april gender diversity maintain strong score september goal female continue drive engagement lets talk session representation senior role executive team workplace collaborative percentage woman management continue online platform enable twoway informal communication rise gsk woman represent collaboration discuss topic matter management role senior employee gsk share knowledge perspective management role vp support great understanding fast effective late hamptonalexander review ftse company decisionmake organisation give month find gsk high proportion woman employee actively connect platform board increase sixth female work read content representation find exceed target company business unit group woman board direct report inclusion diversity corporate executive team believe strongly inclusion diversity gsk prominent healthcare life science right way business lead business success company join healthcare businesswomens association unleash enormous potential differ knowledge gender parity collaborative launch experience style people enhance ability foster measurable gender parity progress industry respond differ need patient consumer improve gender balance encourage employee able bring authentic self support woman develop leader work encouraged result employee provide highperforme female manager coaching survey september include question support accelerate difference programme authentic self work gsk recruit support woman early career receive favourable score say woman represent apprentice feel respected work graduate result effort develop gsk diversity council cover gender female employee year woman gsk ethnicity lgbt disability chair executive include women engineering society woman team member council support inclusion diversity engineering current apprentice gsk agenda input employee resource group india name avtar good company woman work figure include contribution tesaro portfolio gsk annual report trust continue longstanding commitment fair equal pay consider mental wellbee important conduct countrybase review ensure market physical wellbeing raise awareness issue clear guidance tool support ensure pay equity world mental health day encourage people seek unexplainable difference detect address support hour confidential employee assistance compensation process programme resource launch mental health matter train line manager publish uk gender pay gap report help increase awareness skill knowledge gender pay gap permanent ukbased gsk employee well support team mean outperform national average remain committed improve gender balanced representation prevent injury illnesse work fundamental application fair equitable pay practice ensure people health wellbee approximately equal opportunity equal pay equal work employee drive company sale business unfortunately commercial salesforce die motor woman management vehicle accident kenya try prevent sort tragic accident happen run driver safety programme svpvp help employee protect family director combine online learn practical road safety activity manager roughly driver country employee train driver safety reportable injury illness rate continue decline hour work employee gender number remain comparable male female total lead company sector board employee development management want people grow stage employee work live management senior manager define company act strategic report director report regulation includes expect employee development plan person responsible planning direct control activity agree manager support employee company strategically significant company ownership development employee access board include director undertaking include consolidated account new development portal resource health wellbeing development relevant role development need interest aim lead company support employee health addition gsk continue meet commitment wellbee development member club group uk company commit health wellbeing hire young people development programme global comprehensive preventive healthcare package uk role currently people employee eligible dependant include graduate mba programme globally preventative healthcare service little extra cost apprenticeship uk canada ireland singapore participant provide programme help people belgium control health manage energy level strong focus improve effectiveness adopt healthy behaviour people manager performance system employee take critical holding manager accountable energy resilience programme expand manage performance development team personalise digital health platform original employee provide feedback manager employee belgium employee singapore question measure leadership effectiveness mexico spain france switzerland australia new zealand key area know people deliver result maximise potential manager participate understand important employee employee provide flexibility manage live thrive feedback manager great thing work home large market formal flexible working carer policy market introduce new leadership development programme review competitiveness area aim firstline leader training consist virtual module differentiate example strong emphasis conversation matter develop implement care family member pay leave performance lead high perform team industry standard programme pilot leader participant programme roll gsk fourth year row gsk increase participation support continue leadership development level virgin pulse global challenge participant country name gskcom employee engagement learn development active organisation people collectively take billion step gsk annual report strategic report governance remuneration financial statement investor information trust continue reliable supply ensure highquality safe reliable supply product conduct audits supplier quality patient consumer priority process audits clinical study run behalf business page product shortage gsk assess quality safety identify happen variety reason include supply disruption area require improvement engage relevant unexpected demand party develop improvement plan track progress significant issue identify remain unresolved robust quality management system support continuous choose suspend terminate work party improvement help maintain high standard product quality safety comply relevant regulation detect assess understanding prevent adverse include good manufacturing practice good effect drugrelate problem pharmacovigilance laboratory practice good pharmacovigilance practice important evaluate safety pharmaceutical product good clinical practice external regulatory work partner enhance system inspection pharmaceutical vaccine consumer report external collaboration healthcare manufacturing site local operating company transcelerate european federation pharmaceutical find issue result minor industry association innovative medicine observation address issue minor initiative work promote harmonised regulatory authority accept propose approach procedure clinical development plan corrective action safety evaluation drug implement key regulation late summer gsk contact regulatory counterfeit product present risk patient safety support authority detection ndma potential effort prevent manufacture distribution counterfeit human carcinogen zantac ranitidine product base gsk product work closely government body information receive correspondence regulatory international organisation world custom authority gsk decision midseptember organization custom authority industry initiate voluntary recall pharmacyretail level recall zantac association conduct investigation work product market precautionary action enforcement agency tackle counterfeit gsk product number recall initiate api supplier gsk implement serialisation drive traceability pharmaceutical company hold market authority supply chain increase supply chain visibility country include gsk discontinue increase communication government system make sell prescription zantac tablet help raise visibility product prevent theft discontinue make sell overthecounter zantac counterfeiting stock diversion allow system regulatory authority review authenticate product point dispense finding andor conduct test include fda continue work gskcom patient safety reliable supply ethic value commit create ethical valuesdriven culture gsk employee complementary worker require issue respond swiftly transparently complete living value expectation mandatory expect gsk live value expectation training annually employee speak concern engage appropriately complementary worker complete training stakeholder respect human right extend cover content include code conduct human ethical expectation party work safety information reporting report misconduct live value expectation employee fail complete course face value patient focus integrity respect disciplinary action define permit local transparency expectation courage accountability labour law development teamwork help create culture assess different part want employee survey employee agree business value maturity matrix understand work environment encourage ethical behaviour value expectation embed face pressure meet business objective additionally individual area business insight assessment inform plan integrate value way work gsk gsk annual report trust continue example include increase opportunity engagement political engagement leadership team improve trust strengthen work behalf gsk follow people manager capability lead employee code conduct interaction political stakeholder time change deliver pace additionally selection process public policy group include criterion ensure group share value mandatory antibribery corruption abac training tailor consist module highrisk spend million federal lobbying activity employee module focus register federal lobbying principle help employee deepen understanding register spend include cost operate office abac risk lie recognise conflict interest washington dc cost travel consulting cost report mitigate risk conflict represent interest eu institution publish december employee contract eu transparency register million publish worker complete abac training list membership trade association lobby indirectly behalf gskcom ethic value gsk corporate political contribution report investigate concern employee support individual candidate political encourage people speak concern group financially political action committee relate unethical conduct behaviour inconsistent contribute state federal candidate value simply want ask question breakdown spend available online apply code conduct gskcom public policy patient advocacy trade association inside outside gsk raise concern speak membership list criterion work public policy group independent party integrity line human right confidentially anonymously fear retaliation gsk commit uphold universal declaration report concern seriously review human right core standard set international understand formal investigation labour organization strive ensure respect human warrant investigation employee right embed integrate global business breach policy appropriate disciplinary action conduct regular assessment inform external expert employee accuse misconduct human right impact associate activity review case initiate build finding corporatelevel human formal investigation relate right assessment past year focus behaviour workplace result employee strengthen approach manage labour right risk discipline policy violation supply chain carry initial review labour dismiss voluntarily leave organisation right risk associate source activity receive document warning support fair labour ngo verit building instance action short document warning take work identify part supply chain represent employee discipline breakdown type great potential modern slavery risk update policy violation thirdparty labour right standard include expectation policy area recruitment cost bear employer behaviour workplace worker pay job practice lead mandatory training completion force labour good manufacturing distribution practice progress priority human right area market promotional activity access healthcare research practice patient safety expense environment health safety privacy outline relevant section report representative remain policy violation type gskcom human right modern slavery act statement increase focus complete mandatory training improve classification concern alter distribution policy violation compare late available figure figure expect available april submission eus transparency register gsk annual report strategic report governance remuneration financial statement investor information trust continue work party priority supplier significant spend thirdparty oversight programme strengthen supply support significant revenue andor medically rd chain risk management drive improvement global critical business enable provide network party include supplier distributor proactive support engagement visit design build organisation transfer value capability area improvement identify ecovadi want ensure party work share assessment audits value ethical business standard thirdparty risk buy good service transformation programme assessment mitigation programme embed deliver improve guidance integration compliance globally continues simplify refined internal gsk user party programme easy engage party appropriately include new source platform launch make risk assessment complete easy supplier engage party identify high risk gskcom ethic value undergo detailed independent assessment ecovadi continue work thirdparty supplier reduce environment health safety ehs risk conduct audits ehs ethic expand thirdparty ehs team include dedicate ehs professional team base country priority supplier locate datum engagement datum increasingly central business develop comprehensive approach privacy healthcare industry broadly digital data analytic include training drive understand strategy harness power datum technology gsk personally responsible correct handling strengthen business real difference patient personal information apply set privacy principle world believe help scientist ensure use personal information keep develop innovative medicine quickly high minimum necessary fair transparent accurate probability success enhance clinical secure study improve interaction healthcare provider combine privacy train mandatory customer consumer code conduct training approximately individual datum responsibly transparently complete privacy foundation training include privilege individual personal information new hire contingent worker return leave come responsibility treat datum ethically absence explain privacy principle help commit datum responsibly transparently understand apply daily work raise engage patient healthcare provider help meet awareness privacy matter handle patient need include manage datum carefully share personal datum result clinical study integrate patient insight personnel handle personal information rd hr product development provide healthcare globally receive tailor privacy training understand professional relevant accurate information obligation bind corporate rule need enable internal transfer eu hr rd datum datum privacy gsk affiliate people key role recognise people increasingly concern organisation continue undergo certification protection appropriate use personal information international association privacy professional iapp particularly related health new regulation increase expertise enable informed decision world increase requirement handle personal datum number people company use personal information loss inappropriate certification gsk increase use personal information impact individual affect business responsibility datum privacy seriously gsk annual report trust continue protection individual datum privacy high priority improve engagement patient involve clinical exclusive collaboration andme collaboration study develop patient engagement plan key combine andme genetic expertise advanced data asset set dedicated patient panel key science skill gsk extensive scientific capability internal governance process allow patient input scale enhance discovery development entirely development research protocol improve patient new medicine potential cure andme customer experience study informed choose participate research contribute result study complete information unique dynamic database purpose ensure inclusion diverse population clinical advance scientific research participation voluntary study datum generate represent people customer require consent affirmatively datum possible include individual different demographic research choose participate age elderlyfrail paediatric group sex ethnicity information aggregate individual race capture potential variability response identifiable gsk medicine vaccine help characterise clinical trial transparency robust benefitrisk profile generate great insight longstande commitment datum transparency prescribing information ensure right patient get clinical study publish clinical study right medicine particularly important report summary result precision medicine positive negative study change inhouse trial improve clinical study register diversity participant include ensure team develop share anonymise patientlevel datum study plan target population base sex age race external researcher list study datum ethnicity need target recruitment stage sharing wwwvivliorg wwwclinicalstudydatarequestcom lifecycle molecule ask thirdparty launch year ago facilitate innovative datadriven preferred vendor provide plan deliver research multiple study sponsor improve recruitment retention diverse population funder external researcher grant datum access fullservice outsource trial base review scientific merit research engagement healthcare professional hcp proposal independent panel access gsk study aim provide information product way datum approve proposal good suit limit time new medicine gskcom online gsk privacy notice gsk clinical study register significant new datum allow payment expert speak scientific evidence disease treat patient scientific engagement clinical experience disclose annually individual improve delivery groundbreake new therapy level payment hcp legally permit strengthen focus patient need seek aggregate basis insight business continue support update salesforce incentive policy initiative empower patient portfolio evolve grow shift innovative involve development medicine training specialty care medicine area require high level tool dialogue european patient academy expertise deliver information specialised hcp therapeutic innovation eupati strong competition talent held patient advocacy leader summit detail policy change portugal japan switzerland representatives patient organisation provide insight european gskcom operate responsibly health advisory board respiratory health board new patient panel cover hepatitis chronic kidney disease rheumatoid arthritis oncology patient council new methodology introduce gsk annual report strategic report governance remuneration financial statement investor information trust continue environment commit reduce environmental impact carbon emission plus intensity ratio regulation quarter cut greenhouse gas emission tonne coe reduce water impact redirect waste beneficial use scope emission commitment underpin environmental scope emission commitment set baseline scope emission available reduce operational carbon emission scope report intensity ratio reduce value chain carbon emission scope scope emission billion revenue sale revenue tonne co em source electricity renewable source interim target scope emission fte tonne co efte reduce total water use highrisk site scope emissionsbn available ensure waste repurpose beneficial use revenue million tonne report co ebn revenue carbon commit play address climate emission use inhaler product fall change overall value chain carbon footprint mainly reduction ventolin scope emission operation produce new portfolio inhale medicine deliver scope emission supplier base ellipta dry powder inhaler dpi lifecycle logistic use product carbon footprint time lower propellantbase meter dose inhaler inhaler accredit science base target initiative support effort promote low carbon inhaler set scope target line level possible uk example nhs adopt decarbonisation require global temperature commitment increase dpi prescribe longterm plan increase c good progress gsk run public information campaign commitment different footprint inhaler wwwlowcarboninhalerscouk lower scope emission encourage patient discuss inhaler option continue deployment energy efficiency programme healthcare professional gsk support similar low operate site globally electricity carbon inhaler initiative belgium sweden come renewable source plan expand benchmark performance externally combination green certificates onsite score b cdp climate renewable generation global electricity need climate resilience decarbonise uk europe carry scenario analyse product late available datum absolute scope emission supply chain task force climate decrease vs billion revenue relate financial disclosure tcfd framework guideline mainly reduce emission associate raw material business usual scenario low carbon represent reduction billion revenue scenario identify potential area risk opportunity baseline year recognise achievement climate change present business supplier reduce environmental impact annual supplier environmental sustainability award winner supplier encourage excellence agricultural practice india uk energy provider create clean energy inspire generation scientist engineer innovative tackling climate change reduction exist portfolio exclude pfizer site join august figure expect available carbon emission calculate accord greenhouse gas protocol corporate accounting reporting standard revise edition figure scope emission electricity restate base update iea emission factor publish year treatment use propellantbase inhaler result carbon footprint kg coe compare kg coe ellipta dry powder inhaler gsk annual report trust continue water plastic goal reduce total water use highrisk packaging product play important role site climate change tackle deliver safe stable trust medicine vaccine global level water challenge localise consumer healthcare product recognise vaccine pharmaceutical consumer healthcare impact plastic packaging environment manufacturing site complete risk assessment working plan reduce plastic packaging implement action ensure compliance water make recyclable explore increase use stewardship standard assessment identify recycle plastic content recognise medical regulation highrisk site million cubic metre water world place significant constraint use total water use risk rating base recycle material vaccine business remove pvc water scarcity local water quality health social risk packaging end develop regulatory reputational risk new pump flonasesensimist reduce site working strategy reduce water plastic device impact make good progress example site complete review plastic use cape town south africa area affect drought business find plastic footprint initiate water recovery rainwater harvesting project associate consumer healthcare product take water save measure year save place integration pfizer consumer healthcare water site annual water use site business updating include impact karachi pakistan successfully implement project joint venture implement initiative reduce reduce water cool tower shorten clean remove possible single use plastic gsk cycle excess water activity office worldwide eliminate million item decrease water clean plastic food refreshment outlet help reduce site water footprint pharmaceutical environment waste commit ensure compound end aim site send adversely affect people environment carry zero waste landfill avoid harmful environmental impact environmental testing pharmaceutical use landfill keep material solvent circulation datum risk assessment evaluate potential harm use new product waste step minimise risk active pharmaceutical send landfill exclude newlyjoine pfizer consumer ingredient include antibiotic enter environment healthcare site site achieve maintain zero result manufacturing process waste landfill cut waste produce generate total tonne gsk amr industry alliance launch include tonne hazardous waste signatory industry roadmap progress tonne send landfill combat amr effort combat amr publicly commit minimise antibiotic longerterm goal waste discharge supply chain ensure manufacturing direct beneficial use recycling incinerate relate discharge negligible end waste energy recovery waste pharmaceutical supply chain initiative share recycle incinerate energy recovery guidance good practice manage antibiotic discharge paper palm oil manufacturing supplier commit move deforestationfree gskcom environment source key commodity purchase directly gsk indirectly behalf challenge complex nature supply chain reach paper packaging palm oil sustainable source volume work roundtable sustainable palm oil purchase book claim credit rainforest alliance audit assure supply chain date focus paper packaging palm oil palm oil derivative develop supplier selection criterion source standard conjunction rainforest alliance gsk annual report strategic report governance remuneration financial statement investor information risk management risk management framework embed continually review boardlevel oversight provide audit risk committee assist risk oversight compliance council framework enable board identify evaluate year cet conduct formal risk review consider manage principal risk design support longterm emerge risk sufficient information available priority framework provide effective hierarchy support inclusion principal risk list review risk management compliance board support extensive analysis external trend insight business promotes tone establishe senior level interview recommendation gsk key risk culture oversee effective cascade risk intelligence group risk management board escalation information internal control cet agree escalate new risk value expectation speak process standalone principal risk environmental ensure risk associate business activity sustainability nonpromotional engagement work actively effectively identify mitigated provide underway establish appropriate reporting reasonable assurance material misstatement loss transformation risk recognition significant conduct annual confirmation exercise ensure transformation associate intention separate risk management approach consistent gsk gsk consumer healthcare business reinforce leader accountability list principal risk page audit risk committee consider assessment external macro environment risk gsk risk strategy address exposure follow mitigation risk order draw annual business unit risk assurance update significance report strategy paper significant risk annual risk review risk associate propose separation gsk consumer healthcare business principal risk oversee cetlevel risk owner separation consumer healthcare business ensure proportionate control place clear plan dependent number factor outside gsk assign address gap control include require shareholder regulatory gsk consider current emerge risk approval favourable condition public equity market risk management framework gsk define emerge risk public private debt market change applicable threeyear horizon law regulation certainty adequate information impact likelihood separation complete propose warrant investigation addition separation complete inclusion list principal risk assurance gsk consumer healthcare emerge risk assessment perform remit realise expect benefit separation separation risk management compliance board level adversely affect gsk consumer healthcare organisation additionally global level perform value liquidity respective share annual pestle analysis political economic social risk associate coronavirus outbreak technological legal environmental trend external potential impact coronavirus outbreak gsk environment identify emerge risk trading performance supply continuity remain uncertain date report outbreak material impact trading result group continue monitor situation closely include potential impact trading result supply continuity employee situation change time assurance coronavirus outbreak material adverse impact future result group viability statement arc report principal risk uncertainty internal control framework gsk annual report risk management continue risk assessment mitigation activity patient safety macro risk level remain high development datum interrogation present potential benefit patient safety volume datum analyse present significant challenge intensifie couple fragmented regulatory requirement increase expectation technology deliver safe innovative medicine risk gsk exposure remain unchanged deploy new operating model safety activity involve simple central safety organisation outsource local pharmacovigilance activity deployment pass successful audits indicating expect low risk steady state h product quality macro risk level remain unchanged despite continue concern drug shortage security uncertainty complexity associate brexit gsk exposure remain unchanged benefit ongoing investment improvement initiative manufacturing facility operating system training reflect quality performance metric inspection outcome financial control macro risk level increase significant political uncertainty increase societal expectation financial reporting role auditor report highly sophisticated fraudster enable speed technological change gsk exposure maintain current level despite increase external risk exposure result benefit previous transformation programme strengthen control leverage technology centralise process enhance monitor maintain effective tax treasury strategy antibribery macro risk level remain unchanged continue legal framework similar corruption abac uk develop emerge economy high standard expect individual corporation aid improve technology increase enforcement gsk exposure remain unchanged appropriate control place train awareness raise strong monitoring transaction payment party plan continue pre posttransaction abac diligence increase capability business monitoring oversight red flag resolution party continue understand assess moneylaundering risk exposure mitigate exist risk commercial practice macro risk level increase increase pricing pressure great retailer online competition broad set competitor evolve digital landscape increase scrutiny marketing practice industry gsk exposure marginally increase integrate tesaro consumer healthcare joint venture pfizer continue invest proportionate control training monitoring embe new hcp engagement model salesforce incentive programme gsk annual report strategic report governance remuneration financial statement investor information risk management continue risk assessment mitigation activity privacy macro risk level increase diversity datum privacy legislation limit harmonisation occur despite europe adoption gdpr multinational challenge standardise datum privacy approach high local variation rise enforcement regulator gsk exposure remain constant follow successful deployment privacy operating model eu prioritise deployment rest world progress research practice macro risk level increase regulator adapt new technological advancement introduce change datum privacy animal welfare human biological sample fully announce requirement implementation understand gsk exposure remain unchanged increase regulatory expectation offset risk mitigation action embed monitor additional control enhance monitor quality culture particular focus datum integrity access benefit share nagoya protocol party oversight macro risk level increase grow number country vary regulation manufacturing standard require local production increase number party assess continuously oversee gsk exposure remain unchanged thirdparty risk assessment mitigation programme embed continue simplify refined easy engage party appropriately environment macro risk level increase great emphasis environmental control health safety regulator activist stakeholder direct operation supply sustainability chain emerge area focus postconsumption waste associate medicine evermore stringent regulation standard develop develop country gsk risk exposure remain unchanged continue focus appropriate control supply chain particularly active pharmaceutical ingredient api supplier information security macro risk level continue increase result increase digital footprint reflect large multinational organisation combine sophisticated hacking threat gsk risk exposure remain unchanged development control increase cyber operation threat intelligence capability mitigation protect critical information system application enhancement security operational technology system network offset risk supply continuity macro risk level remain unchanged ongoing evolution stringent regulatory expectation include continue regulatory focus contract manufacturer brexit continues provide uncertainty gsk risk exposure level remain unchanged improve risk management supplier portfolio reduce complexity network improve crisis continuity management framework reduce inventory threat pose cyberattack global emergency coronavirus outbreak quality incoming material present ongoing supply risk gsk annual report risk management continue climaterelate financial disclosure provide gsk voluntary disclosure analysis show scenario likely recommendation taskforce climaterelate financial financial risk need manage disclosure tcfd initiative financial stability board materially impact business model promote disclosure climate change risk key impact scenario governance floodrelate disruption manufacture site board oversight responsibility management supply chain climate change risk support cet board water stress lead increase expenditure disruption corporate responsibility committee crc oversee gsk manufacture site supply chain environmental sustainability enterprise risk progress high temperature affect quality availability environmental target crc report raw material increase cost fossil fuel regis simard president pharmaceutical supply chain finding represent initial assessment plan management responsibility environment health safety use understand impact develop sustainability include climate change risk action plan help mitigate risk embed sustainability cet report directly ceo strategy review opportunitie strategy risk management trust longterm priority reduce environmental sustainability include climate environmental impact important trust priority change risk standalone principal risk metric target business previously manage subrisk gain well understand climate change environment health safety sustainability impact business complete scenario analyse risk relate climate change manage different level key product vaccines pharmaceutical organisation depend nature risk consumer healthcare business scenario risk opportunity associate gsk energy water businessasusual assume little mitigation waste reduction programme manage climate lead c warming change energy reduction team representative lowcarbon assume global temperature gsk business unit relevant support increase limit c rapid function meet quarterly change legislation technology operational risk opportunitie asset site level study conduct independent party identify assess manage gsk business unit internationally recognise datum set risk management team intergovernmental panel climate change potential physical risk change climate flooding metric target risk associate transition lowcarbon goal reduce environmental impact quarter economy international climate policy carbon goal underpin environmental target pricing analyse analysis look implication carbon scope renewable electricity source gsk manufacture facility supplier raw material water waste page provider product assessment accredit science base target consider action gsk mitigate initiative set scope target line adapt finding decarbonisation require global temperature increase oc commit move deforestationfree source key commodity work partner roundtable sustainable palm oil rainforest alliance detail progress make achieve target find public response cdp questionnaire gsk annual report strategic report governance remuneration financial statement investor information risk management continue viability statement accordance provision revision follow hypothetical downside scenario code gsk assess prospect evaluate company long period month require scenario business performance risk include key go concern provision director confirm performance risk include low sale new product reasonable expectation gsk continue great adverse impact generic competition operate meet liability fall competitive launch gsk product year director assessment possible supply manufacturing challenge reference gsk current position prospect strategy board risk appetite gsk principal risk scenario external macroeconomic risk scenario manage detailed page reflect incremental risk business drive outside strategic report factor intense competition increase pricing pressure europe potential board review internal control risk management impact material negative change macroeconomic policy approve governance structure code healthcare environment conduct appraise approve major financing investment licensing decision evaluate monitor scenario principal risk scenario include severe performance prospect gsk focus assessment potential loss impact principal largely improve longterm financial performance risk relate patient safety product quality supply chain delivery company business strategy continuity antibribery corruption align innovation performance trust priority consequent regulatory action fine fundamentally threaten operation include board review gsk strategy make significant potential severe impact coronavirus materialise capital investment decision longterm time horizon risk manage mitigating activity describe base multiyear assessment return capital page performance company business unit market opportunity pharmaceutical vaccine scenario option exercise scenario evaluate consumer sector approach align gsk model additional funding requirement assume early potential achieve balanced growth invest high quality exercise outstanding option hold partner innovative product patient consumer healthcare hiv business provider internal external parameter future separation consumer healthcare joint venture increasingly unpredictable long time horizon pfizer approve board potentially occur gsk focus detailed bottomup plan threeyear cycle period cover viability assessment plan review annually director consider scenario conclude approve business forecast show expect financial impact material impact viability group resultant separate director believe threeyear assessment period company threeyear period assessment viability statement appropriate align threeyear review make certain assumption company establish business planning process normal level capital recycling likely occur consider balance longterm nature investment additional financing facility require pharmaceutical vaccine consumer sector respective level funding flexibility headroom assessment period analysis nearterm business performance realistically visible result stress testing certain combination hypothetical scenario increase funding plan stress test series robust operational demand gsk require mitigate change principal risk downside scenario board group funding strategy light liquidity review risk include potential effect brexit available group base analysis director expect material reasonable expectation shortterm disruption downside scenario consider severe stress test company able continue gsk cash flow sustainability dividend funding strategy operation meet liability fall insurance provision recovery key financial threeyear period assessment ratio period metric subject sensitivity analysis involve flex number main assumption underlie forecast individually combination mitigate action realistically take avoid reduce impact occurrence underlie risk gsk annual report risk management continue preparation brexit prepare uks exit eu brexit anticipate subsequent ongoing cost arise override priority maintain continuity supply brexit include custom duty include medicine vaccine consumer healthcare product cost duplicate testing release product people uk eu take riskbase approach continue estimate potential cost approximately plan mitigation place new post million year detail emerge brexit operating model new model business need adapt future ukeu relationship arrange reteste certification medicine assumption underlie forecast change consumer product europe require consequent adjustment brexit complete relevant marketing authorisation transfer update process gsk engage government package secure additional warehousing uk eu brussels institution discuss product continue support employee obtain preparation alongside ambition new ukeu settle status equivalent uk europe normal relationship continue review plan change process manage outstanding tax potential financial impact negotiation regulation custom activity depend new border develop remain ready outcome december place uk eu long term continue believe brexit material impact business nonfinancial information statement follow align nonfinancial reporting requirement contain section cb company act description business model human right policy diligence outcome create value human right summary principal risk social matter datum engagement principal risk uncertaintie party viability statement global health anticorruption bribery audit risk committee report health security nonfinancial key performance affordability availability live value expectation indicator employee report investigate concern antibribery corruption key performance indicator employee engagement environmental matter policy diversity wellbee development carbon water waste public policy code gender pay gap standard available gskcom living value expectation board diversity gsk annual report strategic report governance remuneration financial statement investor information group financial review section report framework approach tax financial performance adjust item cash generation conversion financial position resource treasury policy critical accounting policy ggsskk aannnnuuaall rreeppoorrtt group financial review report framework total adjust result cost ordinary course small scale restructuring group financial review discuss operate legal charge expense retain total financial performance group cash flow financial adjust result position resource result year adjust result include benefit major restructuring compare primarily result precede year programme exclude significant cost significant total result legal major restructure transaction item total report result represent group overall regard complete picture group financial performance performance present total result exclusion adjust item result adjusted gsk use number adjust nonifrs measure earning materially high low total earning report performance business adjust result particular significant impairment restructure nonifrs measure consider addition charge legal cost exclude adjusted earning substitute superior information present high total earning accordance ifrs adjust result define nonifrs measure define gsk undertake number major restructuring programme response significant change group gsk believe adjust result consider trading environment overall strategy follow material total result provide investor analyst acquisition cost cash noncash stakeholder helpful complementary information programme provide individual element understand well financial performance position approve meet accounting recognition criterion group period period allow group result charge incur number year performance easily compare majority follow initiation major restructure programme peer company measure management planning reporting purpose group initiate twoyear separation preparation directly comparable similarly describe measure programme prepare gsk separation new company lead company biopharma consumer healthcare gsk encourage investor analyst rely time time group divest noncore investment single financial measure review gsk annual report product business record profit loss include financial statement note entirety disposal adjust item notable divestment past year disposal oncology business gsk commit continuously improve financial element threepart transaction novartis report line evolve regulatory requirement good practice significant legal charge expense arise adjust result settlement litigation government investigation adjust result exclude follow item total result normal course materially large tax effect item regularly occur individual matter include certain amortisation intangible asset exclude computer major legacy matter software reconciliation total adjust result provide impairment intangible asset exclude computer information key adjust item software goodwill set year set page major restructuring cost include impairment tangible asset computer software specific gsk provide earning guidance investor community boardapprove programme structural basis adjust result line peer company significant scale cost individual relate expectation investor community support easy project exceed million include integration cost comparison group performance peer gsk follow material acquisition able guidance total result reliably transactionrelate accounting adjustment relate forecast certain material element total result significant acquisition particularly future fair value movement contingent consideration option give rise proceed cost disposal associate product significant adjustment drive external factor businesse significant legal charge net insurance currency movement capital market recovery expense settlement litigation government investigation operate income royalty income item gsk annual report strategic report governance remuneration financial statement investor information group financial review continue report framework continue historical record adjust item reconciliation total adjust operating profit year summarise follow total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelate item divestment significant legal item tax reform adjust operate profit analysis impact transactionrelated item operating profit year follow novartis consumer healthcare joint venture option contingent consideration shionogiviiv healthcare jv include shionogi preferential dividend viiv healthcare option pfizer preferential dividend contingent consideration novartis vaccine business release fair value uplift acquire pfizer inventory adjustment transactionrelate item reconciliation total adjusted result set page explanation adjust item report noncontrolle interest viiv healthcare viiv healthcare agree pay additional future cash trading profit allocation consideration shionogi contingent future sale viiv healthcare subsidiary group performance product develop joint operating result turnover operate profit profit tax venture principally dolutegravir ifrs business include group income statement combination gsk require provide estimate portion earning allocate noncontrolle fair value contingent consideration time interest own shareholder line acquisition require update liability late respective equity shareholding pfizer shionogi estimate fair value subsequent period end shareholder include gsk entitle liability contingent consideration recognise preferential dividend determine performance balance sheet date acquisition million certain product shareholder contribute subsequent remeasurement reflect relative performance product change time operating incomeexpense adjust item proportion overall earning viiv healthcare income statement period december allocate shareholder change particular liability discount stand increase proportion sale dolutegravircontaine million posttax basis product favourable impact proportion cash payment settle contingent consideration preferential dividend allocate gsk adjust item shionogi viiv healthcare quarter base allocate shareholder base equity interest actual sale performance relevant product gsk entitle approximately total earning previous quarter payment reduce balance sheet adjust earning viiv healthcare liability record income statement remeasurement liabilitie preferential dividend cash payment shionogi viiv healthcare allocate pfizer shionogi include million operating income liability require record fair value acquisitionrelate arrangement estimate future payment significant timing consideration acquisition shionogis interest difference charge record total shionogiviiv healthcare joint venture income statement reflect movement fair value shionogi receive equity stake viiv healthcare liability actual cash payment settle liability gsk annual report group financial review continue report framework continue cash payment reflect cash flow statement q gsk notify shionogi partly operate cash flow partly investing irrevocably give right accordingly recognise activity tax relief payment reflect liability option group balance sheet group adjust item tax charge q initial value million q payment relate original estimate fair value shionogi irrevocably agree waive option contingent consideration acquisition result gsk derecognise liability option shionogiviiv healthcare joint venture million group balance sheet directly equity value report investing activity cash flow statement liability million derecognise payment relate increase gsk option shionogis shareholde liability acquisition report operate cash viiv healthcare original agreement flow exercisable sixmonth window commencing movement contingent consideration payable shionogi gsk irrevocably agree waive follow exercise window sixmonth window remain option fair value value accounting purpose contingent consideration begin year remeasurement income statement free cash flow cash payment operate cash flow free cash flow define net cash inflow operate cash payment invest activity activity capital expenditure property plant equipment intangible asset contingent consideration contingent consideration end year payment net finance cost dividend pay non contingent consideration payable posttax basis control interest plus proceed sale property shionogi december million december plant equipment intangible asset dividend million expect pay year receive joint venture associate management planning reporting purpose exit right discussion presentation investment analyst pfizer request ipo viiv healthcare time rating agency free cash flow growth calculate gsk consent ipo offering report basis reconciliation net cash inflow complete month pfizer require gsk operation free cash flow set acquire shareholde original agreement gsk unconditional right long subsequent cer aer growth distribution shareholder withhold consent order illustrate underlying performance group exercise pfizer option result accordance practice discuss result term constant exchange ifrs gsk recognise liability option rate cer growth represent growth calculate balance sheet q gsk notify exchange rate determine result overseas pfizer irrevocably give right accordingly company sterling remain unchanged recognise liability option group balance comparative period cer represent growth sheet q initial value million constant exchange rate aer represent growth consistent revise treatment end q actual exchange rate gsk recognise liability future preferential proforma growth dividend anticipate payable pfizer shionogi acquisition pfizer consumer healthcare business group balance sheet complete july gsk report result closing balance liability related pfizer include month result pfizer consumer shareholding follow healthcare business august group present proforma growth rate cer turnover adjust operating profit operating profit pfizer option business take account transaction proforma growth pfizer preferential dividend rate cer calculate compare report result calculate apply exchange rate original agreement shionogi comparative period result adjust request gsk acquire shareholding viiv healthcare include equivalent month result sixmonth window commencing pfizer consumer healthcare business consolidate gsk unconditional right long include pfizer gaap result subsequent distribution shareholder withhold consent exercise shionogi option result gsk recognise liability option balance sheet gsk annual report strategic report governance remuneration financial statement investor information group financial review continue approach tax understand responsibility pay appropriate ongoing public focus tax affair tax fully support effort ensure company multinational company include major project appropriately transparent tax affair organisation economic cooperation development manage tax important element economic oecd address tax challenge digitalisation contribution bring country operate economy gsk welcome oecds effort identify engage artificial tax arrangement longterm sustainable consensus drive solution business commercial substance seek avoid tax challenge result digitalisation active tax use tax haven transaction fully provide relevant business input assist successful disclose tax authority zero tolerance approach delivery aim project order create long tax evasion facilitation tax evasion last stable certain business environment taxpayer government multilateral consensusbase substantial business employment presence approach ground clearly define accept principle country globe pay significant critical incentive innovate dilute tax include corporation business taxis tax associate employee time continue focus tax reform drive responsibility shareholder financially oecds base erosion profit shift bep project efficient deliver sustainable tax rate european commission initiative fiscal state aid approach look align investment strategy investigation introduction mandatory disclosure country substantial economic activity rule output oecd bep project clarify government policy promote regime important principle tax pay profit attractive business investment rd activity supply chain profitmake activity take place transparent intent available relevant tax payer gsk subject taxation supply chain example include uk patent box research gsk support bep proposal particular development expenditure credit implementation oecds recommendation country tax risk manage robust internal policy country report include exchange datum process ensure alignment tax authority datum validate exist business compliance tax legislation audit risk information hold taxpayer support ability ensure committee board responsible approve multinational group pay appropriate tax tax policy risk management approach seek detailed tax implication brexit dependent maintain open positive relationship government outcome negotiation uk eu tax authority worldwide welcome constructive currently unknown continue work debate taxation policy government ensure uk retain trading relationship group corporate tax charge million eu allow supply product swiftly million profit tax million today patient consumer zero tariff million represent effective tax rate good minimal custom procedure vat cash flow cash tax payment cost crossborder trade direct tax implication million year million addition particular expect limited gsk indirect taxis pay profit pay duty levy tax implication significant include potential transactional employment taxis custom duty cost additional transaction administrative cost associate manage import export obligation adjust tax rate movement good uk eu rate benefit settlement open tax ukeu rest world approach position key territory subject material change brexit set product mix material change tax regulation law country operate group tax strategy set detail public policy average effective adjusted tax rate medium term position section website detail expect corporate tax charge year set group total tax rate low adjust tax rate total tax charge include tax effect fair value accounting movement group option liability viiv healthcare hedge share hindustan unilever limited receive disposal horlick consumer healthcare brand reassessment estimate uncertain tax position follow settlement number open issue tax authority gsk annual report group financial review continue financial performance group turnover bn gsk use number adjust nonifrs measure report proforma performance business adjust result bn aer growth cer growth cer growth nonifrs measure consider addition substitute superior information present accordance ifrs adjust result nonifrs measure define page total result group set growth turnover turnover cer turnover cost sale sell general administration total operating profit bn research development royalty income bn aer growth cer growth operating incomeexpense operating profit net finance cost profit disposal interest associate share aftertax profit associate joint ventures profit taxation taxation profit taxation year adjust operating profit bn profit attributable shareholder proforma earning share p bn aer growth cer growth cer growth earning ad adjust result group set reconciliation total result adjust result set growth turnover turnover cer turnover cost sale sell general administration research development royalty income adjust operate profit adjust profit attributable shareholder adjust earning share p gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue group turnover pharmaceutical group turnover business turnover bn growth growth cer bn aer growth cer growth pharmaceutical vaccine group turnover consumer healthcare group turnover corporate unallocated turnover proforma growth group turnover geographic region growth growth cer pharmaceuticals turnover europe revise growth growth international cer respiratory group turnover year increase aer cer hiv million growth deliver vaccine immunoinflammation consumer healthcare pharmaceutical flat cer oncology proforma turnover growth group cer establish pharmaceutical pharmaceutical turnover year million aer flat cer hiv sales aer pharmaceutical turnover year million cer million respiratory sale aer flat cer hiv sales aer cer aer cer million sale establish million growth juluca dovato partly offset pharmaceutical million aer cer decline triumeq tivicay respiratory sale aer cer million growth trelegy vaccine turnover grow aer cer million ellipta nucala sale establish pharmaceutical primarily drive growth sale shingrix meningitis million aer cer include impact vaccine contribute significantly growth loss exclusivity advair pharmaceutical vaccine innovation sale sale sale decline aer cer continue growth product launch year amount nucala trelegy ellipta benlysta offset billion drive sale shingrix trelegy decline establish product include loss ellipta nucala exclusivity advair exclude advair relvarbreo ellipta consumer healthcare sale grow aer cer impact genericisation icslaba million proforma basis sale grow drive market growth aer cer europe sale grow strong performance oral health category partly offset aer cer strong growth respiratory partly decline skin health offset decline establish pharmaceutical international consumer healthcare innovation sale sale product grow aer cer growth therapy area new market year amount consumer healthcare sale reflect continue focus oral health innovation gsk annual report group financial review continue financial performance continue respiratory follow launch dovato april total respiratory sale aer cer combine sale twodrug regimen million strong growth region ellipta product sale grow total dolutegravir sale grow aer flat cer aer cer europe aer cer reflect yearonyear share decline business international aer cer trelegy relvar transition new twodrug portfolio offset net price breo growth nucala aer cer europe benefit europe total dolutegravir sale flat aer aer cer international trelegy flat cer strong growth market share offset price ellipta nucala growth offset decline relvarbreo erosion high clawback payment dovato juluca ellipta post generic icslaba price pressure report combine sale million international grow strongly total dolutegravir sale growth aer sale nucala million year grow cer driven tivicay triumeq aer cer sales million aer cer include impact new athome use oncology application sale zejula million period date sale ellipta product aer cer acquisition comprise million million million drive growth europe international europe region sale grow aer flat cer immunoinflammation reflect continued competitive pricing pressure ics sale benlysta year aer cer labas post generic advair europe sale grow aer million include sale subcutaneous formulation cer international aer cer sale million benlysta grow aer cer trelegy ellipta contribute million globally year million drive increase market share relvarbreo ellipta sale aer cer establish pharmaceutical drive relvarbreo ellipta decline aer sale establish pharmaceuticals year cer result competitive pricing pressure million aer cer impact generic advair icslaba market establish respiratory product decline aer europe international relvarbreo ellipta continue cer million decline advairseretide grow aer cer europe aer partly offset high sale ventolin flovent allergy cer international product generic version advair launch february result aer cer decline year hiv europe seretide sale aer cer hiv sale grow aer cer million year million reflect continued competition generic dolutegravir franchise grow aer cer deliver product transition respiratory portfolio new sale million remain portfolio million product international sale seretide flat aer total hiv sale decline aer cer cer globally ventolin grow aer reduce overall hiv growth percentage point cer drive strong uptake authorise generic aer percentage point cer version sale dolutegravir product million remainder establish pharmaceutical portfolio triumeq tivicay deliver sale million decline aer cer million include million respectively twodrug regimen juluca lamictal aer cer million generic dovato deliver sale million year competition low sale viread international combine growth offset decline decline partly offset augmentin aer threedrug regimen triumeq reflect impact cer million year drive strong growth competition transition business international new portfolio gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue vaccine influenza fluarixflulaval sale aer cer million reflect strong sale execution turnover bn partly offset increase price competition bn aer growth cer growth low demand europe shingle group turnover shingrix record sale million primarily drive continued strong uptake favourable benefit priorperiod rebate adjustment germany canada contribute growth establish vaccine sale dtpacontaine vaccine infanrix pediarix boostrix grow aer cer infanrixpediarix sale grow aer cer million reflect favourable yearonyear cdc stockpile movement strong vaccine turnover demand international partly offset competitive pressure europe boostrix sales aer cer growth growth cer million mainly strong demand international meningitis share gain high demand influenza hepatitis vaccine grow aer cer million shingle primarily favourable yearonyear cdc stockpile establish vaccine movement continue benefit competitor supply shortage partly offset supply constraint low demand europe vaccine turnover grow aer cer million primarily drive growth sale shingrix meningitis synflorix sale grow aer cer million vaccine contribute growth mainly bexsero primarily strong demand international demand share gain strong rotarix sale aer cer million demand international establish vaccine grow aer reflect strong demand international cer million primarily reflect strong growth favourable phase international boostrix hepatitis vaccine synflorix infanrixpediarix partly offset low cervarix sale international supply mmrv vaccine sale decline aer cer constraint mmrv vaccine million largely drive supply constraint europe international meningitis cervarix sale aer cer million meningitis sale grow aer cer million reflect low demand expect return competitive bexsero sale grow aer cer million pressure china low demand drive demand share gain international strong demand international europe partly offset completion vaccination catchup cohort certain market europe menveo grow aer cer primarily reflect improved supply high demand international gsk annual report group financial review continue financial performance continue consumer healthcare wellness wellness sale grow aer cer million year proforma basis sale flat growth turnover bn proforma pain relief offset decline respiratory phasing bn aer growth cer growth cer growth lowmargin contract manufacturing pain relief benefit continue strong performance panadol advil reflect ongoing recovery resolve group turnover supply issue voltaren see weak performance impact retail stock movement respiratory sale decline growth flonase offset weak performance theraflu follow strong cold flu comparator growth impact decline respiratory brand oral health oral health sale grow aer cer million sensodyne see doubledigit broadbase growth strong consumer healthcare turnover performance india benefit new product growth growth innovation gum health grow double digit broadbase cer growth denture care grow midsingle digits oral wellness health growth impact decline sale oral health nonstrategic brand nutrition skin health nutrition nutrition sale grow aer cer million largely inclusion pfizer vitamin mineral supplement portfolio proforma basis sale flat growth growth reflect strong performance horlick offset decline cer nutrition product alignment inmarket europe inventory level pfizer brand growth impact divestment horlick maxinutrition international uk proforma growth skin health consumer healthcare sale grow aer cer skin health sale grow aer cer million million proforma basis sale grow largely addition chapstick pfizer portfolio drive strong performance oral health category partly proforma basis sale decline midsingle digit largely offset decline skin health regional level growth divestment small tail brand uk drive international follow acquisition pfizer portfolio proforma basis growth drive primarily international region strong performance india china divestment phase lowmargin contract manufacture negative impact proforma growth approximately percentage point sale consumer healthcare business include month pfizer brand sale arise creation joint venture pfizer brand include exist category geographic region report consumer healthcare sale gsk expect revise category structure report q onwards gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue cost sale partly offset continue benefit restructure growth growth pharmaceutical tight control ongoing cost cer particularly nonpromotional spending total cost sale business adjust cost sale research development total cost sale percentage turnover growth growth percentage point high aer percentage point cer high cer term compare reflect total research development increase cost major restructuring programme adjust research development primarily result writedown number manufacture total rd expenditure million turnover site unwind fair market value uplift inventory aer cer adjust rd expenditure arise completion consumer healthcare joint venture million turnover high aer pfizer increase amortisation intangible asset high cer proforma basis adjust exclude adjust item adjust cost rd expenditure grow cer compare sale percentage turnover percentage pharmaceutical rd expenditure million point high aer percentage point high cer aer cer significant increase study compare proforma basis adjust cost clinical trial material investment oncology compare sale percentage turnover percentage reflect progression asset tesaro point high cer reflect continue acquisition primarily zejula dostarlimab number adverse pricing pressure pharmaceutical particularly programme include belantamab mafodotin nyeso respiratory unfavourable product mix pharmaceutical icos bintrafusp alfa increase spending number nonrestructure relate writedown progression key nononcology asset agmcsf manufacturing site partly offset favourable rheumatoid arthritis partly offset saving product mix vaccine primarily growth shingrix early phase portfolio reprioritisation late rd favourable impact inventory adjustment vaccine expenditure vaccine consumer healthcare contribution integration restructuring million million respectively saving pharmaceutical consumer healthcare sell general administration royalty income royalty income million million growth growth cer aer cer primarily reflect increase royalty total sell general sale gardasil administration adjust sell general operating incomeexpense administration net operating income million million expense primarily reflect profit disposal total sga cost percentage turnover rabie tickborne encephalitis vaccine million percentage point high aer percentage point number asset disposal increase high cer compare include increase value share hindustan unilever limited receive significant legal charge arise settlement exist disposal horlick consumer healthcare matter provision ongoing litigation cost relate brand cumulative increase value sign acquisition pfizer consumer healthcare business propose transaction million reversal indemnity receivable novartis follow tax settlement equivalent release tax provision income include accounting credit million reflect tax charge increase million expense arise restructuring cost remeasurement contingent consideration liability relate acquisition shionogiviiv healthcare joint exclude adjust item adjust sga venture novartis vaccine business cost percentage turnover percentage liability pfizer option pfizer shionogi point high aer percentage point preferential dividend viiv healthcare include high cer basis proforma basis adjust sga remeasurement charge million million cost percentage turnover percentage contingent consideration liability shionogi point high cer compare primarily arise unwind discount partly offset growth adjust sga cost aer cer change exchange rate assumption sale forecast cer proforma basis reflect increase include remeasurement charge million investment result acquisition tesaro relation consumer healthcare option promotional product support particularly new launch vaccine respiratory hiv increase cost number legal settlement gsk annual report group financial review continue financial performance continue operating profit partly offset continued benefit restructure total operating profit million compare tight control ongoing cost benefit million reduce remeasurement charge reprioritisation rd portfolio contingent consideration liabilitie consumer vaccine operate profit million aer healthcare option charge increase profit disposal cer high turnover increase cer increase value share hindustan unilever operate margin percentage point limited receive disposal horlick high aer percentage point high consumer healthcare brand partly offset increase cer basis primarily drive enhanced operating charge major restructuring primarily arise write leverage strong sale growth particularly shingrix down number manufacture site cost integrate improve product mix high royalty income increase consumer healthcare joint venture increase sga investment support business growth partly offset significant legal charge income oneoff settlement exclude adjust item adjust operate consumer healthcare operate profit million profit million high aer aer cer high turnover increase flat cer turnover increase cer adjust cer proforma basis operate profit million operating margin percentage point low cer high turnover increase cer aer percentage point low cer basis operate margin percentage point high proforma basis adjust operating profit aer percentage point high cer basis low cer turnover increase cer adjust proforma operating margin proforma operating margin percentage percentage point high cer basis primarily point low cer basis reflect continue manufacture restructuring saving reduction proforma adjust operating profit primarily improve growth high margin power brand reflect continue price pressure particularly respiratory divestment low margin tail product tight control include impact launch generic version advair operating expense partly offset increase february investment rd include investment promotion significant increase oncology investment partly net finance cost asset tesaro acquisition investment promotional product support particularly new launch revise vaccine hiv respiratory partly offset finance income benefit sale growth particularly vaccine interest income favourable mix vaccine consumer healthcare fair value movement favourable inventory adjustment vaccine continue benefit restructure tight control ongoing cost business finance expense interest expense contingent consideration cash payment unwind discount provision shionogi company reduce balance sheet remeasurement fair value movement liability record income statement total contingent consideration cash payment finance expense lease liability amount million million include finance expense payment shionogi million million total net finance cost million compare operate profit business million adjust net finance cost pharmaceutical operate profit million million compare million increase aer cer turnover flat cer operate primarily reflect high debt level follow acquisition margin percentage point low aer novartis stake consumer healthcare joint percentage point low cer basis venture june acquisition tesaro january primarily reflect increase cost sale percentage adverse comparison oneoff continue impact low price particularly account adjustment million amortisation interest respiratory include impact launch generic charge partly offset benefit old version advair february unfavourable bond refinance low interest rate fair value gain product mix primarily result decline advair interest rate swap interest million q growth low margin product significant increase historic tax settlement follow introduction ifrs oncology rd investment new product support lease finance cost include unwind discount target priority market number non lease liability million year restructure relate writedown manufacture site high legal cost gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial performance continue share aftertax profit associate joint venture earning share share aftertax profit associate million total earning share p compare p million include oneoff adjustment increase earning share primarily reflect million reflect gsk share increase aftertax profit reduce remeasurement charge contingent innoviva primarily result nonrecurre income tax consideration liability option increase benefit value share hindustan unilever limited receive disposal horlick consumer healthcare profit tax brand reduce effective tax rate increase share take account net finance cost share profit aftertax profit associate innoviva associate profit taxation million compare million adjust eps p compare p aer cer adjust operating profit flat cer taxation improvement primarily result reduce effective tax rate increase share aftertax profit associate result nonrecurre income tax benefit innoviva partly offset increase net finance cost high uk current year charge noncontrolle interest allocation consumer healthcare rest world current year charge profit charge respect prior period total current taxation dividend total defer taxation board declare interim dividend result total taxation total profit dividend year penny line dividend declare note financial statement charge million represent effective tax rate dividend total result reflect different tax effect adjust item tax dividend policy adjust profit amount million represent gsk recognise importance dividend shareholder effective adjust tax rate reflect aim distribute regular dividend payment impact settlement number open issue determine primarily reference free cash flow tax authority generate business funding investment necessary support group future growth issue relate taxation describe note financial statement taxation group continue believe board intend maintain dividend adequate provision liability likely arise current level p share subject material change period open agree tax external environment performance expectation authority ultimate liability matter vary time free cash flow strengthen intend build amount provide dependent outcome free cash flow cover annual dividend target range agreement relevant tax authority x return dividend growth noncontrolle interest outlook allocation total earning noncontrolle interest outlook reflect expectation growth key amount million million increase new product start twoyear period primarily increase allocation viiv healthcare continue increase investment product profit million million high net rd pipeline alongside implementation new programme profit group entity noncontrolle prepare group separation interest partly offset low allocation expect adjust eps decline range consumer healthcare profit million cer guidance exclude impact million follow buyout novartis interest june material divestment previously completion new consumer healthcare joint announce potential impact business venture pfizer july include coronavirus outbreak unwind fair value uplift acquire inventory expectation guidance target future allocation adjust earning noncontrolle interest performance dividend payment read amount million million increase cautionary statement forwardlooke allocation reflect increase allocation consumer statement assumption relate outlook healthcare profit million million inside cover increase allocation viiv healthcare profit million million high net profit group entity noncontrolle interest gsk annual report group financial review continue adjust item divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million gsk annual report strategic report governance remuneration financial statement investor information group financial review continue adjust item continue major restructure integration analysis major restructuring charge income pharmaceutical sector highlyregulate statement line follow manufacture operation supply chain long lifecycle business mean restructure programme particularly involve rationalisation closure manufacturing cost sale rd site likely year complete sell general administration research development major restructuring cost relate specific board approve major restructuring programme exclude operating incomeexpense adjust result major restructuring programme total major restructuring charge include integration cost follow material acquisition combine restructure integration programme structural significant scale deliver incremental annual cost saving year cost individual relate project exceed million billion major restructuring programme deliver ordinary course smallerscale restructuring cost retain incremental cost saving year billion total adjust result total cash charge combine restructure total major restructuring charge incur integration programme expect approximately million million analyse follow billion noncash charge billion total billion represent reduction billion non non originally approve billion programme cash cash total cash cash total deliver approximately billion annual saving include major estimate currency benefit billion programme restructuring expect deliver end total annual saving programme billion constant currency basis include incl tesaro estimate benefit billion currency basis consumer average exchange rate programme substantially healthcare joint complete gsk cease external reporting venture integration total cost benefit combined restructure programme integration programme onwards combined restructuring group acquire tesaro january expect integration incur million integration restructure programme cash cost lead annual costsave benefit million add report cash charge primarily arise restructure exist major restructure programme manufacturing organisation rd administrative major restructuring programme include function integration tesaro tesaro expect cost billion period major restructure programme integration cost cash cost billion noncash cost consumer healthcare joint venture integration programme billion expect deliver annual saving noncash charge major restructuring million rate saving programme primarily relate announced plan restructure intend fully reinveste help fund target increase manufacture network rd commercial support new product total cash payment million completion new consumer healthcare joint venture million exist combined restructuring pfizer expect realise substantial cost synergy integration programme million million generating total annual cost saving billion million major restructuring expect cash cost billion noncash charge programme include settlement certain charge accrue billion plus additional capital expenditure billion previous quarter million relate cost saving intend reinveste consumer healthcare joint venture integration programme business support innovation growth analysis major restructuring charge business opportunity follow group initiate twoyear separation preparation programme prepare separation gsk company new gsk biopharma company rd pharmaceutical vaccine approach focus science relate immune system use genetic new technology new leader consumer healthcare consumer healthcare corporate central function total major restructuring charge gsk annual report group financial review continue adjust item continue programme aim divestment significant legal charge item drive common approach rd improve capital divestment item include profit disposal allocation rabie tickborne encephalitis vaccine million align improve capability efficiency global gain year million arise increase value support function support new gsk share hindustan unilever limited receive disposal horlick consumer healthcare optimise supply chain product portfolio brand equity investment impairment certain include divestment noncore asset strategic adjust item profit number review prescription dermatology underway asset disposal charge million million prepare consumer healthcare operate standalone significant legal matter include settlement exist company matter provision ongoing litigation significant programme target delivery billion annual legal cash payment million million saving billion total cost estimate billion billion expect proforma growth reconciliation cash cost proceed anticipate divestment table set reconciliation report cer largely expect cover cash cost programme growth rate proforma cer growth rate additional onetime cost prepare consumer healthcare report margin percentage proforma margin percentage separation estimate million exclude adjustment transaction cost include august december transactionrelate adjustment result transactionrelated adjustment result net charge pfizer report consumer proforma million million include net growth rate healthcare growth rate million accounting credit remeasurement cer business cer contingent consideration liability relate acquisition group shionogiviiv healthcare joint venture turnover novartis vaccine business liability adjust cost sale pfizer option pfizer shionogi preferential adjust sell general dividend viiv healthcare administration adjust research development chargecredit adjust operate profit consumer healthcare joint venture option consumer healthcare contingent consideration shionogiviiv turnover healthcare joint venture include shionogi wellness sale preferential dividend nutrition sale viiv healthcare option pfizer preferential skin health sale dividend operate profit contingent consideration novartis vaccine business proforma financial information basis release fair value uplift acquire pfizer proforma growth rate calculate follow inventory adjustment august december total transactionrelated charge result gsk pfizer million charge relate contingent consideration report consumer proforma result healthcare result shionogiviiv healthcare joint venture represent business increase valuation contingent consideration bn bn bn shionogi primarily result million unwind group discount partly offset update exchange rate assumption turnover adjustment sale forecast million credit adjust cost sale relate viiv healthcare option pfizer preferential adjusted sell general dividend represent reduction valuation administration option result adjustment multiple sale forecast adjust research development update exchange rate assumption adjust operate profit consumer healthcare adjustment include transaction cost arise turnover completion consumer healthcare joint venture pfizer wellness sale reversal indemnity receivable novartis nutrition sale follow tax settlement equivalent release skin health sale tax provision explanation accounting operating profit noncontrolle interest viiv healthcare set gsk annual report strategic report governance remuneration financial statement investor information group financial review continue cash generation conversion summary consolidate cash flow statement set reconciliation net cash inflow operating activity free cash flow reconciliation net cash inflow operating activity close equivalent ifrs measure free cash flow net cash inflow operating activity show net cash outflow investing activity net cash outflow financing activity increasedecrease cash bank overdraft net cash inflow operating activity purchase property plant equipment cash bank overdraft begin year purchase intangible asset increase cash bank overdraft proceed sale property plant equipment exchange adjustment proceed disposal intangible asset cash bank overdraft end year interest pay cash bank overdraft end year comprise interest receive cash cash equivalent dividend associate joint venture cash cash equivalent report asset contingent consideration pay report hold sale investing activity overdraft contribution noncontrolle interest distribution noncontrolle interest capital expenditure financial investment free cash flow cash payment tangible intangible fix asset future cash flow amount million million long term expect future cash generate disposal realise million million operation sufficient fund operate debt cash payment acquire equity investment amount servicing cost normal level capital expenditure obligation million million primarily relate exist licensing agreement expenditure arise lyell immunopharma sale equity investment realise restructuring programme routine outflow include million million tax pension contribution dividend subject free cash flow principal risk uncertainty discuss page free cash flow cash generate group time time additional demand meet obligation contingent consideration finance acquisition include potentially acquire interest tax dividend pay noncontrolle interest increase ownership interest viiv healthcare business capital expenditure property plant equipment minority shareholder hold option access intangible asset multiple source liquidity short longterm capital market financial institution need addition cash flow operation free cash inflow investment appraisal capital allocation reduction free cash flow primarily reflect adverse strong framework capital allocation include timing payment return rebate initial board govern allocation capital stepdown impact advair generic competition business utilise consistent cash return invest increase capital expenditure include acquisition capital croic methodology prioritise investment intangible asset high restructuring payment high group effectively compare significant legal cost partly offset improved return business allocate capital operating profit include currency benefit reduction consider impact ep inventory low increase trade receivable low credit profile relevant contingent consideration payment compare include milestone payment novartis low dividend payment noncontrolle interest reclassification lease payment operate financing activity follow transition ifrs total cash payment shionogi relation viiv healthcare contingent consideration liability year million million million recognise cash flow operating activity million recognise contingent consideration pay invest cash flow payment deductible tax purpose gsk annual report group financial review continue financial position resource acquisition pfizer consumer healthcare business acquisition pfizer consumer healthcare business asset noncash transaction result increase net noncurrent asset asset billion include intangible asset property plant equipment billion goodwill billion reflect right use asset recognition pfizer noncontrolle interest consumer goodwill healthcare joint venture billion gain retain intangible asset earning billion represent difference investment associate joint venture fair value book value gsk consumer investment healthcare business transfer pfizer defer tax asset derivative financial instrument property plant equipment noncurrent asset business sciencebase technologyintensive highly total noncurrent asset regulate governmental authority allocate significant financial resource renewal maintenance current asset property plant equipment minimise risk interruption inventory production ensure compliance regulatory standard current tax recoverable number process use hazardous material trade receivables derivative financial instrument total cost property plant equipment december million net book value liquid investment million land building represent cash cash equivalent million plant equipment million asset asset hold sale construction million invest total current asset million new property plant equipment mainly total asset relate large number project renewal liability improvement expansion facility worldwide current liability site support new product development launch shortterm borrowing improve efficiency exist supply chain property contingent consideration liability mainly hold freehold new investment finance trade payable liquid resource december contractual derivative financial instrument commitment future capital expenditure million current tax payable believe property plant facility adequate shortterm provision current need total current liability observe stringent procedure use specialist skill manage environmental risk activity environmental noncurrent liability issue date operation modify longterm borrowing discontinue report environment corporation tax payable note financial statement legal proceeding defer tax liability pension postemployment benefit right use asset provision right use asset amount million december derivative financial instrument compare million january contingent consideration liability follow implementation ifrs decrease noncurrent liability year reflect impact depreciation disposal total noncurrent liability million million respectively partly offset total liability addition include business combination net asset million total equity goodwill goodwill increase million december million primarily reflect addition million arise acquisition pfizer consumer healthcare business million acquisition tesaro inc gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial position resource continue intangible asset derivative financial instrument liabilitie intangible asset include cost intangible acquire hold current noncurrent derivative financial liability party computer software net book value fair value million million primarily intangible asset december relate foreign exchange contract designate million million increase primarily designate accounting hedge reflect addition million acquisition trade payable pfizer consumer healthcare business million december trade payable acquisition tesaro inc million compare million investment associate joint venture december increase primarily reflect higher hold investment associate joint venture payable consumer healthcare follow pfizer carry value december million acquisition year partly offset exchange movement million market value december provision million million large carry defer tax provision shortterm investment innoviva inc book value noncurrent provision million december december million million million provision yearend market value million note financial include million million relate legal statement investment associate joint venture dispute million million relate investment major restructuring programme provision hold investment carry value legal dispute indemnify disposal liability december million million employee relate liability cost restructure high value investment hold december programme extent balance sheet date legal andme book value december constructive obligation exist reliably estimate million million progyny inc pensions postemployment benefit book value million million theravance account pension postemployment biopharma inc book value december arrangement accordance ias net deficit million million investment million million pension arrangement include equity stake company million million unfunded research collaboration provide access postemployment liability note financial biotechnology development potential interest interest statement pension postemployment benefit company arise business divestment noncurrent liability derivative financial instrument asset noncurrent liability amount million current derivative financial asset hold fair value december million million million noncurrent derivative financial asset hold fair value million contingent consideration liabilitie million million current derivative financial asset contingent consideration amount million relate derivative embed agreement divest december million horlick nutritional brand unilever plc note million million represent estimate information majority remainder present value amount payable shionogi relate viiv financial instrument relate foreign exchange contract healthcare million million represent designate designate accounting hedge estimate present value contingent consideration payable novartis relate vaccine acquisition inventory inventory million increase million liability shionogi include million respect primarily reflect high inventory consumer preferential dividend liability preferential dividend healthcare follow pfizer acquisition year partly pfizer december million offset impact exchange movement million explanation accounting non control interest viiv healthcare set trade receivable trade receivables million increase contingent consideration payable posttax basis million primarily reflect impact high december million million sale particularly vaccine partly offset well collection expected pay year consideration payable exchange movement expect pay number year result total estimate liability discount present value defer tax asset posttax basis posttax discount rate shionogi defer tax asset amount million viiv healthcare contingent consideration liability discount million december novartis vaccine contingent consideration liability discount partly partly gsk annual report group financial review continue financial position resource continue maturity profile bond debt equivalent gbp bonds eur bond usd bond net debt cash liquid investment billion billion hold centrally december analysis cash gross debt effect hedge cash cash equivalent liquid investment follow cash cash equivalent report asset hold sale borrowing repayable year cash liquid investment borrowing repayable year gross debt fix net debt float december net debt billion compare noninterest bear billion december comprise gross net debt debt billion cash liquid investment include billion equivalent note swap float fix rate interest billion include billion report asset hold rate swap sale net debt increase billion acquisition movement net debt tesaro inc billion tesaro net debt billion impact implementation ifrs dividend pay shareholder billion net net debt begin year investing activity billion partly offset billion net implementation ifrs favourable exchange impact translation nonsterle net debt begin year adjust denominate debt exchange financing item increase cash bank overdraft billion free cash flow decrease liquid investment december gsk shortterm borrowing increase longterm loan include overdrafts lease liability repayable net repayment shortterm loan month billion loan billion repayable repayment lease liability subsequent year debt subsidiary undertaking acquire exchange movement december gsk cash liquid investment movement hold follow net debt end year bank balance deposit bank balance deposit report asset hold sale treasury treasury repo money market fund liquidity fund cash cash equivalent liquid investment government security gsk annual report strategic report governance remuneration financial statement investor information group financial review continue financial position resource continue interest rate benchmark reform total equity interest rate benchmark reform amendment ifrs december total equity increase ias ifrs issue iasb september million december million amendment modify specific hedge accounting summary movement equity set requirement allow hedge accounting continue affect hedge period uncertainty hedge item hedge instrument affect current interest total equity beginning year rate benchmark amend result ongoing implementation ifrs interest rate benchmark reform implementation ifrs december group directly expose implementation ifrs interest rate benchmark reform hold interest rate total equity beginning year adjust derivative reference libor mature end total comprehensive income year float rate bond mature dividend shareholder end recognition interest consumer healthcare joint venture group closely monitor market output industry work group manage ordinary share issue transition new benchmark interest rate include change noncontrolle interest announcement libor regulator include derecognition liability noncontrolle interest financial conduct authority fca commodity sharebase incentive plan future trading commission transition away libor include gbp libor usd libor tax sharebase incentive plan euribor sterling overnight index average rate contribution noncontrolle interest sonia secure overnight financing rate sofr distribution noncontrolle interest euro shortterm rate str respectively fca total equity end year clear end long share purchase seek persuade compel bank submit libor shares repurchase company group undertake interest rate benchmark transition december gsk hold million share programme identify potential exposure business treasury share million share cost deliver smooth transition appropriate alternative million million benchmark rate deduct retain earning ordinary share purchase period january february company expect ordinary share repurchase remainder million treasury share transfer employee share ownership plan esop trust share hold trust satisfy future exercise option award group share option award scheme proportion share hold trust respect award rule scheme require satisfy exercise market purchase issue new share share hold trust match option award grant december esop trust hold million million gsk share future exercise share option share award carry value million million deduct reserve market value share million million gsk annual report group financial review continue financial position resource continue contractual obligation commitment reach agreement trustee financial commitment summarise note uk pension scheme additional contribution financial statement commitment assist eliminate pension deficit identify december actuarial funding valuation table follow table set contractual obligation include commitment exclude normal commitment december fall ongoing annual funding requirement uk approximately payment million information pension obligation total yr yrs yrs yrs note financial statement pension postemployment benefit loan interest loan contingent liability finance lease obligation contingent liability set note financial future finance charge statement contingent liability intangible asset follow table set contingent liability comprise property plant equipment discount bill performance guarantee letter credit investment item arise normal course business purchase commitment expect expire pension total total yr yrs yrs yrs commitment respect loan future interest payable guarantee loan disclose take account effect contingent liability derivative total enter number research collaboration normal course business provide develop new compound pharmaceutical company indemnification guarantee respect business disposal term arrangement include upfront fee legal dispute subsequently arise equity investment loan commitment fund specify provision outflow resource consider level research addition agree probable reliable estimate likely payment future milestone achieve outcome dispute include note agreement relate compound early financial statement provision stage development potential obligation provide outcome tax legal dispute milestone payment continue number year outflow resource consider probable compound successfully development reliable estimate outflow december process generally close product marketing dispute provision approval great probability success amount possible reliable estimate show intangible asset represent maximum potential outflow fund require settle pay milestone achieve include dispute possibility outflow billion relate externalised project remote discovery portfolio increase commitment ultimate liability matter vary significantly result number new rd collaboration amount provide dependent negotiation include merck kgaa lyell immunopharma relevant tax authority outcome litigation proceeding relevant discuss principal risk uncertainty page note financial statement legal proceeding gsk annual report strategic report governance remuneration financial statement investor information group financial review continue treasury policy report sterling pay dividend sterling cash interest rate risk management flow role treasury monitor manage gsk objective minimise effective net interest cost group external internal funding requirement financial balance mix debt fix float interest rate risk support strategic objective gsk operate time policy interest rate risk management limit global basis primarily subsidiary company net float rate debt specific cap review manage capital ensure subsidiary able agree annually board operate go concern optimise return foreign exchange risk management shareholder appropriate balance debt objective minimise exposure overseas equity treasury activity govern policy approve operating subsidiary transaction risk match local annually board director recently currency income local currency cost possible october treasury management group tmg foreign currency transaction exposure arise external meeting chair chief financial officer take place internal trade flow selectively hedge gsk internal regular basis review treasury activity member trading transaction match centrally manage receive management information relate activity intercompany payment term reduce foreign currency risk treasury operation possible manage cash surplus borrow objective gsk treasury activity minimise requirement subsidiary company centrally forward posttax net cost financial operation reduce volatility contract hedge future repayment originate order benefit earning cash flow gsk use variety currency financial instrument finance operation derivative order reduce foreign currency translation exposure financial instrument manage market risk seek denominate borrowing currency operation derivative principally comprise foreign exchange principal asset cash flow primarily forward contract swap swap denominate dollar euro sterling borrowing borrowing liquid asset currency require swap currency require group purpose interest rate swap manage exposure financial risk change borrowing denominate swap foreign interest rate currency match investment overseas group asset treat hedge relevant asset forward derivative exclusively hedge purpose relation contract major currency reduce exposure underlie business activity trading group investment overseas group asset tmg speculative instrument review ratio borrowing asset major currency capital management regularly gsk financial strategy implement group counterparty risk management financial architecture support gsk strategic priority set global counterparty limit banking regularly review board manage capital investment counterpartie base longterm credit rating structure group appropriate mix debt moodys standard poor treasury usage equity continue manage financial policy credit limit monitor daily treasury compliance officer profile particularly target shortterm credit rating tco operate independently treasury breach p maintain single longterm rating consistent limit report cfo immediately target tco monitor credit rating counterpartie gsk longterm credit rating standard poor change rating occur notifie treasury negative outlook moodys investor service change investment level authority limit moodys negative outlook shortterm credit appropriate addition relationship bank credit rating p standard poor moodys rating review regularly report present annually respectively tmg approval liquidity risk management gsk policy borrow centrally order meet anticipate funding requirement cash flow forecast funding requirement monitor tmg regular basis strategy diversify liquidity source range facility maintain broad access financial market day sweep cash number global subsidiary central treasury account liquidity management purpose gsk annual report group financial review continue critical accounting policy consolidate financial statement prepare medicaid programme stateadministere accordance ifrs adopt use european programme provide assistance certain poor union ifrs issue international vulnerable patient medicaid drug rebate accounting standard board iasb follow accounting program establish reduce state federal policy approve board describe note expenditure prescription drug patient financial statement accounting principle policy protection affordable care act law participate provide rebate state accrual require estimate assumption medicaid rebate calculate base specific affect amount asset liability revenue expense term relevant regulation patient protection report financial statement actual amount affordable care act result differ estimate cash discount offer customer encourage critical accounting policy relate follow area prompt payment accrue time turnover invoicing adjust subsequently reflect actual taxation note experience legal dispute note record accrual estimate sale return apply historical experience customer return amount contingent consideration option liability invoice marketrelate information note stock level wholesaler anticipate price increase pension postemployment benefit note competitor activity information judgement estimate reconciliation gross turnover net turnover area give note financial statement key pharmaceutical business follow accounting judgement estimate turnover margin margin margin respect turnover accounting policy large gross turnover business pharmaceutical market complex arrangement rebate discount marketdriven segment allowance follow briefly describe nature government arrangement existence pharmaceuticals business mandate arrangement certain indirect customer state programme customer able buy product cash discount wholesaler reduce price chargeback represent customer return difference invoice price wholesaler prior year adjustment indirect customer contractual discount price prior year item accrual estimate chargeback calculate base item term agreement historical experience total deduction product growth rate net turnover customer rebate offer key manage care marketdriven segment consist primarily manage care group purchasing organisation direct indirect medicare plan negotiate contract pricing customer arrangement require customer honour rebate chargeback mandate segment achieve certain performance target relate value consist primarily medicaid federal government product purchase formulary status predetermine market programme receive governmentmandate pricing share relative competitor accrual customer rebate chargeback rebate estimate base specific term agreement historical experience product growth rate gsk annual report strategic report governance remuneration financial statement investor information group financial review continue critical accounting policy continue increase deduction marketdriven segment position change time gross turnover net turnover reconciliation primarily assurance loss result outcome reflect high rebate chargeback respiratory legal proceeding exceed material product advair particular generic version provision report group financial advair launch february year statement advair account pharmaceutical turnover like pharmaceutical company face approximately total deduction rebate complex product liability antitrust patent litigation return respiratory portfolio include investigation operation conduct establish respiratory product account approximately governmental regulatory agency year total deduction year general counsel group head group legal balance sheet accrual rebate discount allowance function senior vice president head global return pharmaceutical vaccine business litigation group responsible litigation manage combined basis december government investigation routinely brief chief executive total accrual amount million million officer chief financial officer board director significant litigation pende group monthly process operate monitor inventory level governmental investigation group wholesaler abnormal movement process use gross sale volume prescription volume base party meeting appropriate detail status significant data source information receive key wholesaler litigation government investigation review matter aim maintain inventory consistent level number claim notify information year year base pattern consumption potential claim notify assessment validity claim progress settle claim recent settlement basis pharmaceutical vaccine inventory level potential reimbursement insurer level wholesaler distribution channel december estimate approximately meeting include assessment week turnover calculation use party sufficient information available able information accuracy totally verify reliable estimate potential outcome dispute believe sufficiently reliable purpose external counsel assist litigation matter investigation assist brief legal dispute board senior management follow discussion respect accounting policy legal dispute matter possible reliable estimate follow briefly describe process provision require determine level provision necessary level provision legal dispute review accordance requirement ias provision adjust appropriate matter discuss contingent liability contingent asset provide note financial statement legal proceeding anticipate settlement cost outflow resource consider probable reliable estimate likely outcome dispute legal expense arise claim group involved significant legal proceeding respect possible reliable estimate expect financial effect result ultimate resolution proceeding case appropriate disclosure case include annual report provision gsk annual report group financial review continue strategic report strategic report approve board director march iain mackay chief financial officer march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn corporate governance section chairmans governance statement board corporate executive team responsible leadership division responsibilitie composition succession evaluation nomination committee report audit risk internal control audit risk committee report science committee report corporate responsibility committee report section statement director report ggsskk aannnnuuaall rreeppoorrtt chairmans governance statement please present corporate governance report overview change governance arrangement work separation group year important gsk board lead board governance architecture sir philip hampton emma reset strategic direction give company embark period transition company honour opportunity join year particular period significant board lead separation create new change board senior executive perspective worldclass business particularly excited work decide undertake external review gather view emma bring real clarity decision make board cet member ready task pharma veteran dispassionate ahead review insight attract good industry form team introductory meeting investor feedback board focus support management employee meet join help transform group execute strategy refine board governance architecture help focus facilitate board work support management begin important journey company effective efficient possible delivering tenure gsk helpful board meeting transformation pharmaceutical vaccine business september year include joint board cet strategy separation consumer healthcare business offsite session able consider step plan way forward great start description review process carry jan hall follow statement understand gsk inform robust induction process design emma company review board agree critical objective secretary introductory meeting investor year separation board consider board review decide commission good distribute workload committee ensure optimal effectiveness board induction increase time spend science give keen learn gsk start importance strengthen pipeline understand rd hal visit rd site uk include tesaro meeting andme agree board conduct annual important collaboration look forward review group enterprise risk deep enterprise visit group course risk oversight undertaken board committee focus aspect business closely join meet individual basis board enhancement consider way work cet member key executive attend governance architecture board committee meeting board committee assess include understand board culture dynamic companys corporate governance arrangement audit risk committee arc arc continue strong focus financial introductory meeting investor report monitor dashboard gsk want hear shareholder think gsk enterprise risk process identify hold meeting range investor make prioritise oversight internal control approximately register comprise mix framework conduct detailed review gsk uk shareholder plus key investor lead financial control report antibribery corruption annual governance meeting december commercial practice privacy information security note follow point enterprise risk receive business unit risk report clear support emma demonstrate pipeline progress pharmaceutical vaccine consumer healthcare hal team ahead separation global support function addition responsible support separation manage capital allocation debt oversight financial component work group dividend business development separation positive progress evidence positive shift innovation date performance culture rd culture transform gsk annual report strategic report governance remuneration financial statement investor information nominations committee board mindful financial reporting council remit nominations committee expand frc uk corporate governance code code encompass corporate governance matter free indicate nonexecutive director serve time board committee rename year board consider nomination corporate governance committee non appropriate way proceed longterm good interest executive invite participate meeting shareholder believe follow rigorous review committee consider succession talent judy continue act utmost independence despite length tenure transformation separation committee transformation separation committee establish nomination committee continue oversee succession support advise management work transform planning board cet course separate group chair committee consider need post separation board member include senior independent director sid non executive director fee chair arc remuneration corporate review nonexecutive director fee responsibility committee meet require arrangement year remuneration policy expect active near separation review nonexecutive director fee increase rd board science committee follow review conclude give critical importance strengthen pipeline appropriate increase fee bring line board increase time spend rd strategy comparator group take opportunity science committee focus science deep level update policy able remunerate workforce support board understand provide engagement director considerable work undertake reassurance guidance require new expand role investor consult change supportive science committee broad objective detail find scientific assumption drive strategy technical assurance risk oversight support board confirm company comply understanding agree rd strategy external requirement code copy code transaction perform deep review underlie find wwwfrcorguk scientific assumption addition oversight commend report stakeholder rd enterprise significant risk board feel enhancement governance improve effectiveness support sir jonathan symond separation process chairman succession planning march task nominations committee chair focus search judys successor chair arc good progress date look forward announce conclusion search consider ideal transition important role please judy confirm stay board year despite serve year step board annual general meeting facilitate smooth transition judy continue chair annual report complete successor chair arc gsk annual report board board governance architecture board carry evaluation performance commitment board support committee year evaluation normally overarch strategy create great company facilitate externally year external evaluation board confident cet focus drive facilitated year ago ffion hague independent performance year board evaluation action point reason give chairman governance statement meeting organisation improve balance page board agree helpful presentation discussion create time carry external evaluation include review debate governance architecture board dynamic individual contribution facilitate appoint board undertake review great individual contribution create connection company discussion time individual board director committee review remit attendee preparation board committee meeting ensure fit meet chairman ceo advance agree purpose objective scope evaluation exercise timetable activity company secretary provide risk agree board committee ensure deep access board committee material oversight review group enterprise risk preparatory work strategy performance conduct deep dive interview key strategic area ensure focus support november december conduct management execute agree strategy confidential detailed person interview board board knowledge deepen board knowledge cet member meet company understand late scientific development secretary seek view board effectiveness meeting base agree discussion stakeholder business board guideline include topic highlight frc continue focus key area focus cet guidance board effectiveness reflect strengthen rd pipeline growth relevant requirement frc code discussion transformation delivery gsk trust business priority guideline send participant advance externally board maintain strong relationship telephone meeting external remuneration adviser communication shareholder key auditor stakeholder seek input inform progress review output evaluation present discuss succession plan complete appointment board collectively summary report include arc chair successor suggest step compile governance build gsk commitment discuss chairman ceo subsequently environmental social governance esg matter sid summary report present board january proposal implementation suggest recommendation board review feedback summary review conclude board operate effectively new chairman see excellent start business enter period significant positive change opportunity board feel confident cet individual board director bring relevant experience skill collectively appropriate gsk mission produce product help people feel well live long remain heart value culture gsk annual report strategic report governance remuneration financial statement investor information board continue board composition international experience gender diversity composition board executive global male nonexecutive female tenure nonexecutive europe executive year emap male year female year nonexecutive male female sir jonathan symonds cbe skill experience nonexecutive chairman jon extensive international financial life science governance experience jon serve independent nonexecutive director hsbc holdings plc april age deputy group chairman august retirement board february nationality british previously chairman hsbc bank plc hsbcs european subsidiary offer appoint september service client uk continental europe jon chief financial officer novartis ag join novartis partner manage director goldman n sachs chief financial officer astrazeneca plc partner kpmg governance experience include role nonexecutive director chair audit committees diageo plc qinetiq group plc external appointment jon currently chairman proteus digital health inc nonexecutive director rubius therapeutics inc nonexecutive director genomics england limited previously serve chairman jon fellow institute chartered accountant england wale emma walmsley skill experience chief executive officer prior appointment gsk ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma join gsk age loreal work year variety role paris london new york nationality british shanghai emma previously nonexecutive director diageo plc appoint january emma hold classic modern language oxford university chief executive officer april external appointment emma join board microsoft inc independent director december honorary fellow royal society chemistry iain mackay skill experience chief financial officer prior join gsk iain group finance director hsbc holdings plc position hold year charter accountant iain work asia europe hsbc age general electric schlumberger dowell price waterhouse nationality british external appointment appoint january iain trustee british heart foundation chair audit risk committee chief financial officer april member court university aberdeen group iain hold business study account honorary doctorate aberdeen university scotland key c ommittee chair n nomination audit risk r remuneration science c c orporate responsibility gsk annual report board continue dr hal barron skill experience chief scientific officer prior join gsk hal president rd calico llc california life company alphabet fund company use advanced technology increase understand lifespan biology president rd prior hal executive vice president head global product development chief age medical officer roche responsible product combine portfolio roche nationality american genentech genentech senior vice president development chief medical officer appoint january hal nonexecutive director chair science technology committee juno chief scientific officer president therapeutics inc march acquire celgene corporation rd april external appointment hal associate adjunct professor epidemiology biostatistics university california san francisco nonexecutive board director grail inc early cancer detection healthcare company member advisory board verily life sciences llc subsidiary alphabet inc manvinder singh vindi banga skill experience senior independent nonexecutive prior join gsk vindi spend year unilever plc role senior position president global foods home personal care business member director unilever executive board vindi sit prime minister indias council trade industry age board governor indian institute management iim nationality british ahmedabad vindi recipient padma bhushan india high civilian honour vindi nonexecutive director confederation british industry cbi thomson appoint september reuters corp chairman supervisory board mauser group chairman kalle gmbh senior independent nonexecutive director senior independent director mark spencer group plc external appointment n r vindi partner private equity investment firm clayton dubilier rice director high ridge brand co member holdingham international advisory board vindi sit govern board indian school business hyderabad global leadership council sad business school oxford member indo uk ceo forum vindi chair board trustees marie curie dr vivienne cox cbe skill experience independent nonexecutive director vivienne wide experience business gain energy natural resource publishing sector deep understand regulatory government relationship workforce engagement director work bp plc year britain continental europe post include executive vice age president chief executive bps gas power renewable business alternative energy nationality british unit vivienne previously nonexecutive director bg group plc rio tinto plc lead independent director uk governments department international development vivienne appoint july appoint commander order british empire new year honour service uk economy sustainability r c external appointment vivienne main role senior independent director pearson plc chairman supervisory board vallourec nonexecutive director stena ab vivienne hold advisory position advisory board member african leadership institute vice president energy institute member advisory board montrose associates vivienne chair rosalind franklin institute vice chair sad business school oxford sit global leadership council patron hospice st francis lynn elsenhans skill experience independent nonexecutive director lynn wealth experience run global business significant knowledge global market gsk operate serve chair president chief executive officer age sunoco inc prior join sunoco president chief executive nationality american officer lynn work royal dutch shell join hold number appoint july senior role include executive vice president global manufacturing lynn previously nonexecutive director flowserve corporation tee great houston trustee unite way great houston c n external appointment lynn nonexecutive director baker hughes company board director saudi aramco director texas medical center key c ommittee chair n nomination audit risk r remuneration science c c orporate responsibility gsk annual report strategic report governance remuneration financial statement investor information board continue dr laurie glimcher skill experience independent nonexecutive director addition number senior leadership position hold harvard medical school harvard school public health laurie serve stephen suzanne weiss dean professor scientific medical expert medicine weill cornell medical college attend physician new york presbyterian age hospitalweill cornell medical center laurie step board bristolmyers squibb co nationality american bms serve year board laurie cofounder chair scientific advisory board quentis therapeutics inc laurie bring scientific public health expertise appoint september board deliberation wealth global publicly list pharmaceutical business experience external appointment laurie currently professor medicine harvard medical school ceo president attend physician danafarber cancer institute laurie member national academy sciences national academy medicine member scientific steering committee parker institute cancer immunotherapy nonexecutive director water corporation serve corporate governance committee addition laurie scientific advisory board member repare therapeutics inc abpro therapeutic kaleido biosciences inc dr jesse goodman skill experience independent nonexecutive director jesse previously serve senior leadership position food drug administration fda include recently fdas chief scientist previously deputy commissioner science scientific medical expert public health director center biologic evaluation research cber age jesse play leadership role develop fda regulatory science medical countermeasure nationality american initiative work collaboratively industry academia government global public health appoint january regulatory partner prepare respond major public health threat include emerge infectious disease disaster terrorism lead fdas response west nile virus hn c influenza pandemic serve senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovation cepi bring scientific public health expertise board deliberation external appointment jesse currently professor medicine georgetown university direct georgetown university center medical product access safety stewardship compass active clinician serve attend physician infectious disease serve president member board united states pharmacopeia usp member board scientific counselor infectious disease center disease control prevention cdc jesse member board intellia therapeutic cambridge member national academy medicine judy lewent skill experience independent nonexecutive director judy extensive knowledge global pharmaceutical industry corporate finance join merck co serve chief financial officer age retire judy serve nonexecutive director dell inc quaker oats company motorola inc nationality american hold nonexecutive directorship purdue pharma inc napp pharmaceutical holdings limit appoint april certain mundipharma international limited company external appointment n r judy nonexecutive director thermo fisher scientific inc motorola solutions inc trustee rockefeller family trust life member massachusetts institute technology corporation member american academy arts sciences member business advisory board twoxar member advisory board path inc board determine judy recent relevant financial experience agree appropriate qualification background audit committee financial expert urs rohner skill experience independent nonexecutive director urs broad range business legal experience serve chairman number board recently credit suisse worldleading financial service company prior join age credit suisse urs serve chairman executive board ceo prosieben nationality swiss prosiebensat media ag follow number year private practice major law firm appoint january switzerland admit bar canton zurich switzerland state new york r n external appointment urs chairman board credit suisse group ag governance nominations committee conduct financial crime control committee chairman member board trustee credit suisse research institute credit suisse foundation urs appoint vicechairman govern board swiss bankers association sir philip hampton join board january deputy chairman april nonexecutive chairman retire board effect august simon dingemans join board january chief financial officer april retire company key c ommittee chair n nomination audit risk r remuneration science c c orporate responsibility gsk annual report corporate executive team skills experience dr hal barron hal join gsk cet board biography chief scientific officer president rd roger connor roger join cet appoint president gsk global vaccine president global vaccines addition leadership vaccine business responsible gsk global procurement organisation previously president global manufacturing supply vice president office ceo corporate strategy roger join gsk astrazeneca roger hold degree mechanical manufacturing engineering queen university belfast masters manufacturing leadership cambridge university chartered accountant diana conrad diana appoint senior vice president human resource hr member cet senior vice president april previously senior vice president hr pharmaceuticals rd play key strategic role leader rd people culture agenda support human resource hr transformation diana join gsk canadas hr team hold role increase responsibility senior vice president hr consumer healthcare prior join gsk hold hr role company include ge capital gennum corporation zenon environmental laboratories diana honour bachelor art mcmaster university canada james ford james join cet appoint senior vice president general counsel senior vice president join gsk serve general counsel consumer healthcare general counsel global pharmaceutical vice president corporate legal act head global ethic general counsel compliance prior gsk james solicitor clifford chance dla hold law degree university east anglia diploma competition law king college qualified solicitor england wales attorney new york state bar james base london practise law live singapore hong kong james cochair base civil justice reform group nick hiron nick appoint cet senior vice president global ethic compliance senior vice president responsible compliance risk management corporate security investigation nick join gsk international auditor later head audit assurance global ethic compliance combine audit function independent team common riskbase methodology nick relocate china establish governance model china business create consistent approach compliance nick fellow chartered institute management accountant sally jackson sally join cet march senior vice president global communications ceo senior vice president office responsible communication government affair global business market employee engagement group global communication ceo chief staff prior sally senior vice president office ceo cfo ceo office previously serve head investor relation join gsk sally hold degree natural science university cambridge iain mackay iain join gsk cet board biography chief financial officer brian mcnamara brian join cet appoint ceo gsk consumer healthcare ceo gsk consumer healthcare join gsk head europe americas gsk consumer healthcare follow creation previous joint venture gsk novartis previously head novartis otc division brian begin career procter gamble brian board member chairman global selfcare federation gscf board member consumer good forum earn undergraduate degree electrical engineering union college new york mba finance university cincinnati gsk annual report strategic report governance remuneration financial statement investor information corporate executive team continue skill experience luke miel luke join gsk cet president global pharmaceuticals responsible president global pharmaceuticals commercial portfolio medicine vaccine luke cochair portfolio investment board hal previously work astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affair corporate affair head asia roche base shanghai singapore prior hold role increase seniority roche sanofiaventis europe asia luke hold bachelor science degree biology flinder university adelaide mba macquarie university sydney david redfern david join cet chief strategy officer responsible corporate development chief strategy officer strategic planning previously senior vice president northern europe responsibility gsk pharmaceutical business region senior vice president central eastern europe join gsk david appoint chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis join cet president pharmaceutical supply chain president pharmaceutical responsible manufacturing supply gsk pharmaceutical product lead quality environment health safety sustainability corporate level regis join supply chain gsk site director france rise senior vice president global pharmaceutical manufacture current role previously hold senior position sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer hold mba karenann terrell karenann join gsk cet chief digital technology officer responsible chief digital technology officer technology digital data analytic strategy previously work walmart chief information officer prior baxter international chief information officer daimler chrysler corporation karenann begin career general motors member board trustee new york hall science nonexecutive director pluralsight llc earn graduate postgraduate degree electrical engineering kettere purdue university respectively phil thomson phil join cet appoint president global affairs responsibility president global affairs group strategic approach reputation policy development stakeholder engagement global health previously phil senior vice president communication government affair phil chairman whitehall industry group board member chinabritain business council earn degree english history russian study durham university emma walmsley emma join cet board biography chief executive officer deborah waterhouse deborah appoint cet january chief executive officer ceo viiv healthcare viiv healthcare april deborah join gsk recently senior vice president primary care company business prior lead vaccines business strong track record performance specialty primary care deborah lead hiv business uk head hiv centre excellence pharma europe hold international role general manager australia new zealand senior vice president central eastern europe claire thomas member cet svp human resource april retire company september gsk annual report responsible leadership board role promote longterm sustainable leadership capability success gsk drive longterm growth shareholder employee engagement whilst seek add value key stakeholder strategic report page seek demonstrate way work able achieve practice corporate board receive regular update head governance report page explain human resource analyse progress governance contribute delivery strategy dashboard indicator innovation performance trust ipt priority board support approach culture change purpose value culture employ management seek appoint promote purpose improve quality human life help right people enhance company governance control people feel well live long underpin process support incentivise right value patient focus integrity respect transparency behaviour train develop employee purpose value source great company code conduct embody value pride board management employee help expectation corporate standard employee attract retain talented people individual want policy align include longstanding speak group contribute meaningfully society arrangement employee raise matter confidentially drive quality relationship anonymously fear reprisal live patient consumer key stakeholder ultimately value expectation right thing board enable swifter progress get new medicine audit risk committee regularly review speak vaccine consumer healthcare product patient report provide global ethic compliance gec consumer world culture set board speak channel case manage independent intended deliver high standard business conduct party case investigate gec promote longterm success company code conduct available gskcom keep purpose value support expectation review board refresh courage accountability development teamwork year update version publish evolve culture foster increase pace performance edge board receive regular report ceo cfo detail enable culture change head human resource global business invest reward workforce describe page update progress alignment strategy respectively performance valuesbase culture way stakeholders board assures describe engagement company main stakeholder group year board focus culture discussion include patient shareholder consumer customer employee experience gsk way work audit employee level organisation risk committee consider risk compliance aspect enterprise summarise page strategic culture change performance line gsk trust report priority board consider progress culture change section corporate governance report set research corporate reputation insight companys key stakeholder interest consider reflection key external stakeholder board discussion decisionmake culture change complex global organisation gsk year read conjunction section take time sustained effort board fully commit statement area statement work healthy culture vital tool unlocking crossreference annual report provide holistic protect value board acknowledge big view board discharge duty driver culture leadership company stakeholder rightly high expectation culture shift underway continue role model dynamic environment operate present challenge cet board word action behaviour opportunity board seek respond whilst set tone employee wide workforce board remain commercially successful uphold reputation member seek lead example undertaking live maintain licence operate building trust ensure value expectation train alongside rest able identify respond expectation workforce training explore particular value effectively board engage key stakeholder expectation culture application company directly seeks understand view mean operation way work ensure stakeholder sentiment appropriately board receive result regular employee survey consider deliberation decisionmake principal mean assess shift culture influence importance different stakeholder group embed organisation culture dashboard board discussion vary depend matter introduce quantifiable indicator progress consideration different stakeholder interest people culture transformation conflict require balanced judgment exercise appoint promote right people board arrive final decision gsk annual report strategic report governance remuneration financial statement investor information responsible leadership continue stakeholder engagement feedback provide important maintain continual active dialogue mean identify emerge issue bring institutional shareholder performance plan attention board enable consider objective programme regular meeting activity enable deliver purpose year hold individual meeting major ultimately goal world shareholder host total nearly group innovative bestperforming trust healthcare company meeting major shareholder potential major shareholder principal board committees cet delegate power enable indepth assessment senior independent director sid vindi banga conduct understand impact company action plan series meeting investor adviser seek stakeholder engagement briefing view chairman succession process particular board knowledge inform work key induction new chairman jonathan corporate responsibility committee describe symond want hear shareholder think detail gsk jon hold introductory meeting range investor comprise company share register improve understand stakeholder matter keen meet fund portfolio manager board member encourage individual level see governance professional gain full meet employee shareholder key stakeholder picture major shareholder view perspective induction ongoing basis gsk feedback receive summarise business awareness encourage report governance statement informed board experience relevant material board review board advise stakeholder view number annual governance meet different way include addition board hold annual governance event ceo board report institutional shareholder key investment industry body monthly stakeholder perception report proxy advisory firm year event hold december london host chairman business update sid committee chair business development analysis justification jon share update join board key areas board committee evaluation focus board include remuneration policy review wide workforce pay induction shareholder meeting initial impression perspective gsk culture succession planning update audit risk committee chair succession process workforce engagement director update board review potential change governance architecture annual governance meeting provide update behalf workforce annual general meeting engagement director unable attend employee survey report ur rohner remuneration committee chair take briefing annual strategy meeting opportunity discuss progress remuneration annual budget business planning process committee review executive remuneration ahead remuneration policy vote annual general meeting corporate governance regulatory development update judy lewent audit risk committee chair year board receive consider lynn elsenhans corporate responsibility committee chair independent research stakeholder perception dr jesse goodman chairs science committee gsk corporate reputation view approach provide overviews work respective esg issue committee year shareholder engagement annual governance meeting receive board seeks directly engage private retail number thoughtful incisive question ask institutional shareholder way include regular board member present gsk rd capability strategy communication annual general meeting annual plan separation group listening view governance meeting work investor shareholder receive feedback provide relation team company secretary additional direct insight share rest year publication quarterly result board meeting ceo emma walmsley cfo iain mackay presentation institutional investor analyst media webcast teleconference presentation available gskcom gsk annual report responsible leadership continue annual general meeting workforce engagement shareholder invite attend annual general describe year annual report meeting hold sofitel london board choose designate dr vivienne cox heathrow hotel detail workforce engagement director gather view people board believe provide direct annual general meeting good level effective form engagement gsk vivienne please attendance engagement shareholder provide share view inaugural year role helpful insight board issue concern propose resolution approve shareholder board take opportunity engage employee directly reception hold board meeting level support range voting nonexecutive director attend internal meeting outcome available gskcom annual general visit group site report finding meeting provide opportunity shareholder question board chair board committee formal proceeding provide shareholder chance meet informally director available meeting workforce engagement director careful ensure engage diverse year board appoint role crosssection workforce term seniority gender learn great deal rich dialogue enjoy ethnicity tenure employment job type please meeting variety enthusiastic dedicated meeting generate wideranging exchange employee opinion insight start comprehensive briefing group please briefing hr head human resource perspective agree datum collect gsk employee survey understand visit employee work principal feedback generate different business business allow gain understand employee grouping provide helpful insight workforce view attitude range meaningful input determine location visit issue ipt priority culture shift underway person virtually organisation way work employee stand item board agenda share survey manager feedback accountability feedback substance workforce engagement approach global health modern employer board use report non agenda importantly eventual separation executive director visit gsk site measure group create new company progress company modern employer agenda grateful assist head human resource focus inclusion diversity employee health company secretary devising programme wellbee development visit note consist visit key gsk site give clear consistent support group strategy ipt exposure group country prioritie commitment employee feel company significant presence good grow rd upper providence pennsylvania usa work separate group working gsk major pharmaceutical rd hub provide voice workforce important input board look forward develop role vaccine wavre belgium utilise technology virtual meeting consumer healthcare warren site new jersey employee forum explore perspective plan meet cross section new workforce include undertake event quarter possible pfizer employee new joint venture business align board visit hold virtually look forward local management welcome site report progress year great job introduce member workforce finally enlist input feedback fellow explain nature site operation enable nonexecutive director active visit gsk hold direct open honest conversation meeting site meet employee continue hold management present individually build holistic view perspective sentiment group setting gain insight workforce workforce group experience concern perspective partly use let talk gsk initiative use discuss annual report dr vivienne cox encourage workforce talk share different point nonexecutive director view informal setting gsk annual report strategic report governance remuneration financial statement investor information responsible leadership continue table set list principal decision take board committee regard stakeholder interest impact stakeholder group boardcommittee section principal decision decision regard stakeholder interest duty consider board board committee sale force incentive sfi audit risk committee consider stakeholder hcps committee recommend programme recommend board change medical expert employee implementation limited sfi sfi programme certain country investor governments programme change board reflect grow shift gsk regulator patient approval portfolio certain innovative specialty consumer safeguard key stakeholder interest care product include oncology duty new sfi programme implement particular examine value longterm result control phase market review change mean workforce business robustness programme attract retain good sale relationship reputation governance arrangement present force talent committee later year enhance quality dialogue detail available healthcare professional hcp help company well serve patient committee stipulate implementation robust governance arrangement underpin change uphold ethical valuesle approach hcp engagement business development science committee stakeholder patient science committee recommend collaboration board review business consumer employee collaboration scientific perspective development deal collaboration investor prior board approve year include duty collaboration lyell immunopharma longterm result university california help workforce business gsk obtain competitive advantage relationship add pipeline optionality enable gain access key technology arrangement consider context promise help gsk deliver transformational medicine patient capability talent available company esg insight corporate responsibility committee stakeholder committee decide include sasb receive consider perception investor government disclosure company esg study investor specifically interested regulator non performance summary available esg aspect activity governmental organisation gskcom voluntary well understand rapid rise interest multilateral organisation tcfd disclosure annual report investor area chief duty concern longterm result committee raise remuneration committee note discuss business relationship committee chair remuneration investor desire sustained delivery community committee increase importance trust commitment increase environment reputation demonstrate link esg report align sustainability performance remuneration outcome accounting standard board sasb executive director cet taskforce climaterelate financial remuneration committee note disclosure tcfd importance stress link esg delivery gsk bonus award executive director agree devise new remuneration arrangement business post separation look holistically highlight incentivise importance esg success business minimise impact environment gsk annual report responsible leadership continue boardcommittee stakeholder group principal decision decision regard stakeholder interest section duty consider board board committees board governance board engage undertake stakeholder employee board agree change governance architecture external evaluation include review investor patient architecture improve board governance board architecture consumer effectiveness support management duty effective efficient possible longterm result deliver transformation reputation pharmaceutical vaccine business separation consumer healthcare business detail available page remuneration policy prior develop new stakeholder employee committee approve new policy review remuneration policy new policy investor government subject bind shareholder vote behalf remuneration committee regulator proxy annual general meeting chair meet head human adviser include measure align executive resource hr lead director pension arrangement duty area business hear view wide workforce longterm result remuneration arrangement gsk specific area focus investor workforce reputation consider executive wide proxy adviser workforce pay alignment opportunity detail available page chair consult investor proxy adviser new policy proposal committee follow engagement carefully consider feedback finalising design new policy gsk annual report strategic report governance remuneration financial statement investor information responsible leadership continue board programme board responsible longterm success company authority accountable shareholder ensure group appropriately manage achieve strategic objective set performance duty regard interest gsk key stakeholder potential impact decision make stakeholder board discharge responsibility annual programme meeting year focus number specific area outline table line longterm ipt priority underpin continue shift culture addition year ceo meet nonexecutive director discuss matter include progress company strategy succession planning continue regulatory investigation area focus longterm priority link strategy board oversight execution strategy include receive discuss report principal business pharmaceutical vaccine consumer p c healthcare hold joint board cet strategy day discuss ipt priority external landscape change business p c performance competitor governance arrangement receive ceo cfo cso quarterly report p c performance board focus performance include evaluate ceo performance set objective p c set review agree annual budget plan forward look year forecast p annual talent succession plan p c scrutinise group financial performance p review quarterly financial result dividend proposal earning guidance investor material result p announcement confirmation viability statement go concern p approval statutory account p governance board approach discharge corporate governance duty include receive report board committee receive report external auditor p chairman succession appointment new chairman p approve annual report form f review annual general meeting preparation approve notice annual general meeting call general meeting approve joint venture pfizer inc oversee execution deal receive report corporate governance regulatory development receive secretary report consider observation agree action evaluation board performance p annual setting board priority p c approval modern slavery statement approval gender pay gap disclosure receive annual quality update c cultural receive cultural transformation update p c transformation engagement board regard stakeholder impact include review board governance architecture p c receive update workforce engagement director p c review employee survey result update p c corporate reputation research review p c investor perception research review p c link longterm prioritie innovation performance p trust culture c gsk annual report division responsibilitie corporate governance framework corporate governance framework operation establish board set design clearly define responsibility accountability framework design safeguard enhance longterm shareholder value provide platform realise group strategy gsk longterm priority ipt consistent culture value expectation internal control risk management arrangement describe page integral governance framework follow board review gsk board governance architecture review enhance summary change introduce follow review provide chairman statement page board chief nomination audit risk remuneration science corporate executive committee committee committee committee responsibility officer committee corporate executive r ead read read read read team gskcom term reference board committee scheduled board committee attendance corporate board nomination audit risk remuneration science responsibility total number schedule meeting member attend attend attend attend attend attend sir jonathan symonds emma walmsley iain mackay dr hal barron vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner sir philip hampton retire august simon dingemans retire number adhoc meeting director serve year number bracket denote number meeting director eligible attend committee report attendee committee meeting chairman ceo executive director work committee year report include later corporate governance report gsk annual report strategic report governance remuneration financial statement investor information division responsibility continue clear division board role responsibilitie leadership independent oversight rigorous challenge chairman nonexecutive director jonathan symond provide strong independent element board lead manage business board constructively support challenge management provide direction focus scrutinise performance meeting agree ensure clear structure effective operation deliverable board committee shape proposal strategy offer specialist advice set board agenda ensure sufficient time management allocate promote effective debate support sound letter appointment set term decision make condition directorship ensure board receive accurate timely clear devote time necessary proper information performance duty meet nonexecutive director annual expect attend meeting require basis discuss individual contribution independence statement performance training development need board consider nonexecutive director share peer feedback provide identify page independent board evaluation process assess circumstance set meet regularly nonexecutive director provision code review independently executive director explanation continue independence maintain dialogue shareholder commitment judy lewent april governance company serve board year describe chairmans role description available gskcom senior independent director chief executive officer vindi banga emma walmsley act sound board chairman trust responsible management group intermediary director business nonexecutive director lead develop group strategic direction annual review chairman performance take consideration approval board account view executive director implement agree strategy discuss result chairman effectiveness support member cet review chairman maintain continual active dialogue lead search appointment process make shareholder respect company performance recommendation board new chairman act additional point contact shareholder chief executive officer role description available gskcom maintain understand issue concern major shareholder briefing company secretary investor relation senior independent nonexecutive director role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chair annual agenda planning ensure information available board member timely fashion support chairman designing deliver board induction coordinate continue business awareness training requirement nonexecutive director undertake internal board committee evaluation request chairman advise director board practice procedure corporate governance matter chair group disclosure committee operate boardapprove appointment policy reflect board external appointment requirement code point contact shareholder corporate governance matter gsk annual report composition succession evaluation nomination committee report please present report nomination jonathan symonds committee chair nominations committee chair year focus committee chairman succession sid vindi banga lead process result appointment report process outline role comment work committee committee review recommend board year structure size composition board board change appointment director committee member joined board committee focus succession board cet search judy lewents successor chair audit risk committee good progress look forward report conclusion search course membership committee appoint egon zehnder korn ferry committee member committee member assist appointment broad selection criterion sir jonathan symonds chair september september focus potential candidate follow vindi banga january characteristics lynn elsenhans january ideally pharmaceutical industry judy lewent strong preference cfo andor candidates urs rohner january audit committee experience broaden diversity philip hampton january committee chair august talent pool seek ideally qualify accountant detail committee member skills experience give biography board page committee consider ideal transition committee member attendance level important role please judy lewent agree company secretary secretary committee remain post year despite year attend meeting attendee committee service stepping board meeting include annual general meeting help facilitate smooth transition especially give recent change cfo regular attend attendee attendee require auditor work underway transform separate chief executive officer group committee mindful code head human resource indicate nonexecutive director serve appropriate external adviser year engagement shareholder recommend board appropriate way procee longterm interest advisory service shareholder board confirm despite year year egon zehnder korn ferry provide service judy continue demonstrate characteristic recruitment consultancy service committee independence carry role board addition recruitment hr service provide company egon zehnder provide executive iain mackay start role chief financial officer coach service certain director committee april appoint board august support engagement executive search firm join board january elect egon zehnder korn ferry sign annual general meeting simon dingemans voluntary code conduct gender diversity retire company follow annual general good practice egon zehnder korn ferry meeting follow year service chief financial number executive search firm receive officer process committee follow iain mackay accreditation enhance code recruitment describe year report conduct meeting exact performance criterion good practice standard genderbalance selection ftse board gsk annual report strategic report governance remuneration financial statement investor information composition succession evaluation continue nomination committee report continue cet succession progress female board representation year committee review follow combine executive committee direct report target internal senior executive appointment cet publish ftse woman recommendation ceo leader report reproduce diana conrad appoint svp human resource female representation june report female april succeed claire thomas perform representation metrics board combine role year ftse target sally jackson appoint expand role senior gsk vice president global communications ceo office average ftse join cet march high date report woman deborah waterhouse ceo viiv healthcare join board woman cet cet january board composition tenure diversity board seek balance composition tenure closing gap board cet gender committees refresh progressively representation increase pipeline female time benefit experience long direct report cet achieve target serve director fresh external perspective particular area attention please good progress insight new appointee stage exceed target combine executive committee direct nonexecutive director draw wide range report representation woman management industry background include pharmaceutical position gsk illustrate industry rd vaccine consumer product gender diversity gsk global workforce healthcare medical research academia insurance financial service wealth experience complex please report line parker organisation global reach board member report recommendation experience longcycle industry great committee meet nonexecutive director present assistance understand industry operate receive consider succession plan management commit diversity boardroom executive director ensure diverse pipeline gsk commit equal opportunity employee potential successor available committee wide workforce level organisation regularly review succession plan nonexecutive board management seek encourage diverse member board inclusive culture gsk committee evaluation committee annual evaluation exercise externally key requirement effective board comprise facilitate interview committee member range balance skill experience knowledge ethnicity behalf conclude committee continue gender socialeconomic background independence operate effectively individual prepare challenge work effective team need back diversity agree committee role expand personal attribute include character intellect sound encompass corporate governance matter free judgement honesty courage time board committee rename nomination corporate governance committee support promote long term success company addition nonexecutive director invite committee responsible develop measurable participate meeting committee consider objective assist implementation board diversity succession talent policy include gender ethnic diversity monitor progress achievement objective diversity policy line measurable target set sir jonathan symonds nominations committee chair hamptonalexander review increase number march woman senior leadership position ftse company parker review commission report increase ethnic diversity appointment board ftse company gsk annual report composition succession evaluation continue chairman succession report chairman succession follow key personal attribute identify job beginning announce sir philip specification hampton informed board intention step prove respect chair senior executive chairman continue role new considerable nonexecutive director senior chairman select joined board independent lead independent director experience good time transition company deliver business scale complexity improve operating performance develop clear experience uk capital market appreciation new strategy year international shareholder selection process lead board sid good understand uk corporate governance nomination committee expand comprise experience business significant portfolio change nonexecutive director support head include merger acquisition divestment human resource company secretary addition experience global scale international market seek input ceo emma walmsley life sciences experience preferable mandatory process appropriate experience regulate industry committee begin develop agree job reputation stature authority command respect specification role chairman include externally internally skillset experience key leadership characteristic require lead gsk board stage whilst decide job specification describe company engage egon zehnder korn ferry engage shareholder adviser secure specialise recruitment high calibre input advice chair board director firm ensure pool suitable candidate begin long list process truly global search embrace consideration reduce shortlist brief broad talent pool possible work validate report shortlist candidate review timetotime ensure gap search candidate meet board process committee receive good member possible market advice key appointment process result nominations committee job specification emphasise new chairman believe jonathan symond suitable lead board company phase candidate gsk chairman july development involve accordance nomination committee term continue drive gsk strategy building sustainably reference good governance chair meeting grow pharmaceutical vaccine business recommend jon appointment nonexecutive strengthen rd delivery pipeline consolidate director chairman chair board tesaro acquisition undertaking business meeting day sir philip recuse development recommendation approve unanimously july pleased announce jon join successfully integrate pfizer consumer healthcare board nonexecutive chairman effect business gsk consumer business whilst september sir philip step board complete divestment horlick india effect august prepare company creation separate list entity separate governance jon meet independence requirement set structure pharmaceutical vaccine consumer code appointment require boardapprove healthcare external appointment policy significant exist commitment indication time involvement whilst continue improve company operate disclose take consideration prior performance appointment board note particular jon envisage chair remain gsk step role deputy chair director pharmaceutical vaccine company provide appropriate hsbc february stability continuity subject performance board please welcome jon exceptional ratify board appropriate time experience life science financial management governance complex regulated global company career jon demonstrate passion science know integrity professionalism vindi banga senior independent director gsk annual report strategic report governance remuneration financial statement investor information composition succession evaluation continue external evaluation board detail independent external evaluation board conduct set progress board evaluation progress conclusion board evaluation review set area focus progressachievement succession planning board sid run search process chairman support comprehensive process lead sid result appointment global executive search firm attendance nomination committee jonathan symond describe sid process expand include nonexecutive director nomination committee progress search nomination committee focus search judy successor judy lewent chair audit risk committee lewent successor good progress date detail give oversight rd pipeline revival key business development transaction propose consumer healthcare joint venture pfizer board continue monitor performance rd pipeline board committee monitor overseen successful integration operation key business development integration operation recent transaction transaction include tesaro andme merck kgaa darmstadt board please oversee early completion consumer germany review oversee arrangement healthcare joint venture pfizer continue monitor management propose consumer healthcare joint venture pfizer progress integrate grow business building board relationship culture line ceo culture work group continue evolution board culture building relationship good progress evolving board culture note membership change important area focus especially board review undertake impend chairman succession enhancing board decisionmake way work opportunity enhance board decisionmake way implementation agree enhancement way work working continue consider ensure board governance architecture board committee describe operate effectively possible chairman governance statement page gsk annual report audit risk internal control audit risk committee report follow page report aim share insight judy lewent activity undertake oversee committee audit risk committee chair year committee work largely recur structured programme activity devise programme company secretary agree content management role external auditor start year committee review responsible adapt appropriate year progress financial internal reporting process financial reporting integrity financial statement include integrity financial statement include annual annual report quarterly result announcement report quarterly result announcement key focus committee include committee assessment system internal control effectiveness internal control financial reporting identification management risk external committee review quarterly company internal audit process significant accounting matter include contingent initiate audit tender selection appointment consideration liability revenue recognition accrual external auditor set remuneration return rebate restructure tax accounting exercise oversight work significant transaction impact change accounting standard committee position aim clear membership transparent financial disclosure gsk financial reporting committee member committee member support proactive approach step ahead judy lewent april guidance requirement regulator line prior chair january years committee continue review compliance vindi banga january late guidance lynn elsenhans january dr laurie glimcher september committee auditor discuss significant issue relation financial statement committee detail committee member financial accounting scientific experience expertise give biography consider periodically year area particular board page committee member audit focus outcome overlap area attendance level attention disclose separately page company secretary secretary committee annual report attend meeting entire board invite audit reform external auditor attend committee meeting attendee review external audit industry acknowledge include diversity stakeholder use company audit account statement poor quality audits regular attend attendee attendee require significant negative repercussion economy general counsel society albeit auditor responsibility law group financial controller shareholder associate reform head audit assurance external audit market area regulatory head global ethic compliance development committee monitor closely chief medical officer key activity committee monitor chief product quality officer performance deloitte second year deloitte external auditor serve gsks external auditor extensive accordance frc code board change management process include formal handover determine judy lewent recent relevant observation previous auditor deloitte take financial experience board agree action review deloitte audit appropriate qualification background audit complete approximately key member committee financial expert define sarbanesoxley management interview gather feedback act determine independent respect deloitte audit mean security exchange act amended committee competence relevant sector company operate gsk annual report strategic report governance remuneration financial statement investor information audit risk internal control continue audit risk committee report continue learning efficiency identify action review committee consider detail rationale incorporate audit plan objective limited change sfi programme robust audit set agree continue monitor governance arrangement underpin committee information effectiveness context gsk ipt priority recommend year audit process give implementation policy change board new sfi policy implement control committee discuss deloitte example phase market committee receive use analytical tool insight support report december outcome ibm monitoring improve efficiency effectiveness audit work sfi activity control perform gec business development transaction manage change sfi programme continue oversight tesaro transaction consumer significant activity committee give potential healthcare jv pfizer key priority associate risk gec committed perform committee give importance success ibm review sfi change gain traction transaction accelerate group strategy reshape market present finding business committee receive regular report learning committee end year integration management tesaro include fundamental success new sfi programme review rd risk deal monitor strong leadership continue drive culture performance know operational compliance reputational risk trust enforce measure governance control associate mitigation plan integration zero tolerance abuse committee regularly monitor commercial medical function progress review internal control hold deepdive complete effect january session leader gsk principal business committee exercise responsibility monitor discuss individual engagement accountability oversee consumer joint venture risk management view balance performance trust priority post day diligence jv operate business extremely competitive change environment internal framework control risk management committee focus management enterprise development risk relevant delivery joint venture risk management framework embed strategic priority commercial practice supply chain continually review committee enable board continuity portfolio ingredient risk committee identify evaluate manage hcp sfi change principal risk design support innovation committee devote significant time year performance trust priority cultural transformation review design governance arrangement form framework provide effective hierarchy risk hcp engagement policy sfi programme management compliance board rmcbs change promotion speciality medicine gsk business promote tone underpin hcp sfi change establish risk culture oversee effective cascade execute receive positively externally internally escalation information internal control present increase risk potential unethical gsk value expectation speak behaviour comprehensively control process ensure risk associate business mitigate activity actively effectively agree mitigate end committee receive presentation provide reasonable assurance material misstatement result hcp engagement theme review conduct loss gec conduct annual confirmation exercise global ethic compliance gec independent ensure risk management approach consistent business monitor ibm market cover gsk reinforce leadership accountability eligible market review identify year committee consider gsk risk process learning embed strategy address draw market cover hcp engagement programme annual business unit risk strategy paper assurance update report provide audit assurance aa gsk significant risk annual internal control risk management effectiveness review gec gsk annual report audit risk internal control continue audit risk committee report continue principal risk oversee cet member level risk business report committee key internal owner ensure proportionate control place clear control framework icf improvement simplification plan assign address gap committee consider activity improve manage risk current emerge risk oversight summarise gsk risk management framework pharmaceutical embed hcp emerge risk define visible engagement model note general manager organisation threeyear horizon emerge risk confirmation form component cet confirmation assessment perform remit rmcbs process continue important review risk level organisation additionally annual analysis mitigation plan allow detailed area regional oversight political economic social technological legal confirmation allow target discussion environmental pestle trend external environment rmcbs well understand deployment perform aa team identify emerge risk operating model change mitigation action accountability gsk know enterprise risk area year cet local control effort risk oversight compliance council rocc conduct vaccine year vaccine business work formal risk review consider emerge risk increase icf maturity improve effectiveness sufficient information available support inclusion rmcbs new rd governance model build gsk principal risk list principle fast decision make smart risktaking review support extensive analysis external trend approach vaccine continue perform comprehensive insight senior level interview recommendation asset risk assessment complement implementation gsk key risk intelligence group risk management new enterprise risk management framework board base review committee agree consumer healthcare well understand risk incountry cet recommendation escalate environmental country risk radar launch help sustainability standalone principal risk given proactively identify high risk country look culture significance gsk previously manage commercial kpis qualitative aspect provide judgement subrisk environment health safety sustainability specific action plan necessary mitigate risk risk require focus go forward improve management monitoring toolkit include transformation pricing pressure nonpromotional develop support general manager selfassessment engagement enhance control maturity enterprise risk management enhancement committee consumer healthcare distribution activity risk management oversee embed gec new enterprise risk framework develop allow market understand management cycle distributor activity risk dependent type service enterprise risk plan complete deliver service provider tool provide guidance enterprise risk communicate expect control manage risk implement business function implementation globally end march provide great clarity organisation nature viiv healthcare particular area focus viiv risk control expect place improve effectiveness rmcbs drive robust business function give assurance risk discussion clear risk owner accountability adopt enterprise risk plan adapt proportionate risk mitigation approval enterprise risk owner drive monitor compliance activity consistency well oversight monitor key icf gec requirement cet confirmation introduce continue mature ibm framework abac group important risk area reinforce commercial practice risk ibm conduct leader accountability risk management measure enterprise significant focus prioritise monitor control set enterprise risk plan high risk activity risk market review implement gap address gec lead ibm market visit gsk principal business maturity gsk ibm programme help new enterprise risk report rocc provide great confidence issue identify introduce focus datum key risk indicator address early lead well inform discussion risk exposure action need gsk annual report strategic report governance remuneration financial statement investor information audit risk internal control continue audit risk committee report continue gsk value expectation committee evaluation gsk value expectation high priority committee annual evaluation externally facilitated committee aa team conduct value assurance interview committee member behalf review var assess gsk value conclude committee continue operate expectation embed organisation insight effectively term enhancement committee var identify continue area focus deliberation follow improvement point agree create environment people comfortable committee continue strong focus speak issue challenge status quo financial reporting monitor dashboard raise awareness gsk expectation help gsk enterprise risk process people understand mean context role identify prioritise follow review board live value expectation year mandatory governance architecture committee conduct training strategy focus simplify key message detailed review gsk financial control report behaviour gsk want communicate anti bribery corruption practice commercial practice compress train small piece facilitate learn privacy information security enterprise risk detailed retention drive conversation review gsk enterprise risk undertake employee line manager board committee focus aspect business closely addition committee responsible data analytic build exist capability gec oversight financial component work establish data analytic workstream focus separation develop marketlevel key risk indicator design signal potential issue business activity audit risk committee chair succession improve quality gec datum approach end tenure board provide actionable insight assist business facilitate smooth transition successor agree mitigate risk stay board year annual general meeting subject reelection annual monitoring technology infoprotect general meeting look forward work committee continue monitor effectiveness handing successor announce risk management internal control use new technology impact financial control report enterprise risk give fast pace technological development include ability new technology perform task traditionally undertake human judy lewent committee consider particular impact robotic audit risk committee chair artificial intelligence march finance function aim improve performance efficacy reduce cost manage risk well optimise use technology gsk continue develop cloud application robotic visualisation tool advanced analytic governance framework place ensure new technology assess develop piloted deploy monitor control manner infoprotect recognise potential impact continuously evolve environment complexity gsk footprint key enterprise risk committee receive quarterly update information security committee oversee introduction chief information security officer industry standard framework monitoring report information security gsk gsk annual report audit risk internal control continued committee area committee focus item discuss frequency financial review integrity draft financial statement appropriateness accounting policy go concern report assumption consider approval process confirm recommend board annual report fair balance understandable review recommend board approval annual report form f review recommend statutory account review major restructuring report review recommend approval quarterly preliminary result announcement dividend earning q guidance review significant issue relation quarterly preliminary result q review approve director expense review recommend inclusion viability statement annual report review appropriateness accounting policy q review accounting development impact key accounting issue p review financial reporting framework disclosure arrangement p external perform evidencebase assessment external auditor effectiveness external audit auditor consider qualification expertise independence external auditor review approve auditnonaudit expenditure incur approve audit plan fee proposal set performance expectation auditor year consider nonaudit services fee audit budget consider auditor report annual result consider initial result external audit consider external auditor review report progress report key judgemental item consider internal control financial report p global internal review assurance report global pharmaceutical include viiv rd sfi programme update control vaccine consumer healthcare global support function compliance confirm compliance sarbanesoxley act receive litigation report update p receive report continue investigation antibribery corruption issue review gsk internal control framework control financial reporting p review audit assurance work approve work plan review tesaro integration plan p review general datum protection regulation update p review internal audit report p risk review risk management framework compliance review risk element group treasury pension risk insurance tax policy consider emerge risk p receive status report company enterprise risk risk disclose page xx xx p receive fraud site security cyber security risk assessment update p receive rocc meeting update p governance review new provision confirmation compliance code matter review committee term reference confirm adhere review report disclosure committee p review committee performance effectiveness receive corporate governance update p review group modern slavery act statement review company gender pay gap disclosure p consider sfi programme review technology audit assurance p review balance performance trust meet privately separately head gec aa general counsel p meet privately external auditor end meeting appropriate committee activity key annually q quarterly p periodically stand gsk annual report strategic report governance remuneration financial statement investor information audit risk internal control continue significant issue relate financial statement consider quarterly financial result announcement financial result contain annual report committee review significant issue judgement management determine result committee review paper prepare management set key area risk action undertake quantify effect relevant issue judgement management appropriate accounting require address issue financial statement significant issue consider relation financial statement year end december set follow table summary financial outcome appropriate addition committee external auditor discuss significant issue address committee year area particular audit focus describe independent auditor report page significant issue consider committee relation financial statement issue address committee go concern basis preparation committee consider outcome management halfyearly review current forecast net financial statement debt position financing facility option available group follow review risk potential impact unforeseen event committee confirm application go concern basis preparation financial statement continue appropriate revenue recognition include return committee review management approach time recognition revenue accrual rebate rar accrual customer return rebate pharmaceutical vaccine accrual return rebate billion december committee review basis accrual concurred management judgement amount involved full description process operate pharmaceutical vaccine business determine level accrual necessary set critical accounting policy provision legal matter include committee receive detailed report actual potential litigation internal external investigation group legal counsel number detail update investigation group commercial commercial practice practice management outlined level provision correspond disclosure consider necessary respect potential adverse litigation outcome area possible determine provision necessary december provision legal matter billion set note financial statement provision provision uncertain tax position committee consider current tax dispute area potential risk concur management judgement level tax contingency require december tax payable liability billion include provision uncertain tax position recognise group balance sheet acquisition tesaro pfizer committee consider judgement management acquisition date valuation consumer healthcare business asset liability acquire particular valuation intangible asset intangible asset acquire tesaro value billion pfizer consumer healthcare business billion committee concur management valuation judgement detail provide note financial statement acquisition disposal impairment intangible asset committee review management process review testing goodwill intangible asset potential impairment committee accept management judgement intangible asset require writing result impairment charge million note financial statement intangible asset detail valuation contingent consideration committee consider management judgement unwind discount liability relation viiv healthcare largely offset update exchange rate assumption adjustment sale forecast cash payment nearly billion year december group balance sheet include contingent consideration liability billion relation viiv healthcare note financial statement contingent consideration liability detail viiv healthcare option committee review agree accounting pfizer option concur management judgement valuation option billion december gsk annual report audit risk internal control continue auditor reappointment external auditor clarity communication auditor way follow audit tender process conduct committee working conclude december deloitte appointment alignment audit group investment auditor company group approve sap shareholder annual general meeting quality audit team leadership contractual similar obligation restrict group choice external auditor skill experience audit team committee consider company committe chair regularly meet independently comply mandatory audit process audit audit partner addition end face face committee responsibility provision competition meeting committee meet auditor exchange market authority statutory audit service order view progress date appropriate effectiveness quality external audit process review feedback note area committee commit ensure ongoing improvement implement respect audit team basis gsk receive high quality effective audit audit committee satisfy external auditor evaluate deloitte performance effectiveness auditor external audit process prior make recommendation reappointment early committee review auditor independence qualification objectivity expertise effectiveness performance criterion resource agree conjunction management beginning criterion set committee agree recommend board reappointment deloitte forthcoming annual undertaking review committee consider general meeting overall quality audit independence deloitte exhibit appropriate level challenge scepticism work deloitte recently appoint gsk auditor length tenure take account assess independence objectivity committee consider overall effectively deloitte assume role auditor finally committee consider feedback external audit survey seek view committee member financial management team corporate business unit level cover effectiveness challenge auditor deloitte integrity transparency reporting management committee gsk annual report strategic report governance remuneration financial statement investor information audit risk internal control continue auditor reappointment continue detailed criterion committee judging effectiveness deloitte external auditor override responsibility deliver smoothrunne thorough efficiently execute audit set performance expectation gsk external auditor audit approach leverage centrally control audit approach ensure gsk group joint venture local statutory entity audit strategy refine consistent technologyle audit enhance risk assessment analytical procedure provide insight combine datum trend analysis process cycle pathway identification audit risk ensure wellinforme efficient audit deliver focus consistent audit approach globally reflect local risk materiality high quality adhere independence policy gsk frc revise ethical standard applicable sec standards independent maintain relentless focus audit quality deloitte internal quality control procedure audit provide timely clarity assessment accounting treatment ensure consistency advice level maintain forwardthinke approach raise potential issue concern soon identify provide timely uptodate knowledge technical governance issue include evolve market practice viability statement requirement esmasec guideline new ifrss ie ifrs serve industry resource communicate good practice trend report integrate reporting provide high quality succession planning key staff member deloitte ensure technical skillset continuously enhance effective deliver smooth run thorough efficiently execute audit partnership discuss approach area focus advance early engagement understanding implication new operating model ensure sarbane oxley scope additional procedure discuss understand management communicate timely basis gsk deloitte timely reporting issue level group early engagement provision impact assessment key judgement ensure clarity role responsibilitie local deloitte finance service respond issue raise management timely basis meeting agree deadline provide sufficient time management consider draft auditor report respond request query consistent timely communication engagement local central audit team gsk stakeholder group liaise aa avoid duplication work gec ensure common understanding audit finding adopt collaborative approach solve issue ultimately provide highquality service board shareholder relevant stakeholder scrupulous scrutiny group act utmost integrity value work closely management agree scope change overrun efficiency set clear milestone continuous money monitoring provide transparency audit time cost incur analysis budget identify area enable reduction audit hour compromise audit quality commensurately reduce audit fee gsk annual report audit risk internal control continue nonaudit services presumption nonaudit service provide prohibition gsk policy include black list prohibit accountancy firm nonaudit service external auditor skill experience preapproval categorywide preapproval process reflect suitable supplier nonaudit service restriction frc guidance audit authorise provide nonaudit service committees nonaudit service auditrelate tax service accordance gsk preapprove committee chair policy committee ensure auditor objectivity cfo delegate committee independence safeguard review pre preapproved approve service group financial controller follow core policy guideline engage external approve designate group auditor provide nonaudit service observe financial controller process nonaudit service fee pay company auditor associate set competitive tender financial service provider detail given note financial external auditor line group procurement statement operate profit process skill experience external auditor suitable supplier safeguard ensure adequate safeguard place audit service comparisonm objectivity independence group audit threaten compromise deloitte fee cap ensure total fee payable nonaudit service exceed annual audit fee special circumstance clear advantage company auditor undertaking dddeeellloooiiitttttteee additional work company policy complie frc revise ethical standard eu audit regulation pwc sarbanesoxley act company policy contain follow guideline fee cap cap annual audit fee audit assurance service service include tax regulatory compliance stringent frcs fee cap set treasuryrelate service average fee precede threeyear period fair balance understandable assessment key compliance requirement group financial code conduct report line statement annual report fair balance number wellestablishe policy include understandable coordination review groupwide code conduct available gskcom contribution annual report follow wellestablished detail confidential speak reporting line document process perform parallel reporting investigation unlawful conduct update formal process undertake external auditor version code conduct publish april committee receive summary approach take management preparation gsk annual report ensure meet requirement frcs code enable committee board confirm gsk annual report take fair balanced understandable provide information necessary shareholder assess company position performance business model strategy gsk annual report strategic report governance remuneration financial statement investor information audit risk internal control continue internal control framework board recognise obligation present fair balanced group rocc team senior leader mandate diligent assessment gsk current position board assist committee oversee risk prospect board accountable evaluating management internal control activity provide approve effectiveness internal control include business framework risk management upward financial operational compliance control risk escalation significant risk business unit risk management process operate gsk board structure report rocc business unit rmcbs responsible promote local tone internal control framework framework risk culture ensure effective oversight comprehensive enterprisewide risk management model internal control risk management process mean gsk ensure reliability financial reporting compliance law regulation principal risk assign risk owner member framework support continuous process board senior management risk owner accountable identification evaluation management group management hisher respective principal risk include principal risk require frc code set risk mitigation plan implementation design manage risk achieve business report risk management approach progress objective rocc committee year rocc rmcbs assist gec responsible fit purpose framework conjunction corporate advance risk management enterprise value expectation speak process ensure development working practice riskbase risk associate business activity actively ethically sound gec actively promote ethical behaviour effectively control line agree risk appetite enable member organisation operate believe framework provide reasonable accordance value comply applicable absolute assurance material misstatement loss law regulation aa line agree assurance plan provide framework independent assurance senior management board enterprise oversight effectiveness risk management group independent assurance assurance help senior management board meet oversight advisory responsibility fulfil independent business monitoring g othro eu r p ts kt er ha ote ldg eic r b aje c ati v dd u b au l rl ed pin og r tt ir nu gs li nw ei ih n tp oa tt hie en cts f ond disc ep nl fi rce ea mn ed nt b r ui ss ssk e nsm een st w cori ntt te ron ls standards p r pin sh r roi kd e n v c tt c io dh ip eoe ta h alc e r nm io gs aim kt srt oem sue w eit p srt ne e se ae c mnr e ei v ng oe tn e r ncr ee lg aa hu tn eel r tir n ee rp e na ro l n cs l cf nr r oo e tn rm ots r l ob eo lu nfs vs itn rig ohe n nes mss fi e c eu r nn en tit p ts rt p ro blemer ssp n ding activity train w ot fi r teh hni en g te eha e rc enh p tp oh reri n scc tp n ha erl cr li oek n va mir ita n te en e c cnl ou nd f cin lug e ewn sih n oa g nn tc th e em c ee fn fn et ss ci tt io era not eio sn mom na toa rg ine gment communication anf nth ue li ln yt e inrn aa cl cc oo rn dtr ao nl c e en v wir ito hn tm e n ft ra cnd r ep rt c oo th ee p b roo va isr d ns board authority delegate committee conduct robust assessment group principal risk include consideration nature extent risk willing achieve group strategic gsk value expectation objective board committee maintain oversight ensure effectiveness internal control environment risk management process operation group year date approval annual report gsk annual report internal control framework continue board review focus company subsidiary review group risk management approach extend material associate undertaking joint discuss risk management section strategic venture investment consider risk report page management principal company participation activity risk explain principal risk uncertainty page establish procedure control place identify entity group viability discuss group result consolidated group result financial review section strategic report believe process follow board committee review regularly system internal control risk management process accordance guidance risk management internal control relate financial business reporting issue frc governance structure risk management gsk annual report gnirotinom rof ytilibatnuocca responsibility implement audit risk internal control continued board director responsible system corporate governance strategy risk management financial performance responsible review approve audit risk committee adequacy effectiveness risk management internal control corporate executive team support ceo manage business activity authorise board assist audit risk oversight risk committee oversee risk compliance council management internal control activity group responsible system corporate business unit governance strategy risk management financial performance ensure appropriate internal control risk management implement effective risk management compliance board complement country executive risk board ensure consistent approach risk management local territoriesstrategic report governance remuneration financial statement investor information science committee report please present report chair science dr jesse goodman committee committee science committee chair committee work support board dr barron cso consider science role technology culture new rd strategy committee committee operate programme activity help undertake periodic review rd strategy discharge responsibilitie item consider include progress regular update pharmaceutical vaccine assess overall performance include relevant asset financial metric effectiveness competitiveness rd regular update rd strategy helps identify critical emerge trend science scientific technical review business deal medicine potential impact company strengthen pipeline undertake periodic review company scientific oversight rd pipeline milestone include project capability talent portfolio governance gate progress rd goal review scientific opportunity specific large scale progress rd culture talent investment business transaction pharmaceutical rd review output group science advisory committee please observe pharma rds board significant progress strengthen pipeline focus science relate immune system use membership human genetic advanced technology committee member committee member create culture foster innovative mindset new dr jesse goodman january governance model embed centralised key chair january functional capability change include refocus dr laurie glimcher september small number promise project away judy lewent january discovery performance unit model large research detail committee member skill experience give unit focus priority area immunology genetic biography board page pipeline continue evolve asset progress committee member attendance level add termination medicine approve company secretary secretary committee result medicine currently develop attend meeting attendee committee rd continue attract talented individual work meeting include rd help deliver new approach science x technology x culture regular attend attendee attendee require vaccines rd company chairman committee oversee significant change vaccine chief executive officer rd strategy secure growth exist portfolio chief scientific officer president rd unlock new emerge vaccine field key president global vaccine change creation integrate development independent senior external scientific adviser organisation chief financial officer develop maintain great insight company executive understand vaccine business pleased visit wavre belgium rockville washington visit enjoy meet employee member rd bring life impressive scientific activity undertake vaccine gsk annual report science committee report continue collaborative approach committee evaluation committee please review scientific committee annual evaluation externally facilitate perspective new key collaboration strategic partner interview committee member behalf help enable gsk strengthen pipeline conclude committee continue develop gain real advantage patient company give critical importance strengthen pipeline collaboration enable obtain competitive advantage committee focus science deep level support add pipeline optionality enable gain access board understand provide reassurance key technology include guidance go forward committee broad lyell immunopharma gsk enter fiveyear collaboration objective develop new technology improve cell therapy key scientific assumption company strategy cancer patient collaboration apply lyell technology remain valid strengthen complement cell therapy pipeline technical assurance university california establish stateoftheart laboratory crispr technology laboratory risk oversight research practice patient safety genomics research new laboratory explore gene enterprise risk mutation cause disease develop new technology look forward report progress year crispr rapidly accelerate discovery new medicine collaboration build gsk exist collaboration company andme able deliver dr jesse goodman genetic information scale improve probability rd science committee chair success march positive outlookrd priority asset forward strategy addition committee please note number positive development year underscore move promise future outlook rd include rd pipeline achieve major approval submission positive readout pivotal study progress new asset pivotal study pivotal study readout include positive datum key latestage oncology therapy zejula woman ovarian cancer belantamab mafodotin patient multiple myeloma dostarlimab patient endometrial cancer national medical product administration approve shingrix vaccine use china largescale pilot implementation rtssa mosquirix malaria vaccine malawi ghana kenya gsk annual report strategic report governance remuneration financial statement investor information corporate responsibility committee report chair corporate responsibility committee lynn elsenhans committee please present committee corporate responsibility committee chair report committee form important board oversight role company trust priority ensure cet working deliver longterm value shareholders society committee committee rolling agenda receive report review issue potential cet member senior manager ensure action impact gsk business reputation progress company commitment review oversight view interest internal regular basis include monitor company work external stakeholder engage effectively broad range stakeholder consider gsk trust priority annual governance respond high external expectation gsk global oversight progress gsk trust commitment healthcare company reflect important issue responsible area focus sustainable business growth committee focus time area membership material stakeholder longterm business success year work committee include scrutiny membership committee appointment progress commitment support company date set trust priority set context external trend committee member committee member stakeholder expectation committee review lynn elsenhans october approve company report progress chair commitment set trust section dr vivienne cox july pages dr jesse goodman year management present committee detail committee member skill experience number topic breadth trust priority give biography board page committee member attendance level science technology global health committee company secretary secretary committee review area significant progress attend meeting attendee committee company new global health strategy lead science meeting include emphasise importance sustainable funding model committee discuss sustain momentum regular attend good early progress ensure good outcome attendee attendee require patient company acknowledge commercial company chairman business benefit investment area chief executive officer chief scientific officer president rd affordability availability year continue general counsel focus access affordability company president global affairs commitment make product available price president pharma supply chain responsible sustainable business review president global pharmaceutical global pricing strategy pharmaceutical business president global vaccine particular focus environment company ceo gsk consumer healthcare large single market operating context svp human resource continue evolve svp corporate affair modern employer committee review progress vp trust global health company commitment modern employer centre executive engage people inclusion diversity health wellbeing development committee discuss good progress gender lgbt target use employee assistance programme robust deployment manager assessment tool identify issue help improve line management performance gsk annual report corporate responsibility committee report continue responsible business committee review progress committee evaluation gsk commitment fundamental committee annual evaluation externally facilitate responsible business include oversight ethic interview committee member behalf value responsible use datum scientific conclude committee continue operate engagement review progress measure effectively reduce environmental impact quarter give increase importance esg factor emerge environmental risk include plastic usage need regard come year committee discuss assessment company committee pleased board support plastic footprint plan reduce use possible progress work area particular respect stakeholder engagement insight environmental sustainability committee pay close attention evolve view committee aim expectation companys broad range key stakeholder year continue scrutinise monitor regular report stakeholder insight review gsk material trust topic include management discuss meeting ensure committee consider key priority continue build protect company issue bear company reputation reputation strong focus innovation committee delivery responsible business agenda consider company position committee receive update gsk reputation support continue delivery trust priority research understand relevant insight strategy employee insight discuss relation company lynn elsenhans modern employer agenda result employee corporate responsibility committee chair survey march year continue enjoy positive engagement investor approach performance trust work committee meet directly shareholder understand issue concern committee member area responsibility item address external issue health safety update meet informally shareholder annual potential impact general meeting committee review perception regular reputational emerge gsk business reputation study investor interested esg aspect issue update activity well understand rise interest investor oversight corporate reputation area matter committee discuss research kpi perception strength area include hcp engagement sfi change management esg risk opportunity implementation integrate strategy quality esg oversight stakeholder view stakeholder insight update disclosure strong committee note investor desire engagement esg investor insight sustained delivery trust commitment increase employee survey report align sustainability accounting standard shareholder meeting board sasb taskforce climaterelate financial disclosure tcfd company include sasb annual governance oversight approval trust section disclosure esg performance summary available progress gsk annual report online voluntary tcfd disclosure give responsible business oversight progress commitment support trust commitment highlight remuneration committee chair global health strategy emerge importance establish link esg sustainable access affordability performance remuneration outcome executive business conduct director cet responsible use datum finally committee pleased company modern employer engagement perform key external benchmark secure culture position dow jones sustainability index environmental target pharmaceutical industry continue hold position access medicine index key hcp healthcare professional sfi sale force incentive esg enviromental social governance gsk annual report strategic report governance remuneration financial statement investor information section statement statement align section statement requirement engagement company main stakeholder group contain section cza company act include patient shareholder consumer customer act employee level organisation enterprise summarise page strategic statement focus director regard report year matter set section f act perform duty incorporate governance architecture process company information area annual report avoid operate ensure relevant matter consider unnecessary duplication board consider board principal decisionmake mean statement focus risk opportunity contribute delivery gsk longterm priority strategic importance gsk consistent size innovation performance trust summarise page complexity group corporate governance report performance duty promote success table identify annual report company board regard number matter information issue factor stakeholder include listen consider view shareholder board consider relevant disclosure comply company key stakeholder build trust section f act set detail give ensure fully understand potential impact decision strategic importance gsk make stakeholder environment community operate board regard follow matter information longterm result strategic report likely consequence decision long term business model chairman statement ceo statement capital allocation longterm prioritie key performance indicator risk management viability statement corporate governance report responsible leadership audit risk committee report b workforce strategic report interest group employee business model culture modern employer stakeholder engagement page corporate governance report responsible leadership workforce engagement nominations committee report audit risk committee report remuneration report remuneration committee chair statement gskcom gender pay gap report gsk annual report section statement continue board regard follow matter information c business relationships strategic report importance develop group business business model relationship supplier customer industry trend stakeholder engagement performance pharma vaccine consumer reliable supply work party risk management corporate governance report responsible leadership principal decision audit risk committee report corporate responsibility committee report community environment strategic report impact group operation trust section include community environment environment ehss risk page climaterelate financial disclosure corporate governance report corporate responsibility committee report gskcom responsibility report datum e reputation strategic report desire maintain reputation high culture standard business conduct trust ethic value human right report investigate concern antibribery corruption nonfinancial statement approach tax corporate governance report corporate responsibility committee report gskcom modern slavery statement f fairness shareholder corporate governance report aim act fairly member shareholder engagement company investor information gsk annual report strategic report governance remuneration financial statement investor information director director power determine uk legislation nomination committee review register potential article association contain rule conflict authorisation register conflict january appointment replacement director provide report board conflict director appoint ordinary resolution appropriately authorise process authorisation member resolution board provide continue operate effectively recommend approval appoint board director retire register conflict board subsequently annual general meeting follow appointment approve describe note financial statement relate party transaction end article provide director require financial year director person closely associate seek reelection annually annual general meeting material interest contract significance accordance code group company director cease director article prohibit director voting resolution bankrupt concern appointment term termination cease director virtue company act appointment article independent advice suffer mental physical ill health board resolve company agree procedure director shall cease director independent legal andor financial advice company expense deem necessary miss director meeting continuous period indemnification director month permission board resolve qualify party indemnity provision define shall cease director company act force benefit director prohibit director law director hold office resign offer resign board accept offer approval signature annual report require resign board change control essential contract contract arrangement director conflict interest individually fundamental ability business director duty company act operate effectively company party material avoid situation direct agreement effect altered terminate indirect conflict interest possible conflict change control follow takeover bid company article provide general power board agreement director provide compensation authorise conflict loss office employment result takeover board review new potential actual conflict provision company share plan record company secretary director count cause option award grant plan vest quorum authorisation actual takeover potential conflict nomination committee review detail termination provision executive director register conflict annual basis board service contract give version company subsequently approve remuneration policy available wwwgskcom continue basis director responsible investor section update new inform company secretary new actual remuneration policy set page potential conflict arise change annual report provide approve shareholder circumstance affect authorisation previously company annual general meeting give provide authorisation director absolve statutory duty promote success company actual conflict arise postauthorisation board choose exclude director receipt relevant information participation debate suspend director board resort require director resign gsk annual report director continue content director report follow information incorporate director purpose uk company act report director report glaxosmithkline plc year end location annual report december comprise interest capitalise financial statement director report note section page publication unaudited financial information group financial review corporate governance report detail longterm incentive scheme remuneration report employee engagement waiver emolument director applicable director statement responsibility waiver future emolument director applicable investor information non preemptive issue equity cash applicable non preemptive issue equity cash applicable strategic report set matter require unlisted major subsidiary undertaking disclose director report consider parent company participation place applicable strategic importance list subsidiary strategic report provision service control applicable shareholder section page shareholder waiver dividend financial statement risk management objective policy note shareholder waiver future dividend financial statement note likely future development company agreement control shareholder applicable research development activity business relationship director report diversity draw present accordance provision information consultation employee reliance english company law liability carbon emission director connection report shall subject section statement limitation restriction provide law approve board director march sign behalf sir jonathan symonds chairman march gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn remuneration section chairman annual statement annual report remuneration remuneration policy summary remuneration policy report ggsskk aannnnuuaall rreeppoorrtt remuneration report chairman annual statement behalf remuneration committee committee propose new policy consider develop pleased present remuneration report context committee oversight wide workforce include annual statement annual report pay meet hr business lead exchange view remuneration update remuneration policy executive remuneration arrangement align group report set propose change remuneration policy wide pay policy arrangement engagement describe pleased insight generate performance engagement continue develop come set report gsk year ensure alignment pay policy practice significant progress ipt priority addition base external benchmark datum internal innovation strengthen pipeline focus projection committee able satisfy increase investment rd exciting new company remuneration arrangement remain appropriate development oncology significant number positive give committee view design exist policy result portfolio work effectively major structural change propose performance deliver growth sale earning especially avoid distraction prepare separation achieve strong cash generation improvement group certain amendment include ensure operational execution prepare separation group policy implementation remain fit purpose trust continue good progress innovation conclude necessary change engage global health tb malaria hiv rank major shareholder behalf committee pharmaceutical sector dow jones sustainability index feedback receive shareholder greatly value remuneration outcome carefully consider committee decide award relation accordance proceed finalising propose new policy key change approve remuneration policy key decision outlined committee follow pension annual bonus outcome determine reference alignment new executive director pension performance agree financial measure contribution wide workforce committee committee assessment executive director consider level pension director context individual level performance result bonus requirement frc code feedback payment target committee believe investor guidance investment association bonus outcome appropriately reflect overall emerge market practice company exist pension underlie performance arrangement wide workforce new policy future executive director appoint uk vest lti award base preagreed equally provide pension align opportunity available weight measure rd new product performance broad employee population location adjusted free cash flow relative tsr year result overall vest level alignment current uk executive director pension contribution wide workforce committee reduce pension provision current uk base executive committee determine bonus lti outcomes directors align wide uk workforce level include assessment performance january relevant measure exercise discretion determination committee determine maintain current pension contribution dr hal barron cso review remuneration policy base recognise contractual commitment committee review remuneration appointment exceptional talent critical policy objective maintain alignment importance make continue progress rd ipt priority shift culture investor sentiment group prospect come year recognise emerge market practice strong competitive dynamic market outset review committee careful ensure operate exist policy reflect factor set provision extension post employment cessation share frcs code apply consistently ownership requirement develop propose new policy example gsk current share ownership requirement sor mandate factor address new policy include executive director retain shareholding oneyear continue simplify pay arrangement remove post employment cessation extend require year service condition termination mutual agreement sor hold second year post cessation loss office policy employment gsk operate significant sor ceo maintain proportionate approach reduce ceo require hold salary year maximum lti award level base salary follow cessation salary second year gsk annual report strategic report governance remuneration financial statement investor information reduction maximum lti award level ceo remuneration committee aware sensitivity committee initially set emma walmsley pay ceo stakeholder level executive pay light give previous incumbent market reflect committee intention headroom new role ceo position currently available reduce maximum award level emma walmsleys leadership strong permit new policy ceo lti award progress gsk strategic priority base salary propose lti ipt support shift company culture new rd continue grant maximum opportunity strategy deliver significant progress technology propose increase lti award level emma pipeline strengthen target business walmsley implementation new policy development result company deliver strong set financial operating performance sale growth change business growth total adjust broaden malus clawback provision consistent earning share growth free cash flow common practice ftse propose despite genericisation advair extend scope trigger event exist implementation second step plan salary executive financial recoupment policy increase emma walmsley reflect performance update termination policy propose role committee agree follow engagement significant change loss office payment policy shareholder progress pay level implement manage succession proactively propose twostep salary increase disclose year service condition remove year annual report second salary increase termination mutual agreement policy bring new award subject continue development sustain policy line market standard performance detail propose change policy set committee consider emma walmsley performance page light continue progress develop remuneration policy implementation execute business strategy delivery financial new psp performance measure performance second salary increase award previously indicate shareholder intention january result base salary introduce measure recognise importance accelerate set lti award level salary strengthen pipeline reflect innovation priority increase emma walmsley annual lti award level particular importance anticipation separation salary recognise development strong introduce strategic pipeline progress performance competitive landscape gsk measure target reward progress strengthen operate increase lti award remain rd pipeline high quality asset achieve new reduce maximum propose new policy approval major market key asset indication committee consider high regard focus metric achievement material hold virtue performance consider milestone competitive positioning peer make adjustment new performance measure weighting lti lti awards enable emma walmsleys total compensation award position broadly market median level delivery relative tsr strong longterm performance adjust free cash flow board change innovation sale announce august iain mackay join board pipeline progress cet january succeed simon dingemans future lti measure reward chief financial officer april simon retire executive director deliver immediate value outcome company follow agm detail shareholder base company performance join leave arrangement describe remain incentivise innovation commercialisation year report new asset agm introduction european benchmark peer group finally like thank shareholder input committee replace exist ukcross industry peer engagement remuneration policy review group new european peer group reflect feedback welcome shareholder feedback report look shareholder uk peer group forward receive support propose new narrow change result group remuneration policy annual report remuneration reflective nature gsk business annual general meeting methodology select new group base select company range gsk market capitalisation urs rohner ftse stoxx exclude company remuneration committee chairman operate financial service extraction utility industry march gsk annual report glance total remuneration following show breakdown total remuneration pay executive director office december respect emma walmsley iain mackay dr hal barron usm usm usm usm usm usm mackay join board january remuneration show date fix pay salary benefit pension performance pay annual bonus ltis earn respect year performance period pay performance annual bonus financial performance lti outcome performance period end december overall vest maximum target relative rd new target tsr product threshold target adjust group pbit performance achieve vested adjust maximum performance target lapse free cash flow propose executive remuneration policy implementation key change policy alignment pension wide new uk executive director pension contribution level align wide workforce workforce current uk executive director pension contribution level align wide workforce january extension post employment share ownership requirement executive director hold second year post cessation cessation sor employment lti opportunity maximum reduce ceo award maximum reduce base salary implementation great alignment lti measure great alignment innovation business priority ipt business priority introduction pipeline progress performance measure innovation measure comprise performance measure ceo remuneration implementation second step plan salary increase effective january increase ceos lti award level base salary follow continue development sustain performance ee propose nonexecutive director remuneration policy gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration total remuneration audit fix pay pay performance annual bonus vested lti awards maximum opportunity vest measure salary measure rd new product adjust group pbit afcf total benefit personal objective relative tsr remuneration year deferral plan b pension gsk share dabp matching award psp award read page read page read read total remuneration audit emma walmsley iain mackay dr hal barron simon dingemans january fix pay salary benefit pension total fix pay pay performance annual bonus vest lti awards dabp matching awards psp total pay performance total remuneration note detail mandatory bonus deferral defer annual bonus plan dabp set matching award cease long grant dabp dabp matching awards vest february value base share price vest vested relate share price appreciation performance period committee exercise discretion relation vest award share price change ms walmsley psp vest july value base average share price threemonth period december vest relate share price appreciation performance period committee exercise discretion relation vest award share price change committee specific circumstance line state principle apply clawbackmalus determine appropriate follow consideration committee recovery sum pay clawback reduction outstanding award vest level malus apply respect executive director detail vest dabp matching award psp award detail payment past director gsk annual report annual report remuneration continue total remuneration audit continue follow section provide detail element total remuneration include committee implement approve remuneration policy year comparator group pay relative tsr committee pay comparator group consider executive pay global pharmaceutical comparator group measure relative tsr performance primary group executive director follow primary comparator group global pharmaceutical comparator group emma walmsley astrazeneca reckitt benckiser dr hal barron france iain mackay bhp group rio tinto sanofi abbvie bp royal dutch shell switzerland amgen british american tobacco unilever novartis bristolmyers squibb diageo vodafone roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer bbvie amgen include remuneration benchmarking include tsr comparator group review ceo remuneration committee reference pay group lead european company selection base size complexity change comparator group ceo cfo fix pay audit salary benefit table set base salary executive uk remuneration reporting regulation require company director year compare increase add executive director total benefit calculation uk workforce item deem tax authority taxable benefit detail set follow shareholder consultation january committee decide adjust ceo pay tranche reflect development performance role detail salary level provide base salary change emma walmsley iain mackay na dr hal barron simon dingemans uk employee gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue fix pay audit continued pension executive director member pension arrangement emma walmsley base salary matching contribution salary base salary iain mackay lieu pension salary excess dr hal barron dr barron member k plan open employee executive supplemental saving plan essp saving scheme open executive accrue benefit k plan limit complete year service january dr barron receive combine contribution rate k essp plan core contribution plus match total base salary bonus bonus defer dabp dr barron member cash balance supplemental cash balance pension plan gsk make annual contribution base salary line senior executive member gsk cet simon dingemans base salary lieu pension member define contribution plan emma walmsley iain mackay eligible receive matching award salary accordance term plan emma walmsley iain mackay receive cash payment lieu pension base salary excess line gsk define contribution pension plan rate simon dingemans receive cash payment lieu pension base salary line gsk define contribution pension plan rate follow table show breakdown pension value set pension remuneration figure calculate accordance methodology set large mediumsize company group account report amendment regulation remuneration regulation emma walmsley iain mackay dr hal barron simon dingemans janmay pension remuneration value uk define contribution define benefit employer cash contribution total pension remuneration value uk define contribution figure emma walmsley include bonus sacrifice contribution detail pension value dr hal barron set table pension figure disclose dr barron member style define benefit plan accordance paragraph eii schedule remuneration regulation table show accrued benefit ie annual pension accrue date accordance regulation pension remuneration calculate increase accrue benefit adjust inflation multiply reflect fact benefit receive number year accrue pension pension remuneration december december value dr hal barron pension value fund unfunded total detail change pension policy future policy table implementation gsk annual report annual report remuneration continue pay performance audit annual bonus individual annual bonus adjust group pbit objective performance target financial measure weighting follow weight adjusted group pbit performance position performance measure executive director target outcome target adjust group pbit individual objective threshold maximum performance target set target respectively adjust group pbit target outcome purpose annual bonus calculation differ adjust group pbit disclose annual report primarily target outcome number calculate apply gsk budget exchange rate actual exchange rate follow table show actual bonus earn compare bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objective bonus bonus bonus salary salary base salary salary salary salary emma walmsley iain mackay dr hal barron table provide detail delivery adjust group pbit financial performance group turnover billion increase aer cer adjust operating profit million high aer flat cer turnover increase cer adjust operate margin aer cer cer proforma basis total earning share increase p aer cer adjust eps grow aer cer p strong cash generation achieve free cash flow billion dividend continue p gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance audit continue follow table summarise performance scorecard individual objective agree committee executive director addition contribution financial performance individual objective emma walmsley continue focus progress longterm ipt priority supply chain transformation plan deliver brand robust commercial execution result strong performance network simplification building capacity support new product sale pharmaceutical vaccine billion speciality pipeline supply chain reliability target achieve consumer healthcare billion commercial medical progress build global reputation ipt priority speciality capability build track support upcoming launch include rank dow jones sustainability index total respiratory sale billion shingrix sale billion meet significant milestone global health strategy continue drive transition drug regimen hiv include malaria tb paediatric hiv programme strengthen pipeline execution rd strategy continue amr leadership science x technology x culture doubling number focus leadership development include internal cet oncology asset clinical development significant progress promotion hr communication new role advanced technology approach establish laboratory enterprise key role women senior genomic research collaboration lyell immunopharma vice president vice president level outstanding external hire functional genomic aiml record high employee engagement april tesaro acquisition complete integrate positive datum continue focus create performance readout zejula culture underpin value expectation consumer healthcare jv pfizer complete ahead plan integration track preparation creation new company start iain mackay strong financial leadership group year role key leadership role preparation separation deliver financial operating performance plan company group turnover operating profit free cash flow capital strengthen finance investor relation team expenditure cash restructuring structure high engagement period leadership company change dr hal barron rd strategy deliver strong pipeline progress asset tesaro integrate deliver efficiency pipeline advanced phase phase phase goal positive datum readout zejula termination registration decision expect rebuilding gsk reputation innovation support continue drive focus great collaboration partner significant increase internal accountability decision making engagement innovation significant business development support advanced technology approach strong capability build include external hire lead functional genomics aiml new talent key rd role build oncology capability malus clawback policy line disclosure guideline committee detail policy malus clawback refer recoupment committee exercise malus clawback company remuneration policy report available gskcom policy committee review disclose detail exist policy recruitment remuneration recoupment committee exercise malus clawback loss office termination payment refer disclosure matter subject remuneration policy report page public report misconduct fully annual report available gskcom change resolve legally permissible disclose loss office policy remuneration policy report unduly prejudice company propose refer shareholder gsk annual report annual report remuneration continue pay performance audit continue value earn longterm incentive ltis follow table set performance achieve management target set company lti plan include update performance outstanding award line committee agree principle measure applicable lti awards actual performance target review adjustment appropriate ensure vest outcome reflect genuine underlie business performance result deliver line trust business priority reflect company position esg detail adjustment provide time vest award performance period end december committee review performance psp award dabp matching award grant executive director target set detail decision revise adjust free cash flow afcf target set annual report psp award dabp matching award assess performance measure change afcf target addition change target set rd new product performance measure relative tsr performance measure psp award psp value base average share price threemonth period december vested ceo relate share price appreciation performance period committee exercise discretion relation vest award share price change dabp matching award value base share price vest vested ceo relate share price appreciation performance period committee exercise discretion relation vest award share price change performance achieve year december vest level set table outcome vest level performance measure relative weighting performance target outcome maximum award rd new product rd new product sale performance measure aggregate threeyear sale new bn performance product launch threeyear performance period precede rename year ie innovation sale target vest rd maximum bn bn bn threshold bn adjust free line company agree principle afcf figure include adjustment bn cash flow number material distort item include legal settlement exchange rate performance movement special pension contribution rd original revise target target vest maximum bn bn bn bn bn bn threshold bn bn f urther detail revise target set annual report relative tsr rank th tsr ranking comparator group vest performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holding sanofi vest schedule base deliver vest median performance comparator group company median fall company total vest respect award gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue pay performance audit continue update performance ongoing lti awards committee review performance psp award grant executive director follow chart provide estimate vest level take account performance december actual vest level determine base performance threeyear performance period indication regard prediction final vest level afcf target associate vest scale psp award adjust net overall impact reduction bn bn award bn bn award adjustment account follow item cash flow impact pfizer transaction impact vaccine rabipur encepur divestment operate profit impact separation preparation programme include restructure programme cost saving operating profit separation cost change target set rd new product performance measure rename innovation sale relative tsr performance measure award performance update award award rank rd rank rd bn threshold bn threshold maximum maximum commercially commercially median bn sensitive median bn sensitive threshold threshold tsr adjust free rd new tsr adjust free rd new rd cash flow product rd cash flow product rd rd rd rd estimate vest level estimate lapsing level threshold performance award vest respect rd new product performance rename innovation sale afcf measure relative tsr element award award vest median performance respectively tsr comparator group remain unchanged show respect award individual lti award level appear annual report set lti awards year report historical vest lti plan vest year adjust free rd new business total vested grant relative tsr cash flow product diversification lapse dabp award subject tsr performance award subject performance measure psp award gsk annual report annual report remuneration continue pay performance audit continued lti awards dabp award respect deferral bonus psp award show table dabp award psp awards total bonus number face value award level number face value defer share award base salary share award emma walmsley share share iain mackay share dr hal barron ad ad simon dingemans share face value dabp award calculate base share price ad price closing price february day grant nilcost option uk executive director restrict share executive director performance condition attach dabp award reflect mandatory deferral respect annual bonus earn face value psp award calculate base share price ad price closing price march day grant conditional share base equally weight measure rd new product performance rename innovation sale ii adjust free cash flow iii relative tsr performance measure vest threshold performance period psp awards january december iain mackay appoint board january simon dingemans dabp award vest normal year date grant allemployee share plan dilution limit uk executive director participate hmrc approve award plan incorporate dilution allemployee share plan wide uk workforce ie limit consistent guideline publish share save share reward plan investment association limit roll tenyear period plan roll tenyear participant share save plan save period executive share plan grant senior executive month year end period estimate dilution exist award option buy gsk share discount share price year december follow start saving contract participant share reward plan contribute month purchase gsk gsk employee share plan share company match detail executive share plan actual limit gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue ceo pay comparison ceo total remuneration position supplementaladditional ratio gsk ceo pay ratio likely vary potentially significantly time drive largely ceo variable pay outcome line reward principle ceo large portion pay base performance individual p p global pharmaceutical p mean depend gsk performance group ratio increase decrease significantly committee believe senior executive significant european proportion pay directly link performance crossindustry group light provide supplemental ratio lti compensation exclude believe provide additional view ltis form substantial percentage ceo total remuneration highly low quartile median upper emma walmsley median quartile current position variable dependent business performance ceo remuneration include salary expect value incentive base total remuneration exclude long term incentive committee agree benchmarke methodology compensation ceo pay ratio financial year methodology p p p lower upper quartile median quartile option methodology p p p total remuneration vest longterm incentive award option historic ceo remuneration pay ratio calculate actual earning emma walmsley sir andrew witty ceo uk employees ceo total single figure remuneration total give report remuneration total remuneration uk fulltime equivalent employee annual bonus award company december calculate line single figure methodology reflect actual maximum earning receive exclude business expense vest lti award produce percentile calculation option remuneration regulation business expense maximum exclude reimbursed employee ms walmsley total remuneration include pay period january sufficiently substantial value significantly impact march ceo ratio sir andrew receive prorata payment lieu variable bonus opportunity accordance remuneration policy gsk continue choose option psp dabp awards sir andrew grant vest april robust statistically accurate way company accordance term executive financial recoupment policy calculate ratio option available percentage change remuneration ceo remuneration regulation increase pay ratio emma walmsley uk employee outcome psp award award emma walmsley ceo change change set table base salary total pay salary benefit percentile benefit annual bonus p p p wide uk employee population salary increase salary include annual salary review additional total pay change year eg promotion uk employee benefit benefit unchanged previous year change benefit policy level reflect committee believe median pay ratio consistent change level benefit individual receive company pay reward progression policy result change role eg promotion uk base salary employee include executive employee population consider relevant director set reference range factor include comparison closely reflect economic environment market practice experience performance role encounter ceo gsk annual report annual report remuneration continue ceo pay comparison continue performance graph follow graph set performance company relative ftse index pharmaceutical performance comparator group tenyear period december index select comparison purpose reflect primary index gsk constituent industry operate gsk total return gsk pharma peer ftse total return index total return index index comprise astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holding sanofi additional remuneration disclosure relative importance spend pay external appointment executive director table show total employee pay group dividend board encourage executive director hold list pay shareholder company external nonexecutive directorship equivalent change line frc uk corporate governance code establish role broaden total employee pay experience development retain dividend pay year fee figure table reflect payment appointment consider board line year impact movement exchange company policy external appointment ascertain rate set page nature scope appointment ensure dividend declare respect million cause actual potential conflict interest million increase individual executive director continue meet exist total employee pay base employee average commitment gsk number people employ ceo share repurchase company year board approve emma walmsleys year nomination board microsoft corporation independent nonexecutive director join board service contract december shareholder approval expect table set date executive director receive fee annum service contract available review company deliver cash stock option register office office hour gskcom microsoft corporation defer compensation plan executive director service contract contain month notice nonemployee director receive fee period set exist propose new policy cfo date contract effective date expiry date iain mackay trustee british heart foundation emma walmsley member court university aberdeen iain mackay na group receive fee external dr hal barron appointment shareholder vote remuneration matter cso table show recent shareholder vote board recognise importance ensure hal respect remuneration report remuneration policy barron remain connected life science community vote total vote total vote total vote withhold approve appointment board grail cast billion million inc private company nonexecutive director remuneration report earn fee agm remuneration policy agm gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue total benefit audit table provide analysis total benefit receive executive director comprise employee benefit line policy employee vary location role business relate service provide employee assist enable carry role tax authority deem taxable benefit individual business expense company meet tax arise item show gross tax split area business travel include travel cost executive director appropriate spousepartner associate accompany executive director gsk business deem taxable benefit director accommodation whilst business travel benefit gross tax gross tax emma walmsley net uk total net uk total benefit available employee business relate service business travel benefit total benefit gross tax gross tax iain mackay net uk total net uk total benefit available employee business relate service business travel benefit total benefit gross tax gross tax dr hal barron net uk total net uk total benefit available employee business relate service business travel accommodation whilst business travel benefit total benefit gross tax gross tax simon dingemans net uk total net uk total benefit available employee business relate service business travel benefit total benefit note b usiness relate service tax regulation deem taxable benefit uk andor ure gsk review methodology allocate cost certain business travel previous methodology dr barron business travel total approximately net conversely current methodology resulted additional cost approximately bring business travel approximately net r barron place main business move uk result reduction cost gsk annual report annual report remuneration continue payment past director audit vest release lti award past director set annual report sir andrew witty dr moncef slaoui left board march mutual agreement accordance remuneration policy approve shareholder psp award dabp awards vest original timescale subject original performance condition dr moncef slaoui sir andrew witty number vest ad price equate number vest share price equate ad award share award psp psp dabp dabp benefit gross cost post employment benefit gross cost post employment financial planning home security simon dingemans leave psp award lapse dabp matching award dabp awards award vest term executive financial recoupment policy awards vest february february respectively accordance standard vest rule simon dingemans leave board voluntary leaver receive severance payment leave company receive annual bonus respect outstanding ltis treat line approve remuneration policy set table payment loss office audit loss office payment gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue implementation remuneration policy comparator group pay relative tsr follow feedback engagement shareholder committee decide replace uk crossindustry comparator group broad european crossindustry group ceo cfo european crossindustry group comprise ceo cfo europe crossindustry comparator group roche holding ag linde deutsche telekom novartis sanofi kere lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adida loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser cso relative tsr performance executive director global pharmaceuticals comparator group global pharmaceuticals comparator group continue cso remuneration measure relative tsr performance executive director composition group fix pay salary committee consider average increase pension award employee level cet uk committee carefully consider engage consideration agree investor pension provision new executive appropriate award increase line wide workforce director light external focus area cso cfo ensure competitiveness remuneration propose new policy change remuneration maintain follow engagement review ceo continued development committee commit reduce exist uk sustain performance follow engagement executive director pension align wide workforce shareholder agree second base salary january pension contribution cso increase outlined annual report page retain give contractual commitment implement appointment exceptional talent critical importance make continue progress rd group prospect base salary change come year new usbased executive director wide workforce pension align wide workforce emma walmsley appointment iain mackay dr hal barron pension contribution emma walmsley base salary matching contribution base average increase budget employee level cet uk iain mackay salary accordance term plan open employee base salary lieu pension salary excess benefit detail propose new policy dr hal barron base salary benefit change executive director addition line wide workforce benefit january combine contribution rate k essp plan core contribution plus match total base salary bonus bonus defer dabp gsk annual report annual report remuneration continue implementation remuneration policy continue pay performance table provide detail award grant psp annual bonus psp award change operation annual bonus change plan salary award level share adss detail policy relation annual bonus plan emma walmsley refer detail new policy iain mackay dr hal barron bonus opportunity weighting salary performance measure increase award level ms walmsley deliver adjust scorecard award subject shareholder approval remuneration report agm group individual target maximum pbit objective award grant price share ad emma walmsley lti performance measure iain mackay continuous consideration give introduction dr hal barron measure recognise importance accelerate strengthen pipeline support innovation setting assess performance level executive business priority great importance work director committee consider performance separation group committee company trust business priority reflect engagement investor decided introduce strategic group approach esg factor pipeline progress measure inevitably target link directly financial strategic pipeline progress measure plan commercially sensitive committee specifically target reward progress consider appropriate disclose annual bonus target strengthen rd pipeline high quality asset year result competitive harm detail achieve approval major market key asset performance target usual disclose indication focus metric achievement retrospective basis annual report material milestone defer annual bonus plan dabp awards committee set target base relevant milestone table provide detail mandatory deferral commercial value deliver business end dabp annual bonus payment performance period associate award grant share award performance condition hold year pipeline progress measure base equally regardless continue employment weight element key asset indication total bonus defer dabp awards pipeline progress lti award share share ad pipeline progress measure measure emma walmsley pivotal trial start iain mackay focus mainly phase iii dr hal barron registrational trial start include phase ii start example oncology performance share plan psp award follow careful consideration engagement investor major regulatory approval milestone committee intend increase emma walmsley annual psp award level salary recognise point allocate asset submeasure development role strong performance base forecast commercial value peak year sale highly competitive landscape gsk operate end performance period award remain newly reduce maximum grant propose new policy committee consider pipeline progress lti award threshold maximum particular high regard hold virtue measure performance competitive positioning peer pivotal point point point point adjustment bring total compensation broadly trial start market median level provide company deliver strong major point point point point longterm performance compare global regulatory approval pharmaceutical comparator group remain low milestone median easily differentiate exist rd new product sale measure rename innovation sale measure unchanged gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue implementation remuneration policy continue weighting lti measure onwards shareholding versus share ownership requirement sor align interest executive director shareholder require build maintain significant lti measure weight holding share gsk time executive director business priority measure previous new require continue satisfy share ownership innovation innovation sale requirement hold sor month previously rd leave gsk go forward executive director new product performance require hold sor month leave gsk pipeline progress performance relative tsr share ownership vs sor multiple base salary adjust free cash flow emma walmsley x x trust business priority iain mackay x set target review management performance lti measure committee consider dr hal barron x x reflect company trust business priority trust priority reflect company approach esg factor x x x sor december shareholding disclosure measure committee mindful investor concern executive director shareholding nondisclosure target time grant commit february disclose target follow end mr dingemans leave gsk continue hold performance period times previous base salary continue provide shareholder interim performance update measure course performance period exercise rigour assessment performance measure enlist support science committee assess performance new pipeline progress measure innovation target innovation sale pipeline progress measure nature commercially sensitive time grant performance relative tsr continue measure gsk global pharmaceutical comparator group adjusted free cash flow afcf target afcf measure grant target vest maximum bn bn bn threshold bn gsk annual report annual report remuneration continue remuneration governance role committee company secretary secretary committee role committee set company remuneration attend meeting attendee committee include policy regard gsk workforce remuneration committee attendee gsk able recruit retain motivate executive regular attend remuneration policy regularly review ensure attendee attendee require consistent company scale scope operation ceo support business strategy growth plan align cfo wide workforce help drive creation shareholder head human resource value head reward committee adviser pwc term reference committee term reference available judy lewent vindi banga member audit risk company website term reference review remuneration committee provide input audit annually revise december reflect good risk committee review group performance practice development oversight risk factor relevant remuneration decision governance committee chair meet employee hr board consider member committee representative understand employee view independent nonexecutive director accordance remuneration addition dr cox gsk workforce code engagement director provide committee insight view wide workforce remuneration gsk membership member committee appointment adviser committee date set pricewaterhousecooper llp pwc independent adviser committee appoint committee member committee member commercial tender exercise conclude urs rohner january company pwc member remuneration chair chair consultant group voluntarily operate vindi banga january code conduct relation executive remuneration consulting uk code conduct find dr vivienne cox january wwwremunerationconsultantsgroupcom judy lewent january year pwc connection committee meeting usually include closed session committee member board director member committee present provide consulting assurance service individual invite attend committee meeting company line protocol agree set year executive committee attendee committee chair pwc provide advice involve decision present committee satisfy advice objective discussion remuneration independent detail committee member skill experience give pwc provide independent commentary matter biography board page consideration committee update market committee member attendance level practice legislative requirement pwcs fee advice year charge fix time material basis willis tower watson provide additional market data committee committee evaluation committee annual evaluation externally facilitate interview committee member committee chair behalf conclude committee continue operate effectively gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continued committee area committee focus item discuss remuneration policy executive remuneration policy review recommendation committee set broad structure remuneration remuneration impact major group restructure policy determine remuneration executive engagement shareholder director chairman corporate officer salary review review remuneration environment include wide employee committee periodically review consider trend remuneration environment executive director cet executive director cet benchmarking competitiveness approve annual adjustment necessary regard gsk comparator group remuneration wide workforce executive director cet company secretary salary review recommendation annual bonus ceo executive director cet bonus recommendation committee responsible set specific performance ceo bonus objective measure annual bonus assessment performance lti plan lti performance outcome vest lti awards cet committee responsible approve lti plan rule change grant assessment performance vest lti awards confirmation lti grant cet executive director cet include interim award development new innovation pipeline measure governance area focus review term reference committee adhere robust remuneration governance committee evaluation annual review framework ensure alignment internal action remuneration report external reportingcompliance requirement confirmation group budget remuneration purpose remuneration consideration committee programme agm remuneration report feedback external remuneration environment performance target disclosure incentive plan approval new chairmans fee remuneration report disclosure include ceo pay ratio annual governance meeting key committee message presentation remuneration policy consideration feedback receive employer consultation employee employee representative set pay gender pay gap reporting gsk annual report annual report remuneration continue nonexecutive director fee chairman nonexecutive director nonexecutive director fee company aim provide chairman non nonexecutive director fee apply executive director fee competitive set table pay company equivalent size complexity annum subject limit contain article association standard annual fee supplemental fee chairman fee chair audit risk committee chairman pay fee annum senior independent director elect gsk share chairman scientificmedical expert fee review appointment new chair chair remuneration corporate conclude remain appropriate responsibility science committee nonexecutive director undertake intercontinental meet travel meeting implementation nonexecutive director policy nonexecutive director standard fee increase january follow review engagement shareholder agree increase annual fee payable nonexecutive director effect january standard annual fee senior independent director committee chair include remuneration corporate responsibility science committee subject shareholder approval introduce supplemental fee effect january payable workforce engagement director authorise payment nonexecutive director pay committee chair undertake additional duty exceptional unforeseen circumstance require significant additional time commitment change propose fee payable chair audit risk committee scientificmedical expert expect increase fee payable nonexecutive director new policy period increase describe reflect time commitment role nonexecutive director continue require invest total net fee gsk share ad total fee audit audit table set value fee benefit receive nonexecutive director form cash share ad detail nonexecutive director share allocation plan set nonexecutive director fee pay currency sterling convert average exchange rate review time time benefit comprise gross cash value travel subsistence cost incur normal course business relation attendance board committee meeting overseasbase director include travel meeting uk nonexecutive director fix fee fix fee emolument audit cash sharesad benefit total pay cash sharesad benefit total pay vindi banga dr vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent urs rohner sir jonathan symond director professor sir roy anderson philip hampton sir deryck maughan dr daniel podolsky hans wijers professor sir roy anderson retired board dr daniel podolsky sir deryck maughan retired board han wijer retire board gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director interest share audit interest director company office person closely associate pca show table total share plan interest december date leave total director interest sharesad option december january unveste unvested unvested unvested february date date subject subject subject subject vest exercised leave appointment performance performance performance performance exercise year executive director share emma walmsley iain mackay simon dingemans ads dr hal barron share allocation plan nonexecutive director total director interest number share ad december january dividend dividend reinveste reinveste february date date year december allocate december leave appointment end pay year elect nonexecutive director share vindi banga dr vivienne cox urs rohner sir jonathan symonds philip hampton ad lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent u nveste option subject performance emma walmsley represent bonus deferral share save option u nveste share subject performance simon dingemans represent share award end threeyear performance period psp grant subsequent reinveste dividend share subject twoyear hold period end february psp grant february psp grant unvested option subject performance mr dingemans represent bonus deferral share save option share save option lapse leave gsk unvested ad subject performance dr hal barron represent bonus deferral u nveste share subject performance simon dingemans represent psp award grant lapsed leave gsk unvested option subject performance represent dabp matching award grant lapsed leave gsk otal director interest include share purchase glaxosmithkline share reward plan emma walmsley simon dingemans award share respectively plan total number share hold plan follow share reward plan share february december january emma walmsley simon dingemans dr hal barron employee eligible participate share reward plan open uk employee otal director interest include option share ad result deferral bonus subsequent reinvestment dividend dabp total show table include bonus deferral exclude unvested matching award subject ongoing performance criterion matching award grant amount represent gross share ad balance prior sale share ad satisfy tax liability december defer annual bonus plan bonus deferral february date leave january emma walmsley share iain mackay share dr hal barron ad simon dingemans shares gsk annual report annual report remuneration continue director interest share audit continued otal director interest february include share ad vest february performance meet dabp psp award sell satisfy tax liability vest amount follow table set detail option share option plan sop nilcost option dabp exercise executive director number share date market price gain exercise type award date grant option exercise grant price exercise emma walmsley sop dabp deferral dabp match simon dingemans dabp deferral dabp match respect option sop remuneration receivable executive director calculate date option vest remuneration difference executive director require pay buy share total value share vest date executive director choose exercise option vest date subsequent increase decrease realise movement share price vest date date exercise increase decrease value result investment decision executive director record remuneration respect nilcost option dabp bonus defer director record remuneration annual bonus year relate gain record exercise nilcost option comprise remuneration total amount receive reinveste dividend prior vest gain loss result movement share price date grant exercise initial bonus defer ii date dividend reinvestment exercise reinveste dividend matching element dabp remuneration executive director record year performance period end represent number vest share multiply share price vest gain record exercise nilcost option comprise total remuneration gain loss result movement share price vest exercise matching award grant emma walmsley total gain follow exercise option grant sop comprise remuneration respect share option grant july vested july vest price investment gain gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date simon dingemans gain record follow exercise nilcost option relate deferral bonus earn respect comprise remuneration record annual bonus net gain relate reinvestment dividend prior vest movement share price grant dividend reinvestment date exercise date gain record follow exercise nilcost option relate dabp matching award comprise remuneration record relation dabp investment gain relate movement share price vest exercise date nonexecutive director total interest include share ad receive fee nonexecutive director share allocation plan dividend receive share ad plan january convert share ad february imon dingemans retired board sir philip hampton retired board august gsk annual report strategic report governance remuneration financial statement investor information annual report remuneration continue director senior management information provide compensation interest director senior management group group purpose group define nonexecutive executive director members cet company secretary financial year follow table set aggregate remuneration group period serve capacity remuneration total compensation pay aggregate increase accrue pension benefit net inflation aggregate payment define contribution scheme member group award share ad company lti plan set table align interest senior management shareholder executive director cet member require build maintain significant holding share gsk time cet member require hold share equivalent multiple time base salary continue satisfy share ownership requirement minimum month leave gsk award dividend reinvestment award award share ad share ad defer annual bonus plan matching award performance share plan defer investment award share value plan february group pcas follow interest share ad company interest award lti plan describe note financial statement employee share scheme interest february share ad own unexercised option defer annual bonus plan performance share plan defer investment award share value plan n otional share ad e xecutive director eligible receive defer investment award participate share value plan defer investment award grant emma walmsley vest grant prior executive director gsk annual report remuneration policy summary remuneration policy review current remuneration policy policy approve create shareholder value shareholder annual general meeting drive success company benefit patient receive vote favour require customer key stakeholder remuneration regulation shareholder ask approve new policy annual general meeting addition change policy ensure intended apply year implementation support delivery business strategy whilst deliver clear understandable appropriately committee consider policy competitive package attract retain motivate executive decisionmaking process committee follow talent determination review implementation propose new policy set committee chair statement page committee develop new policy executive nonexecutive director context oversight wide workforce pay consult employee committee review policy sought ensure new policy consult large shareholder continue respect propose change take shareholder align company business priority culture feedback account finalise new policy shift wide workforce pay policy emerge good table provide overview main change practice propose respect new policy policy shareholder ask approve set page remuneration element propose change policy rationale change pension new executive director receive pension alignment shareholder align broad workforce contribution level alignment code emerge market current uk executive director similarly practice align january extension post cessation share sor executive director hold alignment shareholder ownership requirement second year post cessation role alignment code emerge market practice lti quantum reduction maximum award level permit pay performance increase award level receive feedback shareholder apply case ceo maximum award level permit policy reduce previous increase target award ceo reflect strong performance role emma walmsley appointment april malus clawback definition trigger event expand alignment market practice include material misstatement result common ftse company reputational damage apply broad definition trigger event loss office payment policy year service condition termination simplification flexibility mutual agreement remove simplify policy allow great flexibility board manage succession proactively nonexecutive director fee introduction fee compensation additional duty designate workforce engagement director reflect work involve carry new role effect january equivalent committee chair authority seek nonexecutive director appropriately remunerate nonexecutive director chairman remunerate work pay committee chair simplification alignment shareholder undertake additional duty exceptional allow direct reinvestment fee share unforeseen circumstance require significant ad additional time commitment nonexecutive director continue require invest total net fee share ad company gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report future policy table subject shareholder approval company annual general meeting remuneration policy remuneration element outline table salary change purpose link strategy opportunity provide core reward role formal maximum limit ordinarily salary increase broadly line average increase wide set level appropriate secure retain high calibre gsk workforce individual need deliver group strategic priority increase higher reflect change operation scope individual role responsibility experience individual role experience performance independently salary adjustment reflect wide market condition source datum relevant comparator group consider geography individual operate determine salary level detail current salary level set annual report salary increase typically effect quarter remuneration year performance measure salary normally pay currency executive overall performance individual key consideration director home country determine salary increase benefit change purpose link strategy executive director base outside uk level set recruit retain high calibre individual require travel uk fulfil responsibility execute business strategy role attend board meeting subject tax business travel expense uk operation provision accommodation uk reality executive director eligible receive benefit line represent business expense tax treatment require policy employee vary location travel accommodation expense include include limited car allowance healthcare benefit business context tax liability life assurancedeath service provide cover company grossedup basis individual pension arrangement personal financial advice contractual postretirement benefit line policy benefit provision tailor reflect market practice employee executive director eligible geography executive director base receive overseas relocation allowance international different policy apply current future executive transferrelate benefit require executive director director base different country uk eligible participate allemployee share opportunity scheme eg share save share reward plan formal maximum limit benefit cost fluctuate subject term depend change provider cost individual employee circumstance order recognise high business travel requirement detail current benefit cost set annual role executive director entitle car travel report remuneration exceptionally accompany spousepartn performance measure business trip benefit include expense incur ordinary course business deem taxable benefit individual gsk annual report remuneration policy report continue future policy table continue pension change purpose link strategy new executive director uk receive date pension arrangement provide competitive level retirement appointment income base salary contribution define contribution plan match contribution subject operation relevant cap line implementation principle pension arrangement structure accordance member plan plan operate country individual likely base salary cash payment lieu pension retire individual choose member contribution portion relevant cap pension plan cash lieu relevant pension contribution pay instead executive director uk base salary cash payment lieu pension entitle join define contribution pension plan contribution receive cash payment lieu pension contribution individual member gsk legacy define cash balance supplemental cash balance pension benefit plan define contribution plan alternative plan provide annual contribution base salary pension plan arrangement subsequently appoint split plan appropriate board remain member plan gsk k plan executive supplemental saving plan opportunity essp core contribution salary bonus policy current executive director match contribution salary bonus uk new executive director receive base salary contribution define contribution plan cash balance supplemental cash balance pension match contribution subject plan provide annual contribution base salary relevant cap line implementation principle bonus split plan appropriate member plan gsk k plan essp core contribution base salary cash payment lieu pension salary bonus match contribution contribution portion relevant cap salary bonus global base salary cash payment lieu pension eligible appropriate equivalent arrangement excess contribution usuk arrangement january current uk executive director performance measure role pension arrangement align new executive director arrangement follow n event change plan operate similar value provide successor arrangement introduce market l ess bonus defer dabp annual bonus change purpose link strategy committee apply judgement make appropriate incentivise recognise execution business strategy adjustment bonus outcome ensure reflect annual basis underlie business performance clawback andor malus provision apply describe reward achievement stretch annual financial strategic business target delivery personal objective opportunity maximum bonus opportunity executive director operation salary threshold performance bonus payout financial operational business target set start financial measure nil target performance year committee bonus level determine bonus payout maximum opportunity committee base performance target performance measure individual objective set start year base combination financial target individual committee performance objective strategic performance objective majority bonus assess committee assess financial measure weight executive director require defer bonus different measure determine year earn share ad appropriate year accord business priority detail include deferred bonus share eligible dividend equivalent measure financial year provide date vest annual report remuneration gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue future policy table continue selection annual bonus measure annual bonus design drive achievement majority annual bonus opportunity base gsk annual financial strategic business target formal review performance stretch financial target delivery personal objective remainder bonus subject balanced scorecard strategic individual target align annual bonus financial target set reference company key objective financial year internal budget external consensus target performance share plan psp change purpose link strategy clawback andor malus provision apply describe incentivise recognise delivery long term business priority financial growth increase opportunity shareholder value compare pharmaceutical normal maximum award limit grant company psp individual year set table addition provide alignment shareholder interest retention element encourage longterm shareholding salary discourage excessive risk take ceo operation cfo conditional award annually vest dependent executive director achievement performance condition year performance measure subject additional twoyear hold period psp base combination financial share price relate target set reference internal budget external strategic performance condition align consensus target companys strategic plan measure award award eligible dividend equivalent date vest threshold performance detail include vest release performance target attach psp respect year weighting target psp award committee adjust formulaic vest outcome provide annual report remuneration ensure overall outcome reflect underlying business performance vest period w e announce annual report reduce threshold vest level tsr measure order align performance measure selection longterm incentive measure committee select performance measure focus major adjustment calculation performance executive director longterm remuneration delivery measure disclose shareholder vest gsk key strategic priority long term addition audit risk committee chair member set robust target committee implement member remuneration committee number safeguard ensure target meet provide input audit risk committee review sustainable way performance reflect genuine achievement group performance oversight risk factor target represent delivery value relevant remuneration decision shareholder detail rationale performance measure performance measure impact acquisition select calculate set divestment quantify adjust event annual report remuneration share ownership requirement change align interest executive director minimum executive director require maintain shareholder require build maintain significant share ownership requirement end holding share gsk time requirement year follow retirement company executive director follow end second year salary ceo executive director gsk annual report remuneration policy report continue future policy table continue clawback malus expansion definition trigger event event trigger event ie significant misconduct respect financial year remuneration committee way violation regulation law significant gsk policy disclose recoupment committee code conduct material misstatement result exercise clawback malus disclosure reputational damage company matter subject public report ability claw year annual defer misconduct fully resolve legally bonus vest unvested ltis addition permissible disclose respect psp award participant unduly prejudice company shareholder subject investigation vest award additionally continuity responsibility delay outcome investigation initiation adverse event emergence separate recoupment committee establish problem adverse event take account investigate relevant claim misconduct recoupment assess annual bonus award lti vest level committee exercise authority wide employee base year problem identify future period comprise senior executive relevant oversight remuneration committee recoupment committee appropriate experience include senior vice president appropriate adjustment individual annual bonus global ethic compliance senior vice president grant vest level lti awards reflect general counsel approach recruitment remuneration change committee determine remuneration package new internal appointment entitlement exist executive director casebycase basis depend remuneration element continue include pension role market operate entitlement outstanding award experience total remuneration level set reference case internal appointment require relevant pay comparator group appropriate executive director contractual term include allow future development role termination provision expect new executive director participate committee mindful sensitivity relate short longterm incentive plan basis recruitment package particular buy exist director exceptional circumstance right relate previous employment seek committee reserve flexibility set incentive limit minimise arrangement certain new executive director additional circumstance enable recruitment exceptional talent exist limit committee determine arrangement good interest company shareholder committee retain flexibility recognition high arrangement possible likeforlike basis level variable pay gsk global pharmaceutical forfeit remuneration term arrangement competitor committee use flexibility vary depend plan arrangement consider good interest company place previous employer form investor cash share subject performance pension arrangement external recruit executive condition explanation provide payment director set remuneration policy table compensation previous remuneration forfeit remuneration arrangement newly appoint benefit provide line policy exist executive director disclose soon practicable executive director appointment require meet business need relocation support provide line company policy gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue future policy table continue loss office payment policy change company policy fix term contract notice period termination employ company generally contract new appointment expire line executive director calendar month applicable policy retirement age ability impose month noncompete period nonsolicitation restriction executive director contract exist executive director expire consider important company ability date show protect group intellectual property staff light committee believe appropriate provide mitigation contract termination employment event executive director employment company terminate follow policy payment apply element remuneration loss office payment policy termination termination notice month annual salary payable termination company prorate notice period work payment termination payment respect notice period extend contract expiry date bonus element normally include termination payment term contract seek balance commercial imperative good practice redundancy termination notice uk statutory redundancy pay apply general severance policy apply retirement death illhealth injury disability termination payment lti award psp award govern plan rule approve shareholder follow provision normally apply termination notice unvested awards lapse redundancy retirement death illhealth injury disability reason generally award continue vest original timescale subject performance prorate time event change control psp award vest take account performance date normally take account proportion performance period elapse alternatively award exchange new award annual bonus termination notice individual individual serve notice termination date fall december bonus forfeit termination notice company redundancy retirement death illhealth injury disability termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result mandatorily dabp defer bonus award respect mandatorily defer bonus amount govern plan rule approve shareholder defer follow provision normally apply bonus termination gross misconduct generally unvested awards lapse dabp reason generally award vest original vest date event change control awards vest exchange new award benefit generally benefit continue apply termination date committee payment connection exist legal obligation respect claim related cessation employment include fee outplacement assistance legal andor professional advice termination notice company retirement executive line policy applicable senior executive eligible future date receive continue medical dental insurance terminationretirement termination mutual agreement certain circumstance good interest company board manage proactively succession planning development senior talent pipeline circumstance board agree executive departure mutual agreement order apply committee need satisfied executive demonstrate performance line expectation require contribute orderly succession case executive director treat good leaver purpose gsk longterm incentive plan termination date fall financial year eligible prorate ontarget bonus employ december bonus payable base actual result gsk annual report remuneration policy report continue loss office payment policy continue committee anticipate exercise discretion executive director leave company provide psp dabp plan rule respect committee carry assessment individual termination payment manner benefit performance conduct time role executive director unforeseen determined individual performance conduct circumstance good interest company contrary legitimate expectation company shareholder necessary exercise committee reserve right apply appropriate mechanism discretion explanation provide clawback reduction lapse outstanding incentive award malus ensure termination payment good interest company shareholder difference remuneration policy executive director employee set remuneration level executive director employee formally consult respect committee consider prevail market condition remuneration policy urs rohner committee chair meet competitive environment comparison senior hr representative business remuneration executive company similar size review employee feedback dr vivienne cox independent complexity international reach position nonexecutive director engage employee relativity pay employment condition topic include remuneration role workforce broad gsk workforce engagement director particular committee consider range base wide organisation align performance salary rise workforce part gsk reward system innovation performance trust executive director employ consider priority value expectation performance relevant comparison population reflect system evaluate employee need closely economic environment encounter senior people individual principle apply remuneration disincentivise unethical working practice clawback policy executive director employee mechanism allow recover performancerelate pay remuneration offer executive director policy strong emphasis performancerelate pay offer employee group salary benefit include pension tailor local market annual bonus plan apply wide employee population base business performance combination performancerelate restricted share plan apply wide employee population allemployee share plan available employee uk include hm revenue customs approve uk share save share reward plan gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue scenario future total remuneration chart opposite provide illustration future total remuneration executive director respect emma walmsley remuneration opportunity grant propose new policy range potential outcome provide executive director underlie assumption set scenario base salary benefit figure ie base actual amount receive hal barron pension figure pension emma walmsley iain mackay base salary amount show value psp award base relevant multiple include propose uplift emma walmsley salary fix expect maximum maximum include amount respect dividend reinveste share price factor change share price vest period increase describe fix exclude pay performance ie annual bonus iain mackay pay psp award vest expect include fix pay annual bonus assume target performance achieve psp award amount reflect vest level maximum assume annual bonus payable maximum level award psp vest maximum share price increase fix expect maximum maximum share price element maximum assume increase increase share price appoint effect january dr hal barron fix expect maximum maximum share price increase fix pay annual bonus psp share price increase gsk annual report remuneration policy report continue nonexecutive director remuneration policy nonexecutive director fee change element purpose link strategy operation chairmans fee provide inclusive flat rate fee formal maximum fee review annually set reference competitive pay review chairman performance independently source market datum company equivalent size committee responsible evaluating make recommendation board complexity subject limit contain fee payable chairman chairman participate discussion gsk article association respect fee fee pay cash chairman require invest total net fee share ad company basic fee formal maximum chairman fee review annually set reference independently source datum chairman ceo responsible evaluating make recommendation board fee payable company nonexecutive director fee pay cash director require invest total net fee share ad company share ad deliver release follow retirement board supplemental compensate nonexecutive director additional fee senior independent director committee chair science fee chairman take medical expert workforce engagement director role intercontinental travel additional board responsibility company authority pay additional fee equivalent undertake intercontinental travel committee chair supplement effect january nonexecutive director company require significant additional time commitment exceptional unforseen circumstance benefit facilitate execution responsibility travel subsistence cost nonexecutive director incur normal duty require role course business relation meeting board committee matter gskhoste event overseasbase nonexecutive director include travel meeting uk event necessary business purpose whilst normal practice nonexecutive director accompany spouse partner meeting event cost associate meet company instance deem taxable treat benefit nonexecutive director approach recruitment remuneration change follow policy principle apply role nonexecutive director chairman nonexecutive director fee level new nonexecutive director set basis exist nonexecutive director chairman company subject local law regulation fee fee set level competitive pay pay partly share company equivalent size complexity fee pay partly share event nonexecutive director different role responsibility appoint fee level benchmarke set reference comparable role company equivalent size complexity loss office change chairman nonexecutive director entitle receive payment respect fee loss office retire step board gsk annual report strategic report governance remuneration financial statement investor information remuneration policy report continue operation scope remuneration policy remuneration policy policy set page ii policy come effect provide term annual report intend policy payment consistent shareholderapprove gsk executive nonexecutive director operate remuneration policy force time agree period year date approval company iii time relevant individual director annual general meeting company opinion committee payment committee write policy principally relation consideration individual director remuneration arrangement executive director whilst company purpose payment include take account possible recruitment replacement committee satisfy awards variable remuneration additional executive director operation relation award share ad term policy committee intend policy operate payment agree time award grant period set entirety performance share plan defer annual bonus plan consideration seek change policy period award subject term relevant plan rule believe appropriate longterm award grant committee adjust success company consultation shareholder amend award accordance provision seek shareholder approval general meeting plan rule include make adjustment reflect oneoff committee reserve right remuneration corporate event change company capital payment andor payment loss office include structure exercise discretion available connection committee minor amendment policy payment notwithstanding line regulatory exchange control tax administrative purpose policy term payment agree account change legislation obtain agm date company shareholder approval amendment shareholderapprove director remuneration policy come statement consideration shareholder view effect committee engage regular dialogue shareholder hold annual meeting gsk large investor discuss feedback remuneration policy governance matter gsk annual report remuneration policy report continue basis preparation annual report remuneration prepare annual report remuneration approve accordance company act large board director sign behalf mediumsize company group account report amendment regulation regulation accordance regulation follow part urs rohner annual report remuneration subject audit total remuneration committee chairman remuneration figure executive director include march detail element remuneration salary benefit pension annual bonus longterm incentive awards nonexecutive director fee emolument receive year director interest share include interest gsk share plan payment past director payment loss office share ownership requirement holding opinion thereon express remain section annual report remuneration subject audit page refer audit section gsk annual report ssttrraatteeggiicc rreeppoorrtt ggoovveerrnnaannccee aanndd rreemmuunneerraattiioonn ffiinnaanncciiaall ssttaatteemmeennttss iinnvveessttoorr iinnffoorrmmaattiioonn financial statement section director statement responsibilitie independent auditor report financial statement note financial statement financial statement glaxosmithkline plc prepare uk gaap ggsskk aannnnuuaall rreeppoorrtt director statement responsibilitie director responsible prepare annual report director responsible keep adequate accounting remuneration report group parent company record sufficient explain company financial statement accordance applicable law transaction disclose reasonable accuracy time regulation financial position group enable ensure group financial statement remuneration uk company law require director prepare financial report comply company act article statement financial year director require ias regulation responsible safeguarding prepare group financial statement accordance asset group take reasonable step international financial reporting standard ifrs adopt prevention detection fraud irregularity european union prepare group financial statement director elect comply group financial statement year end ifrs issue international accounting standard december comprise principal statement board iasb director elect prepare parent support note set financial statement company financial statement accordance united page report parent company kingdom accounting standard applicable law unite financial statement year end december kingdom generally accept accounting practice comprise balance sheet statement change company law director approve financial equity year end december support statement satisfied true note set page fair view state affair group profit responsibility auditor relation financial loss period statement set independent auditor report prepare financial statement director require page financial statement year end december select suitable accounting policy apply include annual report publish print consistently form available website director responsible maintenance integrity annual judgement accounting estimate report website accordance uk legislation reasonable prudent govern preparation dissemination financial state group financial statement comply ifrs statement access website available outside adopt european union ifrs issue uk comparable legislation different iasb subject material departure disclose current director name function explain group financial statement list corporate governance section annual state regard parent company financial statement report confirm good knowledge applicable uk accounting standard group financial statement prepare follow subject material departure disclose accordance ifrs adopt eu ifrs explain parent company financial statement issue iasb true fair view asset prepare financial statement go concern basis liability financial position profit group inappropriate presume group strategic report risk section annual report parent company continue business represent management report include fair review development performance business position company group take description principal risk uncertainty face gsk annual report strategic report governance remuneration financial statement investor information director statement responsibility continue disclosure information auditor uk corporate governance code director office date annual report board consider glaxosmithkline plc apply confirm principle comply provision uk corporate governance code maintain financial report far aware relevant audit council describe corporate governance section information company auditor unaware page board consider take step ought annual report take fair balanced take director aware understandable provide information necessary relevant audit information establish company shareholder assess group position performance auditor aware information business model strategy confirmation give interpret require financial conduct authority list rule accordance provision section auditor consider director statement company act compliance relation point uk corporate governance code specify review go concern basis page contain information performance annual report group financial position cash flow net debt position annual report year end december borrowing facility information include treasury comprising report director remuneration risk management policy exposure market credit risk report financial statement additional information hedging activity give note financial investor approve board director statement financial instrument relate disclosure sign behalf assess principal risk matter consider connection viability statement sir jonathan symond director consider appropriate adopt go concern chairman basis accounting prepare financial statement march internal control board audit risk committee review assessment risk internal control framework operate gsk consider effectiveness system internal control operation group year cover annual report date approval board director gsk annual report independent auditor report members glaxosmithkline plc report audit financial statement opinion basis opinion opinion conduct audit accordance international standard audit uk isas uk applicable law financial statement glaxosmithkline plc parent responsibility standard company subsidiary group true describe auditor responsibility audit fair view state group parent financial statement section report company affair december group profit year end independent group parent company accordance ethical requirement relevant group financial statement properly prepare audit financial statement uk include financial accordance international financial reporting reporting council frc ethical standard applied standard ifrss adopt european union list public interest entity fulfil ifrss issue international accounting standard ethical responsibility accordance requirement board iasb confirm nonaudit services prohibit frcs parent company financial statement properly ethical standard provide group parent prepare accordance united kingdom generally company note audit risk committee report accepted accounting practice include frs reduce corporate governance section annual report disclosure framework believe audit evidence obtain financial statement prepare accordance sufficient appropriate provide basis opinion requirement company act audit scope execution regard group financial statement article ias regulation structured approach audit reflect group organise ensure audit audit financial statement comprise effective risk focus audit approach group summarise follow area enable obtain evidence require form opinion group consolidate balance sheet december parent company financial statement consolidated income statement year end risk assessment audit planning group level consolidate statement comprehensive income central control common system year end group enable structure audit centrally consolidate statement change equity year addition appoint partner end business partner coordinate component consolidated cash flow statement year end legal entity audits country global business partner meet regularly relevant management note financial statement include understand strategy matter arise accounting principle policy year impact financial report regular meeting member internal parent company audit internal legal counsel global ethic balance sheet december compliance team allow understand work statement change equity year end review report enhance risk assessment note financial statement include significant change audit scope group complete accounting principle policie major transaction year acquisition share tesaro inc tesaro financial reporting framework apply commercialstage oncology business preparation group financial statement applicable law ifrss adopt european union financial acquisition pfizer consumer healthcare report framework apply preparation business form new consumer healthcare joint venture parent company financial statement applicable law pfizer inc united kingdom accounting standard include frs result pfizer transaction pfizer reduce disclosure framework united kingdom generally consumer healthcare operation united states accept accounting practice china bring audit scope transaction require increase extent audit effort area include need perform additional opening balance sheet testing consolidation work gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue audit work perform global share service centre residual consist component legal entity significant group operational process annual revenue turnover total group cover financial reporting undertake share service revenue entity component nonsignificant centre central team include senior individual component individually aggregate present responsible global process coordinate reasonable possibility risk material misstatement audit work share service centre scope application materiality group audit ensure develop good understanding endtoend view key process support define materiality magnitude misstatement material account balance class transaction financial statement make probable economic disclosure group financial statement decision reasonably knowledgeable person evaluated effectiveness internal control financial change influence use materiality planning reporting process consider implication scope audit work evaluate result remainder audit work work audit work execute component level individual base professional judgement determine legal entity follow component subject materiality financial statement follow marketspecific audit procedure assessment parent company internal control financial reporting belgium group financial statement financial statement canada china france germany italy japan spain materiality million million switzerland united kingdom united states group million million audit team active dialogue audit basis determine benchmark materiality component audit team responsible audit work determine materiality consider determined direction supervision group audit team materiality metric investor total asset benchmark reader financial include determine work plan statement particular performed accordance overall group audit consider statutory profit strategy requirement group audit instruction tax adjust profit component supervise work tax revenue net cash flow operation component senior group audit team member visit component country location share professional judgement determine preliminary service centre audits materiality million audit procedure undertake group level metric parent company addition perform statutory profit tax audit work group parent company financial adjust profit tax statement include limited consolidation revenue group result preparation financial net cash inflow statement certain disclosure director operating activity remuneration report litigation provision exposure reconciliation statutory addition management entity level oversight control profit tax adjust profit tax detail adjust relevant financial reporting carry analytical item section strategic report procedure confirm conclusion rationale give importance parent company significant risk material misstatement aggregated metric investor hold group financial information remain component benchmark reader financial statement investment subject marketspecific audit procedure apply conclude statutory profit profitoriente tax primary strength internal control testing approach test internal benchmark adjust profit balance sheet key control financial reporting inscope entity tax revenue net cash measure financial entity level control group level able inflow operating activity health important support benchmark shareholder place reliance control plan primary concern efficient notwithstanding control deficiency component materiality parent company disclose key audit matter section report allocate inscope payment component range mitigate control exist allow continue dividend million million reliance control plan benchmark total range materiality allocate asset coverage obtain group scoping strategy component audit appropriate metric summarise follow prior year group financial statement profit total benchmark revenue tax asset million million cover marketspecific procedure cover review group level gsk annual report independent auditor report continue report audit financial statement continue set performance materiality level low materiality principal risk viability statement reduce probability aggregate uncorrecte base solely read director statement undetected misstatement exceed materiality consider consistent knowledge financial statement group performance obtain course audit include knowledge materiality set group materiality obtain evaluation director assessment audit determine performance materiality group parent company ability continue go consider factor include concern require state material add draw attention relation risk assessment include assessment group overall control environment consider disclosure page describe principal appropriate rely control number business risk procedure identify emerge risk process explanation manage mitigate past experience audit indicate low director confirmation carry number correct uncorrected misstatement robust assessment principal emerge risk identify prior period face group include threaten business model future performance solvency liquidity agree audit risk committee report committee audit difference excess director explanation million million difference assess prospect group period threshold view warrant reporting consider period qualitative ground report audit risk appropriate statement committee disclosure matter identify reasonable expectation group able assess overall presentation financial statement continue operation meet liability fall period assessment include related conclusion relate go concern disclosure draw attention necessary qualification principal risk viability statement assumption go concern require report director statement review director statement note relate prospect group require list rule financial statement consider r materially inconsistent knowledge obtain appropriate adopt go concern basis accounting audit prepare identification material confirm material report add uncertainty group parent company ability draw attention respect matter continue period month date approval financial statement consider risk assessment nature group business model relate risk include relevant impact brexit requirement applicable financial reporting framework system internal control evaluate director assessment group ability continue go concern include challenge underlie datum key assumption assessment evaluate director plan future action relation go concern assessment require state material add draw attention relation statement require list rule r report statement materially inconsistent knowledge obtain audit confirm material report add draw attention respect matter gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continued key audit matter key audit matter matter professional judgement significance audit financial statement current period include significant assess risk material misstatement fraud identify matter include great effect overall audit strategy allocation resource audit direct effort engagement team matter address context audit financial statement form opinion thereon provide separate opinion matter key audit matter description scope audit respond key audit matter valuation viiv healthcare shionogi contingent audit procedure perform consideration liability perform follow audit procedure recent year group complete number significant relate sale forecast transaction result recognition material challenge management evidence enquirie key contingent consideration liability key source individual senior leadership team commercial strategy estimation uncertainty significant liability team key personnel involve budgeting viiv healthcare shionogi contingent consideration forecasting process obtain objective evidence liability viiv ccl respect key input assumption group complete acquisition remain challenge volume assumption management interest shionogiviiv healthcare joint venture estimate sale forecast involve benchmarke market completion group recognise contingent share datum external datum total prescription consideration liability fair value expect future volume new patient prescription volume order assess payment shionogi december source contradictory evidence liability value million challenge reasonableness pricing assumption identify viiv ccl key audit matter management compare forecast return significant estimate assumption management make rebate accrual rate product current rate relate sale forecast dolutegravirbase regimen assess forecast return rebate value viiv ccl forecast base comparable product expect change payer policy management assessment expect launch date ability shift market practice prescriber behaviour review result clinical study undertake year drug regimen subsequent sale volume price management key competitor order assess forecast require significant audit effort perform corroborative contradictory management appropriate audit procedure challenge evaluate assumption dolutegravir sale forecast reasonableness forecast benchmarke management forecast analyst report contingent consideration liability include viiv ccl develop range possible outcome analyst disclose key source estimation uncertainty note forecast growth viiv healthcare consensus group financial statement disclosure analyst include bank america merrill lynch morgan provide note matter discuss stanley barclays credit suisse jefferie redburn audit risk committee report corporate test control key input assumption governance section annual report valuation contingent consideration liability include management review control sale forecast dolutegravirbase regimen key observation communicate audit risk committee underlie sale forecast dolutegravirbase regimen valuation viiv ccl update reflect change hiv market viivs product market approach value viiv ccl consistent prior period management forecast benchmarke observable range satisfied valuation viiv ccl reasonable consistent ifrs gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation return rebate rar accrual audit procedure perform group sell customer commercial perform follow audit procedure government mandate contract reimbursement relate management estimate rar accrual arrangement include rebate chargeback right assess historical accuracy management estimate return certain pharmaceutical product revenue actual outcome inform assessment current recognition reflect grosstonet sale adjustment year accrual adjustment know return rebate rar accrual source significant estimation uncertainty perform substantive analytical procedure develop material impact report revenue independent expectation accrual balance significant payer channel refer buy key segment base historical claim receive adjusted group rar accrual manage healthcare reflect market change period include assessment organisation medicaid medicare time lag initial point sale claim receipt compare independent expectation main cause significant estimation uncertainty management evaluate appropriateness management utilisation rate portion total sale end accrual position payer channel estimate management recalculate accrual recognise determine recording accrual utilisation assumption consistent assumption determine challenge key assumption derive accrual management process give influence market demand factor outside control group select sample individual utilisation rate give particular focus product experience increase generic time lag point sale point competition current year challenge obtain exact rebate amount know group receipt support utilisation rate select include claim payer channel long time lag result comparison historical utilisation rate great accrue period great level estimation uncertainty estimate period end accrual challenge appropriateness periodend adjustment liability ongoing review estimate level estimation uncertainty impact significant accrual impact market event year end shift channel mix drive change competitive accrual consider reflected overall audit landscape include competitor generic product launch approach pharmaceutical business million test key control estimation rar accrual rar deduction gross revenue include control associate biannual forecasting million result net revenue million balance utilisation rate process monthend accrual review sheet accrual december combine control pharmaceutical vaccine business amount million key observation communicate audit risk committee pharmaceuticals return rebate disclose key satisfied management estimate liability rar accounting estimate note group financial statement accrual year end appropriate reasonable disclosure provide note matter assess independent expectation discuss audit risk committee report assessment accuracy historical estimate actual corporate governance section annual report rebate gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation intangible asset recognise tesaro audit procedure perform pfizer transaction perform follow audit procedure year group recognise million relate probability success pipeline product intangible asset include licence patent trademark product innovation likelihood regulatory approval future sale brand name exclude goodwill acquisition growth rate profit margin level discount rate tesaro inc pfizer consumer healthcare business valuation acquire intangible asset determination fair value acquire intangible meet key individual senior leadership team asset rely certain management assumption product category lead key personnel involve estimate future trading performance include probability forecasting process discuss evaluate management success pipeline product product innovation evidence support future sale growth rate profitability likelihood regulatory approval future sale growth rate assumption profit margin level discount rate challenge business assumption apply management identify valuation intangible asset recognise estimate sale forecast include benchmarke sale acquisition key audit matter forecast product compound annual growth rate external inherent judgement involve estimate future cash flow datum specific market segment include independent auditing estimate require extensive audit effort market research expect category growth assessment challenge evaluate reasonableness forecast source contradictory evidence engage fair value specialist assess evaluated probability success factor relate regulatory discount rate valuation methodology apply approval apply pipeline product calculate forecast sale disclosure relate intangible asset include derive future commercialise asset note group financial statement matter assess historical accuracy management forecast discuss audit risk committee report include consumption datum estimate new sale corporate governance section annual report innovation compare forecast sale plan datum asset asset internal forecast approve senior management board director assistance fair value specialist assess reasonableness valuationspecific assumption management include discount rate terminal growth rate assumption consistent wellinforme independent party value asset test management review control key input assumption valuation intangible asset control encompass review valuation model contain number assumption revenue growth rate probability success pipeline product profit margin discount rate key observation communicate audit risk committee whilst note potential risk forecast uncertaintie regulatory approval pipeline product sale growth product innovation conclude judgement management reasonable accordance ifrs gsk annual report independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter valuation uncertain tax position include transfer audit procedure perform pricing support tax specialist assess group operate numerous jurisdiction appropriateness uncertain tax provision perform open tax transfer pricing matter exposure uk follow audit procedure overseas tax authority rise uncertain tax assess challenge provision uncertain tax position position range possible outcome provision focus work jurisdiction group contingency wide management require great potential exposure high level certain judgement respect estimate tax judgement require exposure contingency order assess adequacy tax provision complex result assess management policy recognition consideration require multiple tax law measurement uncertain tax position compliance regulation guidance ifric december group record provision involve transfer pricing specialist review transfer million respect uncertain tax position price methodology group associate approach provision valuation uncertain tax position disclose key source estimation uncertainty note group financial involve uk international tax transfer pricing statement disclosure include note specialist challenge conclusion reach matter discuss audit risk committee report management relation expect outcome corporate governance section annual report financial impact consider evidence actual result recent tax authority audits enquiry thirdparty tax advice obtain tax specialist knowledge market practice relevant jurisdiction test key control preparation review report judgmental tax balance transaction include provision uncertain tax provision key observation communicate audit risk committee satisfy management judgement relation uncertain tax position relate disclosure accordance ifrs work conclude management apply consistent approach estimate uncertain tax provision judgement continue prudent appropriately record gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue key audit matter description scope audit respond key audit matter system impact financial reporting audit procedure perform system system group form critical component result control deficiency identify incorporated group financial reporting activity impact account additional consideration perform risk assessment balance control context scope audit procedure follow financial audit primarily relate user access security consider impact risk assessment change control evaluate audit risk context deficiency year group continue implement assistance specialist team remediation plan address user access change test additional manual business process control control deficiency identify prior year primarily address related risk involve removal inappropriate access implementation appropriate privileged access management key observation communicate audit risk committee process control plan fully complete management action significant progress reduce number deficiency year relate user access identify system impact financial change management group layer business report key audit matter process control mitigate risk associate control deficiency reliance system group satisfied mitigating business process control address importance control system maintain risk material misstatement impact financial report effective control environment key interdependency cause control deficiency exist ability rely control ability rely system configure automate control system report pervasive nature system fact remediation activity complete continue considerable involvement specialist additional effort need audit team test compensating control mitigate unaddresse risk system impact financial reporting discuss audit risk committee report corporate governance section annual report key system impact range business process include general ledger procurement sale financial consolidation gsk annual report independent auditor report continue report audit financial statement continue information director responsible information information comprise information include annual report financial statement auditor report thereon opinion financial statement cover information extent explicitly state report express form assurance conclusion thereon connection audit financial statement responsibility read information consider information materially inconsistent financial statement knowledge obtain audit appear materially misstate identify material inconsistency apparent material misstatement require determine material misstatement financial statement material misstatement information base work perform conclude material misstatement information require report fact report respect matter summarise work relation area information include area specifically require report matter specifically require report responsibility report fair balanced understandable consider statement give director consider consider director statement consistent annual report financial statement take fair balanced knowledge obtain audit understandable provide information necessary shareholder assess group position performance business model strategy materially inconsistent knowledge obtain audit audit risk committee report consider deal appropriately matter report matter report appropriately cover audit risk committee audit risk committee report director statement compliance uk corporate governance code code identify matter consider part director statement require listing rule relate parent company compliance code contain provision specify review auditor accordance list rule r properly disclose departure relevant provision code principal risk viability statement review confirmation description light knowledge set section conclusion relate go gather audit consider director concern principal risk viability statement process support statement challenging management key material report add draw attention judgement estimate consideration historical forecasting accuracy respect matter evaluate macroeconomic assumption consider statement align relevant provision code director remuneration report report director remuneration report audit set section opinion matter properly prepare disclosure specify company act prescribed company act opinion director remuneration report audit prepared accordance company act strategic report director report report consistent audit financial statement set section opinion matter prepare accordance applicable legal requirement prescribe company act opinion base work undertake course audit report identify material misstatement report information report consistent light knowledge understanding group parent audit financial statement prepare company environment obtain course audit accordance applicable legal requirement gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue report information responsibility report alternative performance measure apm apm measure define generally accept accounting opinion practice gaap typically include financial use calculation disclosure apm statement annual report group use apm adjust consistent group publish definition profit free cash flow constant currency growth rate quarterly policy annual report financial performance use apm group report result review assess management calculation report consistent guideline produce esma metric assess consistency group publish definition frc policy item appropriate balance use consider assess use apm statutory metric apm clear group report result consistent guideline produce definition reconciliation apm financial regulator european security market authority esma report guideline use apm frc alternative performance measure thematic review publish november consider appropriate balance use statutory metric apm addition clear definition reconciliation apm financial reporting provide dividend distribution policy consider dividend policy transparent dividend opinion dividend policy appropriately pay consistent policy outline strategic report disclose dividend pay consistent policy gsk annual report independent auditor report continue report audit financial statement continue responsibility director enquire management internal audit audit risk committee include obtain review support explain fully director responsibilitie documentation concern group policy statement director responsible preparation procedure relate financial statement satisfy true fair view internal control director identify evaluate comply law determine necessary enable preparation financial regulation aware instance statement free material misstatement noncompliance fraud error detect respond risk fraud prepare financial statement director knowledge actual suspect alleged responsible assess group parent fraud company ability continue go concern disclose internal control establish mitigate risk relate applicable matter relate going concern fraud noncompliance law regulation go concern basis accounting director discuss engagement team include significant intend liquidate group parent company cease component audit team involve relevant internal operation realistic alternative specialist include tax valuation pension industry auditor responsibilitie audit specialist fraud occur financial statement financial statement potential indicator fraud objective obtain reasonable assurance obtain understand legal regulatory financial statement free framework group operate focus material misstatement fraud error law regulation direct effect financial issue auditor report include opinion reasonable statement provision uk company act assurance high level assurance guarantee pension legislation tax legislation audit conduct accordance isa uk fundamental effect operation group include detect material misstatement exist good clinical practice fda regulations general misstatement arise fraud error consider datum protection requirement antibribery corruption material individually aggregate reasonably policy foreign corrupt practice act expect influence economic decision user take audit response risk identify basis financial statement procedure respond risk identify include detail extent audit consider capable follow detect irregularity include fraud set review financial statement disclosure test description responsibility audit support documentation assess compliance financial statement locate frc website provision relevant law regulation describe wwwfrcorgukauditorsresponsibilitie description form direct effect financial statement auditor report enquire management audit risk committee extent audit consider inhouse external legal counsel concern actual capable detecting irregularity include fraud potential litigation claim identify assess risk material misstatement perform analytical procedure identify unusual financial statement fraud error unexpected relationship indicate risk material design perform audit procedure responsive risk misstatement fraud include obtain audit evidence sufficient reading minute meeting charge appropriate provide basis opinion governance review internal audit report correspondence regulator identify assess potential risk relate irregularity consider risk note address identify assess risk material misstatement risk fraud management override control respect irregularity include fraud noncompliance test appropriateness journal entry law regulation consider follow adjustment nature industry sector control environment assess judgement make business performance include design accounting estimate indicative potential bias group remuneration policy key driver director remuneration bonus level performance target evaluate business rationale significant transaction unusual outside normal course business gsk annual report strategic report governance remuneration financial statement investor information independent auditor report continue report audit financial statement continue communicate relevant identify law regulation matter potential fraud risk engagement team member significant component audit team remain alert auditor tenure indication fraud noncompliance law follow recommendation audit risk committee regulation audit effect january appoint board director audit financial statement year report legal regulatory requirement end december subsequent financial period period total uninterrupted engagement firm opinion matter prescribe year company act consistency audit report additional report opinion director remuneration report audit risk committee audit properly prepared accordance audit opinion consistent additional report company act audit risk committee require provide opinion base work undertake course accordance isa uk audit use report information give strategic report director report solely parent company member report financial year financial statement body accordance chapter prepare consistent financial statement company act audit work undertake strategic report director report state parent company member prepare accordance applicable legal requirement matter require state auditor report purpose full extent permit law light knowledge understanding group accept assume responsibility parent company environment obtain parent company parent company member course audit identify material body audit work report opinion misstatement strategic report director report form matter require report parent company pass resolution accordance exception section company act senior statutory auditor state adequacy explanation receive accounting record company act require report opinion receive information explanation require audit adequate accounting record keep deloitte llp parent company return adequate audit statutory auditor receive branch visit london united kingdom parent company financial statement march agreement accounting record return report respect matter director remuneration company act require report opinion certain disclosure director remuneration director remuneration report audit agreement accounting record return report respect matter gsk annual report consolidated income statement year end december note turnover cost sale gross profit sell general administration research development royalty income operating incomeexpense operate profit finance income finance expense profit disposal interest associate share tax profit associate joint ventures profit taxation taxation profit taxation year profit attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p dilute earning share penny p p p consolidate statement comprehensive income year end december profit year comprehensive expenseincome year item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement equity investment defer tax fair value movement equity investment reclassification fair value movement equity investment defer tax reverse reclassification equity investment fair value movement cash flow hedge defer tax fair value movement cash flow hedge reclassification cash flow hedge income statement defer tax reverse reclassification cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment defer tax fair value movement equity investment remeasurement lossesgain define benefit plan tax remeasurement define benefit plan comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholder noncontrolle interest total comprehensive income year gsk annual report strategic report governance remuneration financial statement investor information consolidate balance sheet december note noncurrent asset property plant equipment right use asset goodwill intangible asset investment associate joint venture investment defer tax asset derivative financial instrument noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables derivative financial instrument liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing contingent consideration liability trade payable derivative financial instrument current tax payable shortterm provision total current liability noncurrent liability longterm borrowing corporation tax payable deferred tax liability pension postemployment benefit provision derivative financial instrument contingent consideration liability noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning revise note reserve shareholder equity noncontrolle interest revise note total equity financial statement page approve board march sign behalf sir jonathan symonds chairman gsk annual report consolidate statement change equity year end december shareholder equity share share retain noncontrolle total capital premium earning reserve total interest equity january profit year comprehensive income year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest dividend shareholder change noncontrolle interest share issue share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december implementation ifrs implementation ifrs december adjust profit year comprehensive income year total comprehensive income year distribution noncontrolle interest contribution noncontrolle interest derecognition noncontrolle interest consumer healthcare joint venture dividend shareholder realise profit disposal equity investment share associates joint venture realise profit disposal equity investment share issue writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december report adjustment noncontrolle interest note december revise implementation ifrs december adjust profit year comprehensive income year total comprehensive income year distribution noncontrolle interest change noncontrolle interest dividend shareholder recognition interest consumer healthcare joint venture realise loss disposal equity investment share issue share acquire esop trust writedown share hold esop trust sharebase incentive plan tax sharebase incentive plan december gsk annual report strategic report governance remuneration financial statement investor information consolidated cash flow statement year end december note cash flow operating activity profit taxation year adjustment reconcile profit tax operating cash flow cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment purchase intangible asset proceed sale intangible asset purchase equity investment proceed sale equity investment contingent consideration pay purchase business net cash acquire disposal business investment associate joint venture proceed disposal interest associate decrease liquid investment interest receive dividend associate joint venture equity investment net cash outflow investing activity cash flow financing activity share acquire esop trust issue share capital purchase noncontrolle interest increase longterm loan repayment shortterm note increase inrepayment shortterm loan repayment lease liability interest pay dividend pay shareholder distribution noncontrolle interest contribution noncontrolle interest finance cash flow net cash outflow financing activity increasedecrease cash bank overdraft cash bank overdraft begin year exchange adjustment increasedecrease cash bank overdraft cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent cash cash equivalent report asset hold sale overdraft gsk annual report note financial statement presentation financial statement description business preparation financial statement conformity gsk major global healthcare group engage generally accept accounting principle require management creation discovery development manufacture estimate assumption affect report marketing pharmaceutical product vaccine overthe amount asset liability disclosure contingent counter otc medicine healthrelate consumer asset liability date financial statement product gsk principal pharmaceutical product include report amount revenue expense medicine follow therapeutic area respiratory hiv report period actual result differ estimate immunoinflammation oncology antiviral central nervous adjustment retain earning noncontrolle system cardiovascular urogenital metabolic antibacterial interest balance dermatology group acquire novartis noncontrolle interest compliance applicable law ifrs old consumer healthcare joint venture result financial statement prepare accordance transaction noncontrolle interest cease exist company act article ias regulation fully eliminate consolidated international financial reporting standard ifrs reserve adjustment million related interpretation adopt european union closing balance retain earning noncontrolle interest reallocate cumulative translation financial statement compliance ifrs exchange eliminate remain noncontrolle interest issue international accounting standard board balance impact profit year composition financial statement comprehensive income net asset total equity consolidated financial statement draw sterling impact item early year effect functional currency glaxosmithkline plc adjustment relevant equity balance follow accordance ifrs accounting presentation financial statement comprise december december consolidated income statement report adjustment revise consolidated statement comprehensive income retain earning shareholder equity consolidate balance sheet noncontrolle interest consolidate statement change equity total equity consolidated cash flow statement implementation ifrs lease note financial statement group apply ifrs lease effect composition group january ifrs introduce new requirement list subsidiary associate opinion definition lease lessee accounting lessor accounting director principally affect profit net number new disclosure asset group give note principal group general lease scope ifrs require company bring balance sheet lessee recognise rightofuse asset relate lease liability financial period commencement lease subsequent accounting financial statement cover financial year similar finance lease model set ias ifrs january december comparative figure establish control model identification lease financial year january december distinguish lease service contract basis appropriate january december identify asset control customer accounting principle policy gsk adopt ifrs apply modify retrospective financial statement prepare approach accordingly prior year result historical cost convention modify revaluation certain restate large lease lease annual payment item state accounting policy go million right use asset january concern basis calculate base original lease inception date financial statement prepare accordance small lease lease annual payment group accounting policy approve board million right use asset set equal lease describe note accounting principle policy liability january adjust prepay accrue information application accounting policy lease payment onerous lease provision business include area estimation judgement give note combination fair value adjustment difference key accounting judgement estimate previous carrying revise carrying january recognise adjustment opening retain earning january gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue presentation financial statement continue group apply definition lease relate million reduction property plant equipment guidance set ifrs lease contract enter arise transfer asset retirement obligation date initial application exist finance lease right use asset million significant change result vast majority adjustment noncurrent liability arise business contract combination fair value adjustment derecognise transition ifrs correspond adjustment follow permit practical expedient apply right use asset transition application ifrs material impact rightofuse asset date transition adjust group income statement earning share overall exist onerous lease provision cash flow group presentation december reassessment lease payment cash flow statement change lease end month transition date result increase net cash inflow operating treat shortterm lease leasebylease basis activity free cash flow correspond initial direct cost exclude measurement increase net cash outflow financing item split right use asset transition date leaseby interest pay repayment lease liability lease basis reconciliation operating lease commitment hindsight apply determine lease term previously report year end december contract contain option extend terminate discount group incremental borrowing rate lease lease liability recognise balance sheet initial application ifrs follows weight average incremental borrowing rate apply lease liability recognise january operate lease commitment december impact ifrs balance sheet line item effect discount group incremental borrowing rate table show adjustment january financial statement line item affect application reasonably certain extension option ifrs january termination option reasonably certain exercise shortterm lease ifrs report adjustment adjust adjustment lease liability recognise january noncurrent assets parent company financial statement property plant equipment financial statement parent company right use assets glaxosmithkline plc prepare accordance noncurrent asset uk gaap uk accounting presentation company defer tax asset balance sheet present account current asset policy give page trade receivable current liability trade payable provision shortterm borrowing noncurrent liability longterm borrowing noncurrent liability provision defer tax liability total effect net asset retain earning revise total effect equity gsk annual report note financial statement continue accounting principle policy consolidation payment relate original estimate consolidated financial statement include fair value contingent consideration acquisition report investing activity cash flow statement asset liability result cash flow payment relate increase company subsidiary include esop trust liability acquisition date report operating group share result net asset associate cash flow joint venture consideration transfer non group share asset liability revenue expense control interest exceed fair value net asset joint operation liability contingent liability acquire excess financial statement entity consolidate recorded goodwill cost effecting acquisition december year charge income statement period incur entity group power direct relevant activity affect return group goodwill capitalise separate item case generally control financial operating subsidiary cost investment case policy account subsidiary joint ventures associate goodwill denominate currency operation acquire group ability exercise joint control right net asset entity entity cost acquisition fair value net account joint venture group ability asset acquire difference recognise directly exercise joint control arrangement right income statement specify asset obligation specify liability equity subsidiary acquire arrangement arrangement account joint noncontrolle interest recognise fair value operation group ability exercise noncontrolle interest share net asset significant influence entity account subsidiary casebycase basis change group associate result asset liability associate ownership percentage subsidiary account joint venture incorporate consolidated equity financial statement equity method accounting group right asset liability revenue expense foreign currency translation joint operation include consolidated financial foreign currency transaction book functional statement accordance right obligation currency group company exchange rate ruling date transaction foreign currency monetary asset interest acquire entity consolidated date liability retranslate functional currency group acquire control interest sell deconsolidate rate exchange rule balance sheet date exchange date control cease difference include income statement transaction balance subsidiary eliminate consolidation asset liability include related profit tax take sale subsidiary goodwill overseas subsidiary associate joint product sell customer outside group venture translate sterling rate exchange relevant proportion profit transaction joint rule balance sheet date result cash flow venture joint operation associate defer overseas subsidiary associate joint venture product sell party transaction non translate sterling average rate exchange control interest record directly equity defer tax relief unrealise intragroup profit account exchange adjustment arise open net asset extent consider recoverable profit year retain overseas subsidiary associate joint venture translate sterling business combination exchange difference arise related foreign currency business combination account acquisition borrowing hedge group net investment accounting method identifiable asset liability contingent operation take separate component equity liability acquire measure fair value acquisition date translate sterling asset liability result consideration transfer measure fair value cash flow overseas subsidiary associate joint include fair value contingent consideration venture report currency hyperinflationary fair value contingent consideration liability economy adjustment material reflect reassess balance sheet date change current price level loss net monetary asset charge recognise income statement payment contingent consolidated income statement consideration reduce balance sheet liability result record income statement gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue revenue applicable january advertising promotion expenditure charge income group receive revenue supply good external statement incur shipment cost intercompany customer order receive majority contract transfer charge cost sale distribution cost gsk enter relate sale order contain single sale customer include sell general performance obligation delivery pharmaceutical administrative expenditure vaccine consumer healthcare product average restructuring cost recognise provide duration sale order month appropriate respect direct expenditure business product revenue recognise control good reorganisation plan sufficiently detail pass customer point control pass advanced appropriate communication determine customer arrangement generally affect undertaken occur delivery customer research development product revenue represent net invoice value include fix research development expenditure charge variable consideration variable consideration arise income statement period incur sale good result discount allowance give development expenditure capitalise criterion accrual estimate future return rebate revenue recognise asset meet usually regulatory filing recognise highly probable significant major market approval consider reversal cumulative revenue recognise highly probable property plant equipment occur methodology assumption estimate research development capitalise depreciated rebate return monitor adjust regularly accordance group policy light contractual legal obligation historical trend past experience project market condition environmental expenditure uncertainty associate return rebate resolve environmental expenditure relate exist condition revenue adjust accordingly result past current operation current future benefit discernible charge income gsk enter development marketing collaboration statement group recognise liability sitebysite outlicence group compound product basis reliably estimate liability include party contract rise fix variable group portion total cost portion consideration upfront payment development milestone potentially responsible party cost probable salesbased milestone royalty able satisfy respective share income dependent achievement development cleanup obligation recovery reimbursement milestone recognise highly probable record asset virtually certain significant reversal cumulative revenue recognise occur usually relate legal dispute event occur salesbase milestone income recognise provision anticipated settlement cost legal highly probable sale threshold dispute group outflow resource reach consider probable reliable estimate likely outcome respect product liability claim relate salesbased royalty licence intellectual property certain product provision sufficient recognise relevant product sale occur history claim settlement enable management time recognition revenue payment reliable estimate provision require cover customer expect year unasserted claim certain case incur impact material consideration discount report ibnr actuarial technique determine appropriate discount rate estimate addition provision legal expense arise claim receive dispute value add tax sale taxis exclude revenue group involved legal proceeding respect possible reliable estimate expenditure expect financial effect result expenditure recognise respect good service ultimate resolution proceeding case receive supply accordance contractual term appropriate disclosure case include provision obligation exist future liability provision respect past event obligation reliably estimate manufacturing startup cost associate claim group cost validation achievement normal party charge income statement production expense incur incur gsk annual report note financial statement continue accounting principle policy continue pension postemployment benefit disposal ppe cost relate accumulate cost provide pension define benefit scheme depreciation impairment remove financial calculate project unit credit method statement net proceed take spread period benefit expect income statement derive employee service consistent lease applicable january advice qualified actuary pension obligation measure group recognise right use asset lease present value estimate future cash flow discount arrangement lessee right use asset rate reflect yield highquality corporate bond own party lease agreement capitalise pension scheme asset measure fair value inception lease recognise consolidated balance sheet date balance sheet correspond liability lessor cost postemployment liability calculate recognise lease obligation short longterm similar way define benefit pension scheme spread borrowing carry subsequently increase period benefit expect derive reflect interest lease liability reduce lease employee service accordance advice payment qualified actuary calculate discount lease liability lease actuarial gain loss effect change actuarial annual payment million implicit rate assumption recognise statement comprehensive lease available incremental borrowing income year arise rate lease specific adjustment group contribution define contribution plan available lease annual payment charge income statement incur million incremental borrowing rate incremental borrowing rate calculate rate interest employee share plan gsk able borrow similar term incentive form share provide employee similar security fund necessary obtain share option share award scheme similar asset similar market fair value option award calculate finance cost charge income statement grant date blackschole option pricing model produce constant periodic rate charge remain charge income statement relevant vest balance obligation accounting period period variable rent lease liability right group provide finance esop trust purchase use asset payment charge income company share meet obligation provide share statement incur shortterm lowvalue lease employee exercise option award cost run capitalise lease rental charge income esop trust charge income statement share statement incur hold esop trust deduct reserve nonlease component account separately transfer reserve retain earning lease component plant equipment lease vest period relate share option award separately account land building vehicle lease reflect ultimate proceed receivable employee exercise modification reassessment occur lease liability right use asset remeasure property plant equipment property plant equipment ppe state cost right use asset title expect pass gsk purchase construction provision depreciation point future depreciate basis consistent impairment financing cost capitalise cost similar own asset case right use asset qualify asset construction depreciate short useful life asset lease term depreciation calculate write cost residual value ppe exclude freehold land straightline goodwill basis expect useful life residual value live goodwill state cost impairment goodwill review appropriate adjust annually deem indefinite useful life test normal expect useful life major category impairment annually ppe fair value interest acquire entitys asset liability contingent liability exceed freehold building year consideration pay excess recognise immediately leasehold land building lease term year gain income statement plant machinery year equipment vehicle year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue intangible asset investment associate joint venture joint intangible asset state cost provision operation amortisation impairment investment associate joint venture carry consolidated balance sheet group share net licence patent knowhow marketing right separately asset date acquisition postacquisition acquire acquire business combination retain profit loss goodwill arise amortise estimate useful life generally acquisition group recognise right asset exceed year straightline basis liability revenue expense joint operation time available use estimate useful life determine amortisation charge account patent inventory live applicable value obtain inventory include financial statement low period nonexclusivity asset life review cost include raw material direct labour direct cost appropriate adjust annually relate production overhead net realisable value contingent milestone payment recognise point cost generally determine basis contingent event probable development prelaunch inventory hold asset high cost incur group associate acquire probability regulatory approval product licence patent knowhow marketing right write point provision carry value income statement incur criterion recoverable provision reverse point recognition internallygenerate intangible asset meet high probability regulatory approval determine usually regulatory filing major market financial instrument applicable january approval consider highly probable financial asset acquire brand value independently fair financial asset measure amortise cost fair value value business acquire party brand comprehensive income fvtoci fair value value substantial longterm profit loss fvtpl measurement basis brand contractual legal nature sell determined reference business model separately rest business acquire brand manage financial asset contractual cash flow amortise estimate useful life year characteristic financial asset financial asset consider useful economic life trade receivables month expect credit loss ecl indefinite allowance record initial recognition cost acquire develop computer software subsequent evidence significant increase credit risk internal use internet site external use capitalise asset allowance increase reflect lifetime intangible fix asset software site support ecl realistic prospect recovery asset significant business system expenditure lead write creation durable asset erp system software amortise expect credit loss recognise income statement seven year computer software financial asset measure amortise cost fair value year comprehensive income apart equity impairment noncurrent asset investment carry value noncurrent asset review investment impairment standalone basis large investment comprise equity investment cash generating unit indication asset investment limited life fund group elect impair additionally goodwill intangible asset designate equity investment measure fvtoci indefinite useful live intangible asset initially record fair value plus transaction cost available use test impairment annually remeasure subsequent reporting date fair value provision impairment charge income statement unrealise gain loss recognise year concern comprehensive income impairment goodwill reverse impairment loss disposal equity investment gain loss noncurrent asset reverse defer comprehensive income transfer change estimate determine recoverable amount directly retain earning investment limited life fund extent revise recoverable amount measure fvtpl initially record fair value exceed carry value exist net remeasure subsequent reporting date fair value depreciation amortisation impairment unrealise gain loss recognise income recognise statement gsk annual report note financial statement continue accounting principle policy continue dividend equity investment distribution fund derivative financial asset liability include derivative recognise income statement group right embed host contract separate receive payment establish host contract classify heldfortrading measure fair value change fair value derivative purchase sale investment account instrument qualify hedge accounting trade date recognise immediately income statement trade receivables hedge accounting trade receivables measure accordance derivative designate hedge instrument classify business model portfolio trade receivables inception hedge relationship cash flow hedge net hold group portfolio business investment hedge fair value hedge model ifrs factoring arrangement place collect contractual cash flow measure amortise cost change fair value derivative designate cash flow sell contractual cash flow measure fvtpl hedge recognise comprehensive income collect sell contractual cash flow measure extent hedge effective ineffective portion fvtoci trade receivable measure amortise cost recognise profit loss immediately amount defer carry original invoice allowance comprehensive income reclassify income expect credit loss statement hedge item affect profit loss expect credit loss calculate accordance net investment hedge account similar way simplified approach permit ifrs provision matrix cash flow hedge apply lifetime historical credit loss experience trade change fair value derivative designate fair value receivables expect credit loss rate vary depend hedge record income statement extent settlement trade change fair value hedge asset liability receivables overdue adjust appropriate reflect current economic condition estimate future taxation condition purpose determine credit loss rate current tax provide amount expect pay customer classify grouping similar loss apply tax rate enact substantively pattern key driver loss rate nature enact balance sheet date business unit location type customer defer tax provide temporary difference arise trade receivable determined reasonable tax basis asset liability carry expectation recovery write firstly amount financial statement defer tax asset expect credit loss allowance available recognise extent probable future taxable income statement profit available temporary difference utilise defer tax provide temporary subsequent recovery amount previously provide difference arise investment subsidiary associate write credit income statement longterm joint venture time reversal receivable discount effect material temporary difference control probable cash cash equivalent temporary difference reverse foreseeable cash hold deposit account measure amortise cost future defer tax provide rate tax investment money market fund hold fair value enact substantively enact balance sheet date profit loss fund fail solely payment uncertain tax position identify management principal interest sppi test judgement probable outcome assume relevant tax authority knowledge borrowing situation assess economic outflow borrowing initially record proceed probable arise provision good estimate receive net transaction cost borrowing subsequently liability estimate liability gsk apply riskbase carry amortise cost difference approach take account appropriate proceed net transaction cost probability group able obtain redemption recognise charge income compensatory adjustment international tax treaty statement period relevant borrowing estimate account specific circumstance derivative financial instrument dispute relevant external advice derivative financial instrument manage exposure discount market risk principal derivative instrument time value money material balance gsk foreign currency swap interest rate swap foreign discount current value appropriate discount rate exchange forward contract option group unwind discount record finance income hold issue derivative financial instrument trading finance expense speculative purpose gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue accounting principle policy continue revenue applicable december trade receivable determined uncollectable revenue recognise income statement good write firstly provision available service supply available external customer income statement order receive title risk loss pass subsequent recovery amount previously provide customer reliable estimate relevant deduction credit income statement longterm receivable relevant obligation fulfil discount effect material earning process regard complete borrowing turnover represent net invoice value deduction borrowing initially record proceed discount allowance give accrual estimate receive net transaction cost borrowing subsequently future rebate return methodology assumption carry amortise cost difference estimate rebate return monitor proceed net transaction cost adjust regularly light contractual legal redemption recognise charge income obligation historical trend past experience project statement period relevant borrowing market condition market condition evaluate wholesaler thirdparty analysis market research datum derivative financial instrument hedge internallygenerate information value add tax derivative financial instrument manage exposure sale taxis exclude revenue market risk principal derivative instrument gsk group copromote product counterparty foreign currency swap interest rate swap foreign record sale group record share revenue exchange forward contract option group copromotion income turnover nature co hold issue derivative financial instrument trading promotion activity group record cost speculative purpose sale addition initial eventbase milestone income derivative financial instrument classify heldfortrading exclude royalty income arise development marketing carry balance sheet fair value derivative collaboration group compound product designate hedge instrument classify inception party recognise turnover cash flow hedge net investment hedge fair value royalty income recognise accrual basis hedge accordance term relevant licensing agreement change fair value derivative designate cash flow financial instrument applicable hedge recognise comprehensive income december extent hedge effective ineffective portion recognise profit loss immediately amount deferred availableforsale investment comprehensive income reclassify income liquid investment investment classify statement hedge item affect profit loss availableforsale investment initially record fair value plus transaction cost remeasure subsequent net investment hedge account similar way reporting date fair value unrealised gain loss cash flow hedge availableforsale investment recognise directly change fair value derivative designate fair value comprehensive income impairment arise significant hedge record income statement prolong decline fair value equity investment reduce change fair value hedge asset liability carry asset directly charge change fair value derivative instrument income statement qualify hedge accounting recognise immediately disposal impairment investment gain income statement loss defer comprehensive income reclassify income statement dividend equity lease applicable december investment recognise income statement leasing agreement transfer group substantially group right receive payment establish equity benefit risk ownership asset treat investment record noncurrent asset finance lease asset purchase outright expect sell year asset include ppe computer software capital element leasing commitment show purchase sale equity investment account obligation finance lease asset hold finance trade date purchase sale availablefor lease depreciate basis consistent similar own sale investment account settlement date asset lease term short interest element trade receivables lease rental include income statement lease trade receivable carry original invoice operating lease rental cost charge provision doubtful debt provision income statement straightline basis lease term evidence risk nonpayment take account age previous experience general economic condition gsk annual report note financial statement continue key accounting judgement estimate prepare financial statement management require taxation judgement item tax charge year million recognise financial statement estimate million december current tax payable assumption affect amount asset liability million million noncurrent corporation revenue expense report financial statement tax payable million million current actual amount result differ estimate tax recoverable million million follow consider critical accounting estimate judgement key source estimation uncertainty group open tax issue number revenue turnover authority management make judgement report group turnover million sufficient information able reliable estimate million outcome dispute insufficient information available provision estimate gross turnover reduce rebate discount allowance sufficient information available estimate potential tax product return give expect give liability gsk apply riskbased approach take vary product arrangement buy group account appropriate probability group arrangement purchase organisation dependent able obtain compensatory adjustment international submission claim time initial tax treaty estimate account specific recognition sale accrual time sale circumstance dispute relevant external advice estimate rebate discount allowance payable inherently judgemental change substantially return base available market information time dispute progress new fact emerge historical experience december group recognise provision pharmaceutical business large million respect uncertain tax position complex arrangement rebate discount allowance million nature uncertain pharmaceutical turnover million position practicable meaningful sensitivity million recording deduction estimate million million rebate discount factor affect tax charge future year set allowance return balance sheet accrual rebate note taxation gsk continue believe discount allowance return pharmaceutical adequate provision liability likely arise open vaccine business manage combined basis assessment open issue exist ultimate liability december total accrual amount matter vary amount provide million million nature dependent outcome negotiation relevant accrual practicable meaningful sensitivity tax authority necessary litigation proceeding estimate legal dispute amount estimate fully reflect legal cost year million final outcome amount subject change million december provision legal dependent thing type buy dispute amount million million group product sale mix estimate level accrual rebate return review management make judgement sufficient adjust regularly light contractual legal information able reliable estimate likely obligation historical trend past experience project outcome dispute legal expense arise market condition market condition evaluate claim group insufficient information wholesaler thirdparty analysis market research datum available provision disclosure claim internallygenerate information revenue recognise give highly probable significant reversal cumulative revenue recognise occur estimate provision account specific turnover recognise year performance circumstance dispute relevant external advice obligation satisfy previous period set note inherently judgemental change substantially time turnover segment information dispute progress new fact emerge detail status uncertainty involve significant future event cause assumption unresolved dispute set note legal proceeding accrual base change materially affect future result group gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue key accounting judgement estimate continue company director take legal advice pension postemployment benefit establish provision take account relevant judgement fact circumstance matter accordance surplus define benefit scheme arise accounting requirement respect product liability claim potential surplus arise commit future relate certain product sufficient history claim contribution right trustee prevent group settlement enable management reliable obtaining refund surplus future consider estimate provision require cover unasserted claim determine necessary restrict group involved legal proceeding respect surplus recognise uk scheme surplus possible reliable estimate combine surplus million december expect financial effect practicable million gsk judgement meaningful range outcome result ultimate amount meet requirement recoverability resolution proceeding case appropriate disclosure case provide provision estimate contingent liability quantify cost provide pension postemployment benefit assess basis assumption select ultimate liability legal claim vary amount management assumption include future earning provide dependent outcome litigation pension increase discount rate expect longterm rate proceeding investigation possible settlement negotiation return asset mortality rate disclose note position change time pension postemployment benefit assurance loss result outcome legal proceeding exceed provision discount rate derive aa rate corporate bond yield report group financial statement material country deep market corporate bond government bond yield sensitivity contingent consideration analysis provide note pension post income statement charge contingent employment benefit reduction discount consideration million million rate lead increase net pension deficit december liability contingent consideration approximately million increase annual amount million million pension cost approximately million selection million million relate different assumption affect future result acquisition shionogiviiv healthcare joint venture group estimate contingent consideration include consideration payable business combination record fair value date acquisition fair value generally base riskadjuste future cash flow discount appropriate posttax discount rate fair value review regular basis annually change reflect income statement note contingent consideration liability new accounting requirement follow new amend accounting standard interest rate benchmark reform amendment ifrs issue iasb likely affect future annual ias ifrs issue september report implement group january amendment modify specific hedge accounting requirement amendment ifrs business combination issue allow hedge accounting continue affect hedge october implement group period uncertainty hedge item hedge amendment clarify definition business instrument reference current interest rate benchmark permit simplify initial assessment acquire amend result ongoing interest rate benchmark set activity asset group asset reform business amendment expect material impact amendment apply prospectively acquisition result financial position group complete implementation date change accounting acquisition date gsk annual report note financial statement continue exchange rate group use average exchange rate prevail period translate result cash flow overseas subsidiary joint venture associate sterling period end rate translate net asset entity currency influence translation relevant exchange rate average rate period end rate euro euro yen yen turnover segment information operating segment report base financial information provide chief executive officer responsibilitie corporate executive team cet gsk report result segment pharmaceutical pharmaceutical rd vaccine consumer healthcare individual member cet responsible segment group management reporting process allocate intragroup profit product sale market sale record profit analysis present basis corporate unallocated turnover cost include result certain consumer healthcare product hold sale number market order meet antitrust approval requirement cost corporate function revenue recognise year performance obligation satisfy previous period total million million include million million report turnover arise change prior year estimate rar accrual million million royalty income turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover gsk review presentation respiratory product sale january report ellipta product portfolio nucala respiratory category respiratory product establish pharmaceutical comparative information revise consistent basis revise revise pharmaceutical turnover therapeutic area respiratory hiv immunoinflammation oncology establish pharmaceutical vaccine turnover category meningitis influenza shingle establish vaccine gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue turnover segment information continue operation pharmaceutical vaccine business sale wholesaler approximately million million million million million million million million million respectively allocate finalcustomer discount wholesaler consumer healthcare turnover category wellness oral health nutrition skin health segment profit pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment profit corporate unallocated cost reconcile item segment profit operating profit operating profit finance income finance cost profit disposal interest associate share aftertax profit associate joint ventures profit taxation taxation profit taxation year reconcile item segment profit operating profit comprise item specifically allocate segment profit include impairment amortisation intangible asset major restructuring cost include impairment tangible asset computer software transactionrelate adjustment relate significant acquisition proceed cost disposal associate product business significant legal charge expense settlement litigation government investigation operate income royalty income item pretax impact enactment tax cut job act depreciation amortisation segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconcile item segment depreciation amortisation total depreciation amortisation total depreciation amortisation gsk annual report note financial statement continue turnover segment information continue ppe intangible asset goodwill impairment segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment impairment corporate unallocated impairment reconcile item segment impairment total impairment total impairment ppe intangible asset impairment reversal segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment impairment reversal corporate unallocated impairment reversal reconcile item segment impairment reversal total impairment reversal total impairment reversal net asset segment pharmaceutical pharmaceutical rd pharmaceutical include rd vaccine consumer healthcare segment net operating asset corporate unallocated net operating asset net operating asset net debt investment associate joint venture derivative financial instrument current defer taxation asset hold sale exclude cash cash equivalent net asset pharmaceutical segment include shionogiviiv healthcare contingent consideration liability million million pfizer option million million net asset pharmaceutical consumer healthcare segment increase year follow acquisition tesaro pfizer consumer healthcare business respectively gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue turnover segment information continue geographical information uk regard group country domicile turnover location customer uk rest world external turnover noncurrent asset location subsidiary uk rest world noncurrent asset noncurrent asset location exclude amount relate investment defer tax asset derivative financial instrument pension asset amount receivable insurance contract certain noncurrent receivables operating incomeexpense fair value remeasurement equity investment ifrs disposal business asset fair value remeasurement contingent consideration recognise business combination remeasurement viiv healthcare option liability preferential dividend remeasurement consumer healthcare option liability fair value adjustment derivative financial instrument incomeexpense impairment availableforsale equity investment ias disposal availableforsale equity investment ias disposal business asset include profit disposal rabie tickborne encephalitis vaccine million gain arise increase value share hindustan unilever limited receive disposal horlick consumer healthcare brand million include fair value movement relate derivative fair value remeasurement contingent consideration recognise business combination include million related acquisition shionogiviiv healthcare joint venture million relate vaccine acquisition novartis fair value movement relate hedging contract gsk annual report note financial statement continue operating profit follow item include operate profit employee cost note advertising distribution cost depreciation property plant equipment impairment property plant equipment net reversal depreciation right use asset impairment right use asset amortisation intangible asset impairment intangible asset net reversal impairment goodwill allocate disposal group net reversal net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal prior year writedown inventory shortterm lease charge lowvalue lease charge variable lease payment operate lease rental minimum lease payment contingent rent sublease payment fee payable company auditor associate relation group reversal prior year writedown inventory principally arise reassessment usage demand expectation prior inventory expiration net foreign exchange gain include net gain million nil million loss arise reclassification exchange liquidation disposal overseas subsidiary include operate profit major restructuring charge million million million note major restructuring cost fee payable company auditor associate audit parent company consolidate financial statement include attestation sarbanesoxley act audit company subsidiary total audit service taxation compliance taxation advice audit relate assurance service service total auditrelated nonaudit service assurance service provide auditor relate agree procedure assurance service outside statutory audit requirement service provide auditor primarily relate advisory service year end december addition fee pay auditor respect gsk pension scheme audit service fee million nil nil pay auditor respect audits certain company subsidiary acquire year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue employee cost wage salary social security cost pension postemployment cost include augmentation note cost sharebase incentive plan severance cost integration restructuring activity increase wage salary include impact movement exchange rate group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance cost sharebase incentive plan analyse follow share value plan performance share plan share option plan cash settle plan average monthly number person employ group include director year number number number manufacturing sell general administration research development average monthly number group employee exclude temporary contract staff number group employee end financial year give financial record compensation director senior management member cet aggregate follow wage salary social security cost pension postemployment cost cost sharebase incentive plan information remuneration director give remuneration report page gsk annual report note financial statement continue major restructuring cost pharmaceutical sector highly regulate manufacture operation supply chain long lifecycle business mean restructure programme particularly involve rationalisation closure manufacturing rd site likely year complete major restructuring cost relate specific boardapprove major restructuring programme include integration cost follow material acquisition structural significant scale cost individual relate project exceed million exist combined restructure integration programme incorporate previous major change programme pharmaceutical restructure programme restructure integration programme follow novartis transaction programme subsequently complete july boardapprove major restructure programme design significantly improve competitiveness efficiency group cost base saving deliver primarily supply chain optimisation reduction administrative cost february boardapprove new major restructure programme generate synergy integration pfizer consumer healthcare business gsk consumer healthcare business total restructuring cost million incur follow area manufacture site restructuring include worthe united kingdom cork ireland restructuring follow integration pfizer consumer healthcare business gsk consumer healthcare restructure pharmaceutical consumer healthcare supply chain lead simplification operating model improve resource allocation continue transformation central function include gsk technology platform interface deliver great digital synergy simplification application staff reduction analysis cost charge operating profit programme follow increase provision major restructuring programme note provision reverse unused note impairment loss recognise noncash charge cash cost provision reversal million million million reflect provision release combined restructure integration programme asset impairment million noncash charge million principally comprise fix asset writedown manufacture research facility accelerate depreciation asset live rd manufacturing shorten result major restructuring programme charge settle cash include termination lease site closure cost consultancy project management cost analysis major restructuring charge programme follow cash noncash total major restructure programme include tesaro consumer healthcare joint venture integration programme combine restructure integration programme analysis major restructuring charge income statement line follow cost sale sell general administration research development operating expense gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue finance income year december december ifrs finance income arise financial asset measure amortise cost financial asset measure fair value profit loss net gain arise forward element forward contract net investment hedge relationship year december ias interest income arise cash cash equivalent availableforsale investment loan receivables fair value adjustment derivative fair value profit loss finance income arise financial asset measure amortise cost include interest income arise asset classify availableforsale investment loan receivables ias include interest income arise certain cash cash equivalent finance income arise financial asset measure fair value profit loss include interest income arise cash cash equivalent net gain arise hedge ineffectiveness net investment hedge record fair value adjustment derivative fair value profit loss derivative account fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument finance expense finance expense arise financial liability amortise cost derivative fair value profit loss net loss arise financial instrument mandatorily measure fair value profit loss reclassification hedge comprehensive income unwind discount provision finance expense arise lease liability finance expense derivative account fair value profit loss designate effective hedging instrument note financial instrument relate disclosure classify heldfortrade financial instrument finance expense arise derivative fair value profit loss relate swap interest expense prior year figure finance expense arise lease liability relate interest arise finance lease previous leasing standard ias originally report finance expense finance expense include million charge interest relate historical income tax settlement gsk annual report note financial statement continue associate joint venture group share aftertax profit loss associate joint venture set share aftertax profit associate share aftertax lossesprofit joint venture december group hold significant associate innoviva inc summarise income statement information respect innoviva set group share aftertax profit associate comprehensive income include profit million comprehensive income nil respect innoviva result innoviva include summarise income statement information represent estimate earning innoviva relevant period base publicly available information balance sheet date innovivas turnover arise royalty income gsk relation relvarbreo ellipta anoro ellipta trelegy ellipta sale turnover profit taxation comprehensive income total comprehensive income estimate result innoviva exclude defer tax credit million announce innoviva group finalise result accordingly gsk share credit million recognise share aftertax profit associate aggregate financial information respect gsk share associate undertaking joint venture set share turnover share aftertax lossesprofit share comprehensive income share total comprehensive expenseincome group sale associate joint venture million million million gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation group tax charge sum total current defer tax expense taxation charge base profit year uk current year charge rest world current year charge credit respect prior period current taxation defer taxation gsk payment million uk corporation tax hmrc amount uk corporation tax include business taxis bear uk gsk year defer tax credit reflect origination current year expense offset taxable profit future period probable include uplift tax carrying value certain consumer healthcare brand result acquisition novartis interest consumer healthcare joint venture defer tax credit reflect revaluation exist defer tax liability reflect low swiss tax rate applicable follow swiss tax reform increase defer tax asset relate intragroup profit inventory impact item partly offset revaluation exist defer tax asset reflect low tax rate applicable follow enactment tax reform follow table reconcile tax charge calculate uk statutory rate group profit tax actual tax charge year revise revise reconciliation taxation group profit profit tax uk statutory rate taxation difference overseas taxation rate benefit intellectual property incentive rd credit fair value remeasurement nontaxable option tax loss benefit recognise permanent difference disposal acquisition permanent difference reassessment prior year estimate change tax rate tax chargetax rate gsk substantial business presence country world impact difference overseas taxation rate arise profit earn country tax rate high uk statutory rate significant belgium india japan adverse impact partly offset increase benefit intellectual property incentive uk patent box belgian patent income deduction regime regime provide reduce rate corporate income tax profit earn qualifying patent claim incentive manner intend relevant statutory regulatory framework change tax rate include item expense tax relief available future period low rate reduction statutory tax rate uk belgium respectively impact swiss tax reform incorporate change tax rate category year respective value million debit million credit group tax rate influence reassessment open issue tax authority jurisdiction fair value accounting movement group option liability viiv healthcare hedge share hindustan unilever limited receive disposal horlick consumer healthcare brand future tax charge effective tax rate affect factor acquisition disposal restructuring location research development activity tax regime reform resolution open matter continue bring tax affair date world gsk annual report note financial statement continue taxation continue tax item charge equity statement comprehensive income current taxation sharebase payment define benefit plan defer taxation sharebase payment define benefit plan fair value movement cash flow hedge fair value movement equity investment total creditcharge equity statement comprehensive income item charge statement comprehensive income tax sharebase payment issue relate taxation integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket line current oecd guideline base transfer pricing policy arm length principle different tax authority seek attribute profit activity undertake jurisdiction potentially result double taxation group open item jurisdiction concern matter deductibility particular expense tax treatment certain business transaction gsk apply risk base approach determine transaction likely subject challenge assume relevant tax authority review knowledge relevant information probability group able obtain compensatory adjustment international tax treaty calculation group total tax charge necessarily involve degree estimation judgement respect certain item tax treatment finally determine resolution reach relevant tax authority appropriate formal legal process december group recognise provision million respect uncertain tax position million decrease recognise provision drive reassessment estimate utilisation provision uncertain tax position follow settlement number open issue tax authority jurisdiction whilst ultimate liability matter vary amount provide dependent outcome agreement relevant tax authority litigation appropriate group continue believe appropriate provision period open agree tax authority provision defer tax liability million december million respect taxation payable remittance profit certain overseas subsidiary whilst aggregate unremitte profit balance sheet date approximately billion billion majority unremitted profit subject tax include withhold tax repatriation uk legislation relate company distribution provide exemption tax overseas profit subject certain exception defer tax provide temporary difference million million arise unremitted profit management ability control future reversal consider reversal probable gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue taxation continue movement defer tax asset liability pension share accelerate post option net capital intangible contingent intragroup employment tax award temporary allowance asset consideration profit benefit loss scheme difference total january exchange adjustment creditcharge income statement creditcharge statement comprehensive income equity reclassification disposal december implementation ifrs december adjust exchange adjustment creditcharge income statement creditcharge statement comprehensive income equity acquisition disposal rd credit utilisation december defer tax liability provide relation intangible asset predominately relate temporary difference arise asset liability acquire historic business combination acquisition disposal include defer tax liability million relate pfizer consumer healthcare business acquisition million relate tesaro acquisition group continue recognise defer tax asset future obligation respect contingent consideration amount payable minority shareholder payment tax deductible point time payment deferred tax asset recognise intragroup profit arise intercompany inventory eliminate consolidated account intragroup profit eliminate individual entity tax return temporary difference arise reverse point time inventory sell externally defer tax asset recognise tax loss million million relate trading loss include defer tax asset million relation loss recognise basis sufficient future taxable profit utilise loss forecast entity loss relate net temporary difference include accrue expense tax deduction available pay basis pension defer tax asset liability recognise balance sheet follow defer tax asset defer tax liability defer tax asset recognise foreign tax credit probable future taxable profit available net foreign tax credit defer tax provide million million unrecognised unrecognised defer tax defer tax tax loss asset tax loss asset unrecognised tax loss trading loss expire year year available indefinitely december capital loss expire available indefinitely december gsk annual report note financial statement continue earning share pence pence pence basic earning share dilute earning share basic earning share calculate divide profit attributable shareholder weight average number share issue period deduct share hold esop trust treasury share trustee waive right dividend share hold esop trust diluted earning share calculate adjust weight average number share basic calculation assume conversion potentially dilutive share potentially dilutive share form employee share scheme exercise price average market price gsk share period performance condition attach scheme meet balance sheet date number share calculate basic diluted earning share reconcile weight average number share issue million million million basic dilution share option award dilute dividend dividend total dividend total dividend total share dividend share dividend share dividend paidpayable penny pay penny pay pence interim july july july second interim october october october interim january january january fourth interim april april april total ifrs interim dividend recognise financial statement pay declare gsk normally pay dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december implementation ifrs december adjust exchange adjustment addition business combination addition capitalise borrowing cost disposal writeoff reclassification transfer asset hold sale cost december depreciation january exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december implementation ifrs december adjust exchange adjustment charge year disposal writeoff transfer asset hold sale depreciation december impairment january exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december implementation ifrs december adjust exchange adjustment disposal writeoff impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december gsk annual report note financial statement continue property plant equipment continue weight average interest rate capitalise borrowing cost year disposal writeoff year include number asset nil net book value long use business impairment loss principally arise decision rationalise facility calculate base fair value cost disposal value use fair value cost disposal valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital wacc adjust appropriate specific segment country currency risk value use calculation posttax cash flow include impact future uncommitted restructuring plan improvement impairment indicate pretax cash flow calculation expect materially different result test reperforme pretax cash flow pretax discount rate group wacc equivalent pretax discount rate approximately net impairment loss charge cost sale million million rd million million sga million million include million million arise major restructuring programme reversal impairment arise subsequent review impaired asset condition gave rise original impairment deem long apply reversal credit cost sale million million computer software reclassify asset construction intangible asset ready use right use asset land plant building equipment vehicle total net book value january exchange adjustment addition business combination addition depreciation disposal impairment reclassification net book value december total cash outflow lease amount million significant lease commitment lease commence yearend analysis lease liability set note net debt gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue goodwill cost january exchange adjustment addition business combination note transfer fromto asset hold sale cost december net book value january net book value december goodwill allocate group segment follow pharmaceutical vaccine consumer healthcare net book value december recoverable amount cash generating unit assess fair value cost disposal model fair value cost disposal calculate discount cash flow approach posttax discount rate apply project riskadjuste posttax cash flow terminal value discount rate base group wacc cash generating unit integrate operation large part group discount rate adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy detail relate discount cash flow model impairment test pharmaceutical vaccine consumer healthcare cash generating unit follow valuation basis fair value cost disposal key assumption sale growth rate profit margin terminal growth rate discount rate taxation rate determination assumption growth rate internal forecast base internal external market information margin reflect past experience adjust expect change terminal growth rate base management estimate future longterm average growth rate discount rate base group wacc adjust appropriate taxation rate base appropriate rate region period specific project cash flow year terminal growth rate discount rate terminal growth rate discount rate pharmaceutical pa vaccines pa consumer healthcare pa terminal growth rate exceed longterm project growth rate relevant market reflect impact future generic competition account new product launch goodwill monitor impairment segmental level case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment relate goodwill pharmaceutical cash generating unit comprise collection small cash generating unit include asset indefinite live carry value nil million consumer healthcare cash generating unit comprise collection small cash generating unit include brand indefinite live carry value billion billion detail indefinite life brand give note intangible asset gsk annual report note financial statement continue intangible asset licence patent computer amortise indefinite life software brand etc brand total cost january exchange adjustment capitalise development cost capitalise borrowing cost addition disposal asset writeoff transfer asset hold sale reclassification cost december exchange adjustment capitalise development cost capitalise borrowing cost addition business combination addition disposal asset writeoff transfer asset hold sale reclassification cost december amortisation january exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december exchange adjustment charge year disposal asset writeoff transfer asset hold sale amortisation december impairment january exchange adjustment impairment loss reversal impairment disposal asset writeoff transfer asset hold sale impairment december exchange adjustment impairment loss reversal impairment disposal asset writeoff transfer asset hold sale impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weight average interest rate capitalise borrowing cost year net book value computer software include million million internally generate cost carry value december intangible asset impairment charge reversed year follow impairment reversal million million patent expiry date group significant asset relevant set page gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue intangible asset continue amortisation impairment loss net reversal charge income statement follow amortisation net impairment loss cost sale sell general administration research development licence patent amortise brand etc include large number acquire licence patent knowhow agreement marketing right market use development note acquisition disposal give detail addition business combination year book value large individual item follow zejula meningitis portfolio dolutegravir benlysta bms merck asset fluarixflulaval stiefel trade meningitis portfolio include menveo bexsero man abcwy menjugate stiefel trade move licence patent amortise brand etc follow decision start amortisation indefinite life brand comprise portfolio consumer healthcare product primarily acquire acquisition sterling winthrop inc block drug company inc cns inc novartis consumer healthcare business pfizer consumer healthcare business book value major brand follow advil voltaren centrum caltrate otrivin preparation h robitussin nexium fenistil chapstick emergenc theraflu panadol lamisil sensodyne breathe right stiefel trade gsk annual report note financial statement continue intangible asset continue brand consider indefinite life give strength durability brand level marketing support brand relatively similar stable profitable market sector similar risk profile size diversification market share mean risk marketrelated factor cause reduction live brand consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortise brand test annually impairment amortise intangible asset test indicator impairment arise testing apply fair value cost disposal methodology generally posttax cash flow forecast terminal value calculation discount rate equal group posttax wacc adjust appropriate specific segment country currency risk valuation methodology use significant input base observable market datum valuation technique classify level fair value hierarchy main assumption include future sale price volume growth product contribution future expenditure require maintain product marketability registration relevant jurisdiction exchange rate assumption base past experience review management budget strategic planning cycle change market condition sale erosion competition terminal growth rate apply management estimate future longterm average growth rate relevant market case valuation indicate sufficient headroom reasonably possible change key assumption unlikely result impairment intangible asset investment associate joint venture joint joint ventures associates total ventures associates total january exchange adjustment addition disposal distribution receive movement profitloss tax recognise consolidated income statement december group hold significant associate december innoviva inc december group own million share innoviva biopharmaceutical company list nasdaq innoviva partner gsk development long act beta agonist vilanterol currently receive royalty income sale product contain component relvarbreo ellipta anoro ellipta economic interest royalty pay gsk sale trelegy ellipta remain economic interest royalty hold theravance biopharma inc group hold common stock investment innoviva market value million december million summarise balance sheet information base information publish post balance sheet date respect innoviva set december december noncurrent asset current asset current liability noncurrent liability net asset carry value group investment innoviva analyse follow interest net asset associate goodwill fair value adjustment carry value december gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue investment investment investment designate investment designate investment measure measured measured measured fvtoci fvtpl fvtoci fvtpl january addition net fair value movement comprehensive income net fair value movement profit loss disposal settlement transfer asset hold sale december investment comprise noncurrent equity investment record fair value balance sheet date investment trade active market fair value determine reference relevant stock exchange quote bid price investment fair value estimate management reference relevant available information include current market value similar instrument recent financing round discount cash flow underlie net asset net fair value movement include impact exchange loss million comprehensive income million profit loss gain million million respectively investment include list investment million million gsk elect designate majority equity investment measure fair value comprehensive income fvtoci significant investment hold december andme group hold common stock progyny inc group hold theravance biopharma inc group hold lyell immunopharma inc group hold investment fair value december million million million million million million million respectively investment individually material investment include equity stake company gsk research collaboration company provide access biotechnology development potential interest disposal equity investment measure fvtoci accumulate fair value movement reclassify fair value reserve retain earning investment fair value million million dispose year cumulative gain investment tax million million certain investment investment fund limit life measure fair value profit loss fvtpl investment fair value million dispose year cumulative impairment investment designate measured fvtoci ifrs transfer retain earning fair value reserve january adoption ifrs noncurrent asset amount receivable insurance contract pension scheme surplus receivables amount receivable insurance contact hold fair value profit loss receivables million million million million classified financial asset million million classify fair value profit loss remain balance million million expect credit loss allowance immaterial december gsk annual report note financial statement continue inventory raw material consumable work progress finish good trade receivable trade receivables net loss allowance accrue income prepayment interest receivable employee loan advance receivables trade receivables include nil million associate joint ventures receivables include nil nil associate joint venture loss allowance january implementation ifrs january adjust exchange adjustment charge year subsequent recovery amounts provide utilise december total trade receivables balance million million consider credit impair million million expect credit loss allowance apply purchase originated credit impair receivables million million million million classified financial asset nil million classify fair value profit loss remain balance million million expect credit loss allowance million million recognise december charge report profit loss year discussion credit risk practice refer note gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue cash cash equivalent cash bank hand shortterm deposit addition million million cash cash equivalent report asset hold sale note asset hold sale cash cash equivalent include billion billion available general use restriction apply subsidiary hold restriction include exchange control taxis repatriation asset hold sale property plant equipment right use asset lease liability goodwill intangible inventory cash cash equivalent noncurrent asset disposal group transfer asset hold sale expect carry amount recover principally disposal sale consider highly probable hold low carrying fair value cost sell asset hold sale primarily reflect thermacare disposal group acquire pfizer consumer healthcare business sell group meet antitrust requirement disposal group represent horlick consumer healthcare nutritional brand sell unilever plc include asset hold sale inventory write fair value cost sell million million valuation methodology significant input base observable market datum valuation classify level fair value hierarchy impairment allocate goodwill million recognise reflect fair value cost sell disposal group gsk annual report note financial statement continue trade payable trade payable wage salary social security viiv healthcare option payable defer income customer return rebate accrual accrual trade payable include million million associate joint ventures group provide limited supplier financing arrangement certain customer amount involve december material revenue recognise year include deferred income january million million customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer include million million respect pharmaceutical vaccine fully describe group financial review accrual time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome subject change dependent thing type buy group product sale mix level accrual review adjust quarterly light historical experience actual amount pay change arrangement future event cause assumption accrual base change affect future result group pfizer option shareholding viiv healthcare currently exercisable pfizer request ipo viiv healthcare time gsk consent ipo offering complete month pfizer require gsk acquire shareholding liability option hold gross redemption basis derive internal valuation viiv healthcare business utilise discount forecast future cash flow multiplesbase methodology table show indicative basis income statement balance sheet sensitivity pfizer option reasonably possible change key assumption increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue net debt list exchange current asset liquid investment cash cash equivalent cash cash equivalent report asset hold sale shortterm borrowing commercial paper bank loan overdraft draw bank facility european medium term note london stock exchange euribor european medium term note london stock exchange european medium term note london stock exchange lease liability longterm borrowing euribor european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange libor medium term note new york stock exchange euribor european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange medium term note new york stock exchange european medium term note london stock exchange european medium term note london stock exchange medium term note new york stock exchange european medium term note london stock exchange longterm borrowing lease liability net debt gsk annual report note financial statement continue net debt continue current asset liquid investment classify financial asset amortise cost december include treasury note government bond effective interest rate liquid investment december approximately approximately liquid investment balance december earn interest float rate million million liquid investment balance december earn interest fix rate million nil balance report cash cash equivalent original maturity month effective interest rate cash cash equivalent december approximately approximately cash cash equivalent december earn interest float fix rate amount million million respectively million million noninterest bearing holding amount million million gsk policy credit quality cash cash equivalent set note financial instrument relate disclosure shortterm borrowing gsk billion billion commercial paper programme billion billion issue december billion billion gsk billion threeyear commit facility billion billion day commit facility threeyear commit facility day commit facility agree september undrawn december additional bank facility agree support transaction remain active december june billion draw support acquisition novartis remain stake consumer healthcare joint venture billion repay november leave billion outstanding december weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december shortterm loan rate argentina disproportionate effect weight average interest rate average effective preswap interest rate note classify shortterm december continue decrease rate reflect maturity euribor coupon note coupon note september longterm borrowing yearend gsk longterm borrowing billion billion billion billion fall year average effective preswap interest rate note issue december approximately approximately longterm borrowing repayable year carry interest effective rate repayment date range pledge asset group hold pledge investment treasury note par value million million million million security irrevocable letter credit issue group behalf respect group selfinsurance activity provision respect selfinsurance include provision legal dispute discuss note provision lease liability maturity analysis discount lease liability recognise group balance sheet follow revise rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total lease liability gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit pension postemployment cost uk pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme analyse fund define benefithybrid pension scheme unfunded define benefit pension scheme unfunded postretirement healthcare scheme define benefit scheme define contribution pension scheme cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee arrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length service pension cost define benefit scheme accounting purpose calculate project unit method certain country pension benefit provide unfunded basis administer trustee company formal independent actuarial valuation group main plan undertake regularly normally year actuarial movement year recognise statement comprehensive income discount rate derive aa rate corporate bond yield country deep market corporate bond government bond yield discount rate select reflect term expect benefit payment project inflation rate pension increase longterm prediction base yield gap longterm indexlinke fix interest gilt uk mortality rate determine adjust sap standard mortality table reflect recent scheme experience rate project reflect improvement life expectancy line cmi projection longterm rate improvement year male female mortality rate calculate rp white collar table adjust reflect recent experience rate project mp allow future improvement life expectancy gsk annual report note financial statement continue pension postemployment benefit continue average life expectancy assume individual age project apply individual age follow uk male female male female year year year year current project asset fund scheme generally hold separately administer trust specific asset proportion general fund insurance contract asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment physical asset allocation strategy uk plan adjusted returnseeke asset liabilitymatche asset returnseeke asset liabilitymatche assets buyin insurance contract purchase cover substantially obligation uk plan december value insurance contract million asset allocation plan currently set returnseeke asset liabilitymatche asset pension plan expose risk arise estimate market value plan asset decline investment return reduce estimate value plan liability increase line agree mix returnseeke asset generate future return liabilitymatche asset well match future pension obligation group define overall longterm investment strategy plan investment broad range asset main market risk asset hedge portfolio credit risk interest rate longterm inflation equitie property currency bank counterparty risk plan liability series future cash flow relatively long duration ias basis cash flow sensitive change expect longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation correspond increase liability increase discount rate correspond decrease liabilitie interest rate risk credit rate risk partially hedge target base accounting measure plan liability uk plan interest rate inflation hedge strategy place target base economic measure plan liability furthermore plan currently hedge portion equity exposure stagger maturity profile uk define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent uk employee entitle join define contribution scheme addition group operate number postretirement healthcare scheme principal group apply follow financial assumption assess define benefit liability uk rest world pa pa pa pa pa pa pa pa pa rate increase future earning discount rate expect pension increase na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detail effect change assumption provide analysis provide reflect assumption change material impact result group gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue amount record income statement statement comprehensive income year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement loss record statement comprehensive income postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest incomecost gain settlement expense remeasurement gainslosse record statement comprehensive income postretirement pension benefit uk rest world group group amount charge operating profit current service cost past service costcredit net interest cost expense remeasurement gainslosse record statement comprehensive income amount include past service cost uk include million million million augmentation cost million arise major restructuring programme note provision past service cost uk include charge million relation estimate impact gmp equalisation gsk annual report note financial statement continue pension postemployment benefit continue summarise balance sheet presentation group define benefit pension scheme postretirement benefit set table recognise noncurrent asset pension scheme surplus recognise asset hold sale postretirement benefit recognise pension postemployment benefit pension scheme deficit postretirement benefit event plan windup gsk believe uk pension scheme rule provide company right refund surplus asset follow settlement plan liability result net surplus uk define benefit pension scheme recognise fair value asset liability uk define benefit pension scheme aggregate datum define benefit pension scheme group follow uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset multiasset fund comprise investment pool investment vehicle invest range asset class increase diversification growth portfolio asset category comprise cash mark market value derivative position indexlinke gilt hold uk repo programme include government bond relate loan million december nil million deduct asset gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue uk rest world group december equity list unlisted multiasset fund property list unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset uk rest world group december equity list unlisted multiasset fund property unlisted corporate bond list unlisted government bond list insurance contract asset fair value asset present value scheme obligation net surplusobligation include noncurrent asset include pension postemployment benefit actual return plan asset gsk annual report note financial statement continue pension postemployment benefit continue postretirement pension benefit uk rest world group group movement fair value asset asset january exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december exchange adjustment addition business combination interest income expense settlement curtailment remeasurement employer contribution scheme participant contribution benefit pay asset december group special funding contribution uk pension scheme million nil million nil million million scheme gsk reach revise agreement trustee uk pension scheme additional contribution eliminate pension deficit identify scheme december actuarial funding valuation base funding agreement additional contribution eliminate pension deficit expect million payment agree year include note commitment fund commitment supersede previous agreement contribution base government bond yield curve approach select discount rate rate choose include allowance expect investment return reflect asset mix scheme employer contribution include special funding contribution estimate approximately million respect define benefit pension scheme million respect postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue postretirement pension benefit uk rest world group group movement define benefit obligation obligation january exchange adjustment service cost past service costcredit interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment service cost past service costcredit interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement scheme participant contribution benefit pay obligation december define benefit pension obligation analyse follow fund unfunded liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation grade december postretirement healthcare scheme obligation million million million postretirement benefit unfunded gsk annual report note financial statement continue pension postemployment benefit continue movement net define benefit liability follow january exchange adjustment addition business combination service cost past service cost interest cost settlement curtailment remeasurement return plan asset exclude amount include interest gain change demographic assumption lossgain change financial assumption experience loss employer contribution expense december remeasurement include postretirement benefit detailed gain change demographic assumption lossgain change financial assumption experience gain define benefit pension obligation analyse membership category follow active retire defer postretirement benefit obligation analyse membership category follow active retired defer weight average duration define benefit obligation follow year year year pension benefit postretirement benefit gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue pension postemployment benefit continue sensitivity analysis effect change assumption benefit obligation annual define benefit pension post retirement cost detailed information determine take account duration liability overall profile plan membership decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease discount rate follow approximate effect increase annual pension cost decrease annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation oneyear increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation increase rate future healthcare inflation follow approximate effect increase annual postretirement benefit cost increase postretirement benefit obligation increase inflation follow approximate effect increase annual pension cost increase pension obligation gsk annual report note financial statement continue provision legal major employee restructure relate dispute programme provision provision total january implementation ifrs january adjust exchange adjustment addition business combination charge year reverse unused unwind discount utilise reclassification movement transfer pension obligation december settle year settle year december legal dispute group potential settlement discussion number group involve substantial number legal dispute amount provide base dispute include notification possible claim set current assessment progress dispute note legal proceeding provision legal estimate million provide dispute include amount relate product liability antitrust december settle year december government investigation contract termination self expect million million insurance provision legal dispute reimburse party discussion legal issue net charge year million include reversal note legal proceeding estimate insurance recovery primarily relate provision product liability case commercial dispute major restructuring programme government investigation group undertake major restructuring programme combine restructure discount provision increase million integration programme substantially complete increase million discount calculate major restructure programme consumer riskadjuste project cash flow riskfree rate healthcare joint venture integration programme return programme focus primarily simplify supply chain respect product liability claim relate certain product process rationalise group manufacture network provision sufficient history claim restructuring pharmaceutical commercial operation settlement enable management reliable integrating pfizer consumer healthcare business estimate provision require cover unasserted claim provision staff severance payment ultimate liability matter vary amount management formal decision eliminate certain provide dependent outcome litigation position communicate group proceeding investigation possible settlement employee affect appropriate consultation procedure negotiation complete appropriate provision staff nature group business number severance payment immediately matter subject negotiation litigation pension augmentation arise staff redundancie year litigation proceeding include million million charge appeal procedure year reach resolution year transfer pension obligation provision outofcourt settlement discussion show note pension postemployment protract indemnify dispute result provision benefit asset writedown recognise charge correspond receivable impairment property plant equipment note property plant equipment majority amount provide expect utilise year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue provision continue employee relate provision employee relate provision include obligation certain give nature provision amount likely medical benefit disabled employee spouse settle year december provision benefit provision amount million million employee include provision insurance provision benefit reflect variety provision severance cost million million number jubilee awards longservice benefit provision include vehicle insurance regulatory matter contingent consideration liability consideration certain acquisition include amount contingent future event development milestone sale performance group provide fair value contingent consideration follow shionogi viiv novartis healthcare vaccine total january remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement cash payment operate cash flow cash payment invest activity december remeasurement income statement cash payment operate cash flow cash payment invest activity movement december contingent consideration payable december million million expect pay year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccine business expect pay number year result total estimate liability discount present value show shionogiviiv healthcare contingent consideration liability discount novartis vaccine contingent consideration liability discount commercialise product pipeline asset shionogiviiv healthcare novartis vaccine contingent consideration liability calculate principally base forecast sale performance specify product live product table show indicative basis income statement balance sheet sensitivity reasonably possible change key input valuation contingent consideration liability shionogi novartis viiv healthcare vaccine increasedecrease financial liability lossgain income statement increase sale forecast decrease sale forecast increase discount rate decrease discount rate increase probability milestone success decrease probability milestone success cent appreciation dollar cent depreciation dollar cent appreciation euro cent depreciation euro explanation accounting viiv healthcare set gsk annual report note financial statement continue noncurrent liability accrual defer income payable payable include number employeerelate liability include employee saving plan prior year include acquisition accounting market value lease adjustment reclassify right use asset transition ifrs contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december million nil financial asset pledge collateral contingent liability provision outcome tax legal dispute probable group suffer outflow fund possible reliable estimate outflow december dispute provision possible reliable estimate potential outflow fund require settle dispute possibility outflow remote description significant legal dispute group party set note legal proceeding commitment contractual obligation commitment contract provide financial statement intangible asset property plant equipment investment purchase commitment pension interest loan future finance charge lease commitment related intangible asset include milestone payment dependent successful clinical development meeting specify sale target represent maximum pay milestone unlikely achieve amount riskadjuste discount increase intangible commitment mainly attributable number new rd collaboration include merck kgaa lyell immunopharma gsk reach agreement trustee uk pension scheme additional contribution eliminate pension deficit identify december actuarial funding valuation payment million payment million table include commitment exclude normal ongoing annual funding requirement uk approximately million group commitment principally relate revenue payment licence alliance commitment respect future interest payable loan disclose take account effect interest rate swap gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue share capital share premium account share ordinary share p premium number share capital issue fully pay january issue employee share scheme ordinary share acquire esop trust december issue employee share scheme december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme gsk annual report note financial statement continue movement equity retain earning reserve amount million december million loss revise million loss million million million relate associate joint venture adjustment cumulative translation exchange retain earning noncontrolle interest million describe note presentation financial statement cumulative translation exchange equity follow net translation exchange include non total retain fair value control translation earning reserve interests exchange january exchange movement overseas net asset reclassification exchange liquidation disposal overseas subsidiary december exchange movement overseas net asset december report adjustment exchange movement overseas net asset december revise exchange movement overseas net asset reclassification exchange movement liquidation disposal overseas subsidiary december analysis comprehensive income equity category follow non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange movement liquidation disposal overseas subsidiary fair value movement cash flow hedge reclassification cash flow hedge income expense defer tax fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment defer tax fair value movement equity investment remeasurement loss define benefit plan tax remeasurement loss define benefit plan comprehensive expenseincome year non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge fair value movement cash flow hedge reclassification cash flow hedge income expense defer tax fair value movement cash flow hedge defer tax reverse reclassification cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest fair value movement equity investment defer tax fair value movement equity investment remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive incomeexpense year gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue movement equity continue non retain control earning reserve interest total item subsequently reclassify income statement exchange movement overseas net asset net investment hedge reclassification exchange liquidation disposal overseas subsidiary fair value movement availableforsale investment reclassification fair value movement availableforsale investment defer tax fair value movement availableforsale investment defer tax reverse reclassification availableforsale investment fair value movement cash flow hedge item reclassify income statement exchange movement overseas net asset noncontrolle interest remeasurement gain define benefit plan tax remeasurement gain define benefit plan comprehensive incomeexpense year analysis reserve follow esop trust fair value cash flow share reserve hedge reserve reserves total january exchange adjustment transfer income expense year disposal net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december implementation ifrs december adjusted exchange adjustment transfer retain earning year disposal equity investment net fair value movement year writedown share hold esop trust december exchange adjustment transfer retain earning year disposal equity investment net fair value movement year ordinary share acquire esop trust writedown share hold esop trust december reserve include nondistributable merger premerger reserve amount million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million gsk annual report note financial statement continue noncontrolle interest total noncontrolle interest includes follow individually material noncontrolle interest noncontrolle interest individually material viiv healthcare gsk hold viiv healthcare subgroup give rise material noncontrolle interest summarise financial information respect viiv healthcare subgroup follow turnover profit taxation comprehensive expenseincome total comprehensive income noncurrent asset current asset total asset current liability noncurrent liability total liability net liability net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity increasedecrease cash bank overdraft year financial information relate viiv healthcare group standalone basis impact grouprelate adjustment primarily relate recognition preferential dividend profit taxation million million million state charge preferential dividend payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable consideration expect pay number year follow amount attributable viiv healthcare group include gsk financial statement share profit year attributable noncontrolle interest dividend pay noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue noncontrolle interest continue consumer healthcare joint venture gsk hold consumer healthcare subgroup give rise material noncontrollling interest summarise financial information respect consumer healthcare subgroup follow turnover profit taxation comprehensive expense total comprehensive expense noncurrent asset current asset total asset current liability noncurrent liability total liability net asset net cash inflow operating activity net cash outflow investing activity net cash outflow financing activity decrease cash bank overdraft period financial information relate consumer healthcare joint venture standalone basis formation july impact grouprelate adjustment classification cash pooling account group company outside consumer healthcare joint venture major restructuring charge follow amount attributable consumer healthcare joint venture include gsk financial statement share profit period attributable noncontrolle interest noncontrolle interest consolidate balance sheet gsk annual report note financial statement continue related party transaction december gsk own million share innoviva inc biopharmaceutical company list nasdaq gsk begin recognise innoviva associate september royalty gsk innoviva year million million december balance payable gsk innoviva million million january gsk hold interest japan vaccine co ltd jvc subsidiary glaxosmithkline kk joint venture daiichi sankyo co ltd primarily responsible development marketing certain prophylactic vaccine japan gsk sell million vaccine product joint venture daiichi sankyos share jvc acquire gsk point jvc cease relate party loan million medicxi venture lp million index venture life vi jersey lp remain gsk december gsk increase investment kurma biofund ii fcpr million apollo therapeutic llp million investment medicxi venture lp million index venture life vi jersey lp million joint venture agreement qura therapeutics llc group obligation fund joint venture million quarter april june agreement extend second fiveyear period april gsk joint venture partner commit additional financial support million december outstanding liability qura million cash distribution receive investment medicxi venture lp million longwood founder fund lp million aggregate compensation director cet give note employee cost acquisition disposal detail acquisition disposal significant subsidiary associate joint venture business give business acquisition pfizer consumer healthcare business acquisition pfizer consumer healthcare business complete july gsk pfizer contribute respective consumer healthcare business new consumer healthcare joint venture noncash transaction gsk acquire pfizer consumer healthcare business return share joint venture gsk equity interest majority control joint venture pfizer equity interest group control consumer healthcare joint venture consolidate group financial statement number territory legal completion acquisition occur regulatory constraint consumer healthcare joint venture obtain control majority business territory july consolidate net asset business date case entitle benefit trading business delay territory noncontrolle interest consumer healthcare joint venture calculate apply proportionate goodwill method represent pfizer share net asset joint venture exclude goodwill goodwill billion expect deductible tax purpose recognise goodwill represent potential synergy arise combine acquire business gsk exist business value workforce acquire total transaction cost recognise acquisition amount million acquisition july sale billion arise pfizer consumer healthcare business include group turnover business acquire beginning year estimate group turnover approximately billion high business integrate group exist activity practicable identify impact group profit period tesaro inc january gsk acquire tesaro inc oncology focus biopharmaceutical company cash consideration billion billion order strengthen group pharmaceutical pipeline transaction cost amount million goodwill billion expect taxdeductible recognise goodwill represent potential synergy arise combine acquire business gsk exist business value workforce acquire acquisition january sale billion arise tesaro business include group turnover business integrate group exist activity practicable identify impact group profit period gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue fair value asset acquire business combination include goodwill set table amount relate pfizer consumer healthcare business acquisition provisional subject change pfizer consumer healthcare business tesaro net asset acquire intangible asset property plant equipment right use asset inventory trade receivables asset include cash cash equivalent trade payable net defer tax liability liabilitie term loan noncontrolle interest goodwill total consideration settle share gsk consumer healthcare joint venture cash consideration pay fair value investment joint venture convert subsidiary total consideration noncontrolle interest million represent pfizer share fair value pfizer consumer healthcare business exclude goodwill total noncontrolle interest initially recognise consolidated statement change equity million include pfizer share book value gsk consumer healthcare business disposal gsk number business disposal net cash consideration receive year million profit disposal business year million calculate follow total cash consideration receivable net subsidy payable net asset sell goodwill intangible asset property plant equipment inventory cash cash equivalent net asset transaction cost reclassification exchange comprehensive income noncontrolle interest divest transaction sign complete gain embed derivative transaction sign complete transaction cost total profit disposal transaction sign complete december gsk agree divest horlick consumer healthcare nutrition brand unilever plc form merger glaxosmithkline consumer healthcare limit hindustan unilever limited total consideration value approximately billion glaxosmithkline consumer healthcare limited public company list national stock exchange nse bombay stock exchange bse gsk hold stake follow merger glaxosmithkline consumer healthcare limit hindustan unilever limited public company list nse bse gsk million hindustan unilever limited share gsk annual report note financial statement continue acquisition disposal continue group enter forward foreign exchange contract relation transaction contract value billion designate cash flow hedge foreign exposure arise transaction contract value billion designate net investment hedge inr eur asset addition exposure share price movement forward purchase share hindustan unilever limited recognise embed derivative embed derivative asset position fair value million december million associate joint venture year gsk investment million associate joint venture million pay cash cash flow associate joint business business venture acquisition disposal investment cash consideration paidreceive net defer consideration receive transaction cost cash cash equivalent acquireddiveste cash outflowinflow business acquisition business acquisition business disposal gsk number small business disposal year net cash consideration million cash flow associate associate joint joint business venture venture disposal investment disposal cash consideration net defer consideration receive cash inflowoutflow business acquisition business acquisition business disposal gsk number small business disposal year net cash consideration million include contingent consideration receivable million profit disposal determine follow total consideration include currency forward purchase adjustment net asset sell goodwill intangible asset property plant equipment inventory cash cash equivalent net asset transaction cost reclassification exchange comprehensive income profit disposal gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue acquisition disposal continue associate joint ventures year gsk cash investment million associate joint venture addition gsk sell holding associate million cash total cash consideration net book value share reclassification exchange comprehensive income transaction cost profit disposal cash flow associate associate joint joint business venture venture disposal investment disposal cash consideration net defer consideration receive cash cash equivalent divest transaction cost pay cash inflowoutflow adjustment reconcile profit tax operating cash flow profit tax tax profit share aftertax profit associate joint venture finance expense net finance income depreciation amortisation intangible asset impairment asset write profit sale business profit sale intangible asset profit sale investment associate profit sale equity investment gain novartis consumer healthcare joint venture option hedge business acquisition cost change work capital decreaseincrease inventory increase trade receivables increase trade payable increasedecrease receivables contingent consideration pay note noncash increase contingent consideration liability increase payable decreaseincrease pension provision sharebase incentive plan fair value adjustment cash generate operation gsk annual report note financial statement continue reconciliation net cash flow movement net debt net debt previously report implementation ifrs net debt begin year adjust increasedecrease cash bank overdraft decrease liquid investment net increase longterm loan repayment shortterm note increase inrepayment shortterm loan repayment lease liability debt subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year ifrs january implement debt profit reclass december ation exchange acquire loss ification cash flow analysis change net debt liquid investment cash cash equivalent cash cash equivalent ahfs overdraft debt year commercial paper europeanu medium term note bank facility lease liability debt year europeanu medium term note bank facility lease liability net debt analysis change liability finance activity debt year debt year hedge borrowing derivative financial instrument finance item interest payable total liability financing activity information significant change net debt note net debt gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure objective gsk treasury activity minimise additional bank facility agree support posttax net cost financial operation reduce volatility transaction remain active december benefit earning cash flow gsk use variety june billion draw support acquisition financial instrument finance operation derivative novartis remain stake consumer financial instrument manage market risk healthcare joint venture billion repay november operation derivative principally comprise foreign exchange leave billion outstanding december forward contract swap swap december facility extend june borrowing liquid asset currency require group gsk billion european medium term note purpose interest rate swap programme december billion manage exposure financial risk change interest note issue programme group rate financial instrument reduce uncertainty billion billion note issue december foreign currency transaction interest payment shelf registration gsk borrowing mature derivative exclusively hedge purpose date relation underlie business activity trading option own pfizer viiv healthcare speculative instrument exercisable review liquidity requirement gsk consider capital management sufficient financing option available gsk financial strategy support group strategic option exercise priority regularly review board gsk manage market risk capital structure group appropriate mix interest rate risk management debt equity objective gsk treasury activity minimise capital structure group consist net debt effective net interest cost balance mix debt fix billion note net debt total equity float rate time include item relate noncontrolle interest group main interest rate risk arise borrowing billion consolidated statement change investment float rate refinance mature fix equity total capital include provide rate debt change interest rate affect future noncontrolle interest billion cash flow fair value financial instrument policy group continue manage financial policy credit interest rate risk management limit net profile particularly target shortterm credit rating float rate debt specific cap review agree p maintain single longterm rating consistent annually board target group longterm credit rating majority debt issue fix interest rate standard poor negative outlook moodys change float rate interest significantly investor service moodys negative outlook affect group net interest charge include group shortterm credit rating p borrowing interest rate swap place standard poor moodys respectively remove impact associate periodic repricing liquidity risk management shortterm borrowing include bank facility expose gsk policy borrow centrally order meet anticipate risk future change market interest rate funding requirement strategy diversify liquidity majority cash liquid investment source range facility maintain broad access financial market interest rate benchmark reform interest rate benchmark reform amendment ifrs december gsk billion borrowing ias ifrs issue iasb september repayable year hold billion cash amendment modify specific hedge accounting cash equivalent liquid investment billion requirement allow hedge accounting continue hold centrally gsk access shortterm finance affect hedge period uncertainty billion billion commercial paper programme hedge item hedge instrument affect current billion billion issue december interest rate benchmark amend result billion billion gsk billion ongoing interest rate benchmark reform threeyear commit facility billion billion day commit facility threeyear commit december group directly expose facility day commit facility agree interest rate benchmark reform hold interest rate september facility undrawn derivative reference libor mature end december gsk consider level commit float rate bond mature facility adequate give current liquidity requirement end gsk annual report note financial statement continue financial instrument relate disclosure continue group closely monitor market output group consider maximum credit risk december industry work group manage million december transition new benchmark interest rate include million total group financial asset announcement libor regulator include exception investment comprise equity financial conduct authority fca commodity investment bear equity risk credit risk future trading commission transition away detail group total financial asset libor include gbp libor usd libor december gsk great concentration euribor sterle overnight index average rate credit risk billion legal general investment sonia secure overnight financing rate sofr management class gbp liquidity fund aaaaaa euro shortterm rate str respectively fca billion citibank aa clear end long change estimation technique seek persuade compel bank submit libor significant assumption current reporting group undertake interest rate benchmark transition period assess loss allowance financial asset programme identify potential exposure business amortise cost adoption ifrs start deliver smooth transition appropriate alternative reporting period benchmark rate treasuryrelate credit risk foreign exchange risk management gsk set global counterparty limit gsk banking group objective minimise exposure overseas investment counterpartie base longterm credit operating subsidiary transaction risk match local rating moodys standard poor usage currency income local currency cost possible limit monitor daily foreign currency transaction exposure arise external gsk actively manage exposure credit risk reduce internal trade flow selectively hedge gsk internal surplus cash balance possible gsk trading transaction match centrally intercompany strategy regionalise cash management concentrate payment term manage reduce foreign currency risk cash centrally possible table set possible gsk manage cash surplus credit exposure counterpartie rate liquid borrowing requirement subsidiary company centrally investment cash cash equivalent derivative forward contract hedge future repayment originate currency gross asset position derivative contract consider purpose table isda order reduce foreign currency translation exposure agreement risk net position group seek denominate borrowing currency counterparty table e set group principal asset cash flow primarily financial asset liability offset basis denominate dollar euro sterling borrowing swap currency require december million cash categorise hold unrated subinvestment grade rate counterpartie borrowing denominate swap foreign low bbbbaa million cash transit currency match investment overseas group asset remain exposure concentrate overseas bank treat hedge relevant asset forward local cash management investment purpose include contract major currency reduce exposure million nigeria hold united bank africa zenith group investment overseas asset net bank stanbic ibtc bank million btv austria investment hedge section note detail million bradesco brazil million banco de credit risk la nacion panama million halk bank uk credit risk risk counterparty default million bank balance deposit hold contractual obligation result financial loss group bbbbaa rate counterpartie million hold arise cash cash equivalent favourable bbbbaa rate counterpartie include balance derivative financial instrument hold bank financial deposit million hdfc bank india institution credit exposure wholesale retail million state bank india bank customer include outstanding receivable local investment purpose gsk measure expect credit loss cash cash equivalent function individual counterparty credit rating associate month default rate expect credit loss cash cash equivalent thirdparty financial derivative deem immaterial loss experienced gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue credit rating assign standard poor moodys respectively opinion rating agency differ gsk assign low rating counterparty local rating agency fitch datum source available rating convert global rating equivalent standard poor moodys publish conversion table credit rating form basis assessment expect credit loss treasury relate balance hold amortise cost bank balance deposit government security bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security rd party financial derivative total bbba aaaaaa aaaa aa bbbbaa unrated total bank balance deposit treasury treasury repo money market fund liquidity fund government security rd party financial derivative total gsk centrally manage cash reserve amount new customer subject credit vetting process billion december available exist customer subject review annually month include billion cash manage vetting process subsequent review involve obtain group viiv healthcare own subsidiary information include customer status government billion cash manage group gsk consumer private sector entity audit financial statement credit bureau healthcare own subsidiary group invest report debt rating agency eg moodys standard poor centrally manage liquid asset bank deposit aaaaaa report payment performance history trade reference rate treasury treasury repo money market fund industry credit group bank reference aaaaaa rate liquidity fund trade receivables consist amount large number wholesale retail credit risk customer spread diverse industry outside customer account geographical area ongoing credit evaluation perform group trade receivable balance financial condition account receivable appropriate credit insurance purchase factor line pharmaceutical company arrangement place group sell product small number wholesaler addition hospital pharmacie physician information obtain proportional level group sale large wholesaler amount exposure consider information evaluate approximately sale pharmaceutical quantitatively ie credit score qualitatively ie judgement vaccine business december conjunction customer credit requirement group trade receivable wholesaler determine credit limit totalling million million group trade receivables group customer segment expose concentration credit risk respect similar loss pattern assess credit risk wholesaler encounters receivables financial asset assess individually financial difficulty materially adversely affect historical forwardlooking information consider group financial result determine appropriate expect credit loss allowance group credit risk monitoring activity relate group believe credit risk provision wholesaler include review quarterly financial require excess allowance expect credit loss information standard poor credit rating development note trade receivables gsk internal risk rating establishment periodic review credit limit gsk annual report note financial statement continue financial instrument relate disclosure continue credit enhancement follow method assumption estimate group use credit enhancement include factor fair value significant financial instrument credit insurance minimise credit risk trade measure fair value balance sheet receivables group december million receivables payable include option million gsk trade receivables insure approximate carry protect gsk trade receivable balance loss credit risk default insolvency bankruptcy liquid investment approximate carry group entity assess credit risk private cash cash equivalent approximate carry customer determine credit insurance require factoring arrangement manage locally entity longterm loan base quote market price level mitigate risk arise large credit risk fair value measurement case european concentration factor arrangement nonrecourse medium term note approximate carry case fix rate borrowing float rate bank fair value financial asset liability loan table present carry amount fair value group financial asset liability shortterm loan overdraft commercial paper december december approximate carry short maturity instrument fair value financial asset liability include price receive sell asset pay lease liability approximate carry transfer liability orderly transaction market participant measurement date follow method assumption measure fair value significant financial instrument carry fair value balance sheet investment equity investment trade active market determine reference relevant stock exchange quote bid price equity investment determine reference current market value similar instrument recent financing round discount cash flow underlie net asset trade receivables base invoice interest rate swap foreign exchange forward contract swap option base present value contractual cash flow option valuation model market source datum exchange rate interest rate balance sheet date companyowne life insurance policy base cash surrender value cash cash equivalent base net asset value fund contingent consideration business acquisition divestment base present value expect future cash flow gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue carry fair carry fair value value value value note financial asset measure amortise cost noncurrent asset b trade receivables b liquid investment cash cash equivalent item asset hold sale b financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables ab financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent assets ab trade receivables ab hold trading derivative designate effective hedge relationship ade cash cash equivalent derivative designate effective hedging instrument fair value movement comprehensive income ade total financial asset financial liability measure amortise cost borrowing exclude obligation lease liability bond designate hedge relationship bond bank loan overdraft commercial paper borrowing total borrowing exclude lease liability f lease liability total borrowing trade payable c provision c noncurrent liability c item asset hold sale c financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability ac hold trading derivative designate effective hedge relationship ade derivative designate effective hedging instrument fair value movement comprehensive income ade total financial liability net financial asset financial liability valuation methodology measure fair value table describe categorise trade receivables noncurrent asset trade payable provision noncurrent liability contingent consideration liability item asset hold sale reconcile relevant note page cash cash equivalent table include million report asset hold sale note asset hold sale gsk annual report note financial statement continue financial instrument relate disclosure continue fair value investment gsk share december employee share ownership plan esop trust hold gsk share carry value million million market value million million base quote market price share hold esop trust satisfy future exercise option award employee incentive scheme carry value low cost expect proceed share recognise deduction reserve december gsk hold treasury share cost million million deduct retain earning financial instrument hold fair value follow table categorise group financial asset liability hold fair value valuation methodology apply determine fair value possible quote price active market level price available asset liability classify level provide significant input valuation model base observable market datum significant input valuation model base observable market datum instrument classified level investment classify level table comprise equity investment unlisted entity group enter research collaboration investment emerge life science company level level level total december financial asset fair value financial asset measure fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci level level level total december financial asset fair value financial asset fair value comprehensive income fvtoci investment designate fvtoci trade receivables financial asset mandatorily measure fair value profit loss fvtpl investment noncurrent asset trade receivable hold trading derivative designate effective hedge relationship cash cash equivalent derivative designate effective hedging instrument fair value movement oci financial liability fair value financial liability mandatorily measure fair value profit loss fvtpl contingent consideration liability hold trading derivative designate effective hedging relationship derivative designate effective hedging instrument fair value movement oci gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue movement year financial instrument measure level valuation method present january net loss recognise income statement net gain recognise comprehensive income settlement contingent consideration liability settlement contingent consideration receivables addition disposal settlement transfer level movement december net loss million million attributable level financial instrument recognise income statement include net loss million million respect financial instrument hold end year loss million million report operate income gain million nil report finance income charge million million arise remeasurement contingent consideration payable acquisition shionogiviiv healthcare joint venture million million arise remeasurement contingent consideration payable acquisition novartis vaccine business net gain million million attributable level financial instrument report comprehensive income fair value movement equity investment include net gain million net gain million respect financial instrument hold end year net gain million net gain million arise prior transfer level equity investment transfer level valuation methodology result list recognise stock exchange year net gain loss include impact exchange movement financial liability measure level valuation method december include million million respect contingent consideration payable acquisition shionogiviiv healthcare joint venture consideration expect pay number year vary line future performance specify product movement certain foreign currency include million million respect contingent consideration acquisition novartis vaccine business consideration expect pay number year vary line future performance specify product achievement certain milestone target movement certain foreign currency sensitivity analysis balance provide note contingent consideration liability b trade receivables noncurrent asset item asset hold sale scope ifrs follow table reconcile financial instrument trade receivables noncurrent asset item asset hold sale fall scope ifrs relevant balance sheet amount financial asset predominantly noninterest earn financial instrument noncurrent asset balance include companyowne life insurance policy nonfinancial instrument include tax receivables pension surplus balance prepayment outside scope ifrs non non amortise financial financial amortise financial financial fvtpl fvtoci cost instrument instrument total fvtpl fvtoci cost instrument instrument total trade receivable note noncurrent asset note item asset hold sale note gsk annual report note financial statement continue financial instrument relate disclosure continue c trade payable provision noncurrent liability contingent consideration liability item asset hold sale scope ifrs follow table reconcile financial instrument trade payable provision noncurrent liability contingent consideration liability item asset hold sale fall scope ifrs relevant balance sheet amount financial liability predominantly noninterest bear accrue wage salary include financial liability nonfinancial instrument include payment account tax social security payable provision arise contractual obligation deliver cash financial asset outside scope ifrs non non amortise financial financial amortise financial financial fvtpl cost instrument instrument total fvtpl cost instrument instrument total trade payable note provision note noncurrent liability note contingent consideration liability note item asset hold sale note derivative financial instrument hedge programme derivative economic hedging purpose speculative investment classify hold trading designate effective hedging instrument present current asset liability expected settle month end reporting period classified noncurrent group follow derivative financial instrument fair value fair value asset liability asset liabilitie noncurrent cash flow hedge interest rate swap contract principal million million net investment hedge cross currency swap principal million million current cash flow hedge interest rate swap contract principal million nil cash flow hedge foreign exchange contract principal million million net investment hedge foreign exchange contract principal million million derivative designate effective hedging instrument noncurrent embed derivative current foreign exchange contract principal million million embed derivative derivative classify hold trading total derivative instrument fair value hedge december group designate fair value hedge gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue net investment hedge december certain foreign exchange contract designate net investment hedge respect foreign currency translation risk arise consolidation group net investment european euro singaporean sgd indian inr japanese jpy foreign operation show table carry value bond include million million designate hedging instrument net investment hedge cash flow hedge group enter forward foreign exchange contract designate cash flow hedge enter hedge foreign exchange exposure arise cash flow euro denominate coupon payment relate note issue group european medium term note programme buyout novartis noncontrolle interest consumer healthcare joint venture plan divestment horlick nutrition brand refinance exist debt maturity group manage cash flow interest rate risk floatingtofixed interest rate swap addition group carry balance reserve arise prehedge fluctuation longterm interest rate pricing bond issue prior year current year balance reclassify finance cost life bond foreign exchange risk current year group designate certain foreign exchange forward contract swap cash flow net investment hedge foreign exchange derivative financial asset liability present line derivative financial instrument asset liability consolidate balance sheet follow table detail foreign exchange forward contract swap outstanding end report period information relate hedge item notional value foreign exchange forward contract swap absolute total outstanding position balance sheet date hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessment ensure economic relationship exist hedge item hedging instrument group enter hedge relationship critical term hedge instrument match exactly term hedge item qualitative assessment effectiveness perform change circumstance affect term hedge item critical term long match exactly critical term hedge instrument group use hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationship effect counterparty group credit risk fair value foreign exchange forward contract swap reflect fair value hedge item attributable change foreign exchange rate ineffectiveness roll cash flow hedge divestment mention source ineffectiveness emerge hedging relationship ineffectiveness record cash flow hedge amount million nil ineffectiveness record net investment hedge nil include table borrowing bond notional value billion swap fix interest rate eur debt cross currency interest rate swap notional carry average foreign value value hedge instrument exchange rate currency cash flow hedge foreign exchange contract buy foreign currency month eur months eur sell foreign currency month inrgbp month inrsgd gsk annual report note financial statement continue financial instrument relate disclosure continue notional carry average foreign value value hedge instrument exchange rate currency net investment hedge foreign exchange contract sell foreign currency month eur month sgd month inr month jpy borrowing include cross currency interest rate swap month eur month eur cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment foreign operation balance cash flow hedge reserve arise hedge relationship hedge accounting long apply average foreign notional carry exchange rate currency value value hedge instrument cash flow hedge foreign exchange contract buy foreign currency month eur sell foreign currency month inr net investment hedge foreign exchange contract sell foreign currency month eur month eur borrowing include cross currency interest rate swap month eur gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue cumulative balance cash periodic change value flow hedge reserveforeign calculate hedge currency translation reserve ineffectiveness continue hedge hedge item cash flow hedge variability cash flow highly probable forecast transaction variability cash flow foreign exchange exposure arise euro denominate coupon payment relate debt issue net investment hedge net investment european foreign operation balance cash flow hedge reserve arise hedge relationship hedge accounting long apply follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow highly probable forecast transaction operate operate income income expense expense variability cash flow foreign exchange exposure arise finance finance euro denominate coupon payment relate debt issue income income expense expense net investment hedge net investment foreign operation finance finance income income expense expense follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow highly probable forecast transaction operate operate income income expense expense variability cash flow foreign exchange exposure arise finance finance euro denominate coupon payment relate debt issue income income expense expense net investment hedge net investment european foreign operation finance finance income income expense expense gsk annual report note financial statement continue financial instrument relate disclosure continue interest rate risk group manage cash flow interest rate risk floatingtofixed interest rate swap quarterly interval difference fix contract rate float rate interest amount calculate reference agree notional principal amount exchange interest rate swap contract exchange float rate interest fix interest designate cash flow hedge hedge variability interest cash flow associate float rate debt relate note issue group european medium term note programme interest rate swap interest payment loan occur simultaneously accumulate equity reclassify profit loss period float rate interest payment affect profit loss critical term interest rate swap contract correspond hedged item qualitative assessment effectiveness perform expect value interest rate swap contract value correspond hedge item systematically change opposite direction response movement underlie interest rate main source ineffectiveness hedge relationship effect group credit risk fair value interest rate swap contract reflect fair value hedge item attributable change interest rate source ineffectiveness emerge hedging relationship follow table provide information interest rate swap contract outstanding related hedge item december december interest rate swap contract asset liability present line derivative financial instrument asset liability consolidate balance sheet change fair value average notional recognise fair value contract fix principal hedge asset rate value ineffectiveness liability hedge instrument year year change value balance cash flow hedge calculate reserve hedge continue ineffectiveness hedge hedge item variable rate borrowing change fair value average notional recognise fair value contract fix principal hedge asset rate value ineffectiveness liability hedge instrument year year change value balance cash flow hedge calculate reserve hedge continue ineffectiveness hedge hedge item variable rate borrowing gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue follow table detail effectiveness hedge relationship amount reclassify hedging reserve profit loss reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate finance finance income income expense expense reclassify profit loss line item hedge profit future cash line item hedge hedge loss flow gainslosse ineffectiveness hedge long hedge reclassification recognise recognise ineffectiveness expect item affect adjustment reserve profit loss include occur profit loss include cash flow hedge variability cash flow finance finance income income expense expense prehedge longterm interest rate finance finance income income expense expense e offset financial asset liability financial asset liability offset net report balance sheet legally enforceable right offset recognise amount intention settle net basis realise asset settle liability simultaneously arrangement meet criterion offset allow related amount offset certain circumstance bankruptcy termination contract follow table set financial asset liability offset subject enforceable master netting arrangement similar agreement offset december december column net show impact group balance sheet offset right exercise gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument gsk annual report note financial statement continue financial instrument relate disclosure continue gross financial financial liability net financial relate asset asset asset amount net liability offset liability offset balance december financial asset trade receivables derivative financial instrument financial liability trade payable derivative financial instrument amount meet criterion offset balance sheet settle net certain circumstance principally relate derivative transaction isda international swap derivative association agreement party option settle amount net basis event default party presently legally enforceable right offset amount offset balance sheet present separately table f debt interest rate repricing table follow table set exposure group interest rate debt include commercial paper maturity analysis fix rate debt state contractual maturity float rate debt interest rate repricing date purpose table debt define class borrowing lease liability total debt total float fix rate debt year year year year year year great year total original issuance profile fix rate interest float rate interest total interest bear noninterest bearing gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue g sensitivity analysis table illustrate estimate impact income statement equity result hypothetical market movement foreign exchange interest rate relation group financial instrument range variable choose sensitivity analysis reflect management view change reasonably possible oneyear period foreign exchange sensitivity group operate internationally primarily expose foreign exchange risk relation sterling movement dollar euro japanese yen foreign exchange risk arise translation financial asset liability functional currency entity hold base group net financial asset liability december weaken strengthen sterling currency variable hold constant illustrate table table exclude financial instrument expose group foreign exchange risk risk fully hedge financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposure cent depreciation dollar cent depreciation euro yen depreciation yen equity impact show foreign exchange sensitivity relate derivative nonderivative financial instrument hedge group net investment european euro foreign operation cash flow hedge foreign exchange exposure arise euro denominate coupon payment relate note issue group european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposure cent depreciation euro gsk annual report note financial statement continue financial instrument relate disclosure continue table present group sensitivity weakening strengthen sterle relevant currency base composition net debt show note adjust effect foreign exchange derivative net debt affect future foreign currency cash flow increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent appreciation dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movement net debt cent depreciation dollar cent depreciation euro yen depreciation yen interest rate sensitivity group expose interest rate risk outstanding borrowing investment change interest rate affect future cash flow fair value financial instrument majority debt issue fix interest rate change float rate interest significantly affect group net interest charge majority cash liquid investment earn float rate interest table hypothetically show group sensitivity change interest rate relation sterling dollar euro float rate financial asset liabilitie interest rate applicable float rate financial asset liability increase basis point assume variable remain constant estimate group finance income decrease approximately million million decrease basis point movement interest rate deem material effect equity increasedecrease increasedecrease income income income statement impact interest rate movement basis point increase sterling interest rate basis point increase dollar interest rate basis point increase euro interest rate gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue financial instrument relate disclosure continue h contractual cash flow nonderivative financial liability derivative instrument follow table provide analysis anticipate contractual cash flow include interest payable group non derivative financial liability undiscounte basis purpose table debt define class borrowing lease liability interest calculate base debt hold december take account future issuance float rate interest estimate prevail interest rate balance sheet date cash flow foreign currency translate spot rate december finance trade payable charge interest lease lease liability debt debt liability liabilitie net debt total december year year year year year year great year gross contractual cash flow contractual cash flow respect operating lease vacant space provision december exclude table finance charge trade payable obligation obligation interest finance finance liability debt debt lease lease net debt total december year year year year year year great year gross contractual cash flow anticipate contractual cash flow repayment debt debt interest increase billion year primarily funding acquisition tesaro table provide analysis anticipate contractual cash flow group derivative instrument exclude equity option rise cash flow embed derivative material undiscounted cash flow cash flow foreign currency translate spot rate december gross cash flow foreign exchange contract present purpose table practice group use standard settlement arrangement reduce liquidity requirement instrument cash flow interest rate swap show table significant gross cash inflow gross cash ouflow gross cash inflow gross cash outflow foreign foreign foreign foreign cross exchange cross exchange cross exchange cross exchange currency forward currency forward currency forward currency forward interest rate contract interest rate contract interest rate contract interest rate contract swap swap swap swap swap swap swap swap year year year gross contractual cash flow amount gross cash inflow outflow foreign exchange forward contract swap year increase compare december predominantly increase level net investment hedging hedge increase level external internal commercial paper balance gsk annual report note financial statement continue employee share scheme gsk operate employee share scheme include share value plan award grant employee acquire share ad glaxosmithkline plc cost year vest period performance share plan award grant employee acquire share ad glaxosmithkline plc cost subject achievement group specify performance target grant restrict share award replace grant option employee cost scheme readily equate potential gain employee group operate saving relate share option scheme option grant employee acquire share glaxosmithkline plc discount price grant restrict share award normally exercisable end threeyear vest performance period award normally grant employee acquire share ad glaxosmithkline plc circumstance settle cash grant savingsrelate share option scheme normally exercisable year save accordance uk practice majority option savingsrelate share option scheme grant price market price ruling date grant option historical share option scheme grant market price ruling date grant total charge sharebase incentive plan million million million million million million arise share value plan note employee cost detail glaxosmithkline share award scheme share value plan share value plan share award grant certain employee cost award vest half year performance criterion attach fair value award determine base closing share price day grant deduct expect future dividend yield duration award share weight ad weight number share ad issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december performance share plan performance share plan share award grant director senior executive cost percentage award vest base performance group define measurement period dividend reinveste period award grant performance condition base equally weight measure threeyear performance period adjust free cash flow tsr rd new product performance fair value award determine base closing share price day grant tsr performance element adjust likelihood condition meet assess time grant award million share weight fair value million ad weight fair value december outstanding award million share million ad gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue employee share scheme continue share option savingsrelate option purpose value savingsrelated option arrive sharebased payment charge blackschole option pricing model assumption model follow grant grant grant riskfree interest rate dividend yield volatility expect life year year year savingsrelate option grant price include discount share option share option savingsrelate option outstanding scheme share scheme ad share option scheme weight weight weight number exercise number exercise number exercise price price price december range exercise price option outstanding year end weight average market price exercise year weight average remain contractual life year year year option million share grant year savingsrelate share option scheme weight average fair value december million savingsrelate share option exercisable share option ad option currently exercisable expire exercise july change effective exercise price outstanding option year employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share finance provide group way loan contribution cost run esop trust charge income statement share hold esop trust deduct reserve amortise value proceed receivable employee exercise transfer retain earning trustee waive right dividend share hold esop trust share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value gsk annual report note financial statement continue principal group company follow represent principal subsidiary country incorporation group december equity share capital entity wholly own group percentage interest show company incorporate principal country operation state england glaxo group limited block drug company inc glaxo operation uk limited corixa corporation glaxosmithkline capital plc glaxosmithkline capital inc glaxosmithkline consumer healthcare holdings limited glaxosmithkline consumer healthcare holding llc glaxosmithkline consumer healthcare uk trading limited glaxosmithkline consumer healthcare lp glaxosmithkline export limited glaxosmithkline holdings americas inc glaxosmithkline finance plc glaxosmithkline llc glaxosmithkline holdings limit human genome sciences inc glaxosmithkline research development limited gsk consumer health inc glaxosmithkline service unlimited pf consumer healthcare llc glaxosmithkline uk limited sr limited setfirst limited stiefel laboratories inc smithkline beecham limited tesaro inc viiv healthcare finance limited viiv healthcare company viiv healthcare limited viiv healthcare uk limited europe glaxosmithkline pharmaceuticals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline sante grand public sas france glaxosmithkline consumer healthcare australia pty ltd australia laboratoire glaxosmithkline france glaxosmithkline brasil limitada brazil viiv healthcare sas france glaxosmithkline consumer healthcare inc canada glaxosmithkline consumer healthcare gmbh co kg germany glaxosmithkline inc canada glaxosmithkline gmbh co kg germany d biomedical corporation quebec canada gsk vaccines gmbh germany pf consumer healthcare canada ulcpf soin de sante sri canada glaxosmithkline consumer healthcare spa italy glaxosmithkline limited china hong kong glaxosmithkline spa italy sinoamerican tianjin smith kline french laboratories ltd china gsk vaccines srl italy wyeth pharmaceutical co ltd china pfizer consumer manufacturing italy srl italy glaxosmithkline asia pvt limited india gsk service sp z oo poland glaxosmithkline consumer healthcare limited india glaxosmithkline trading services limited republic ireland glaxosmithkline pharmaceuticals limited india glaxosmithkline healthcare ao russia glaxosmithkline consumer healthcare japan kk japan glaxosmithkline sa spain glaxosmithkline kk japan laboratorios viiv healthcare sl spain viiv healthcare kabushiki kaisha japan gsk consumer healthcare sa switzerland glaxosmithkline pakistan limited pakistan glaxo wellcome manufacturing pte ltd singapore glaxosmithkline korea limited republic korea glaxosmithkline llaclari sanayi ticaret turkey e xempt provision section company act ireland accordance exemption note section act subsidiary disclose page exempt provision consolidate group financial statement directly hold whollyowne subsidiary glaxosmithkline plc subsidiary associate list principally affect figure group financial statement glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowne finance subsidiary company company fully unconditionally guarantee security issue glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc page complete list subsidiary undertaking associate joint venture form financial statement gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding group involve significant legal administrative intellectual property proceeding principally product liability intellectual property intellectual property claim include challenge validity tax antitrust consumer fraud governmental investigation enforceability group patent product significant matter tax matter process assertion noninfringement describe group make provision patent loss case result loss patent proceeding regular basis summarise note protection product issue consequence accounting principle policy note loss significant decrease sale product provision materially affect future result operation group group involved significant legal proceeding dolutegravirtivicaytriumeqdovatojuluca respect possible reliable estimate september october viiv healthcare receive patent expect financial effect result challenge letter hatchwaxman act cipla ultimate resolution proceeding case dr reddys labs apotex triumeq tivicay letter appropriate disclosure case include lupin mylan triumeq letter sandoz note provision case tivicay viiv healthcare list patent fda orange book tivicay triumeq patent cover molecule respect legal proceeding describe dolutegravir expire october second patent provision claim crystal form dolutegravir expire december group unable reliable estimate expect letter challenge laterexpire crystal financial effect stage group believe form patent generic company allege information seek plaintiff crystal form patent invalid claim crystal know meaningful respect legal form patent invalid infringe propose proceeding number factor include product viiv healthcare file patent infringement limited stage proceeding entitlement suit generic company case mylan party appeal decision clarity theory liability proceed northern district west virginia damages govern law set trial september case legal expense incur provision relate legal claim defendant proceed district court charge sell general administration cost provision district delaware court set trial date take appropriate legal specialist matter advice outflow resource consider probable september viiv healthcare receive paragraph iv reliable estimate likely outcome letter cipla relate dovato challenging dispute certain product liability claim group crystal form patent november viiv healthcare provision sufficient history claim file suit cipla district court district settlement enable management reliable estimate delaware provision require cover unasserted claim december group aggregate provision legal january viiv healthcare receive paragraph iv letter dispute include tax matter describe note lupin relate juluca challenging crystal form taxation million ultimate liability legal patent patent relate combination claim vary amount provide dependent dolutegravir rilpivirine expire january outcome litigation proceeding investigation february viiv healthcare file suit lupin possible settlement negotiation patent group position change time february viiv healthcare file patent infringement assurance loss result litigation gilead sciences inc gilead bictegravir outcome legal proceeding exceed material district court district delaware patent provision report group canadian federal court canadian financial statement happen patent viiv healthcare allege gilead material adverse impact result operation triple combination hiv drug contain hiv integrase group report period judgement inhibitor bictegravir infringe viiv healthcare patent cover incur settlement enter dolutegravir compound include dolutegravir unique chemical scaffold canada viiv healthcare seek financial redress injunctive relief gsk annual report note financial statement continue legal proceeding continue july gilead file motion judgement seroxatpaxil paxil cr pleading case arguing matter law group receive numerous lawsuit claim allege bictegravir compound infringe viiv healthcare use paxil paroxetine cause variety injury patent february court deny gilead motion lawsuit contain follow case gilead set trial september allegation use paxil pregnancy cause canadian matter fourday summary trial congenital malformation persistent pulmonary hypertension issue infringement hold january autism ii paxil treatment cause patient commit decision canadian court expect end suicidal violent act iii group fail warn march november viiv healthcare patient experience certain symptom commence action uk france germany japan discontinue paxil treatment korea australia gilead allege gilead pregnancy biktarvy infringe certain viiv healthcare hiv integrase group reach agreement settle majority inhibitor patent claim relate use paxil pregnancy kivexa january lawsuit relate use june biogaran commence proceeding france pregnancy pende court seek revocation french spc cover kivexa singh action alberta canada seeks certify national trial date set action class action relate birth defect generally court hear q viiv healthcare commence proceeding argument january plaintiff class certification sandoz switzerland sandoz counter challenging motion rule validity patent relate kivexa matter settle canadian class action jensen allege claim paxil q ssri use autism file saskatchewan product liability january activity case group currently defendant number product file liability lawsuit relate group pharmaceutical act violence vaccine consumer healthcare product group january pende claim case able reliable estimate expect concern allegation patient take paroxetine financial effect matter discuss category paxil commit attempt commit suicide act include provision appropriate matter violence claim case case provision legal dispute matter canada case dolin involve suicide group provision note note man allegedly take generic paroxetine manufacture provision mylan result million verdict plaintiff avandia august court appeal seventh january remain avandia circuit reverse jury verdict find favour case class action bring thirdparty payer group supreme court deny plaintiff certiorari assert claim racketeer influence corrupt request review case plaintiff organization act rico state consumer protection law file motion federal district court ask reinstate december circuit court appeal reverse jury verdict light supreme courts preemption summary judgement grant favour group decision merck v albrecht district court deny remand thirdparty payer case district court plaintiff motion july plaintiff appeal case santa clara county california action decision seventh circuit oral argument hear party reach agreement settle remain january rule court appeal claim pende remain case involve claim violence largely dormant additionally class action settlement canada approve avandia class action canada pende canadian action carmichael group discontinue dismiss file motion summary judgement base statute limitation deny group appeal rule oral argument take place december ruling issue gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue discontinuation manufacturer ppi name codefendant uk longpende group action allege seroxat mdl group file motion dismiss cause severe discontinuation symptom legal case mdl court rule services commission lsc withdraw public funding motion ppi bellwether trial set november hundred claimant cause termination claim zantac legal aid agency lsc discharge group contact regulatory authority public funding certificate follow recommendation detection genotoxic nitrosamine ndma special case review panel case poor zantac ranitidine product base information receive prospect success date correspondence regulator group recently fortitude law engage decision september suspend release purpose resurrect seroxat group action obtain distribution supply dose form zantac market thirdparty funding expert remain pende outcome ongoing test investigation claimants group ask court require thirdparty precautionary action group decision funder provide security litigation cost event early october initiate voluntary pharmacyretail level plaintiff lose recall zantac product globally ranitidine subject regulatory scrutiny group continue december high court rule favour investigation potential source ndma group application order claimant litigation zantac personal injury claim file october funder security cost sum excess total gsk pharmaceutical company fund commit case trial action federal court eastern district california follow commenced april judge dismiss case additional filing february multidistrict ground allegation insufficient prove litigation mdl proceeding hear zantac case plaintiff claim case far advanced establish southern district florida allow plaintiff reframe plaintiff appeal hear late october november court zofran appeal hold favour gsk dismiss appeal plaintiff allege child suffer birth defect unanimously january supreme court issue result mother ingestion zofran andor generic order deny plaintiff request appeal court ondansetron pregnancyrelate nausea vomiting case send trial court judge plaintiff assert group sell zofran know determination judgement case unsafe pregnant woman fail warn risk enter gsk illegally market zofran offlabel use pregnant woman addition uk matter individual january group defendant personal discontinuationtype claim pende central district injury lawsuit lawsuit multi california plaintiff matter allege claim district litigation mdl proceed federal court dystoniadyskinesia cause ingestion paxil trial set district massachusetts october wake supreme court preemption decision ppi litigation merck v albrecht mdl judge directed gsk refile group defendant ongoing proton pump inhibitor motion summary judgment federal preemption ground ppi litigation plaintiff allege use ppis cause bodily injury include acute kidney injury chronic kidney disease endstage renal failure january approximately personal injury lawsuit involve prevacidhr pende group nearly pende multidistrict litigation mdl proceeding district new jersey addition consumer business transaction pfizer approximately case involve nexiumhr pende group mdl small subset case involve product pende state court gsk annual report note financial statement continue legal proceeding continue court hear oral argument gsk renew motion average wholesale price november additionally response plaintiff claim attorney general illinois file suit group fda changed zofrans label gsk number pharmaceutical company claim provide certain additional information fda november damage restitution average wholesale price awp gsk submit citizen petition fda provide andor wholesale acquisition cost wac price reporting information identify plaintiff request fda pharmaceutical product cover state medicaid provide guidance information merit label programme case allege group report change court defer trial date caused report false awp wac price allow fda time respond petition turn allegedly cause state medicaid agency reimburse provider money cover medicine agency gsk defendant propose class action intend state seek recovery behalf payer canada significant activity matter behalf instate patient consumer gsk settle sale marketing regulation matter state announce october group marketing promotion pharmaceutical conclude matter vaccine product subject certain governmental cidra thirdparty payer litigation investigation private lawsuit bring litigant july major healthcare insurer file lawsuit theory law group able group seek compensation reimbursement reliable estimate expect financial effect matter medicine manufacture discuss category include provision group cidra plant puerto rico matter provision legal dispute insurer claim group knowingly market sell note adulterate drug manufacture condition noncompliant matter group provision cgmp current good manufacturing practice note note provision thirdparty insurer unlawfully induce pay sfo secdoj anticorruption enquiry november group resolve lawsuit uk fraud office sfo begin reach settlement plaintiff conclude formal criminal investigation group commercial matter operation number country include china sfo inquiry follow investigation initiate chinas ministry public security june china investigation parallel investigation undertake securities exchange commission sec department justice doj underlie commercial operation investigation resolve previously report course inquiry sfo request additional information group thirdparty adviser engage company course china investigation sec doj investigate matter group cooperate respond request february sfo announce closed investigation confirm take action group sec doj investigation matter continue group unable reliable estimate expect financial effect investigation provision gsk annual report strategic report governance remuneration financial statement investor information note financial statement continue legal proceeding continue antitrustcompetition commercial corporate certain governmental action private lawsuit group defendant certain case allege bring group allege violation competition violation federal security erisa law group antitrust law group able reliable able reliable estimate expect estimate expect financial effect matter financial effect matter discuss category discuss category include provision include provision matter provision matter provision legal dispute legal dispute matter group note provision note note provision matter group provision securitieserisa class action stiefel note note provision december securities exchange commission sec file formal complaint stiefel uk competition market authority investigation laboratories inc charles stiefel district court february uk competition market district florida allege stiefel principal authority cma issue decision fine group violate federal security law induce stiefel employee million infringement competition act sell share employee stock plan connection agreement settle patent dispute company greatly undervalue price disclose group enter potential supplier employee company sell generic paroxetine formulation group appeal group year inactivity case competition appeal tribunal cat deliver initial reassign new judge set trial date july judgement uphold fine march refer february party reach agreement certain question law european union court justice principle settle case subject final approval ecj january ecj issue judgement sec endorse criterion cma levy fine matter return cat entry final addition sec case private matter martinolich judgement case remain pende federal district court florida stay pende trial sec matter lamictal allegation martinolich case largely track purport class direct indirect purchaser file suit sec matter plaintiff stiefel employee allege district court district new jersey allege stiefel officer director violate employee group teva pharmaceuticals unlawfully conspire retirement income security act erisa federal state delay generic competition lamictal result overcharge security law induce stiefel employee sell share purchaser enter allegedly anticompetitive employee stock plan stiefel greatly reverse payment settlement resolve patent infringement undervalue price disclose employee litigation separate count accuse group monopolising stiefel sell group market june court appeal reverse trial court decision dismiss case remand action trial court trial court deny indirect purchaser class plaintiff motion reconsideration court dismissal claim result indirect purchaser class representative agree settlement exit case resolve remain claim december trial judge grant plaintiff class certification motion certify class direct purchaser action group pursue appeal court appeal class certification march circuit court appeal grant group motion agree review class certification decision briefing appeal conclude oral argument expect occur march gsk annual report company balance sheet uk gaap include frs reduce disclosure framework december note fix asset investment e current asset trade receivables f cash bank total current asset bank overdraft short term borrowing g trade payable h total current liability net current asset total asset current liability provision liability noncurrent liability j net asset capital reserve share capital k share premium account k reserve retain earning january loss year change retain earning l equity shareholder fund financial statement page approve board march sign behalf sir jonathan symonds chairman glaxosmithkline plc register number company statement change equity year end december share share premium retain total capital account reserve earning equity january loss total comprehensive expense attributable shareholder dividend shareholder share issue employee share scheme december loss year distribution receive glaxosmithkline consumer healthcare holdings limit total comprehensive income year dividend shareholder share issue employee share scheme treasury share transfer esop trust december gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet uk gaap include frs reduce disclosure framework presentation financial statement accounting principle policy description business preparation balance sheet conformity glaxosmithkline plc parent company gsk major generally accept accounting principle require management global healthcare group engage creation estimate assumption affect report discovery development manufacture marketing amount asset liability disclosure contingent pharmaceutical product include vaccine overthecounter asset liability date balance sheet actual otc medicine healthrelate consumer product amount differ estimate preparation financial statement balance sheet prepare accordance financial statement prepare company accounting policy approve board historical cost convention modify include revaluation describe note b policy consistently certain financial instrument go concern basis apply state prepared accordance financial reporting standard key accounting judgement estimate reduce disclosure framework uk accounting key accounting judgement estimate require presentation company act december current year comparative figure december b accounting policy permit section company act foreign currency transaction income statement company present foreign currency transaction record exchange annual report rate ruling date transaction foreign currency asset company include group financial statement liability translate rate exchange ruling glaxosmithkline plc publicly available balance sheet date follow exemption requirement ifrs dividend pay receive apply preparation financial statement dividend pay receive include financial accordance frs statement period relate dividend paragraph b ifrs sharebase actually pay receive payment expenditure ifrs financial instrument disclosure expenditure recognise respect good service receive supply accordance contractual term paragraph ifrs fair value measurement provision obligation exist future liability paragraph ias presentation financial statement respect past event comparative information requirement respect obligation reliably estimate paragraph iv ia investment subsidiary company paragraph f b investments subsidiary company hold cost ias presentation financial provision impairment adjust movement statement contingent consideration ias statement cash flow impairment investment carry value investment review impairment paragraph ias accounting policy change indication investment accounting estimate error impair provision result impairment review paragraph ias relate party disclosure charge income statement year concern requirement ia disclose related party sharebase payment transaction enter member issuance company subsidiary grant group company share represent additional capital accounting convention standard contribution company subsidiarie additional balance sheet prepare historical investment subsidiary result correspond increase cost convention complie applicable uk accounting shareholder equity additional capital contribution standard base fair value grant issue allocate underlying grant vest period gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework continue taxation financial guarantee current tax provide amount expect pay liability relate guarantee issue company apply tax rate enact substantively behalf subsidiary initially recognise fair value enact balance sheet date amortise life guarantee defer tax provide liability method c perate profit temporary difference arise tax basis asset fee relate audit liability carry amount financial company charge operate profit statement defer tax asset recognise dividend extent consider recoverable future director declare interim dividend result taxable profit dividend year penny line dividend defer tax measure average tax rate detail note group financial expect apply period temporary statement dividend difference expect realise settle defer tax liability asset discount e fix asset investment share glaxosmithkline service unlimited share glaxosmithkline holding limited share glaxosmithkline holdings limited share glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited capital contribution relate sharebased payment contribution relate contingent consideration share glaxosmithkline consumer healthcare holding limit receive year dividend specie group reorganisation prior acquisition pfizer consumer healthcare business f trade receivables amount year uk corporation tax recoverable amount owe group undertaking amount year amount owe group undertaking gsk annual report strategic report governance remuneration financial statement investor information note company balance sheet uk gaap include frs reduce disclosure framework continue g shortterm borrowing billion borrowing december relate balance facility take june finance buyout noncontrolle interest consumer healthcare joint venture hold novartis maturity date remain borrowing june h trade payable amount year creditor contingent consideration payable amount owe group undertaking company guarantee debt issue subsidiary company receive fee aggregate company outstanding guarantee billion debt instrument billion amount subsidiary company relation guarantee fee recover life bond disclose trade receivable note f provision liabilities january exchange adjustment charge year utilise december provision relate number legal dispute company currently involve j noncurrent liability contingent consideration payable contingent consideration relate payable acquisition novartis vaccine portfolio current year liability include trade payable gsk annual report note company balance sheet uk gaap include frs reduce disclosure framework continue k share capital share premium account share premium ordinary share p account number share capital issue fully pay january issue employee share scheme december issue employee share scheme ordinary share acquire esop trust december december december number share issuable employee share scheme number unissue share option december issue share capital share hold esop trust share hold treasury share share free issue issue share fully pay nominal carry market value share hold esop trust disclose note employee share scheme l retain earning loss glaxosmithkline plc year million million loss dividend pay million million effect million treasury share transfer subsidiary company nil million distribution receive share subsidiary company retain earning december stand million million million unrealise million dividend shareholder pay realise profit company december amount million million group company page complete list subsidiary associate joint venture form financial statement gsk annual report ssttrraatteeggicic r erepporotrt ggoovveerrnnaannccee nadn dre rmeumnuernaetiroantion ffiinnaanncciaial ls stattaetmemenetsnt iinnvveessttoor ri ninfoformrmataiotnion investor information section quarterly trend pharmaceutical turnover vaccine turnover year record product development pipeline product competition intellectual property principal risk uncertainty share capital share price dividend financial calendar annual general meeting tax information shareholder shareholder service contact law regulation group company glossary term ggsskk aannnnuuaall rreeppoorrtt financial record quarterly trend unaudite analysis group result provide quarter sterle financial year income statement total month q q q q report proforma report report report report cer cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny p p p p p calculation adjust result describe gsk annual report strategic report governance remuneration financial statement investor information financial record continue quarterly trend quarterly trend continue unaudite analysis group result provide quarter sterle financial year income statement total month q q q q report proforma report report report report cer cer cer cer cer cer turnover pharmaceutical vaccine consumer healthcare corporate unallocated turnover total turnover cost sale sell general administration research development royalty income operating incomeexpense operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder basic earning share penny p p p p p dilute earning share penny p p p p p income statement adjust total turnover cost sale sell general administration research development royalty income operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolle interest profit attributable shareholder adjust earning share penny p p p p p calculation adjust result describe gsk annual report financial record continued pharmaceutical turnover therapeutic area total europe international growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory ellipta product anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir product tivicay triumeq juluca dovato epzicomkivexa selzentry immunoinflammation benlysta oncology zejula establish pharmaceutical establish respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report strategic report governance remuneration financial statement investor information financial record continue pharmaceutical turnover therapeutic area total europe international growth growth growth growth therapeutic areamajor product cer cer cer cer respiratory ellipta product anoro ellipta arnuity ellipta incruse ellipta relvarbreo ellipta trelegy ellipta nucala hiv dolutegravir product tivicay triumeq juluca dovato epzicomkivexa selzentry immunoinflammation benlysta oncology zejula establish pharmaceutical establish respiratory seretideadvair flixotideflovent ventolin avamysveramyst respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report financial record continue vaccine turnover total europe international growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine represent growth actual exchange rate cer represent growth constant exchange rate vaccine turnover total europe international growth growth growth growth major product cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingle shingrix establish vaccine infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccine represent growth actual exchange rate cer represent growth constant exchange rate gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record record financial performance provide analysed accordance current reporting practice information include year record prepare accordance ifrs adopt european union ifrs issue international accounting standard board group turnover geographic region europe international group turnover segment pharmaceutical vaccine consumer healthcare segment turnover corporate unallocated turnover revise revise revise revise pharmaceutical turnover respiratory hiv immunoinflammation oncology establish pharmaceutical vaccine turnover meningitis influenza shingle establish vaccine consumer healthcare turnover wellness oral health nutrition skin health gsk annual report financial record continue year record continue financial result total turnover operate profit profit taxation profit taxation pence pence pence pence pence basic earning share dilute earning share million million million million million weight average number share issue basic diluted financial result adjust turnover operate profit profit taxation profit taxation pence pence pence pence pence adjust earning share return capital employ return capital employ calculated total profit taxation percentage average net asset year gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue balance sheet noncurrent asset current asset total asset current liability noncurrent liability total liability net asset shareholder equity revise note noncontrolle interest revise note total equity number employee europe international manufacturing sell administration research development geographic distribution employee table base location gsk subsidiary company number employee number permanent employ staff end financial period exclude employee employ manage gsk contract basis exchange rate guide holder ad follow table set period indicate information exchange rate dollar sterling report bank england pm buy rate average rate year calculate average pm buy rate day year average feb jan dec nov oct sep high low pm buying rate february gsk annual report financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million gsk annual report strategic report governance remuneration financial statement investor information financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal tax adjust result amortisation impairment restructure relate item reform result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p p weight average number share million divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million gsk annual report financial record continue year record continue divestment intangible intangible significant adjust result reconciliation total asset asset major transaction legal adjust result amortisation impairment restructure relate item result december turnover cost sale gross profit sell general administration research development royalty income operate expenseincome operating profit net finance cost profit disposal associate share aftertax profit associate joint ventures profit taxation taxation tax rate profit taxation lossprofit attributable noncontrolle interest profit attributable shareholder earning share p p p p p p p weight average number share million gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition pharmaceutical vaccine product development pipeline key nlicense alliance relationship party maa marketing authorisation application europe exception rituxan own biogen inc nda new drug application v iiv healthcare global specialist hiv company phase e valuation clinical pharmacology usually conduct gsk pfizer inc shionogi limited shareholder volunteer responsible developing deliver hiv medicine phase ii etermination dose initial evaluation efficacy optionbase alliance immunocore ltd conduct small number patient r receipt complete response letter phase iii l arge comparative study compound versus placebo bla biological licence application andor establish treatment patient establish clinical benefit safety maa ndabla regulatory review milestone show table achieve future filing date include list achieve regulatory review milestone compound type indication phase maa ndabla oncology zejula poly adpribose polymerase parp inhibitor fourth line treatment ovarian cancer approve oct niraparib quadra line maintenance ovarian cancer submit feb dec solid tumours prima iii dostarlimab antiprogramme cell death protein receptor dmmrmsih endometrial cancer submit dec pd antibody tumour garnet iii belantamab bcell maturation antigen antibody drug conjugate multiple myeloma submit dec dec mafodotin dreamm iii induce tcell costimulator icos agonist head neck squamous cell carcinoma iiiii antibody nonsmall cell lung cancer solid tumour bintrafusp alfa transform growth factor beta tgf trap biliary tract cancer l l iiiii immune checkpoint pd inhibitor bispecific nonsmall cell lung cancer tumour ii nyeso autologous engineer tcrt cell sarcoma solid heme malignancies ii engineered tcr molibresib bet family bromodomain inhibitor er breast cancer solid tumours ii cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer tumours ii tsr tim antibody protein arginine methyltransferase prmt solid tumour heme malignancy iii inhibitor antilymphocyte activation gene lag cancer iii tsr antibody ox agonist monoclonal antibody cancer tolllike receptor tlr agonist cancer type protein arginine methyltransferase cancer type prmt inhibitor nyesotargete bispecific cancer sting cytosolic dna pathway agonist cancer hiv infectious disease dectova neuraminidase inhibitor iv influenza approve apr zanamivir iv dolutegravir hiv integrase strand transfer inhibitor nucleoside hiv infection approve jul apr lamivudine reverse transcriptase inhibitor nrti fostemsavir hiv attachment inhibitor hiv infection submit jan dec cabotegravir hiv integrase strand transfer inhibitor non hiv infection submit jul apr rilpivirine nucleoside reverse transcriptase inhibitor nnrti r dec longacting regimen cabotegravir hiv integrase strand transfer inhibitor longacte hiv preexposure prophylaxis iii gepotidacin triazaacenaphthylene bacterial type ii topoisomerase uncomplicate urinary tract infection uuti iii inhibitor gonorrhea gc hbv antisense oligonucleotide hepatitis b ii gsk annual report pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla hiv infectious disease continue hiv maturation inhibitor hiv infection ii leucyl trna synthetase inhibitor tuberculosis ii hiv broadly neutralize antibody hiv infection crk inhibitor visceral leishmaniasis combinectin hiv entry inhibitor hiv infection immunoinflammation benlysta rituxan b lymphocyte stimulator monoclonal systemic lupus erythematosus iii antibody sc cluster differentiation cd sjogren syndrome ii monoclonal antibody iv benlysta b lymphocyte stimulator monoclonal lupus nephritis iii antibody sc otilimab granulocyte macrophage colony rheumatoid arthritis iii stimulate factor monoclonal antibody oncostatin osm monoclonal systemic sclerosis ii antibody lymphocyte activation gene lag ulcerative colitis ii protein monoclonal antibody ccl inhibitor pain osteoarthritis respiratory fluticasone furoate glucocorticoid agonist longacte asthma submit jan sep vilanterol beta agonist muscarinic umeclidinium acetylcholine antagonist mepolizumab interleukin il monoclonal antibody copd iii hypereosinophilic syndrome nasal polyposis interleukin r ilr monoclonal asthma ii antibody selective androgen receptor modulator copd muscle weakness ii interleukin il longacting monoclonal asthma antibody nemiralisib phosphatidylinositol kinase delta activate pik delta syndrome pik inhibitor pharmaceutical daprodustat prolyl hydroxylase inhibitor oral anaemia associated chronic renal disease jnda jnda submit aug iii oxytocin inhale oxytocin postpartum hemorrhage ii linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus pbc ii hematopoietic prostaglandin duchenne muscular dystrophy hpgd synthase inhibitor gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical vaccine product development pipeline continue achieve regulatory review milestone compound type indication phase maa ndabla vaccine shingrix recombinant protein adjuvante herpe zoster prophylaxis immunocompromise submit dec zoster vaccine bexsero recombinant protein meningococcal b disease prophylaxis infant iii rotarix live attenuate pcv porcine circovirus rotavirus prophylaxis submit nov free mmr live attenuate measle mump rubella prophylaxis iii therapeutic recombinant protein adjuvante reduction frequency moderate severe ii copd acute exacerbation copd patient target nontypeable haemophilus influenzae moraxella catarrhalis malaria recombinant protein adjuvante malaria prophylaxis plasmodium falciparum ii generation fractional dose man abcwy recombinant protein conjugate meningococcal abcw disease prophylaxis ii adolescent menveo conjugate liquid formulation meningococcal acw disease prophylaxis ii adolescent shigella conjugate tetravalent outer shigella diarrhea prophylaxis ii membrane vesicle monovalent rsv replicationdefective recombinant respiratory syncytial virus prophylaxis paediatric ii viral vector population recombinant protein respiratory syncytial virus prophylaxis pregnant woman ii population prevent respiratory syncytial virus low respiratory tract illness infant month life transfer maternal antibodie recombinant protein adjuvante respiratory syncytial virus prophylaxis old adult iii population therapeutic hbv primeboost viral vector vaccine hepatitis b virus therapeutic functional elimination iii co sequentially administrate immune system mediate chronic infection adjuvante recombinant protein c difficile recombinant protein adjuvante active immunization prevention primary c diff disease prevention recurrence sam rabies model selfamplifye mrna rabie prophylaxis brand name appear italic trade mark own license gsk group company gsk annual report pipeline product competition continue pharmaceutical product competition intellectual property major patent expiry date product compound indication competitor brand eu respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere formulation formulation arnuity ellipta fluticasone furoate asthma qvar pulmicort asmanex alvesco nce nce device device formulation formulation avamysveramyst fluticasone furoate rhinitis nasonex flixotideflovent fluticasone propionate asthmacopd qvar singulair expire expire diskus device diskus device expire hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat eklira genuair nce nce seebri breezhaler device device formulation formulation nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair expire fasenra dupixent relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate flutiform dulera nce nce device device formulation formulation seretideadvair salmeterol xinafoate asthmacopd symbicort foster expire expire fluticasone propionate flutiform dulera diskus device diskus device expire hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate brextri aerosphere nce nce umeclidinium bromide device device formulation formulation ventolin hfa albuterol sulphate asthmacopd generic company expire hfadevice hfadevice antiviral valtrex valaciclovir genital herpe coldsore shingle famvir expire expire central nervous system lamictal lamotrigine epilepsy bipolar disorder keppra dilantin expire expire imigranimitrex sumatriptan migraine zomig maxalt relpax expire expire seroxatpaxil paroxetine depression anxiety effexor cymbalta expire expire disorder lexapro cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia proscar flomax expire expire finasteride antibacterial augmentin amoxicillinclavulanate common bacterial generic product na expire potassium infection oncology zejula niraparib ovarian cancer lynparza rubraca nce nce immunoinflammation benlysta benlysta sc belimumab systemic lupus erythematosus generic competition commence include supplementary protection certificate grant multiple country eu patent term extension grant data exclusivity expire eu gsk annual report strategic report governance remuneration financial statement investor information pipeline product competition continue pharmaceutical product competition intellectual property continue major patent expiry date product compound indication competitor brand eu hiv juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce selzentrycelsentri maraviroc hivaids isentress intelence prezista nce nce tivicay dolutegravir hivaid isentress prezista symtuza reyataz nce nce biktarvy triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce vaccine product competition intellectual property major patent expiry date product compound indication competitor brand eu bexsero meningococcal groupb meningitis group b prevention trumenba vaccine boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expire expire pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expire expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxeli cervarix hpv virus like human papilloma virus gardasil silgard particle vlp type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtype vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigen virus subtype fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis prepandrix derive split inactivated pandemic hn influenza aflunov vepacel influenza virus antigen prophylaxis adjuvant priorix priorix tetraab live attenuate measle mump measle mump rubella mmr ii mmrvaxpro expire expire varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugate pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis medium shingrix zoster vaccine herpe zoster zostavax recombinant adjuvante shingle note financial statement legal proceeding generic competition commence market include supplementary protection certificate grant multiple country eu patent term extension grant relate compoundsindication measle mump rubella vaccineprophylaxis b relate compound varicella vaccine gsk annual report pipeline product competition continue consumer healthcare product competition brand product application market competition wellness respiratory otrivin nasal spray nasal decongestant germany netherlands afrin bayer nasivin proctor norway russia sweden gamble tyzine johnson johnson theraflu hot liquids tablet syrup cold flu relief russia poland tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser flixonaseflonase nasal spray tablet allergy relief china uk ireland claritin bayer allegra sanofi piriton zyrtec johnson johnson nicorette lozenge gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm transdermal patch aid smoking reduction niquitin perrigo nicotinell cessation ex australia pain relief panadol tablet caplet infant paracetamolbase treatment global aspirin bayer panadol cold syrup drop headache joint pain fever tylenol johnson johnson flu cold symptom voltaren topical gel nonsteroidal diclofenac base global aspirin bayer antiinflammatory tylenol johnson johnson advil tablets caplets gel caplet ibuprofen base treatment canada brazil tylenol tylenol pm tylenol nonrespiratory liquid fill suspension drop headache toothache backache colombia mexico childrens motrin motrin range children menstrual cramp muscular children johnson johnson pain minor pain arthritis aleve aleve pm bayer advil respiratory tablet allergy relief cold flu tylenol cold flu johnson cold flu relief johnson lemsip mucinex advil respiratory reckit benckiser allergy eno effervescent immediate relief antacid global estomazil hypermarca gelusil tums chewable tablet immediate relief antacid alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi oral health sensodyne toothpaste toothbrushe relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protect colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste dailymedicate help stop prevent global colgate total gum health corsodyl mouthwash gel spray bleed gum treat colgatepalmolive prevent gingivitis oral b gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipe denture clean denture procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavity global colgate colgatepalmolive mouthwash maintain healthy tooth gum crest procter gamble fresh breath oralb procter gamble skin health zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicate patch onset cold sore carmex carma labs blistex blistex incorporate retail label chapstick lip balm protect moisturise prevent global blistex burt bee carmex soothe chap lip carma labs eos nivea beiersdorf vaseline unilever nutrition centrum tablet vitamin mineral global nutralite infinitus cheongkwan gummie supplementation jung byhealth nature herbalife swisse caltrate tablet gummie calcium supplement global citracal bayer oscal nature soft chew private label gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie principal risk discuss risk affect cost product development uncertaintie relevant business financial condition time require reach market likelihood result operation affect performance successfully uninterrupted basis ability achieve objective risk rule regulation change government interpretation believe cause actual result differ materially evolve business activity change nature expect historical result particular risk change change certain regulatory continue embed change risk regime substantial change failure management reporting cycle help identify manage comply applicable law regulation materially report important risk organisation adversely affect financial result consistent proportionate way complete similarly global business expose litigation enterprise risk plan important risk government investigation include limited product ensure business adopt adapt liability litigation patent antitrust litigation sale approval deploy confirmation marketing litigation litigation government investigation organisation reinforce leader accountability risk include related provision unfavourable management measure control set outcome increase related cost insurance enterprise risk plan implement gap premium materially adversely affect financial close evolve risk management process result introduce new report board focus datum key risk indicator lead well inform discussion detail status uncertainty risk exposure action need introduce new significant unresolved dispute potential litigation set approach annual risk review support cet decision note legal proceeding change require important risk uk regulation require discussion mitigation activity require comply broad range law company take address principal risk uncertainty regulation apply research development description principal risk manufacturing testing approval distribution sale summary activity manage risk marketing pharmaceutical vaccine consumer business principal risk uncertaintie healthcare product list order significance patient safety risk definition question safety product raise failure appropriately collect review follow report ongoing safety surveillance postmarkete human safety information hsi include adverse event study governmental agency party potential source act relevant finding analyse publicly available clinical trial result constant timely manner vigilance flexibility require order respond varied regulatory environment continue evolve diverge risk impact globally externally development datum interrogation present risk impact potential compromise ability potential benefit patient safety volume datum conduct robust safety signal detection interpretation analyse present significant challenge intensifie ensure appropriate decision take respect couple fragmented regulatory requirement privacy risk benefit profile product include completeness concern economic arena merger acquisition accuracy product label pursuit additional activity introduce datum integrity risk technology present study analyse appropriate additionally risk significant opportunity patient safety risk management potentially negatively impact ability incorporate verify create reliable datum interrogation tool accurate safety signal local country labelling lead data collection mechanism pace artificial potential harm patient reputational damage product liability intelligence development great claim litigation governmental investigation regulatory expect cyberattack evergrowe concern give action fine penalty loss product authorisation volume datum digital dependency context group currently defendant number product liability preclinical clinical trial conduct lawsuit include class action involve significant claim development investigational pharmaceutical vaccine damage relate product litigation particularly consumer healthcare product determine safety inherently unpredictable class action seek sweep efficacy product use human notwithstanding person product increase potential effort determine safety product liability claim pain suffer punitive damage appropriate preclinical clinical trial unanticipate frequently assert product liability action allow effect evident product widely represent potentially openende exposure introduce marketplace materially adversely affect group financial result gsk annual report principal risk uncertainty continue patient safety continue mitigate activity group product approve marketing chief medical officer cmo accountable extensive postmarkete surveillance signal detection patient safety enterprise risk authoritative role system information possible effect product evaluate addressing matter human safety cmo receive source include unsolicited report support enterprisewide safety governance board healthcare professional hcp patient regulatory provide oversight management control framework authority medical scientific literature traditional medium include risk management process product specific safety social medium governance board place ensure human safety information change riskbenefit profile address proactively product lifecycle product result certain action characterise business name medical officer subsidiary business communicate minimise risk propose action specific board provide oversight governance discuss regulatory authority include modify policy employee require report immediately prescribe information communication physician issue relate safety quality product healthcare provider restriction product prescribe country manager responsible monitoring exception availability help assure safe use carry tracking training helps assure collection safety clinical trial certain case appropriate information report information relevant central stop clinical trial withdraw medicine market safety department accordance policy legal implement organisational change create requirement flexible scalable fit purpose organisation meet change internal external demand invest system upgrade quality check reduce risk individual case safety report product quality risk definition technological development increasingly failure gsk contractor supplier ensure enhance manufacture support inclusion packaging feature help secure legitimate supply chain eg appropriate control governance quality product serialisation threat cyberattack remain key risk development integrity product quality datum audit trail compliance good manufacturing practice good significant change take place gsk implement distribution practice regulation commercial clinical new organisational alignment iptc strategy trial manufacture distribution activity change assess quality organisation ensure compliance term gsk product licence quality procedure governance facilitate support regulatory activity strategy whilst ensure unintended consequence risk impact increase product quality risk failure ensure product quality far reach mitigating activity implication term patient consumer safety delay extensive global network quality compliance launch product drug shortage product recall professional align business unit provide regulatory legal financial consequence oversight assist delivery quality performance materially adversely affect gsk reputation financial operational compliance site level senior management result level management oversight activity accomplish context hierarchy quality council external environment product quality continue independent chief product quality officer global product challenge single big change quality office provide oversight product quality risk political instability uncertainty surround delivery company brexit implication medicine supply continuity develop implement single quality mainland europe new set requirement management system define quality standard implement ema shortly system business associate pharmaceutical prepare quarter vaccine consumer healthcare product clinical trial new reporting requirement potential drug shortage material system broad scope applicable new regulation cover product lifecycle rd mature license medical device commercial supply augment consolidation numerous regulatory requirement define market world assure meet external expectation product quality market supply base internationally recognise principle ich q pharmaceutical quality system framework gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie continue product quality continue quality management system routinely update product incident committee process place ensure keep pace evolve external regulatory investigate product issue recommendation environment new scientific understanding remediation activity include necessary recall product process drive continually product marketplace order protect patient improve operational deployment quality management consumer complaint process place ensure system make policy procedure simple gsk respond product quality issue raise patient understand implement adopt innovative tool customer userfriendly experience staff member allegation noncompliance misconduct receive regularly train regulatory expectation learning formal informal speak channel review inspection current procedure ensure continue triaged independent function global disciplinary maintenance cgmp standard enforcement procedure apply breach implement riskbase approach assess standard initiate follow investigation manage party supplier provide material key risk indicator leverage support risk management finished product contract manufacturer make activity provide corporate executive team product expect comply gsk standard risk oversight compliance council integrate regularly audit provide assurance standard meet assessment product quality performance financial control report risk definition treasury group deal high value transaction failure comply current tax law incur significant foreign exchange cash management transaction loss treasury activity failure report accurate daily transaction involve market volatility financial information compliance accounting standard counterparty risk applicable legislation group effective tax rate reflect rate tax risk impact jurisdiction group operate high noncompliance exist new financial reporting low uk rate consider regime disclosure requirement change recognition income encourage innovation investment science provide expense expose litigation regulatory action tax incentive change affect group tax materially adversely affect financial result rate addition worldwide nature operation mean current period significant political uncertainty especially intellectual property rd manufacturing operation usa uk significant change short center key location consequence notice failure comply change substance crossborder supply route necessary ensure application govern law cover transfer pricing supply medicine numerous end market dividend tax credit intellectual property materially complex result conflict claim tax authority adversely affect financial result profit tax individual country tax legislation complex differ country significant loss arise inconsistent application operate tax risk arise difference treasury policy transactional settlement error interpretation legislation tax charge include counterparty default financial statement good estimate tax liability context pende audits tax authority group require law jurisdiction expect continue focus tax reform drive disclose publicly financial result event initiative organisation economic cooperation materially affect financial result group regulator development address taxation digital economy routinely review financial statement list company european commission initiative include use fiscal state compliance new revise exist accounting aid investigation domestic initiative regulatory requirement group believe complie world result significant change establish appropriate regulatory requirement concern tax principle increase tax authority dispute financial statement disclosure material information regardless merit outcome costly divert include transaction relate business restructure management attention adversely impact reputation acquisition divestiture subject relationship key stakeholder investigation potential noncompliance accounting disclosure requirement lead restatement previously report result significant penalty gsk annual report principal risk uncertainty continue financial control report continue mitigate activity counterparty exposure subject define limit approve financial result review approve regional board credit rating individual counterpartie management review financial controller oversight treasury role manage counterparty risk line chief financial officer cfo allow financial agree policy perform corporate compliance controller cfo assess evolution business officer operate independently treasury detail time evaluate performance plan significant mitigation treasury risk find page judgment review confirm senior management note financial instrument relate disclosure technical organisational transformation newly acquire tax risk manage robust internal policy process activity integrate risk assessment appropriate training compliance programme ensure control review apply alignment business meet tax obligation maintain control environment design identify material seek maintain open positive relationship error financial reporting disclosure design government tax authority worldwide welcome operating effectiveness key financial reporting control constructive debate taxation policy monitor government regularly review management test external debate tax policy key jurisdiction deal proactively party minimum standard control set place potential future change tax law engage finance location irrespective size review advisor legal counsel confirm implication management monitor independently provide business tax legislation appropriate active assurance control key financial reporting provide relevant business input tax policy maker disclosure process operate effectively global significant decision submit consideration finance risk management control centre excellence tax governance board meet quarterly comprise provide extra support significant transformation senior personnel gsk finance division system deployment managementstructural tax affair manage global basis reorganisation add operational resource ensure coordinated team tax professional lead global head process control maintain change tax work closely business tax professional additional risk mitigation introduce amend suitably qualified role perform support programme timeline system upgrade optimize delivery training need order continue able disclosure committee reporting board review provide date technical advice submit tax return group quarterly result annual report determine accord statutory time limit engage tax authority year consultation legal advisor seek ensure tax affair current enter necessary disclose publicly information arrangement continuous audit programme group stock exchange announcement advance pricing agreement appropriate uptodate late development financial reporting agreement provide longterm certainty tax authority requirement work external auditor legal tax treatment business exceptional advisor case matter settle agreement tax authority resolve dispute formal treasury management group meet regular basis appeal proceeding seek ensure liquidity interest rate counterparty foreign currency transaction foreign currency translation risk manage line conservative approach detail associate risk strategy policy adopt board antibribery corruption abac risk definition risk impact abac risk comprise subrisk area failure mitigate risk expose group associate persons governmental investigation regulatory bribery public official gsk action civil criminal liability compromise bribery commercial nonpublic entity gsk group ability supply product certain government bribery party act behalf gsk contract addition legal financial penalty failure prevent bribery comply abac legislation gsk employee receive andor request bribe andor regulation substantial implication reputation undue personal benefit company credibility senior leader erosion corruptionnoncompliance law regulation investor confidence governance risk management relate money launder facilitation tax evasion partiesclientspartner gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue antibribery corruption abac continue context abac programme build good class principle macro risk level remain unchanged continue subject ongoing review development provide legal framework similar uk develop emerge basis seek manage risk economy high standard expect individual example programme comprise corporation aid improve technology increase toplevel commitment board director enforcement leadership new data analytic programme create embe local key risk indicator enable target overall environment abac remain intervention risk management activity challenge divergence legislation make compliance hard country increasingly hold individual programme underpin global abac policy accountable corporation increase employer write standard address commercial duty care society hold corporation high practice rise abac risk addition standard technology provide speedy anonymous programme mandate enhance control interaction avenue dissemination previously privileged information government official business development damage false report enforcement action penalty transaction control abac policy establish increase globe focus use diligence requirement engagement party party intermediary supportive aspect new policy abac team continually work tpo team include latin america move compliance regime address improve control monitoring requirement like establish uk india engage party amendment corruption act explicitly provide mandatory periodic abac training staff make offence pay bribe china introduce relevant party accordance role significant antibribery anticorruptionlegislative responsibility risk face regulatory reform dedicate abac team responsible gsk exposure remain unchanged implementation evolution programme response mitigate activity development internal external environment programme governance provide enterprise risk example introduce global process management oversee abactpo governance board centrally document conflict interest coi employee include representation key functional area complementary worker support simple policy business joint board create ensure ensure collate report coi management strategic focus principle risk area organisation considerable codependency complement independent oversight enterprisewide abac programme design assurance undertake audit assurance ensure compliance abac policy mitigate risk independent business monitoring team issue identify bribery corruption build business standard oversight assurance exercise result value expectation form comprehensive practical investigation identify area specific approach compliance flexible evolve nature intervention market continuously improve business programme appropriate control place train continually benchmark abac programme awareness raise strong monitoring transaction large multinational company use external expertise payment party plan continue pre internal insight drive improvement programme posttransaction abac diligence increase capability formal informal speak channel available report business monitoring oversight red flag resolution misconduct noncompliance allegation noncompliance party review control accountability review triaged central investigation team government official continue understand assess allocate investigation appropriate moneylaundering risk exposure mitigate exist risk code conduct value expectation commitment zero tolerance integral mitigate risk light complexity geographic breadth risk constantly evolve oversight activity datum reinforce workforce clear expectation acceptable behaviour maintain regular communication centre local market gsk annual report principal risk uncertainty continue commercial practice risk definition promotion approve product seeks ensure hcp failure engage commercial activity consistent globally access information need patient letter spirit law industry group consumer access information product requirement relate marketing communication need product prescribe recommend medicine associate therapeutic area appropriate manner provide maximum healthcare benefit interaction healthcare professional hcp patient patient consumer commit communicate legitimate transparent transfer value information relate approve product responsible legal ethical manner risk impact failure manage risk relate commercial practice mitigate activity materially adversely affect ability deliver strategy strategic objective design ensure achieve longterm priority failure comply applicable law purpose help people feel well live long rule regulation result governmental investigation continue strive new product launch regulatory action legal proceeding bring competitive resource effectively strive group governmental private plaintiff result healthy proportion group sale ratio attributable new government sanction criminal andor financial penalty product innovation sale failure provide accurate complete information relate innovation help defray effect example product result incomplete awareness risk downward price pressure major market decline emerge benefit profile product possibly suboptimal market growth rapidly evolve digital landscape negative treatment patient consumer practice foreign exchange impact establish new product find misalign value result price balance expectation patient consumer reputational harm dilute trust establish external hcp payer shareholder community enable stakeholder maintain strong global business remain relevant context need patient consumer value behaviour continue evolve business operation include provide guide lead decision acquisition joint venture operate global basis constantly strive right thing deliver quality industry highly competitive highly regulate product ensure supply sustain meet customer competitor significant product innovation need demand requirement seek ensure action technical advance intensify price competition reflect value behaviour purpose company light competitive environment continue development take action enhance improve standard commercially viable new product development application datum analytic ecommerce channel additional use exist product reflect insight policy standard govern commercial help ensure product address need activity undertake behalf training patientsconsumer hcp payer critical achieve implement support evolution activity strategic objective relevant employee activity conduct worldwide pharmaceutical vaccine consumer company conform high ethical regulatory industry standard face downward price pressure major market decline local standard differ global standard emerge market growth rapidly evolve digital landscape stringent apply standard acquire negative foreign exchange impact company joint venture partner differ global standard expediently remediate legacy policy implement develop new pharmaceutical vaccine consumer revision gain alignment harmonised policy healthcare product costly lengthy uncertain procedure guide abovecountry commercial practice process product candidate fail stage include process clarify applicable standard significant economic human resource operation market operate invest competitor product pricing strategy business adopt internal control framework support failure develop commercially successful assessment management risk commercial product develop additional use exist product practice activity appropriate monitoring programme materially adversely affect ability achieve oversight business unit risk management compliance strategic objective board manage risk incountry business activity commit ethical responsible past fall commercialisation product support purpose regulatory industry standard seek improve improve quality human life enable people framework culture compliance process feel well live long accomplish purpose engage healthcare community way provide important information medicine gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue commercial practice continue promotional material activity review allow fair market value payment gsk approve accord policy standard expert practitioner speak innovative medicine conduct accordance local law regulation vaccine limited number country restrict seek ensure material activity fairly represent time period product lifecycle control training ensure product service group necessary appropriate oversight market report payment discipline include termination employee individual hcp commitment transparency engage misconduct claw remuneration responsible disclosure senior management event misconduct consumer healthcare develop digital risk plan change incentive programme support implementation robust control framework action pharmaceutical vaccine sale representative include development new write standard use tool well recognise reward individual effort specifically increase visibility control social medium presence specialty care cap variable pay element sale increase management monitoring representative compensation evaluate basis gsk commit comply applicable sanction individual sale target change implement law regulation deploy sanction uk canada july support programme design enable management sanction comprehensive training control monitor framework risk programme own finance comprise ensure implementation new programme fully align system control include limited policy gsk valuesbase approach hcp engagement procedure train awareness screen monitor risk report privacy risk definition mitigate activity failure collect secure use destroy personal chief compliance officer chairperson information pi accordance datum privacy law lead privacy governance board pgb oversee gsk harm individual gsk include fine operational overall datum privacy operating model business financial reputational risk function appoint risk owner accountable oversight privacy risks business functional area risk impact support privacy leader business noncompliance lead harm individual gsk function additionally countrie datum privacy law damage trust gsk individual require datum protection officer dpo appoint community business partner government authority gsk appoint single dpo european union general data protection regulation gdpr represent support specific country privacy legislation follow suit increase enforcement country privacy advisor chief compliance officer power supervisory authority include ability impose enterprise risk owner ero ero appoint fine suspend processing pi gdpr privacy delegate risk owner global privacy officer gpo law individual right bring collective legal accountability daytoday basis designing action gsk failure comply datum privacy law implement control framework gpo colead context crossfunctional privacy centre excellence coe datum privacy legislation diverse limited harmonisation global privacy counsel support privacy simplification despite europe adoption gdpr officer privacy counsel region multiple challenging multinational standardise approach country privacy advisor familiar local privacy compliance datum privacy law highlevel regulation local variation government enforce compliance gsk evolve initial control framework implement datum privacy law rigorously focus ethical use gdpr comprehensive privacy control framework base pi grow compliance datum privacy global privacy principle common local privacy law increase datum volume process law global framework deploy country advancement technology individual aware robust privacy legislation place come effect right datum privacy law soon strengthen local risk mitigation measure gsk annual report principal risk uncertainty continue privacy continue privacy centre excellence global ethic monitor continuously improve process compliance responsible improve control issue identification report handling framework ii implement control framework implement legislative scanning process detect outside european economic area iii remediate certain assess new privacy regulation early allow prepare exist business activity ensure compliance gdpr mitigate regulatory risk gsk privacy centre iv deploy comprehensive training programme drive excellence involve new business development great awareness accountability manage pi opportunity early stage ensure appropriate entire organisation key role privacy network diligence perform right step take gsk certify accredit international privacy onboarding split business unit association research practice risk definition integrity datum essential success stage research practice risk failure adequately conduct research datum lifecycle design generation record ethical sound preclinical clinical research addition management analysis report storage retrieval failure engage scientific activity research datum govern legislation regulatory consistent letter spirit law industry requirement research datum support document group requirement comprise follow sub core component stage pipeline progression risk nonclinical laboratory research human subject decisionmake form content regulatory research datum integrity care welfare treatment animal submission publication patent filing poor datum integrity human biological sample management datum disclosure compromise research effort negatively impact regulatory filing engagement scientific engagement company reputation intellectual property innate complexity interdependency require risk impact regulatory filing particularly give global research impact risk include harm human subject development footprint continually change increasingly reputational damage failure obtain necessary regulatory stringent submission requirement continue increase approval product governmental investigation legal complexity worldwide product registration continue proceeding bring group governmental supply gsk medicine patient dependent private plaintiff product liability suit claim damage ongoing compliance maintenance license loss revenue inadequate patent protection inability geography requirement timeline differ supply gsk product regulatory action fine secure management high volume lifecycle change penalty loss product authorisation license renewal critical enable compliant consequence materially adversely affect financial supply failure maintain license directly impact patient result cause loss trust customer patient company revenue context scientific engagement define interaction exchange research relate animal raise ethical concern information gsk external community case research animal method advance scientific medical understanding include investigate effect potential new appropriate development use product medicine live body human animal research essential scientific discourse nonpromotional provide critical information cause mechanism engagement external stakeholder group vital gsk disease remain vital research purpose necessary scientific medical advance continually seek way minimise use scientific engagement activity essential present legal animal research whilst comply regulatory regulatory reputational risk sharing datum invite requirement reduce impact animal medium coverage payment hcp perceive promotional intent clinical trial healthy volunteer patient assess demonstrate investigational product efficacy wide variety biological material gsk safety evaluate product discovery research development phase approve marketing work human biological convention biological diversity cbd nagoya sample sample fundamental discovery protocol international community establish global development safety monitoring product gsk framework regulate access use genetic resource commit ensure human biological sample nonhuman origin rd manage accordance relevant law regulation ethical principle manner respect interest sample donor gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue research practice continue support principle access benefit share global human biological sample management genetic resource outline cbd nagoya hbsm governance framework place oversee ethical protocol recognise importance appropriate effective lawful acquisition management human biological proportionate implementation measure national sample hbsm enterprise risk management team work regional level minimise risk relate acquisition storage use transfer disposal hbs patent right award protect innovation play important role provide gsk competitive advantage remain important priority enhance datum integrity market limited period time loss patent control datum integrity committee place provide protection market gsk product develop oversight datum integrity quality assurance team conduct rd include reduce term availability scope assessment provide independent business monitoring patent right materially adversely affect financial internal control rd activity result market absence adequate patent datum regulatory governance board serve global exclusivity protection lead example regulatory risk management compliance board promote competition manufacturer generic biosimilar compliance regulatory requirement procedure pharmaceutical product limit opportunity rely oversee groupwide write standard cross business market future sale growth product regulatory process significant program progress materially adversely impact financial result transform regulatory information management system follow expiration certain intellectual property right replace modernise information system crossenterprise generic biosimilar manufacturer lawfully produce establish access benefit sharing centre generic version product introduction generic product excellence oversee applicable requirement enforcement typically lead rapid dramatic loss sale reduce measure acquisition use genetic material revenue margin proprietary product nonhuman origin scope nagoya protocol mitigating activity rd maintain control prepublication procedure establish office animal welfare ethic guard public disclosure advance filing patent strategy oawes lead chief veterinary officer application addition loss patent protection support humane responsible care animal share occur lack datum integrity prepare patent knowledge advocate application nonanimal application datum information legal expert collaborate alternative oawes provide framework animal rd support review process new patent application welfare governance promote application rs replacement refinement reduction animal research conduct research practice risk oversee enterprise quality assessment manage program external animal framework seeks ensure strengthen governance diligence develop deploy strategy rd business pharmaceutical vaccine reproducibility translatability consumer healthcare chief medical officer oversee follow enterprise leadership research practice enterprise medical governance board risk owner management risk take pragmatic approach information sharing streamline risk identification human subject research board place provide escalation ensure ownership stay oversight human subject research sponsor business support ensure conform ethical medical scientific standard datum disclosure board provide oversight disclosure sponsor support human subject research information available clinical study include summary result positive negative company publish clinical study report form basis submission regulatory agency publicly post clinical study report addition study result summarie specific accountability authorisation scientific engagement oversee scientific engagement promotional practice board board responsible oversight applicable policy seek ensure high level integrity continuous development scientific engagement gsk annual report principal risk uncertainty continue party oversight tpo risk definition enterprisewide tpo programme take enterprisewide risk party fail meet contractual view party relate risk ensure compliance regulatory ethical obligation result significant abac policy additional risk labour right operational reputational legal financial risk gsk health safety human safety information form case employee directly comprehensive practical approach party oversight flexible evolve nature business simply risk party fail deliver type engagement manage programme good service expect fail deliver legal design govern global ethic compliant way compliance organisation globally deploy risk impact operational service assist business completion failure adequately manage party relationship assessment transition global procurement early result business disruption exposure risk range bring close core procurement process suboptimal contractual term condition severe tpo strengthen risk assessment contractual term business legal sanction andor significant reputational diligence effort party improve overall damage consequence materially management party risk lifecycle adversely affect business operation financial result party engagement context dedicate tpo team responsible party critical business delivery implementation evolution programme response integral solution meeting business objective development internal external environment rely party include supplier advisor programme governance provide enterprise risk distributor individual contractor license management oversee abac tpo governance pharmaceutical biotechnology collaboration partner board include representation key functional area discovery manufacture marketing product business joint board create support important business process ensure strategic focus principle risk area business relationship present material risk considerable codependency example example share critical sensitive information new abac conflict interest tool well protect marketing plan clinical datum employee datum specific gsk work party global ethic party conduct relevant outsourced compliance work global procurement legal business activity inadequate protection misuse tech organisation plan simplification order information party significant business maintain oversight reduce complexity business impact similarly use distributor agent range business leadership team retain ultimate accountability activity promotion tender inherent manage party interaction risk work risk inappropriate promotion corruption insufficient party employee expect manage internal compliance control distributor affect external interaction commitment responsibly reputation risk increase expectation embed value code conduct complexity work large number party responsibility activity carry behalf diverse geographical spread perform safely compliance applicable law mitigate activity value expectation standard code conduct guide enforce global principle interaction abac report party global policy framework applicable programme complement independent oversight buy good service manage external spend assurance undertake audit assurance pay work party policy framework independent business monitoring team review tpo apply employee complementary worker programme large multinational company use worldwide external expertise internal insight drive improvement programme gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertaintie continue environment health safety sustainability ehss risk definition mitigate activity failure management corporate executive team cet responsible ehss governance risk oversight ensure effective execution hazardous activity control framework place use manage risk gsk physical asset infrastructure impact legal compliance issue relate ehss handling process hazardous chemical business include assign biological agent responsibility senior manager provide maintain control ensure tiere monitor control release substance harmful environment governance process place business short long term lead incident individual manager seek ensure ehss control disrupt rd supply activity harm employee framework effective implement respective harm community operate harm business area fully compliant applicable environment longerterm sustainability law regulation adequately resource maintain risk impact communicate monitor additionally employee failure manage ehss risk lead significant harm personally responsible ensure applicable local people environment community operate standard operating procedure follow fine failure meet stakeholder expectation regulatory expect responsibility ehss matter requirement litigation regulatory action damage riskbase proactive approach articulate global group reputation materially adversely affect ehss policy detailed global ehss standard financial result audit operation ensure compliance context ensure hazards appropriately control safe gsk subject health safety environmental law design facility plant equipment follow jurisdiction law impose duty protect rigorous procedure help provide effective barrier people environment community protect employee health wellbee operate potential obligation remediate control antibiotic emission manufacturing effluent contaminate site overall control framework manage increase concern number stakeholder form ehss risk effective frequency event wide concern amr antimicrobial similar peer low high hazard industry resistance address ensure eg petrochemical manufacture facility supplier follow good operational practice meeting emission limit define amr alliance manufacturing framework year assessment business resilience climate change task force climate relate financial disclosure tcfd framework guideline identify fundamental risk overall business gsk annual report principal risk uncertainty continue information security risk definition mitigate activity risk unauthorised disclosure theft unavailability global information security policy accompany corruption gsk information key information system information technology standard process lead harm patient workforce customer support dedicated team programme activity disruption business andor loss commercial gsk technology security risk function provide strategic advantage damage reputation regulatory strategy direction oversight include active monitoring sanction cybersecurity enhance global information security capability ongoing programme investment risk impact follow mitigation activity represent significant failure adequately protect critical sensitive system investment past year continue information result loss commercial strategic improve come year advantage materially affect ongoing business operation scientific research clinical trial engage external expertise generation tool fully manufacture supply chain activity map inventory ot environment enable high confidence real time snapshot connect device inadequately apply control expect network improve patch timeframe gsk result regulatory fine present reputational system month weeksday risk organisation site technology refresh plan approve context underway gsk substantial site rely critical sensitive system datum corporate strategic plan intellectual property manufacturing significant upgrade tool fund progressing system trade secret potential focus key control area computer system information expose misuse gsk core information technology organisation information unauthorised disclosure security organisation business unit work gsk operate highly connect information network validate critical app datum store ensure expose confidential research development adequate backup restore capability manufacture commercial workforce financial datum new unified security standard approve risk external attack gsk digital data analytic site operational technology security office strategy substantially increase business establish ciso tool extend dependency digital asset distribute datum deployment ot programme increase number asset potentially impact cyberattack threat evolve provide broad deployment new tool prioritise deployment plan assurance significant effort deliver identity access management fully resource protection monitoring system information move speed address financial manufacturing successful prevent compromise disruption system priority continue cybersecurity loss increasingly involve highlyresource balance system come year organise threat actor nationstate online plan enhancement thirdparty practice criminal collective target gsk large complex automate visibility security critical vendor information technology operational technology ot establish process footprint system supply chain partner team dedicate solely secure system datum include outsourced operation mean system expansion growth market eg china information continue target form overseen ciso cyberattack additionally extensive use party store process datum increase gsk reliance supplier operate effectively dependence increase complexity security control practice reduce gsk ability monitor control effectively investigate respond incident involve gsk information system gsk stand ready address cybersecurity incident risk occur past year gsk experience material cybersecurity incident resulted substantial harm gsk eg injury reputation financial performance customer vendor relationship gsk annual report strategic report governance remuneration financial statement investor information principal risk uncertainty continue supply continuity risk definition mitigate activity failure deliver continuous supply compliant finished supply chain model adopt pharmaceutical vaccine product inability respond effectively crisis incident consumer healthcare business unit design ensure timely manner recover sustain critical operation supply quality security product globally far possible risk impact recognise failure supply product adversely supply chain governance committee business impact consumer patient rely material unit closely monitor inventory status delivery interruption supply exclusion healthcare programme product aim ensure customer expose litigation regulatory action financial product need improved link commercial penalty adversely affect group financial forecasting manufacturing possible core result group international operation commercial cycle time reduce risk associate partner expose workforce facility operation demand fluctuation impact ability supply information technology potential disruption natural cost writeoff product exceed expiry event eg storm earthquake manmade event eg trading date node supply chain periodically barrier impose short notice civilpolitical unrest terrorism review ensure adequate safety stock balance global emergencies eg coronavirus outbreak ebola work capital endtoend supply chain particular outbreak flu pandemic important robust attention place mitigate supply risk associate crisis management recovery plan place manage medically critical highrevenue product event routinely monitor compliance manufacture external context supplier service provider identify manage risk supply chain operation subject review approval supply base practical minimise dependence regulatory agency effectively provide single source supply critical item alternative license operate failure manufacturing distribution source arrangement possible certain material facility supplier key service material lead inventory strategy aim limit impact ultimately litigation regulatory action product recall protect supply chain unanticipated disruption seizure interruption supply delay approval new continue implement anticounterfeit system product suspension manufacturing operation pende product serialisation accordance new emerge resolution manufacture logistic issue supply chain requirement world eu rely material service provide party falsify medicine regulation supplier product include active pharmaceutical corporate policy require business functional area ingredient antigen intermediate commodity head ensure effective crisis management business component development manufacture packaging continuity plan place include authorise response pharmaceutical vaccine consumer healthcare recovery strategy key area responsibility clear product thirdparty service procure communication route business disruption occur service provide contract manufacturing clinical corporate security support business coordinate research organisation support development key product crisis management business continuity training facilitate important ensure continuous operation business simulation exercise assess preparedness recovery undertake risk mitigation recognise certain capability provide assurance oversight central event result delay service repository plan support critical business process interruption use effective crisis management business business unit perform risk oversight continuity planning provide health safety respective risk management compliance board rmcb people minimise impact maintain functional assure adequate risk mitigation include identify new operation follow natural manmade disaster public emerge threat example take coordinated health emergency approach evaluate manage implication business arise brexit activity help ensure appropriate level readiness response capability maintain develop maintain partnership external body like business continuity institute un international strategy disaster risk reduction help improve business continuity initiative disasterprone area support development community resilience disaster gsk annual report shareholder information share capital control detail issue share capital number share interest voting right hold treasury december found state far aware note financial statement share capital share person significant direct indirect holding premium account company information provide company pursuant financial conduct authoritys disclosure guidance ordinary share list london stock exchange transparency rule dtr publish regulatory quote new york stock exchange nyse information service company website form american depositary share ad ad wwwgskcom represent ordinary share detail list debt list refer note financial statement company receive notification accordance net debt dtr follow notifiable interest voting right company issue share capital holder ordinary share ad entitle receive dividend declare company annual report december february attend speak general meeting company percentage percentage appoint proxy exercise voting right total voting total voting voting right right voting right right restriction transfer limitation blackrock inc hold ordinary share ad requirement c omprise indirect interest ordinary share obtain approval prior transfer ordinary share hold qualify financial instrument cfd ad carry special right regard control p ercentage total voting right date notification company company restriction vote right major company acquire disposed interest shareholder voting right share share period review shareholder know arrangement exception transfer treasury satisfy awards financial right hold person holder group employee share plan share know agreement restriction share transfer voting right share buyback programme board authorise issue allot ordinary share acquire group employee share plan share article company article association rank equally share issue special power article authority company right trustees employee share ownership plan purchase share subject shareholder trust waive right dividend share hold authority seek annual basis annual trust general meeting agm share purchase exchange control limitation affect security company cancel hold treasury share holder satisfy share option grant group certain economic sanction employee share plan force time time currently applicable law programme cover purchase share cancellation decree regulation force uk restrict import hold treasury share accordance export capital restrict remittance dividend authority renew shareholder agm payment holder company share company authorise purchase maximum nonresident uk similarly certain economic million share detail share purchase sanction force time time cancel hold treasury share limitation relate nonresident uk english subsequently transfer treasury satisfy awards law company article association right group employee share plan disclose holder vote respect company share note financial statement share capital share premium account determine specific share repurchase level company consider development free cash flow year share purchase company confirm currently intend market purchase company review potential future share buyback line usual annual cycle subject return rating criterion gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue share capital control continue market capitalisation uk market capitalisation base share issue exclude treasury share gsk december billion date gsk th large company market capitalisation ftse index share price january december increasedecrease high year low year table set middle market closing price company share price increase uk share price uk ad price compares increase ftse index year middle market closing share price february nature trading market follow table set period indicate high low middle market closing price penny company share london stock exchange high low closing price dollar company ad nyse ordinary share ad pence share dollar share high low high low february january december november october september quarter end december quarter end september quarter end june quarter end march quarter end december quarter end september quarter end june quarter end march year end december year end december year end december year end december year end december year end december february gsk annual report shareholder information continue analysis shareholding december number total total number account account share share hold share hold nominee company investment trust company insurance company individual corporate body guaranty nominee limit hold treasury share glaxosmithkline effective july jp morgan chase bank na appoint successor depositary company american depository receipt adr programme company ad list nyse ordinary share represent company adr programme manage depositary register guaranty nominee limit february guaranty nominee limit hold ordinary share represent issue share capital exclude treasury share date february number holder ordinary share holding ordinary share number register holder ad holding ad certain ordinary share ad hold broker nominee result number holder record register holder representative number beneficial holder residence beneficial holder dividend company pay dividend quarterly continue return board intend maintain dividend cash shareholder dividend policy dividend current level p share subject material change remain essential component total shareholder return external environment performance expectation gsk recognise importance dividend shareholder time free cash flow strengthen intends build free cash company aim distribute regular dividend payment flow cover annual dividend target range determine primarily reference free cash flow x return dividend growth detail generate business funding investment dividend declare amount payment date necessary support group future growth give note financial statement dividend dividend share dividend calendar table set dividend share ad exdividend year dividend ad translate quarter date record date payment date q february february april dollars applicable exchange rate q july year dividend pence q august august october q november november january q february february april special q ordinary dividend receivable ad holder calculate base exchange rate april annual fee ad ad quarter charge depository cumulative dividend receivable ad holder q q q special dividend relate return net cash proceed novartis transaction complete march pay fourth quarter ordinary dividend gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue financial calendar result announcement event date result announcement issue london stock quarter result announcement april exchange available news service annual general meeting send securities exchange commission quarter result announcement july nyse issue medium available website quarter result announcement october preliminaryquarter result announcement february financial report annual report publication februarymarch company publish annual report annual report distribution march available website date publication shareholder elect receive notification email information company include share ad publication annual report register price available website wwwgskcom information wwwshareviewcouk elect receive available website constitute print copy annual report contact registrar annual report equiniti limited copy previous annual report available website print copy obtain registrar contact detail annual general meeting annual general meeting agm hold pm ad holder wish attend meet contact uk time wednesday sofitel london depositary jp morgan chase bank na request heathrow terminal london heathrow airport tw gd proxy appointment contact detail enable attend vote business agm company principal forum communication transact ad holder remind private shareholder addition formal business instruct depositary way share presentation ceo performance represent ad vote complete group future development return voting card provide depositary opportunity question ask board chair share vote board committee workforce engagement director question relate role document display investor hold share nominee service article association company director arrange nominee service appoint proxy service contract applicable letter appointment respect shareholding order attend vote director company subsidiary meet letter relate severance term pension arrangement available inspection company register office available inspection agm gsk annual report shareholder information continue tax information shareholder summary certain uk tax federal income tax corporation taxpayer entitle indexation consequence holder share ad citizen allowance apply reduce capital gain extent uk set complete gain arise inflation indexation allowance analysis possible tax consequence purchase reduce chargeable gain create allowable loss ownership sale security intend asset acquire january legislation general guide holder advise consult adviser finance act freeze level indexation allowance respect tax consequence purchase ownership give calculate company chargeable gain sale share ad consequence state value apply disposal asset december local tax law implication current asset acquire january onwards ukus tax convention legislation finance act remove indexation allowance disposal holder ad generally treat owner underlie share purpose current usuk inheritance tax double taxation convention relate income gain individual ukdomicile shareholder income tax convention estate gift taxis estate gift liable uk inheritance tax transfer share ad tax convention purpose internal revenue tax charge value code amend shareholders estate reduce result transfer way lifetime gift disposal market uk shareholder value case bequ death tax charge summary apply uk resident shareholder value share date shareholder death hold share capital asset gift disposal subject uk taxation dividend inheritance tax estate gift tax estate gift tax uk year uk resident individual convention generally provide tax pay entitle dividend tax allowance credit tax payable uk dividend receive tax year free stamp duty stamp duty reserve tax tax dividend excess allowance tax uk stamp duty andor stamp duty reserve tax sdrt basic rate taxpayer high rate taxpayer subject certain exemption payable transfer additional rate taxpayer share rate round near uk resident shareholder corporation taxpayer case stamp duty consideration transfer note dividend payable ordinary share generally notwithstanding provide instrument execute entitle exemption corporation tax pursuance agreement give rise charge sdrt instrument stamp year taxation capital gain agreement include stamp exempt sdrt uk resident shareholder liable uk tax gain charge cancel sdrt disposal share ad pay repay disposal individual uk tax year taxable capital gain accrue disposal share ad shareholder tax basic rate taxpayer summary apply shareholder citizen allowable deduction individual taxable income resident domestic corporation person year exceed basic rate income tax limit note subject federal income tax net income follow use exemption available individual basis respect share ad hold share ad taxpayer annual exempt capital asset resident uk uk tax purpose hold share purpose trade profession vocation carry uk branch agency summary address tax treatment holder subject special tax rule bank taxexempt entity insurance company dealer security currency person hold share ad integrate investment include straddle comprise share ad position person directly indirectly company stock vote value address tax treatment applicable result international income tax treaty gsk annual report strategic report governance remuneration financial statement investor information shareholder information continue tax information shareholder continue taxation dividend taxation capital gain gross dividend receive treat foreign generally holder subject uk capital gain source dividend income tax purpose eligible tax subject tax capital gain realise dividend receive deduction allow corporation sale disposal share ad gain dividend ad payable dollar dividend longterm capital gain subject reduce rate taxation ordinary share payable sterling dividend pay individual holder share ad hold sterling include income dollar year date share vestedrelease calculate reference exchange rate day shortterm capital gain subject taxation rate dividend receive holder subject certain longterm capital gain subject exception shortterm hedge position individual rate state local tax rate capital gain eligible holder subject taxation maximum apply federal rate plus applicable state local tax information report backup withholding respect qualified dividend qualified dividend define dividend payment proceed sale share internal revenue service irs dividend ad pay certain usrelated financial meet follow criterion intermediary subject information reporting ust issue corporation corporation subject backup withholding holder incorporate possession corporation corporation exempt recipient provide taxpayer eligible benefit comprehensive income tax treaty identification number certifie loss exemption deem satisfactory publish irs occur nonus holder generally subject dividend list irs dividend information report backup withholding qualify require provide certification nonus status connection payment receive amount withhold require dividend hold period meet allow refund credit holder federal share own day income tax liability provide require information furnish hold period define day irs period begin day exdividend date day stock trade dividend price estate gift taxis example stock exdividend date october estate gift tax convention shareholder share hold day period generally subject uk inheritance tax august november year order capital shareholder subject estate gift tax count qualified dividend stamp duty dividend qualified subject taxation uk stamp duty andor sdrt subject certain exemption federal graduate tax rate maximum rate payable transfer share ad custodian type dividend automatically exclude depository rate consideration qualified dividend meet requirement provide transfer sale value transfer include limited consideration capital gain distribution stamp duty sdrt payable dividend bank deposit transfer agreement transfer ad ividend hold corporation employee stock ownership plan esop dividend pay taxexempt corporation state local tax rate qualify nonqualified dividend vary assess addition federal tax rate communicate gsk annual report statutory disclosure shareholder service contact registrar company registrar equiniti limited aspect house spencer road lance bn da wwwshareviewcouk tel uk tel outside uk equiniti provide range service shareholder service offer participate dividend reinvestment plan alternative receive cash dividend choose drip election form download drip reinvest dividend buy gsk share wwwshareviewcouk request contact equiniti dividend payment direct bank april gsk cease pay dividend cheque dividend bank mandate form account bank mandate dividend pay directly bank building download wwwshareviewcouk society account receive cash dividend request contact equiniti provide equiniti bank building society account detail quick secure method payment avoid risk cheque go astray dividend payment direct bank april gsk cease pay dividend cheque detail service cost account overseas shareholder instead equiniti convert dividend local involve contact equiniti currency send direct local bank account service available country worldwide electronic communication shareholder elect receive electronic notification register wwwshareviewcouk company communication include annual report dividend payment dividend confirmation availability online vote general meeting time gsk mail hard copy shareholder document receive email contain link document relevant website shareview portfolio service enable create free online portfolio view register wwwshareviewcouk share balance movement update address dividend payment instruction register vote general meeting deduplication publication mailing receive duplicate copy mailing contact equiniti account contact equiniti arrange account merge convenience avoid waste unnecessary cost share deal service shareholder trade share hold certificate online transaction log note market trading hour form hold corporate sponsor nominee online wwwshareviewcoukdeale pm uk time telephone postal dealing service provide equiniti telephone transaction monday friday exclude public financial service limit uk holiday england wale outside uk postal transaction request deal form corporate sponsor nominee account convenient way manage share require application form request share certificate service provide facility hold wwwshareviewcouk share nominee account sponsor company contact equiniti continue receive dividend payment annual report attend vote company general meeting shareholder name appear publicly available share register service free join individual saving account isas company arrange equiniti financial service detail available wwwshareviewcouk limited provide gsk corporate isa hold gsk share request telephone equiniti line open pm deal pm enquiry monday friday exclude public holiday england wale lline open pm monday friday exclude public holiday england wale provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue shareholder service contact continue ad depositary contact adr programme administer jp morgan investor relation chase bank na investor relation contact follow regular correspondence uk eq shareowner services great west road po box brentford middlesex tw gs st paul mn tel delivery stock certificate overnight mail eq shareowner services crescent drive centre point curve suite philadelphia pa mendota heights mn tel toll free wwwshareowneronlinecom tel outside general gsk response center outside tel toll free depository provide global invest direct direct share scam alert ad purchasesale dividend reinvestment plan ad receive unsolicited telephone offering sell buy holder detail enrol visit wwwadrcom share extra care caller helpline number obtain enrolment pack highly organise financial scam glaxo wellcome smithkline beecham uk shareholder contact financial corporate pep conduct authority wwwfcaorgukconsumer share centre limited consumer helpline oxford house oxford road aylesbury buck hp sz tel tel uk wwwsharecom tel outside uk donate share save child line open pm uk time monday friday uk public holidays pm saturdays gsk embark ambitious global partnership save child share expertise resource aim help save live million child shareholder small number share value make uneconomical sell wish consider donate save child donate share aggregate sell save child use fund raise help reach goal obtain share donation form contact registrar equiniti manage donation sale uk share save child free charge provision share deal detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser gsk annual report statutory disclosure continue law regulation number provision law regulation apply section corporate responsibility company share quote nyse financial report form ad sarbanesoxley require ceo cfo complete formal certification confirm nyse rule general nyse rules permit company follow uk review annual report form f corporate governance practice instead apply base knowledge annual report form f provide explain significant variation contain material misstatement omission explanation contain form f base knowledge financial statement access security exchange commission financial information fairly present material respect sec edgar database website nyse rule require financial condition result operation cash flow file annual interim write affirmation concern date period present annual report audit risk committee arc statement significant form f difference corporate governance responsible establish maintain sarbanesoxley act disclosure control procedure ensure material follow number corporate accounting scandal information know evaluate congress pass sarbanesoxley act effectiveness control procedure year sarbanesoxley wideranging piece legislation end result evaluation contain concerned largely financial report corporate annual report form f governance responsible establish maintain internal recommend sec company establish control financial reporting provide reasonable disclosure committee committee report ceo assurance reliability financial reporting cfo arc chair company secretary preparation financial statement external purpose member consist senior manager finance legal accordance generally accept accounting principle corporate communication investor relation disclose annual report form f external legal counsel external auditor internal expert change internal control financial reporting invite attend disclosure committee meeting period cover annual report form f periodically committee responsibility consider materially affect reasonably likely affect materially materiality information timely basis determine company internal control financial reporting disclosure information responsibility disclose base recent evaluation timely filing report sec formal review internal control financial report external auditor annual report form f committee meet arc significant deficiency material time weaknesse design operation internal control sarbanesoxley require annual report form f financial reporting reasonably likely affect contain statement member arc adversely company ability record process audit committee financial expert define rule summarise report financial information fraud sarbanesoxley statement relevant member regardless materiality involve person arc judy lewent include arc report significant role company internal control financial biography additional disclosure reporting requirement arise section section group carry evaluation supervision sarbanesoxley respect disclosure control participation management include ceo procedure internal control financial reporting cfo effectiveness design operation group disclosure control procedure december inherent limitation effectiveness system disclosure control procedure include possibility human error circumvention override control procedure accordingly effective disclosure control procedure provide reasonable assurance achieve control objective gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue law regulation continue ceo cfo expect complete certification group export certain pharmaceutical vaccine report conclusion effectiveness disclosure consumer product iran sale nonus entity control procedure march follow subsidiary entity privately hold iranian certification file sec group distributor form f group regularly receive information section management annual report internal identity distributor downstream customer control financial reporting intermediary iran possible party accordance requirement section include entity governmentowne hospital sarbanesoxley follow report provide pharmacy own directly indirectly iranian management respect company internal control government person entity sanction connection financial reporting define rule af df terrorism proliferation activity group understand securities exchange act amend subdistributor group privately hold exchange act distributor iran previously sell group medicine entity property block pursuant executive order management responsible establish maintain consequence indirect ownership structure adequate internal control financial reporting learn subdistributor potential ownership group internal control financial reporting design structure group require distributor iran terminate provide reasonable assurance reliability relevant subdistributor financial reporting preparation financial statement external purpose accordance ifrs group regularly receive information identity distributor downstream customer management conduct evaluation effectiveness establish proportion gross revenue sale internal control financial reporting base potentially attributable entity affiliate iranian framework internal control integrate framework government party sanction disclosable activity issue committee sponsor organisation result group report entire gross revenue treadway commission coso million net loss million group change group internal control sale iran financial reporting materially group aware hospital medical affect reasonably likely affect materially facility lebanon affiliate control group internal control financial report hezbollah group designate united management assess effectiveness internal state pursuant executive order group control financial reporting december deal directly hospital facility sell conclusion file group form distributor group unable establish f proportion gross revenue sale potentially attributable reportable activity result group reporting deloitte llp audit consolidated financial entire gross revenue million net profit statement group year end december million group sale lebanon assess effectiveness group internal control financial reporting auditing note group intend continue activity standard public company accounting oversight describe board united states audit report file addition section r exchange act law group form f generally restrict dealing person dealing section r exchange act subject jurisdiction certain country territory subject comprehensive sanction currently section r exchange act require issuer crimea cuba iran north korea syria specific disclosure annual report certain type government venezuela country dealing iran include transaction dealing venezuela group business nonus governmentowne entity dealing entity entity own control entity sanction activity relate terrorism proliferation certain jurisdiction believe group complie weapon mass destruction activity applicable sanction material respect prohibit law involve person law complex continue evolve rapidly gsk annual report statutory disclosure continue donation political organisation political expenditure ensure consistent approach political contribution result definition cover legitimate business group global policy introduce activity ordinary sense consider political voluntarily stop corporate political contribution donation political expenditure design support political party independent election candidate period january december group political donation eu notwithstanding policy noneu organisation intend donation eu political party organisation incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act continue expenditure support employeeoperate political action committee pac facilitate voluntary political donation eligible authority precautionary measure ensure gsk employee company subsidiary inadvertently breach legislation pac control gsk decision amount recipient contribution authorisation process expenditure participate employee exercise legal right pool year date agm hold follow resource political contribution introduction political party election subject strict limitation total referendum act authority donate political organisation renew annually gsk employee pac english law require prior shareholder approval political contribution eu political party independent election candidate eu political expenditure definition political donation political expenditure political organisation legislation broad particular definition eu political organisation extend body concern policy review law reform representation business community special interest group concern environment company subsidiary wish support gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company accordance section company act list subsidiary associate joint venture joint arrangement address register office effective percentage equity own december disclose state share capital disclose comprise ordinary share indirectly hold glaxosmithkline plc percentage hold class share state state subsidiary company register office tax resident country incorporation security register address wholly own subsidiary alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limit ordinary great west road brentford middlesex tw gs england adechsa gmbh ii ordinary co prv provide treuhandgesellschaft ag dorfstrasse baar switzerland affymax research institute common corporation service company gateway oak drive suite n sacramento california united states alenfarma especialidades farmaceuticas limitada ii ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal allen hanbury limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria barrier therapeutics inc common corporation service company little fall drive wilmington delaware united states beecham group plc p shares p share b great west road brentford middlesex tw gs england beecham pharmaceutical pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaproduto farmaceuticos e quimicos lda ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal beecham sa ii ordinary parc de la noire epine rue fleming wavre belgium biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey burrough wellcome co bangladesh limited ordinary sweden tower harinnachala konabari gazipur bangladesh cascan gmbh co kg partnership capital industriestrasse bad oldesloe germany castleton investment ltd iv ordinary co dtos cybercity th floor standard charter tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome therapeutics inc ii common corporation service company little fall drive wilmington delaware united states cellzome inc common corporation service company little fall drive wilmington series preferred delaware united states series b prefer series c convertible prefer series c convertible prefer charles midgley limited ii ordinary cumulative preference great west road brentford middlesex tw gs england clarge pharmaceutical trustee limited ii iv ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little fall drive wilmington delaware united states corixa corporation common corporation service company little fall drive wilmington delaware united states coulter pharmaceutical inc ii common corporation service company little fall drive wilmington delaware united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energia solar alternativa sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain duncan flockhart australia pty limited ii iv ordinary mountain highway boronia vic australia etex farmaceutica ltda social capital avenue andre bello piso las conde santiago cp chile fipar thailand ltd liquidation ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand genelabs technologies inc common corporation service company gateway oak drive suite n sacramento california united states glaxo group limit ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxo laboratory limited ii ordinary great west road brentford middlesex tw gs england gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxo new zealand pension plan trustee limited ordinary level zurich house queen street auckland new zealand glaxo operation uk limit ordinary great west road brentford middlesex tw gs england glaxo property bv ordinary huis ter heideweg lz zeist netherlands glaxo trustees limited ii iv ordinary great west road brentford middlesex tw gs england glaxo verwaltung gmbh ordinary industriestrasse bad oldesloe germany glaxo wellcome australia pty ltd ii iv ordinary mountain highway boronia vic australia glaxo wellcome farmaceutica limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxo wellcome international bv ii iii ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production sas ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgo spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited ii ordinary creek road apapa lago pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmaceuticos limitada ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal glaxosmithkline cambodia co ltd liquidation ordinary th floor dksh building preah monivong boulevard corner street sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room building ocean international center mid th east ring road bejing chaoyang district china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center th th floor zone district bucharest romania glaxosmithkline ireland limited vii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limit ordinary floor de la cruz avenue qormi qrm malta glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline aebe ordinary kifissias avenue halandri athens greece glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada iv quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aire caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline asia pvt limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia vic australia glaxosmithkline bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline beteiligung gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biological shanghai ltd ordinary niudun road china shanghai pilot free trade zone glaxosmithkline biological kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biological sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biological sa ordinary preference rue de b rixensart belgium glaxosmithkline brasil limitada quotas estrada do bandeirante rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andre bello piso las conde santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare investment ireland ordinary knockbrack dungarvan co waterford x ry ireland limited iii iv gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline consumer healthcare ireland ip limited iii iv ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline consumer hold bv ii ordinary huis ter heideweg lz zeist netherlands glaxosmithkline doo quota zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline el salvador sa de cv ordinary avenida el boqueron calle izalco parque industrial el boqueron santa elen antiguo custatlan la libertad el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limit ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary novena avenida zona guatemala city guatemala glaxosmithkline hold ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington delaware united states glaxosmithkline holdings ireland limited ordinary defer great west road brentford middlesex tw gs england glaxosmithkline holding limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holding limit ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limit ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common class c preference mississauga road north mississauga ln l canada glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holding limit ordinary b ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limit ordinary defer great west road brentford middlesex tw gs england glaxosmithkline intellectual property management limit ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investments ireland limited iii iv ordinary riverwalk citywest business campus dublin ireland glaxosmithkline investments pty ltd ordinary mountain highway boronia vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul republic korea glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary dunte iela riga latvia glaxosmithkline lietuva uab ordinary ukmerge st vilnius lt lithuania glaxosmithkline limit ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline manufacture spa ordinary alessandro fleming verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou ham el glaza casablanca morocco glaxosmithkline medical healthcare product limit ordinary h csorsz utca budapest hungary glaxosmithkline mercury limit ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary ordinary b calzada mexicoxochimilco colonia san lorenzo huipulco delegacion tlalpan mexico gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue glaxosmithkline nz limit ordinary level zurich house queen street auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer brondby dk denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline pharmaceutical kenya limit ordinary likoni road po box nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary metros al este de la rotonda de la betania mercede de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline pharmaceuticals sa ordinary ordinary b ul grunwaldzka poznan poland ordinary c ordinary glaxosmithkline pharmaceutical sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceutical ukraine llc charter capital pavla tychyny avenue v kiev ukraine glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common prenticehall corporation system puerto rico inc co fast solution llc ponce de leon avenue floor san juan puerto rico glaxosmithkline republica dominicana sa ordinary ave lope de vega torre novocentro local santo domingo dominican republic glaxosmithkline research development limit ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline spa ordinary alessandro fleming verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline services inc ii common corporation service company little fall drive wilmington delaware united states glaxosmithkline service unlimite ordinary great west road brentford middlesex tw gs england glaxosmithkline sl holdings llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline sl llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline sl lp ii ix partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flush meadow build campus sloane street bryanston south africa glaxosmithkline trade ordinary leningradskiy prospect build floor premise xv room moscow russian federation glaxosmithkline trading services limit iii vii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble les quatre r rue du lac lochness berge du lac tunis tunisia glaxosmithkline uk limit ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa register share provisory stock salto cp montevideo uruguay glaxosmithkline trading limit ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela glaxosmithkline vietnam limited liability company ii iv equity capital metropolitan dong khoi street district th floor unit ho chi minh city viet nam glycovaxyn ag iv common prefer prefer b grabenstrasse schlieren switzerland prefer c groupe glaxosmithkline sas ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd ii iv ordinary mountain highway boronia vic australia gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petale jaya selangor malaysia gsk capital kk ordinary akasaka minatoku tokyo japan gsk ch argentina sa nominative non endorseable ordinary tucumn piso buenos aire caaa argentina share gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue security register address wholly own subsidiary continue gsk finance limit ordinary great west road brentford middlesex tw gs england gsk kazakhstan llp participationparticipating interest nursultan nazarbayev ave almaty medeu district kazakhstan gsk limited ii ordinary great west road brentford middlesex tw gs england gsk pharmaceutical trading sa ii iv ordinary poienelor street brasov romania gsk service sp z oo ordinary ul grunwaldzka poznan poland gsk vaccine bv ordinary hullenbergweg amsterdam cl netherlands gsk vaccine gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quota fiorentina siena italy gsk vaccines srl quota fiorentina siena italy gsk vaccines vertriebs gmbh ii ordinary rudolfdieselre holzkirchen germany hgs france sarl ii iv ordinary rue de la belle feuille boulognebillancourt france horlick limited ordinary preference great west road brentford middlesex tw gs england human genome sciences inc common corporation service company little fall drive wilmington delaware united states d biomedical corporation quebec common boul du parc technologique qubec gp r canada instituto luso farmaco limitada ii ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal interpharma dienstleistungen gmbh quotas wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc ii llc interest corporation service company shockoe slip nd floor richmond va united states laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerde algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerde algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoire saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologico darier sa de cv ordinary ordinary b calzada mexico xochimilco san lorenzo huipulco district federal mexico mexico laboratorios farmaceuticos stiefel portugal ltda ii ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge portugal montrose pharma company limited ii iv ordinary quota h csorsz utca budapest hungary okairos ag liquidation common prefer preferred b co obc suisse ag aeschenvorstadt basel switzerland penn labs inc ii common corporation service company little fall drive wilmington delaware united states sr international bv ordinary huis ter heideweg lz zeist netherlands sr limit unit common corporation service company interstate drive suite harrisburg pennsylvania united states setfirst limit ordinary preference great west road brentford middlesex tw gs england sitari pharma inc common stock corporation service company little fall drive wilmington delaware de united states smith kline french portuguesaprodutos farmaceuticos ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge lda ii portugal smithkline beecham bangladesh private limited ii ordinary house road gaishari dhaka bangladesh smithkline beecham cork limited vii ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limited vii ordinary riverwalk citywest business campus dublin ireland smithkline beecham biological partnership partnership interest corporation service company little fall drive wilmington delaware united states smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham interamerican corporation ii common corporation service company little fall drive wilmington delaware united states smithkline beecham limit ordinary great west road brentford middlesex tw gs england gsk annual report statutory disclosure continue group company continue security register address wholly own subsidiary continue smithkline beecham overseas limit ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltung gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii iv ordinary flush meadow build campus sloane street bryanston south africa smithkline beecham pharmaceutical co common corporation service company little fall drive wilmington delaware united states smithkline beecham port louis limited iv ordinary co cim corporate services ltd les cascade build edith cavell street port louis mauritius smithkline beecham senior executive pension plan ordinary great west road brentford middlesex tw gs england trustee limited ii stiefel distributor ireland limited ii iv vii ordinary finisklin business park sligo ireland stiefel dominicana srl ii iv ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital industriestrasse bad oldesloe germany stiefel india private limited equity wing th floorfloral deck plaza opp rolta bhavan central midc road mumbai andheri e india stiefel laboratory legacy ireland limited vii ordinary finisklin business park sligo ireland stiefel laboratory limited ii ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratory pte limited ii ordinary gul circle singapore stiefel laboratories inc common corporation service company little fall drive wilmington delaware united states stiefel maroc sarl ii iv ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia vic australia stiefel research australia pty ltd ordinary mountain highway boronia vic australia stiefel west coast llc llc interest corporation service company little fall drive wilmington delaware united states strebor inc common corporation service company little fall drive wilmington delaware united states tempero pharmaceuticals inc series preference corporation service company little fall drive wilmington series b preference common delaware united states tesaro bio austria gmbh common fleischmarkt vienna austria tesaro bio france sas share avenue le jour se lve boulogne france tesaro bio germany gmbh share leopoldstr munich germany tesaro bio gmbh ordinary poststrasse zug switzerland tesaro bio italy srl share vincenzo bellini roma italy tesaro bio netherlands bv x shares joop geesinkweg ab amsterdamduivendrecht netherland tesaro bio spain slu sharesparticipation quota severo ochoa parque tecnolgico de madrid tres cantos madrid spain tesaro bio sweden ab common co bdo mlarden ab skatt box stockholm sweden tesaro development limit share clarendon house church street hamilton hm bermuda tesaro security corporation iv common ct corporation federal st ste boston united states tesaro inc common corporation service company little fall drive wilmington delaware de united states sydney ross co ii common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states wellcome foundation investment company limited ii iv limited guarantee great west road brentford middlesex tw gs england ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petale jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome consumer product limited ii ordinary great west road brentford middlesex tw gs england wellcome developments pty ltd ii iv ordinary mountain highway boronia vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd ii iv ordinary mountain highway boronia vic australia gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest alacer corp common c corporation system west th street los angeles california united states amoun pharmaceutical industry co sae new monetary share el salam city po box cairo egypt beecham enterprises inc ii common corporation service company little fall drive wilmington delaware united states biddle sawyer limited equity dr annie besant road mumbai india block drug company inc common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states block drug corporation ii common corporation service company princeton south corporate center suite charle ewing blvd ewe new jersey united states british pharma group limited captial great west road brentford middlesex tw gs england consumer healthcare holding limit ordinary ramsgate road sandwich kent ct nj england consumer healthcare intermediate holding limit ordinary ramsgate road sandwich kent ct nj england duncan consumer healthcare philippines inc common chino roce avenue makati city philippines duncan pharmaceuticals philippines inc common chino roce avenue city makati philippines exlax inc common prentice hall corporation system puerto rico inc co fast solution llc citi tower ponce de leon avenue floor san juan puerto rico ferrosan aps share b share lautrupvang ballerup denmark ferrosan international aps ordinary lautrupvang ballerup denmark ferrosan srl register capital c calea turzii clujnapoca cluj county romania galvani bioelectronics inc common corporation service company little fall drive wilmington delaware united states galvani bioelectronic limit ordinary b ordinary great west road brentford middlesex tw gs england glaxo saudi arabia limit ordinary po box area warehouse city stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limit ordinary ordinary b galle road kaldemulla moratuwa sri lanka glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline bangladesh limit iv ordinary fouzderhat industrial area dhaka trunk road north kattali chittagong bangladesh glaxosmithkline brasil produtos para consumo quota bl vitor civita street barra tijuca rio de janeiro e saude ltda brazil glaxosmithkline consumer healthcare china co ltd ordinary floor xizangzhong road huangpu district shanghai china glaxosmithkline consumer healthcare hong kong ordinary f tower gateway canton road tsimshatsui kowloon limited hong kong glaxosmithkline consumer healthcare ireland limited vii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare ip llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare ab v ordinary nykaer brondby dk denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington nsw australia glaxosmithkline consumer healthcare bv ordinary huis ter heideweg lz zeist netherlands glaxosmithkline consumer healthcare colombia sa ordinary avenida el dorado bpiso bogota colombia glaxosmithkline consumer healthcare czech ordinary hvezdova c prague czech republic republic sro glaxosmithkline consumer healthcare finance limit ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline consumer healthcare greece societe ordinary kifissias avenue halandri athens greece anonyme glaxosmithkline consumer healthcare holding b preference great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare holding llc llc interest corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare inc common mississauga road north mississagua ln l canada glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan co waterford x ry ireland ireland limited iii vii glaxosmithkline consumer healthcare investment ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company iii vii glaxosmithkline consumer healthcare japan kk ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interest corporation service company interstate drive suite harrisburg pennsylvania united states glaxosmithkline consumer healthcare limit iv ordinary patiala road nabha dist patiala punjab india glaxosmithkline consumer healthcare mexico ordinary calzada mexicoxochimilco colonia san lorenzo huipulco de rl de cv delegacion tlalpan mexico df mexico glaxosmithkline consumer healthcare new zealand ulc ordinary level zurich house queen street auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common chino roce avenue makati city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare spa ordinary zambeletti sncbaranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower th floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampangulu kelang industrial estate ampang selangor darul ehsan malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa ordinary flush meadow build campus sloane street bryanston pty ltd south africa glaxosmithkline consumer healthcare spzoo ordinary ul grunwaldzka poznan poland glaxosmithkline consumer healthcare srl ordinary costache negri street opera center th floor zone district bucharest romania glaxosmithkline consumer healthcare vietnam charter capital floor metropolitan dong khoi ben nghe ward district company limited ii ho chi minh city viet nam glaxosmithkline consumer healthcare lp partnership capital corporation service company little fall drive wilmington delaware united states glaxosmithkline consumer healthcare produto para ordinary quota rua dr antonio loureiro borge arquiparque miraflore alge saude e higiene lda portugal glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading service limit ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary metros al este de la rotonda de la betania mercede de montes de oca sabanilla montes de oca san jose costa rica glaxosmithkline dungarvan limited vii ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary premise iii room floor presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline limit ordinary likoni road po box nairobi kenya glaxosmithkline pakistan limit ordinary syke building dockyard road west wharf karachi pakistan glaxosmithkline panama sa ordinary urbanizacion industrial juan calles b republic panama panama glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncion paraguay gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued glaxosmithkline pharmaceutical limited equity dr annie besant road mumbai india glaxosmithkline philippines inc common chino roce avenue city makati philippines glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sante grand public sas ordinary rue franois jacob rueilmalmaison france glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer hungary limited liability membership h csorsz utca budapest hungary company gsk canada hold company limit ordinary great west road brentford middlesex tw gs england gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little fall drive wilmington delaware de united states gsk consumer healthcare holding inc common corporation service company little fall drive wilmington delaware de united states gsk consumer healthcare holdings llc iii unit corporation service company little fall drive wilmington delaware de united states gsk consumer healthcare israel ltd iv ordinary basel street petech tikva israel gsk consumer healthcare levice sro ordinary priemyselny park gena ul e sachsa levice slovakia gsk consumer healthcare sa ordinary route de prangin switzerland gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little fall drive wilmington delaware united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk new zealand hold company limit ordinary great west road brentford middlesex tw gs england gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary zambeletti sncbaranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt nch nutrition consumer health ltd ii ordinary hamephalsim st petach tikva israel new pch llc membership interest corporation trust company corporation trust center orange street wilmington delaware united states pt smithkline beecham pharmaceuticals shares b share jl pulobuaran raya kav iii dd kawasan industri pulogadung jakarta indonesia pt sterling product indonesia share b shares graha paramita build th f jalan denpasar raya blok jakarta indonesia panadol gmbh ordinary barthstr mnchen germany pf consumer fzllc ordinary atlas business center dubai united arab emirates pf consumer healthcare llc membership interest corporation trust company corporation trust center orange street wilmington delaware united states pf consumer healthcare bv class class b rivium westlaan ld capelle aan den ijssel netherlands pf consumer healthcare brazil importadora e distribuidora quota barueri state sao paolo avenida ceci block iii de medicamentos ltda park tambore district brazil pf consumer healthcare canada ulc pf soin de common burrad street bentall centre po box suite sante sri vancouver british columbia canada vx l pf consumer healthcare hold bv ordinary rivium westlaan ld capelle aan den ijssel netherlands pf consumer healthcare mexico de rl de cv quota paleo de los tamarindo piso bosque de las lomas cuajimalpa de morelos mexico mexico pf consumer healthcare new zealand ulc ordinary level queen street auckland central auckland new zealand pf consumer healthcare singapore pte ltd ordinary pasir panjang road mapletree business centre singapore pf consumer healthcare uk limit ordinary ramsgate road sandwich kent ct nj england pf consumer ireland company limit ordinary riverwalk national digital park citywest business park dublin ireland pf healthcare australia pty ltd ordinary hughes avenue emington nsw australia pfizer consumer healthcare ab ordinary vetenskapsvagen se sollentuna sweden pfizer consumer healthcare gmbh ordinary linkstrasse berlin germany pfizer consumer healthcare italy srl quota stock latina isonzo italy pfizer consumer manufacturing italy srl quota stock nettunese aprilia prov di latin italy gsk annual report statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continue pfizer laboratory pfe pty ltd common flush meadow build campus sloane bryanston south africa pfizer pfe colombia sas common avenida suba bogota colombia pfizer sante familiale sas ordinary avenue du docteur lannelongue paris france phivco jersey ii limited ii iii iv vii ordinary ifc st helier je st jersey united kingdom phivco jersey limited ii iii iv vii ordinary ifc st helier je st jersey united kingdom phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limit ordinary great west road brentford middlesex tw gs england phivco llc llc interest corporation service company little fall drive wilmington delaware united states phivco llc llc interest corporation service company little fall drive wilmington delaware united states prism pch limited voting share non voting ramsgate road sandwich kent ct nj england share pt glaxo wellcome indonesia share b share jl pulobuaran raya kav iii dd kawasan industri pulogadung timur jakarta indonesia pt gsk consumer healthcare indonesia ordinary graha paramita build th f jalan denpasar raya blok kuningan jakarta selatan indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia shionogiviiv healthcare llc ii common interest corporation service company little fall drive wilmington delaware united states sinoamerican tianjin smith kline french laboratory ordinary cheng lin zhuang industrial zone dong li district tianjin ltd china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lanka smithkline beecham research limit ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiome ooo participation interest leningradskiy prospect build floor premise xiv room moscow russian federation staffordmiller ireland limited vii ordinary clocherane youghal road dungarvan co waterford ireland sterling drug malaya sdn berhad ordinary lot jalan enggang ampanghung kelang industrial estate ampang selangor darul ehsan malaysia sterling product international incorporate ii common corporation service company little fall drive wilmington delaware united states stiefel consumer healthcare uk limit ordinary great west road brentford middlesex tw gs england stiefel egypt llc ii quota amoun street po box el salam city cairo egypt stiefel laboratories ireland limited vii ordinary finisklin business park county sligo ireland treerly health co ltd capital contribution unit room east zhujiang road tianhe district guangzhou city prc china vesteralens naturprodukter ab ordinary uddevallavgen se strmstad sweden vesteralens naturprodukter aps ordinary lautrupvang ballerup denmark vesteralens naturprodukter common drammensveien oslo lysaker norge po box norway vesteralen naturprodukter oy common tietokuja fi helsinki finland viiv healthcare south africa proprietary limited ii iv ordinary flush meadow build campus sloane street bryanston south africa viiv healthcare bv ordinary huis ter heideweg lz zeist netherlands viiv healthcare company common corporation service company little fall drive wilmington delaware united states viiv healthcare finance limit iv ordinary great west road brentford middlesex tw gs england viiv healthcare finance limit ordinary great west road brentford middlesex tw gs england viiv healthcare finance limit ordinary redeemable great west road brentford middlesex tw gs england preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ii ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kabushiki kaisha ordinary akasaka minatoku tokyo japan gsk annual report strategic report governance remuneration financial statement investor information statutory disclosure continue group company continue effective security ownership register address subsidiary effective interest continued viiv healthcare limited class share defer great west road brentford middlesex tw gs england class b share class c share class class class e cumulative preference viiv healthcare pty ltd ordinary mountain highway boronia vic australia viiv healthcare puerto rico llc llc interest centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota alessandro fleming verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect build floor premise xiv room moscow russian federation viiv healthcare trading service uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ii iv ordinary ifc st helier je st jersey united kingdom viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare uk limit ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interest corporation service company little fall drive wilmington delaware united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borge arquiparque miraflore alge portugal vog au pty ltd ii ordinary redeemable hughe avenue ermington nsw australia preference winster pharmaceutical limited ii ordinary association avenue ilupeju industrial estate lago po box nigeria wyeth consumer healthcare llc membership interest ct corporation system n nd st suite harrisburg pennsylvania united states wyeth pharmaceutical co ltd register capital baodai west road suzhou jiangsu province china wyeth pharmaceuticals company viii capital contribution state road kilometer guayama puerto rico associates apollo therapeutics llp partnership interest gunnel wood road stevenage sg fx england glaxosmithkline landholding company inc common chino roce avenue city makati philippines index ventures life vi jersey lp partnership interest esplanade st helier je wg jersey innoviva inc common sierra point parkway suite brisbane united states kurma biofund ii fcpr partnership interest rue royale e tage paris france longwood founders fund lp partnership interest prudential tower boylston street suite boston united states medicxi ventures lp partnership interest great pulteney street soho london wf nd england joint ventures chiron panacea vaccines private limited ii equity share th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limit ordinary robinson road singapore quell intellectual property corp llc membership interest corporation service company little fall drive wilmington delaware united states qura therapeutics llc unit corporation service company little fall drive wilmington delaware united states gsk annual report statutory disclosure continue group company continue follow uk subsidiary advantage audit exemption set section company act period end december state undertaking list own directly indirectly glaxosmithkline plc company security register address number uk register subsidiary exempt audit burrough wellcome international limited ordinary great west road brentford middlesex tw gs england cellzome limited ordinary great west road brentford middlesex tw gs england clarge pharmaceutical limit ordinary preference great west road brentford middlesex tw gs england domantis limit ordinary great west road brentford middlesex tw gs england edinburgh pharmaceutical industry limit ordinary preference shewalton road irvine ayrshire ka ap scotland sc eskaylab limited p ordinary great west road brentford middlesex tw gs england glaxochem uk unlimite ordinary ordinary b great west road brentford middlesex tw gs england ordinary c glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline consumer healthcare uk limit ordinary great west road brentford middlesex tw gs england glaxosmithkline investment holding limit iv ordinary great west road brentford middlesex tw gs england glaxosmithkline investment service limit iv ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limit ordinary great west road brentford middlesex tw gs england mixis genetic limit iv ordinary ordinary euro great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap scotland sc smithkline beecham export limit ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinary smithkline beecham investment limit ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical ordinary great west road brentford middlesex tw gs england services limited smithkline beecham nominee limit ordinary great west road brentford middlesex tw gs england smithkline beecham swg limit ordinary great west road brentford middlesex tw gs england smith kline french laboratory limit ordinary great west road brentford middlesex tw gs england staffordmiller ltd ordinary noncumulative great west road brentford middlesex tw gs england non redeemable preference stiefel laboratory maidenhead ltd iv ordinary eurasia headquarters concorde road maidenhead berkshire sl england stiefel laboratory uk ltd ordinary eurasia headquarters concorde road maidenhead berkshire sl england tesaro uk limited ordinary baker street london wu eu england wellcome foundation limit ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england company effective ownership viiv healthcare overseas limited accordance section c company act company guarantee debt liability uk subsidiary undertaking december total sum debt liabilitie million key directly own glaxosmithkline plc ii ormant entity iii ax resident uk iv entity expect disposed remove v incorporate sweden vi consolidated subsidiary accordance section company act ground dominant influence vii exempt provision section company act ireland accordance exemption note section act viii principal business address puerto rico ix exempt provision regulation partnership account regulation accordance exemption note regulation regulation x company provide undertake accordance article paragraph subparagraph f dutch civil code asume joint liability act tesaro bio netherlands bv gsk annual report strategic report governance remuneration financial statement investor information glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ad gsk adr represent ordinary share american depositary share ad list new york stock exchange represent ordinary share basic earning share basic income share call share capital ordinary share issue fully pay cer growth growth constant exchange rate company glaxosmithkline plc currency swap exchange currency couple subsequent reexchange currency agree exchange rate date define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy sharebase employee incentive plan equity shareholder fund shareholder equity finance lease capital lease freehold ownership absolute right perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement make offset commitment intangible fix asset asset physical substance computer software brand licence patent knowhow marketing right purchase outside party novartis transaction threepart interconditional transaction novartis ag involve consumer healthcare vaccine oncology business complete march ordinary share fully pay ordinary share capital company profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay share option stock option share premium account additional paidup capital paidin surplus distributable share issue number share outstanding subsidiary entity gsk exercise control treasury share treasury stock turnover revenue uk corporate governance code require uk list authority company disclose annual report apply good practice corporate governance provision financial reporting council uk corporate governance code gsk annual report index remuneration policy report investment associate joint venture remuneration policy summary investor relation accounting principle policy key accounting judgement estimate acquisition disposal key performance indicator adjustment reconcile profit tax operate legal proceeding cash flow major restructuring cost affordability availability modern employer annual general meeting movement equity approach tax net debt asset hold sale new accounting requirement associate joint ventures nomination committee report audit risk committee report noncontrolle interest business model noncontrolle interest viiv healthcare cash cash equivalent nonexecutive director fee cash generation conversion nonfinancial information statement ceo statement note financial statement chairman statement operate profit chairman governance statement intangible asset chairman remuneration annual statement investment climaterelate financial disclosure noncurrent asset commitment noncurrent liability composition succession evaluation operating incomeexpense consolidate balance sheet provision consolidate cash flow statement board consolidate income statement culture consolidate statement change equity longterm priority consolidate statement comprehensive income preparation brexit consumer healthcare pension postemployment benefit consumer healthcare product competition pharmaceutical contingent consideration liability pharmaceutical product competition contingent liability intellectual property corporate executive team pipeline corporate governance presentation financial statement corporate responsibility committee report principal group company critical accounting policy principal risk uncertaintie datum engagement property plant equipment director senior management quarterly trend director interest share reconciliation net cash flow movement net debt director statement responsibility registrar dividend relate party transaction donation political organisation reliable supply political expenditure remuneration governance earning share remuneration report employee cost report framework employee share scheme responsible leadership environment right use asset ethic value risk management exchange rate science technology executive director remuneration science committee report finance expense section statement finance income share capital control financial calendar share capital share premium account financial instrument relate disclosure shareholder information financial performance shareholder service contact financial position resource stakeholder engagement financial statement glaxosmithkline plc prepare taxation uk gaap tax information shareholder year record trade payable glossary term trade receivables goodwill treasury policy group company trust group financial review turnover segment information independent auditor report law regulation industry trend vaccine inventory vaccine product competition intellectual property viability statement gsk annual report gsk glaxosmithkline plc incorporate english brand name brand name appear italic report public limited company december trade mark own andor license gsk associate company exception gardasil form merger glaxo wellcome plc own merck sharp dohme corp rituxan own biogen inc zofran own novartis ag smithkline beecham plc gsk acquire acknowledgement english company december print print sustainably uk pureprint carbonneutral merger arrangement company fsc chain custody iso certify environmental management system recycle dry waste share list london stock exchange paper new york stock exchange print innovation premium fsc certify paper pulp totally chlorine free manufacturing mill iso environmental management certification mill energy produce read wwwgskcom biomass fuel source local forestry fossil fuel carbon emission measure offset world land trust carbon balanced scheme download pdfs nnual report f orm f cautionary statement number nonifrs measure report group expectation assume successful delivery forwardlooke statement performance business measure define group integration restructuring plan group report file furnish page reconciliation adjusted result period include extension security exchange commission sec include total result set enhancement combine programme announce b c tnh ht ue va ai es rh et yr ee se dm ml tno f toc e e r e nu n nf c x om tt aps sh tn e e e r fn ec ig dat lt aa eda rr ttwo nen eiou td snp ft r tow r itm r co hlhi ot tra eet l ye f p kn e tc ri ou n eoi n b g hcn tf l iato ssc tsr e tt m otai n mn st r ef iet cot h ni f aro e tw fe ln u na u tr b rt ure sd cu rl ee g ur tl hea rev res ob v ee e ek fy natd ni thno c fegr tgr c h ar nr u l ps p u pfh l nvcfe oe e n nr ui n r tt ao mf lo n rs e r e n ein l g pla v ao u ot iti c iro ra ttan ei v sn htn tn oi e uv fh uri li ta p un bd rdio e eo su n c p cc u pt e oeom e r nm frb soe fe tu r rn r ut ed ato dho n n ce e acr es n se e gn ncao pon agt r n tec g ohn fin noln gt ax f obt n ii n rt es yu e tm rot chee aii lh st ia sh e en tdk r line p p nn ir r tvo oe e ej g dg gsu r ur rtl aa cj ttu ie ol nn not ote p u nr f dt nhhh g ie l ie e n ya r v vn h lm e eie ce l r sm sw k tc co e lm oo ea sn sa n nn essj tdo suu p r mm rhr nt oe hee e q gs e r not rrhh r eu w c mtt l nhu eh ser e suc n p p mag fa r n eep la dp lr l otj oi h will hsi en ian ea n tt dpn g l tv n r hh teeo hecpnu e u rr ec r ae e ti n use word anticipate estimate expect assumption relate outlook tesaro acquisition consumer healthcare joint win ot dn sd nw tll e r mp sro oje f c st m ip lala r n e ab ne il nie gv e ct oa nrg neet c ion nd w th r pn e riu ot dli n g th e e x pe tc ht ea gio rn os u f po r h dn ed c eh ta fi inv eyear v sue cn ctu er se w fui lt lh pfizer period deliver discussion future operate financial assumption healthcare sector different material cost investment new product launch performance particular include statement market group operate delivery rd factor expectation give give relate future action prospective product product revenue financial benefit current portfolio potential development option group pipeline approval future performance result current pipeline restructuring programme outlook affect additional datadriven rd anticipate product sale effort expense investment decision expectation give outcome contingency legal proceeding group specifically period gsk constant currency basis outlook cer dividend payment financial result expect decline sale seretideadvair accordance legal regulatory obligation introduction generic alternative advair notice limitation include market abuse regulation factor group assessment director liability english law uk list rule disclosure transparency future performance group assume premature uk company act safe harbour limit rule financial conduct authority group loss exclusivity key product period liability director respect statement u e c lot n nvn aio l osa le yy ud c ct kr n tee u e pa il omr ad ast gs nd ra e eo u eek sn intr r c de r ti et au ss nn tt l e h wn owa w r meo tl h h h er c td eio ew oe c xci nb rs pt hi pe th cl e si rv lie eg l adt c e r cp ti rs not aat euui l g th oo b ir ul en ce ya l n n sr dr ne h e uoa h esu eid lsu lp e rl b sd er ehn hoa ls iu od aet f mhe r n un ao g e cla e ndu r ern w c l fi ad e alu n e f n nkp c dho ef iw hw n nnwr em voia ey thr fa v ee od mt e ri goho wl ao ife n rvk c aso e e h ro k f n eu n eii rnn tt ec hug eu ar l n e c f w l tioo htech iiv r ogtsqse mi hn sd aau u es tpe rp ios tp fiiis hot nd zlu ty ano e h e e n r rx sp f h fp ip r ntt eo le h eri l vo orc e ae n pt l ne lsga rs oi h nw etst isf cr g apoo e u daonr u r n ys ost ep h c da n r pe es e nl ss v c dr upg ce mr e ou nr gx tm u e md nc tu c iu e sep et h c p fn en c os eto dt ts e r afr mom ote l hn f turv r h ba h eo e n fct eh e cim rle ru er r r oa l ve c cl e hj k rie q p ci aa u ia n n r ail n n nr dnm pyr ii v dn u rtie e oog h sp mor n vn e gt ii vh ue oa e ien rr en f es rs frd n rl u c r k soe nom tn ia p r ro et ai os w e c te pt rs erh tr ia ni gs eo e n g l r n c cy sns f ao g rt b cn rr ef l ia ir tu ps eo th oe pbm n n g roul ta e rtc ewh adt tw ne r e pte ehd ar ap u r ne n pgi oo lnr aede rr gt sc r r ea h eo hn ssi c rr ed tsd h w p rh r e ie n se r w e e op ur iny loo ne ct ur oim lnf ct ul fd co ou sbf r ln nno ib ue ve ne cer sce e c er lw ik va caa ui lr eah e ob l si mmboi c mlc ie vsn l oeoh e e pn n r r p rt eee cto ie pa ss p oo oe g est ro mfh f e r op tate phet sh ra e g hs e eee forwardlooke statement subject assumption share repurchase company remuneration report draw inherent risk uncertaintie relate change group shareholding viiv present accordance reliance factor group control precise healthcare assumption assume material english company law liability director estimate group caution investor number change macroeconomic healthcare connection report shall subject important factor include document environment guidance outlook limitation restriction provide law cause actual result differ materially factor divestment product exit website express imply forwardlooke statement include divestment exit noncore tail brand billion annual sale gsk website wwwgskcom give additional information factor include limited discuss announce july product divestment group notwithstanding reference principal risk uncertaintie page plan connection formation consumer annual report gsk website annual report forwardlooke statement healthcare joint venture pfizer information available website constitute behalf group speak date annual report shall deem base knowledge incorporate reference information available director date annual reporthead office register office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel search register number wwwgskcom